
<html lang="en"     class="pb-page"  data-request-id="49038f11-a890-48e5-8482-d9ef13f79a16"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c02145;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation" /></meta><meta name="dc.Creator" content="Francesco  Calzaferri" /></meta><meta name="dc.Creator" content="Paloma  Narros-Fernández" /></meta><meta name="dc.Creator" content="Ricardo  de Pascual" /></meta><meta name="dc.Creator" content="Antonio M.G.  de Diego" /></meta><meta name="dc.Creator" content="Annette  Nicke" /></meta><meta name="dc.Creator" content="Javier  Egea" /></meta><meta name="dc.Creator" content="Antonio G.  García" /></meta><meta name="dc.Creator" content="Cristóbal  de los Ríos" /></meta><meta name="dc.Description" content="The ATP-gated P2X7 purinergic receptor (P2X7) is involved in the pathogenesis of many neurodegenerative diseases (NDDs). Several P2X7 antagonists have been developed, though none of them reached cl..." /></meta><meta name="Description" content="The ATP-gated P2X7 purinergic receptor (P2X7) is involved in the pathogenesis of many neurodegenerative diseases (NDDs). Several P2X7 antagonists have been developed, though none of them reached cl..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 9, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02145" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02145" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02145" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02145" /></link>
        
    
    

<title>Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02145" /></meta><meta property="og:title" content="Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0021.jpeg" /></meta><meta property="og:description" content="The ATP-gated P2X7 purinergic receptor (P2X7) is involved in the pathogenesis of many neurodegenerative diseases (NDDs). Several P2X7 antagonists have been developed, though none of them reached clinical trials for this indication. In this work, we designed and synthesized novel blood–brain barrier (BBB)-permeable derivatives as potential P2X7 antagonists. They comprise purine or xanthine cores linked to an aryl group through different short spacers. Compounds were tested in YO-PRO-1 uptake assays and intracellular calcium dynamics in a human P2X7-expressing HEK293 cell line, two-electrode voltage-clamp recordings in Xenopus laevis oocytes, and in interleukin 1β release assays in mouse peritoneal macrophages. BBB permeability was assessed by parallel artificial membrane permeability assays and P-glycoprotein ATPase activity. Dichloroarylpurinylethanones featured a certain P2X7 blockade, being compound 6 (2-(6-chloro-9H-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one), named ITH15004, the most potent, selective, and BBB-permeable antagonist. Compound 6 can be considered as a first non-nucleotide purine hit for future drug optimizations." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02145"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02145">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02145&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02145&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02145&amp;href=/doi/10.1021/acs.jmedchem.0c02145" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 2272-2290</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02104" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00034" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Francesco Calzaferri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francesco Calzaferri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto-Fundación Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francesco++Calzaferri">Francesco Calzaferri</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4781-2925" title="Orcid link">http://orcid.org/0000-0002-4781-2925</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paloma Narros-Fernández</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paloma Narros-Fernández</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto-Fundación Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</div><div class="loa-info-affiliations-info">Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa, C/ Diego de León, 62—1a Planta, 28006 Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paloma++Narros-Fern%C3%A1ndez">Paloma Narros-Fernández</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ricardo de Pascual</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ricardo de Pascual</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto-Fundación Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ricardo++de+Pascual">Ricardo de Pascual</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Antonio M.G. de Diego</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Antonio M.G. de Diego</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto-Fundación Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Antonio+M.G.++de+Diego">Antonio M.G. de Diego</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Annette Nicke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Annette Nicke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-Universität München, 80336 Munich, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Annette++Nicke">Annette Nicke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Javier Egea</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Javier Egea</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto-Fundación Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</div><div class="loa-info-affiliations-info">Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa, C/ Diego de León, 62—1a Planta, 28006 Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Javier++Egea">Javier Egea</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4704-3019" title="Orcid link">http://orcid.org/0000-0003-4704-3019</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Antonio G. García</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Antonio G. García</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto-Fundación Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</div><div class="loa-info-affiliations-info">Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa, C/ Diego de León, 62—1a Planta, 28006 Madrid, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#6b0a0c0c2b1e0a06450e18"><span class="__cf_email__" data-cfemail="59383e3e192c3834773c2a">[email protected]</span></a>. Phone: (+34)914975397. Fax: (+34)-914973453.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Antonio+G.++Garc%C3%ADa">Antonio G. García</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Cristóbal de los Ríos</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cristóbal de los Ríos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto-Fundación Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</div><div class="loa-info-affiliations-info">Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa, C/ Diego de León, 62—1a Planta, 28006 Madrid, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#0566776c76716a6764692b6160696a76776c6a76456c6b732b7064682b6076"><span class="__cf_email__" data-cfemail="0c6f7e657f78636e6d6022686960637f7e65637f4c65627a22796d6122697f">[email protected]</span></a>. Phone: (+34)-914972765.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Crist%C3%B3bal++de+los+R%C3%ADos">Cristóbal de los Ríos</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6456-7589" title="Orcid link">http://orcid.org/0000-0002-6456-7589</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02145&amp;href=/doi/10.1021%2Facs.jmedchem.0c02145" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 2272–2290</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 9, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 December 2020</li><li><span class="item_label"><b>Published</b> online</span>9 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02145" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02145</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2272%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DFrancesco%2BCalzaferri%252C%2BPaloma%2BNarros-Fern%25C3%25A1ndez%252C%2BRicardo%2Bde%2BPascual%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D4%26contentID%3Dacs.jmedchem.0c02145%26title%3DSynthesis%2Band%2BPharmacological%2BEvaluation%2Bof%2BNovel%2BNon-nucleotide%2BPurine%2BDerivatives%2Bas%2BP2X7%2BAntagonists%2Bfor%2Bthe%2BTreatment%2Bof%2BNeuroinflammation%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2290%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02145"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1122</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02145" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Francesco&quot;,&quot;last_name&quot;:&quot;Calzaferri&quot;},{&quot;first_name&quot;:&quot;Paloma&quot;,&quot;last_name&quot;:&quot;Narros-Fernández&quot;},{&quot;first_name&quot;:&quot;Ricardo&quot;,&quot;last_name&quot;:&quot;de Pascual&quot;},{&quot;first_name&quot;:&quot;Antonio&quot;,&quot;last_name&quot;:&quot;M.G. de Diego&quot;},{&quot;first_name&quot;:&quot;Annette&quot;,&quot;last_name&quot;:&quot;Nicke&quot;},{&quot;first_name&quot;:&quot;Javier&quot;,&quot;last_name&quot;:&quot;Egea&quot;},{&quot;first_name&quot;:&quot;Antonio&quot;,&quot;last_name&quot;:&quot;G. García&quot;},{&quot;first_name&quot;:&quot;Cristóbal&quot;,&quot;last_name&quot;:&quot;de los Ríos&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2272-2290&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02145&quot;},&quot;abstract&quot;:&quot;The ATP-gated P2X7 purinergic receptor (P2X7) is involved in the pathogenesis of many neurodegenerative diseases (NDDs). Several P2X7 antagonists have been developed, though none of them reached clinical trials for this indication. In this work, we designed and synthesized novel blood–brain barrier (BBB)-permeable derivatives as potential P2X7 antagonists. They comprise purine or xanthine cores linked to an aryl group through different short spacers. Compounds were tested in YO-PRO-1 uptake assays and intracellular calcium dynamics in a human P2X7-expressing HEK293 cell line, two-electrode voltage-clamp recordings in Xenopus laevis oocytes, and in interleukin 1β release assays in mouse peritoneal macrophages. BBB permeability was assessed by parallel artificial membrane permeability assays and P-glycoprotein ATPase activity. Dichloroarylpurinylethanones featured a certain P2X7 blockade, being compound 6 (2-(6-chloro-9H-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one), named ITH15004, the most potent, selective,&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02145&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02145" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02145&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02145" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02145&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02145" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02145&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02145&amp;href=/doi/10.1021/acs.jmedchem.0c02145" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02145" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02145" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02145%26sid%3Dliteratum%253Aachs%26pmid%3D33560845%26genre%3Darticle%26aulast%3DCalzaferri%26date%3D2021%26atitle%3DSynthesis%2Band%2BPharmacological%2BEvaluation%2Bof%2BNovel%2BNon-nucleotide%2BPurine%2BDerivatives%2Bas%2BP2X7%2BAntagonists%2Bfor%2Bthe%2BTreatment%2Bof%2BNeuroinflammation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D4%26spage%3D2272%26epage%3D2290%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/jmcmar.2021.64.issue-4/20210225/jmcmar.2021.64.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The ATP-gated P2X7 purinergic receptor (P2X7) is involved in the pathogenesis of many neurodegenerative diseases (NDDs). Several P2X7 antagonists have been developed, though none of them reached clinical trials for this indication. In this work, we designed and synthesized novel blood–brain barrier (BBB)-permeable derivatives as potential P2X7 antagonists. They comprise purine or xanthine cores linked to an aryl group through different short spacers. Compounds were tested in YO-PRO-1 uptake assays and intracellular calcium dynamics in a human P2X7-expressing HEK293 cell line, two-electrode voltage-clamp recordings in <i>Xenopus laevis</i> oocytes, and in interleukin 1β release assays in mouse peritoneal macrophages. BBB permeability was assessed by parallel artificial membrane permeability assays and P-glycoprotein ATPase activity. Dichloroarylpurinylethanones featured a certain P2X7 blockade, being compound <b>6</b> (2-(6-chloro-9<i>H</i>-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one), named ITH15004, the most potent, selective, and BBB-permeable antagonist. Compound <b>6</b> can be considered as a first non-nucleotide purine hit for future drug optimizations.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Brain disorders affect 1 billion people around the world.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Neurodegenerative diseases (NDDs) are the most common form of brain disorder and, since they are age-dependent, this results in a high socio-economic burden as the longevity of the global population increases.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Current available medicines only mitigate some of the symptoms. For this reason, new innovative, more potent, and selective drugs are urgently needed to hinder disease progression. The NDDs, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), feature diverse symptomatology and physiopathology. However, recent evidences focus on neuroinflammation as a common central stage in their pathogenesis.</div><div class="NLM_p">In this context, the ATP-gated P2X7 purinergic ion channels (P2X7) are emerging as important gatekeepers of neuroinflammation<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and as novel therapeutic targets for the above-mentioned diseases.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> P2X7 is a non-selective ligand-operated ion channel, physiologically activated by ATP. They are permeable to Na<sup>+</sup>, Ca<sup>2+</sup>, and K<sup>+</sup> as well as to small molecules up to 900 Da of molecular weight.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> P2X7s have a low affinity for ATP. Thus, they are considered as important sensors of tissue damage and inflammation, conditions where extracellular ATP levels considerably rise. P2X7 activation triggers immune responses that mediate maturation and secretion of interleukins, such as interleukin-1β (IL-1β).<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Each P2X7 subunit is structurally characterized by a dolphin-like shape and assembles into homotrimers that present three extracellular ATP-binding pockets at the subunit interfaces.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Two main allosteric binding sites have been described so far,<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> which are located in the extracellular domain along the longitudinal axis of the receptor. Most of the antagonists developed so far bind to the allosteric pocket placed in the upper vestibule of the receptor, hindering the conformational changes that lead to the pore opening.</div><div class="NLM_p">Concerning AD, an <i>in vivo</i> study using the Tg2576 AD mouse model reported that P2X7s are overexpressed in both astrocytes and microglia around Aβ senile plaques<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> as was also observed in AD patients.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Pharmacological inhibition of P2X7 using Brilliant Blue G (BBG) (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) in the transgenic J20 mice carrying the human APP protein induced a significant decrease of hippocampal amyloid plaques.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Moreover, the P2X7 antagonist GSK1482160 (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) reduced ATP-induced microglia migration and restored their phagocytic activity in mice.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Chemical Structure of Some P2X7 Antagonists, Including the Adamantane-<i>o</i>-chlorobenzamide Scaffold Reported by Astra-Zeneca (<b>1</b>)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As for PD, P2X7s are overexpressed in PD patients,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and their activation is cytotoxic for dopaminergic SN4741 neurons.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> BBG succeeded in preventing dopaminergic neuron loss in the 6-hydroxydopamine-injected rat model of PD.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a></div><div class="NLM_p">P2X7s have an important role in ALS neuroinflammation,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and their expression is up-regulated in the post-mortem spinal cord tissue of ALS patients.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The treatment with BBG improved motoneuron survival and motor performance deficit of the treated SOD1<sup>G93A</sup> mice,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> a disease model for ALS, though no effect was observed when JNJ-47965567 (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), a more potent and selective antagonist, was used.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Finally, a high expression of P2X7 in activated microglia and astrocytes of post-mortem MS patients has been reported.<a onclick="showRef(event, 'ref21 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref24">(21,24)</a></div><div class="NLM_p">The earliest attempts to synthesize P2X7 antagonists based on nucleotide analogues resulted in the irreversible inhibitor <i>o-</i>ATP (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Then, the discovery of the triphenylmethane dye BBG, which is blood–brain barrier (BBB)-permeable<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> but a non-selective P2X7 antagonist, constituted a real breakthrough. Other first-generation P2X7 antagonists were the non-selective pyridoxalphosphate derivative PPADS,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> the naphthylsulfonate suramine, and its isoquinoline derivative KN-62<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>). During the last 2 decades, the search for more potent, selective, and CNS-penetrant P2X7 antagonists has been a continuous challenge, which has led to a series of KN-62 derivatives,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> the discovery of berberine alkaloids as P2X7 blockers,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and the development of adamantine-<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and <i>o</i>-chlorobenzamide-based new ligands as well as their juxtaposition products (<b>1</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Several other scaffolds have been explored, such as 4,5-diarylimidazolines,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> pyrazolodiazepines,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> 1-piperidinylimidazoles,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> quinolones and quinolinones,<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> arylboronic acids,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> thiadiazoles,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and tetrazoles, yielding the derivative A438079.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> They all have different structural motifs, but we noticed that the <i>o</i>-chlorobenzamide and its isosteres are recurrent patterns. For instance, it is present in a series of triazole rings disclosed by Janssen<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> as well as in the pyroglutamic acid amide analogue GSK1482160 (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> as a superior homologue and an inverse isostere. Also, the heteroaryl-cyanoguanidines A740003<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and A804598 (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>)<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> can be considered as <i>o</i>-chlorobenzamide isosteres since both the cyano group and ortho-halogen induce the dihedral torsion of the aromatic ring over the vicinal guanidine or carbonyl group, respectively. Finally, the two Janssen derivatives JNJ-55308942<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and JNJ-54175446<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) also contain an <i>o</i>-halobenzamide moiety. The former passed three phase I clinical trials,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> while the latter is currently in a phase II trial for major depression.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Apart from this, the other few P2X7 antagonists that have entered clinical trials were intended for the treatment of peripheral disorders.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Hence, there is still a great need for defining accurate drug-like properties to target the CNS, such as sufficient lipophilicity and brain tissue half-life. Our research group has recently embarked on a project aiming at the development of new P2X7 antagonists with enhanced BBB penetration for the potential treatment of brain diseases such as NDDs. We designed a novel series of compounds that combined the essential structural features for their inhibitory capacity on P2X7: the presence of a heteroaromatic cycle bound to a halobenzene through a non-complex spacer (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scheme of the designed molecules. A purine scaffold (blue) was linked to an <i>o</i>-halophenyl (green) through three different spacers (red): carbonyl (A), ethanoyl (B), or sulfonyl (C) groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On this basis, we surprisingly noticed that the purine scaffold had been only explored in the earliest nucleotide P2X ligands,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> but it had been never linked to the <i>o</i>-chlorobenzamide moiety. We then synthesized such non-nucleotide purine derivatives, hypothesizing that the halobenzamide substructure would afford potency and selectivity, whereas the purine-like heterocycles would contribute to favor BBB penetration.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32103" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32103" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">Following the chemical design (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), several structures were proposed. At a first glance, the simplest design was based on connecting a purine analogue with <i>o-</i>chlorobenzamide through benzoylation. 6-Chloropurine was selected as a substrate to achieve regioselective nucleophilic acyl substitution, assuming that chlorine at that position would hinder the N7 nucleophilic center. We first selected <i>o-</i>chlorobenzoic acid as the electrophile, assisted by cyanuric chloride,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> unsuccessfully. With the use of <i>o-</i>chlorobenzoyl chloride as the acylating reagent, several bases, for example, pyridine or TEA, and solvents such as DMF, CH<sub>2</sub>Cl<sub>2</sub>, or MeCN were probed, achieving the best yield (78%) for the synthesis of <b>2</b> with the TEA/DMAP system as the base in THF (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Analogously, 6-methoxypurine (<b>3</b>), prepared by aromatic nucleophilic substitution with Na in MeOH, furnished benzoyl purine <b>4</b> in moderate yields (53%, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>o</i>-Chlorobenzoylpurines <b>2</b> and <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TEA, DMAP, THF, 4.5–6 h, 0 °C to rt; (b) Na, MeOH, 2 h, 60 °C.</p></p></figure><div class="NLM_p">Subsequently, the homologous derivatives of <i>N</i>-acylpurines were synthesized to assess the effect of the spacer lengthening over the P2X7 antagonist capability and to improve the critical chemical stability (acid-catalyzed hydrolysis of the amide) of <i>N</i>-acylpurines. The nucleophilic substitution of 6-chloropurine on 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>) assisted by NaH as the base in DMF afforded <b>6</b> (R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> = Cl, R<sup>2</sup> = H, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Purinyl-2′,4′-disubstituted Phenylethanones (<b>6</b> and <b>12–20</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. For the synthesis of <b>6</b> and <b>12–18</b>: (a) NaH, DMF, 15–40 h, 0 °C to rt. For the synthesis of <b>19</b>: (a) KOH, Bu<sub>4</sub>NHSO<sub>4</sub>, DMF, 26 h, 0 °C to rt. For the synthesis of <b>20</b>: (a) K<sub>2</sub>CO<sub>3</sub>, Bu<sub>4</sub>NHSO<sub>4</sub>, DMF, 30 h, 0 to 80 °C.</p></p></figure><div class="NLM_p">When tested on the selected pharmacological assays described below, purinylethanone <b>6</b> presented the most promising P2X7 antagonist profile. For this reason, we synthesized several new analogues of <b>6</b> to optimize its pharmacological properties (<b>12–20</b>). Modifications of <b>6</b> mainly pursued to probe the effect of substitution at C2 (R<sup>2</sup>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) and the replacement of chlorine at C6 (R<sup>1</sup>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Compounds <b>12–20</b> were obtained in low to good yields (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) following the experimental procedures depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Compound <b>14</b> (R<sup>1</sup> = Ph, R<sup>2</sup> = H, R<sup>3</sup>, R<sup>4</sup> = Cl, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was synthesized from 6-phenylpurine (<b>9</b>, Scheme S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">Supporting Information</a>), easily accessible through Suzuki coupling of the THP-protected 6-chloropurine <b>7</b> with phenylboronic acid that gives rise to intermediate <b>8</b> and the subsequent deprotection to form 6-phenylpurine <b>9</b>. Compound <b>17</b> (R<sup>1</sup> = Cl, R<sup>2</sup> = F, R<sup>3</sup>, R<sup>4</sup> = Cl, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was synthesized from 6-chloro-2-fluoropurine <b>10</b>, which was obtained from 6-chloropurin-2-amine and an HF solution in pyridine. Compound <b>18</b> (R<sup>1</sup> = I, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> = Cl, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was synthesized from 2-chloro-6-iodopurine <b>11</b>, which was prepared by treating 2,6-dichloropurine with HI. Compounds <b>19</b> and <b>20</b>, bearing a methylamine at C6 or an amine at C2, respectively, were prepared through nucleophilic substitution of commercial purines (2-chloro-<i>N-</i>methylpurin-6-amine and 6-chloropurin-2-amine, respectively) over the alkyl chloride <b>5</b>, assisted by tetrabutylammonium hydrogensulfate (TBAHS) phase transfer catalysis (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). As expected, the presence of amines, susceptible to compete with N9 as nucleophile centers, lowered the chemical yield of the reactions (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). X-ray analysis of <b>19</b> confirmed the expected regioselectivity of the reaction toward the N9-alkylation (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). To understand whether the chlorine at the ortho position was relevant for blocking the P2X7 opening, we synthesized other derivatives of compound <b>6</b> bearing only the halogen at the para position (R<sup>3</sup> = H, i.e., <b>12</b> and <b>13</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray diffraction of compounds <b>19</b> and <b>31</b>. Purine and theophylline scaffolds used in this study have the same influence on N7 and N9 nucleophilicity for all the respective derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also explored if lengthening the spacer present in compound <b>6</b> affected the pharmacological activity by inserting a propanone instead of an ethanone as the spacer between the purine core and the aryl group (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). We prepared compound <b>22</b> through a Friedel–Crafts reaction of 1,3-dichlorobenzene with 3-chloropropanoyl chloride to form intermediate <b>21</b> and the subsequent nucleophilic substitution with 6-chloropurine (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 3-(6-Chloro-9<i>H</i>-purin-9-yl)-1-(2′,4′-dichlorophenyl)-propan-1-one <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AlCl<sub>3</sub>, 4 h, rt to 60 °C; (b) 6-chloropurine, NaH, DMF, 18 h, 0 °C to rt.</p></p></figure><div class="NLM_p">Another strategy to modify the spacer and to improve the stability was the insertion of a sulfonamide moiety (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), which is considered a non-classical bioisostere of amides. For this purpose, 6-chloropurine reacted with <i>o-</i>chlorobenzenesulfonyl chloride to give <b>23</b> (R<sup>1</sup> = Cl, R<sup>2</sup> = H) in low yield when NaH was used as a base. Yield was enhanced (77%) by using the TEA/DMAP system (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Although compound <b>23</b> did not show a relevant P2X7 blockade (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), we prepared new purine derivatives bearing a sulfonyl spacer by considering the good biological results obtained with sulfonamide <b>31</b>. Thus, we replaced the chlorine at C6 of <b>23</b> (R<sup>1</sup>, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) by polar groups and evaluated the influence of substitutions at C2 (R<sup>2</sup>, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) over the pharmacological activity. Following the synthetic procedure provided in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>, analogues of compound <b>23</b> (<b>24–27</b>) were prepared in low to good yields and mild conditions.</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 2-Chlorophenylsulfonyl Purines (<b>23–27</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TEA, DMAP, CH<sub>2</sub>Cl<sub>2</sub>/THF, 0 °C to rt, 2–4 h.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. P2X7 Antagonist Profile of the First Purine and Xanthine Derivatives Assessed by the YO-PRO-1 Aye Assay in hP2X7-HEK293 Cells and by TEVC in hP2X7-Expressing <i>X. laevis</i> Oocytes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">scaffold</th><th class="colsep0 rowsep0" align="center">spacer</th><th class="colsep0 rowsep0" align="center">YO-PRO-1<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center" char="±"><i>I</i><sub>ATP</sub><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JNJ</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">56 ± 5<sup>***</sup></td><td class="colsep0 rowsep0" align="char" char="±">49 ± 4*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">purine</td><td class="colsep0 rowsep0" align="left">–CO–</td><td class="colsep0 rowsep0" align="left">7 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">purine</td><td class="colsep0 rowsep0" align="left">–CO–</td><td class="colsep0 rowsep0" align="left">1 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">0 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">purine</td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>CO–</td><td class="colsep0 rowsep0" align="left">63 ± 4<sup>***</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">47 ± 1<sup>***</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">purine</td><td class="colsep0 rowsep0" align="left">–SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">17 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">theobromine</td><td class="colsep0 rowsep0" align="left">–CO–</td><td class="colsep0 rowsep0" align="left">5 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">theobromine</td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>CO–</td><td class="colsep0 rowsep0" align="left">nb</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">theophylline</td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>CO–</td><td class="colsep0 rowsep0" align="left">0 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">theophylline</td><td class="colsep0 rowsep0" align="left">–SO<sub>2</sub>–</td><td class="colsep0 rowsep0" align="left">52 ± 4<sup>***</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">28 ± 2<sup>**</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">purinone</td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>–</td><td class="colsep0 rowsep0" align="left">16 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">hP2X7-HEK293 cells stimulated with BzATP 30 μM. Compound concentration was 10 μM, except for JNJ-47965567 (JNJ, 1 μM). Data are mean ± S.E.M. of triplicates of three different cultures.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> data of <b>6</b> and <b>31</b> were calculated, being 9 ± 3 and 10 ± 4 μM, respectively.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Oocytes expressing hP2X7 stimulated with ATP 0.3 mM. Compound concentration was 100 μM, except for JNJ (1 μM). Data are mean ± S.E.M. of triplicates of three different oocytes from two different frogs. *<i>P</i> < 0.05, <sup>**</sup><i>p</i> < 0.01, <sup>***</sup><i>p</i> < 0.001, nb = no blockade.</p></div></div></div><div class="NLM_p">The xanthine scaffold was also considered to build ligands under the chemical design outlined in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. Xanthine derivatives (e.g., theobromine, theophylline, caffeine, and so on) are substances with well-known CNS effects, thus eligible as the starting point to develop drugs with extended brain penetration. Hence, theobromine suffered benzoylation with <i>o-</i>chlorobenzoyl chloride under the conditions outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> to yield benzoyltheobromine <b>28</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 2′,4′-Dichlorophenylethanones and 2′-Chlorobenzamides, Using Xanthine Derivatives as the Starting Material<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-chlorobenzoyl chloride, TEA, DMAP, THF, 48 h, 0 to 70 °C; (b) 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>), K<sub>2</sub>CO<sub>3</sub>, Bu<sub>4</sub>NHSO<sub>4</sub>, DMF, 1–6 h, 150 °C.</p></p></figure><div class="NLM_p">Unlike 6-chloropurine, theobromine reacted better with <b>5</b> when using K<sub>2</sub>CO<sub>3</sub> as the base in DMF at 150 °C under phase transfer catalysis (TBAHS) to form <b>29</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) presumably due to the low nucleophilic strength of N1. Analogously but using theophylline as the starting material, we isolated <b>30</b> in moderate yields (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>, 45%). Only one of the two possible regioisomers was obtained. NOESY analysis did not show any spatial coupling between methylene and the methyl group at N3 (Figure S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">Supporting Information</a>), confirming the more probable N7 alkylation.</div><div class="NLM_p">The incorporation of the <i>o</i>-chlorophenylsulfonyl moiety to theophylline, following the procedure shown in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>, gave <b>31</b> in a regioselective fashion, as proved by X ray diffraction (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). We thus confirmed that N7 is the most nucleophilic center in theophylline as proposed for <b>30</b>. The theophylline <b>31</b> was the most promising analogue among the xanthine derivatives (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). For this reason, we proposed tiny chemical modifications to increase its potency over P2X7. In this case, we focused on modifying substitutions at the pending phenyl ring (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). Compounds <b>32–38</b> were obtained following the procedure shown in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a> with good yields.</div><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Arylsulfonyl Theophyllines (<b>31–38</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, THF, 4–48 h, 0 °C to rt.</p></p></figure><div class="NLM_p">Finally, to further explore possible modifications on the spacer and to evaluate whether a more stable amide than the one present in benzoylpurines <b>2</b> and <b>4</b> could be essential for P2X7 antagonism, we designed a compound starting from 6-purinone and that included a methylene group as purinylarylethanones <b>6</b> and <b>12–20</b>. The result was the synthesis of <b>40</b> by nucleophilic substitution of 6-purinone <b>39</b><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> over 1-chloro-2-(chloromethyl)benzene (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).</div><figure id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of 2-Chloro-1-(2′-chlorobenzyl)-9-methyl-1,9-dihydro-6<i>H</i>-purin-6-one (<b>40</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) basic alumina, MeOH, 24 h, 70 °C; (b) 1-chloro-2-(chloromethyl)benzene, NaHCO<sub>3</sub>, DMF, overnight, 75 °C.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Biological Evaluation</h3><div class="NLM_p">Compounds <b>2</b>, <b>4</b>, <b>6</b>, <b>23</b>, <b>28–31</b>, and <b>40</b> were initially assessed as P2X7 antagonists by two experimental procedures, YO-PRO-1 dye uptake assay<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> and inhibition of ATP-activated currents in hP2X7-expressing <i>Xenopus laevis</i> oocytes (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In the former, the potent P2X7 agonist benzoyl-ATP (BzATP) activates the human P2X7 receptors (hP2X7), stably transfected in HEK293 cells. After channel opening, the dye enters the cell and binds to nucleic acids, giving a fluorescent signal. In the latter, ionic currents are evoked by ATP (300 μM) in the presence or absence of the assessed compounds to test their ability to inhibit channel opening. The percentages of blockade in both assays are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. JNJ-47965567 (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) was used as the reference P2X7 antagonist.</div><div class="NLM_p">YO-PRO-1 uptake and ATP-activated currents were not affected by purines <b>2, 4, 23</b>, and the N1-benzyl-6-purinone <b>40</b>. By contrast, the ethanoyl spacer successfully contributed to the blockade of YO-PRO-1 uptake exerted by purine derivative <b>6</b> (63% at 10 μM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) but not in xanthine derivatives <b>29</b> and <b>30</b>. The sulfonyl spacer was only effective when linked to theophylline, as in <b>31</b>, which halves the YO-PRO-1 uptake at 10 μM and reduces ATP currents in hP2X7-expressing oocytes (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Those compounds possessing a %blockade of YO-PRO-1 uptake higher than 40% at 10 μM were subjected to concentration–response experiments. Thus, compounds <b>6</b> and <b>31</b> presented an IC<sub>50</sub> defined as their concentration capable of reducing the BzATP-induced YO-PRO-1 uptake by 50% of 9 ± 3 and 10 ± 4 μM, respectively. Interestingly, the two screening methods confirmed each other’s outcomes despite the experimental differences.</div><div class="NLM_p">Considering the promising pharmacological profile of <b>6</b> as P2X7 antagonist, its analogues <b>12–20</b> were prepared and biologically assessed (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Most of the compounds <b>12–20</b> did not reach the blocking properties of their head compound <b>6</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), as measured by the YO-PRO-1 assay and two-electrode voltage-clamp (TEVC). Compounds <b>12</b>, <b>14</b>, and <b>16</b> presented an IC<sub>50</sub> to block the BzATP-induced YO-PRO-1 uptake of 10 ± 2, 6 ± 1, and 13 ± 2 μM, respectively, comparable data to that of compound <b>6</b>. In any case, the use of the ethanoyl spacer seemed appropriate since most of them reduced the YO-PRO-1 uptake in a significant manner. Generally, we noticed that an increase in polarity of the substituents on the purine scaffold lowered the inhibitory potential. Moreover, hydrophobic bulky substituents at the C6 position (R<sup>1</sup>) were well tolerated, like the phenyl present in <b>14</b>. By contrast, only the highly halogenated derivatives <b>16</b> and <b>17</b> showed a decent mitigation of the ATP-evoked currents, slightly worse than that exerted by compound <b>6</b>. Interestingly, substitutions at C2 (R<sup>2</sup>) decreased ligands’ potency, presumably due to steric effects since halogens are better tolerated than an amine, but no substitution still affords the best result.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. P2X7 Antagonist Profile of Purinylarylethanones <b>12–20</b>, Analogues of <b>6</b>, Assessed by the YO-PRO-1 Dye Uptake Assay in hP2X7-HEK293 Cells and by TEVC in hP2X7-Expressing <i>X. laevis</i> Oocytes</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0018.gif" alt="" id="GRAPHIC-d7e1589-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">R<sup>4</sup></th><th class="colsep0 rowsep0" align="center">yield<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center" char="±">YO-PRO-1<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (%)</th><th class="colsep0 rowsep0" align="center" char="±"><i>I</i><sub>ATP</sub><a class="ref internalNav" href="#t2fn4" aria-label="d">d</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JNJ</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">56 ± 5<sup>***</sup></td><td class="colsep0 rowsep0" align="char" char="±">49 ± 4**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="char" char="±">63 ± 4<sup>***</sup><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">37 ± 1***</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="char" char="±">55 ± 4<sup>***</sup><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">11 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="char" char="±">34 ± 7<sup>**</sup></td><td class="colsep0 rowsep0" align="char" char="±">7 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="char" char="±">62 ± 3<sup>***</sup><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">11 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">MeO</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="char" char="±">25 ± 3***</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 2*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 3***<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">24 ± 2**</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="char" char="±">27 ± 5**</td><td class="colsep0 rowsep0" align="char" char="±">24 ± 3*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 9</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 16</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Chemical yields of the reaction in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">hP2X7-HEK293 cells stimulated with BzATP 30 μM. Compounds assayed at 10 μM, except for JNJ-47965567 (JNJ, 1 μM). Data are mean ± S.E.M. of triplicates of three different cell cultures.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>50</sub> data of <b>6</b>, <b>12</b>, <b>14</b>, and <b>16</b> were calculated, being 9 ± 3, 10 ± 2, 6 ± 1, and 13 ± 2 μM, respectively.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Oocytes expressing the hP2X7 stimulated with ATP 0.3 mM. Compounds assayed at 100 μM, except for JNJ (1 μM). Data are mean ± S.E.M. of triplicates of three different oocytes from two different frogs. *<i>P</i> < 0.05, <sup>**</sup><i>p</i> < 0.01, <sup>***</sup><i>p</i> < 0.001.</p></div></div></div><div class="NLM_p">According to ATP current data of compounds <b>12</b> and <b>13</b>, the removal of chlorine at C2′ of the aryl residue leads to a decrease in potency, meaning that the chlorine is necessary for antagonism, and confirming our hypothesis that an <i>o</i>-haloaryl moiety (or its structural isostere-like aryl-cyanoguanidine) is essential for the P2X7 blocking activity, as represented in the majority of P2X7 antagonists.</div><div class="NLM_p">Compound <b>22</b>, the superior homologue of compound <b>6</b>, scarcely affected both YO-PRO-1 uptake (19 ± 9% blockade) and ATP currents (6 ± 1% blockade), indicating that lengthening the spacer is not beneficial to inhibit the P2X7. Hence, we did not launch further similar analogues.</div><div class="NLM_p">As for analogues of arylsulfonylpurine <b>23</b> (<b>24–27</b>), the insertion of polar substituents hindered the P2X7 inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Apparently, the addition of a chlorine atom at C2 (R<sup>2</sup> = Cl, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), as in compound <b>24</b>, conferred potency to these derivatives according to the YO-PRO-1 assay. For this reason, its IC<sub>50</sub> was calculated, being 10.2 ± 0.6 μM, a similar value to those found for the best compounds of these series. However, considering that these data were not confirmed by TEVC (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), we speculate that the potency of compound <b>24</b> is not strictly related to P2X7 pore opening.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. P2X7 Antagonist Profile of 2-Chlorophenylsulfonylpurines <b>24–27</b>, Analogues of <b>23</b>, Assessed by the YO-PRO-1 Dye Uptake Assay in hP2X7-HEK293 Cells and by TEVC Analysis in hP2X7-Expressing <i>X. laevis</i> Oocytes</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0019.gif" alt="" id="GRAPHIC-d7e2084-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">yield<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center">YO-PRO-1<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> (%)</th><th class="colsep0 rowsep0" align="center"><i>I</i><sub>ATP</sub><a class="ref internalNav" href="#t3fn4" aria-label="d">d</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JNJ</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">56 ± 5***</td><td class="colsep0 rowsep0" align="left">49 ± 4*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">17 ± 6</td><td class="colsep0 rowsep0" align="left">9 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">46 ± 4<sup>**</sup><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">MeO</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">nb</td><td class="colsep0 rowsep0" align="left">8 ± 8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">9 ± 9</td><td class="colsep0 rowsep0" align="left">Nb</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">4 ± 8</td><td class="colsep0 rowsep0" align="left">2 ± 1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Chemical yields of the reaction in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">hP2X7-HEK293 cells stimulated with BzATP 30 μM. Compounds assayed at 10 μM, except for JNJ-47965567 (JNJ, 1 μM). Data are mean ± S.E.M. of triplicates of three different cell cultures.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>50</sub> of <b>24</b> was calculated, being 10.2 ± 0.6 μM.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">hP2X7-expressing oocytes stimulated with ATP 0.3 mM. Compounds assayed at 100 μM, except for JNJ (1 μM). Data are mean ± S.E.M. of triplicates of three different oocytes from two different frogs. *<i>P</i> < 0.05, <sup>**</sup><i>p</i> < 0.01, <sup>***</sup><i>p</i> < 0.001, nb = no blockade.</p></div></div></div><div class="NLM_p">Derivatives <b>32–38</b> were prepared and pharmacologically assessed according to the apparent blocking properties of arylsulfonyltheophylline <b>31</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). However, they elicited a very weak blockade of P2X7 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). It seems that the substitution at the phenyl ring in the theophylline subfamily dramatically impairs the favorable interactions of ligands with the binding site of the receptor.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. P2X7 Antagonist Profile of Arylsulfonyltheophyllines <b>32–38</b>, Analogues of <b>31</b>, Assessed by the YO-PRO-1 Dye Uptake Assay in hP2X7-HEK293 Cells and by TEVC Analysis in hP2X7-Expressing <i>X. laevis</i> Oocytes</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0020.gif" alt="" id="GRAPHIC-d7e2335-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">yield<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center" char="±">YO-PRO-1<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (%)</th><th class="colsep0 rowsep0" align="center"><i>I</i><sub>ATP</sub><a class="ref internalNav" href="#t4fn4" aria-label="d">d</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JNJ</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">56 ± 5<sup>***</sup></td><td class="colsep0 rowsep0" align="left">49 ± 4*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">69</td><td class="colsep0 rowsep0" align="char" char="±">52 ± 4<sup>***</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">28 ± 2<sup>**</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">74</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 3</td><td class="colsep0 rowsep0" align="left">9 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 4</td><td class="colsep0 rowsep0" align="left">nb</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 3</td><td class="colsep0 rowsep0" align="left">nb</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 4</td><td class="colsep0 rowsep0" align="left">1 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 7</td><td class="colsep0 rowsep0" align="left">nb</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 5</td><td class="colsep0 rowsep0" align="left">nb</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1</td><td class="colsep0 rowsep0" align="left">nb</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Chemical yields of the reaction in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">hP2X7-HEK293 cells stimulated with BzATP 30 μM. Compounds assayed at 10 μM, except for JNJ-47965567 (JNJ, 1 μM). Data are mean ± S.E.M. of triplicates of three different cell cultures.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>50</sub> of <b>31</b> was calculated, being 10 ± 4 μM.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">hP2X7-expressing oocytes stimulated with ATP 0.3 mM. Compounds assayed at 100 μM, except for JNJ (1 μM). Data are mean ± S.E.M. of triplicates of three different oocytes from two different frogs. *<i>P</i> < 0.05, <sup>**</sup><i>p</i> < 0.01, <sup>***</sup><i>p</i> < 0.001.</p></div></div></div><div class="NLM_p">Cytosolic Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>c</sub>) changes were assessed in the presence of most of the synthesized compounds to corroborate the pharmacological results acquired (Table S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">Supporting Information</a>). The [Ca<sup>2+</sup>]<sub>c</sub> was monitored in hP2X7-expressing HEK293 cells with the fluorescent dye FURA-2 after P2X7 activation by BzATP. Compound <b>6</b> showed the best receptor inhibition (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), in agreement with previous assays. It exerted a concentration-dependent P2X7 blockade with an IC<sub>50</sub> of 13.7 μM. The activity of compound <b>14</b> in the Ca<sup>2+</sup> dynamics assay is in line with the YO-PRO-1 data (Table S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">Supporting Information</a>) but not with those of TEVC (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). This incongruence could be ascribed to the high concentration used in the TEVC experiments, which would be reaching the solubility threshold of <b>14</b>.</div><figure id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Raw data representation of a FURA-2 intracellular Ca<sup>2+</sup> dynamics experiment in the presence of increasing concentrations of compound <b>6</b> (ITH15004). The BzATP (100 μM) control response is shown in black. (B) Dose–response curve of <b>6</b> (ITH15004) in [Ca<sup>2+</sup>]<sub>c</sub> dynamics. Dots represent the mean ± S.E.M. of three triplicates of three different cell cultures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The potency of a selection of the novel antagonists reported in this paper was then evaluated in a well-known model of P2X7-induced inflammation,<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> which is the quantification of IL-1β released by murine peritoneal macrophages (MPMs), after LPS priming, and ATP stimulation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Only compounds <b>6</b> and <b>31</b> reduced IL-1β release in a concentration-dependent fashion (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B, respectively), in agreement with their P2X7-blocking properties found in the previous assays. In addition, these experiments demonstrated that the two most promising hit compounds are also active on <i>Mus musculus</i> P2X7.</div><figure id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. IL-1β release (%) from LPS-primed, ATP-stimulated MPMs in comparison to control (only ATP; black bar). (A) Cells were primed with LPS for 4 h and the compounds were added for 15 min at 1 μM. Cells were then stimulated with ATP for 30 min and the levels of IL-1β in medium were determined by ELISA. (B) Dose–response effect of compound <b>6</b>. (C) Dose–response effect of compound <b>31</b>. JNJ-47965567 (JNJ, tested at 0.1 μM) was used as the reference compound. Data are mean ± S.E.M. of triplicates of three different mice. *<i>P</i> < 0.05, <sup>**</sup><i>p</i> < 0.01, <sup>***</sup><i>p</i> < 0.001 with respect to control (black bar).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All the pharmacological data classified by chemical families have been collected and reorganized in Table S1 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">Supporting Information</a>). Since compound <b>6</b> stood out as the most potent P2X7 antagonist, we evaluated its selectivity in three rat P2X receptor subtypes by TEVC in <i>X. laevis</i> oocytes (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Compound <b>6</b> showed high selectivity for the human P2X7 against rat P2X1, P2X2, and P2X4 receptors. The selectivity is unlikely to be ascribable to species difference since compound <b>6</b> could still inhibit the rat P2X7, apparently with a higher potency (Figure S2, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Evaluation of <b>6</b> by TEVC analysis. (A) Typical TEVC recording of ATP (300 μM, 2 s)-activated hP2X7 currents in the presence (red) and absence (black) of <b>6</b> at 100 μM. (B) Selective inhibition of hP2X7 but not of rP2X1, rP2X2, and rP2X4 by <b>6</b> at 100 μM. Data represent the mean ± S.E.M. of three oocytes from two different frogs, normalized to control current amplitude (marked as a horizontal dashed red line). *<i>P</i> < 0.001 compared to control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To direct the synthesis of the novel compounds toward BBB-permeable ligands, we had initially evaluated their physico-chemical properties, such as lipophilicity, number of hydrogen bonds donors and acceptors, and the molecular weight.</div><div class="NLM_p">Later, we took advantage of the parallel artificial membrane permeability assay (PAMPA), which measures the molecular ability of compounds to cross a lipophilic membrane by passive diffusion. We selected the best inhibitory compounds among all the families. The majority of the tested compounds showed an elevated permeability that should guarantee their distribution within the CNS according to Di et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Curiously, compound <b>16</b> has a lower permeability than the other structural analogues, although it bears an additional chlorine atom with respect to <b>6</b>. Replacement of chlorine with fluorine (<b>17</b>) leads to better permeability but not as much as when a hydrogen occupies the C2 position of the purine core. <i>N</i>-Alkylation and <i>N</i>-sulfonylation of theophylline induced a huge increase of BBB permeability as initially hypothesized (compounds <b>29–31</b>). Indeed, compound <b>31</b> showed a huge permeability rate. These derivatives, together with <b>6</b>, showed better permeability than the P2X7 antagonist JNJ-47965567 (JNJ).</div><figure id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Permeability values of selected new compounds (reddish bars are purine analogues and bluish bars are xanthine analogues), measured by PAMPA experiments. Theophylline (T), piroxicam (P), and verapamil (V) were used as low-, middle-, and high-permeability standards, respectively. Their permeability constants in 10<sup>–6</sup>·cm·s<sup>–1</sup> are 0.12 (T), 2.5 (P), and 16 (V), similar to those described by Di et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The red line at 4·10<sup>–6</sup>·cm·s<sup>–1</sup> marks the theoretical threshold for guaranteeing CNS permeability. Data are presented as the mean ± S.E.M. of triplicates of three individual experiments performed in three different days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>6</b> and <b>31</b> showed an interesting inhibitory activity on P2X7 and high permeability through lipid membranes. In order to predict whether they are able to endure in the CNS, we measured in addition their ability to stimulate the P-glycoprotein (Pgp) ATPase activity as potential substrates of this efflux pump, highly expressed in the BBB and responsible of expulsion of most of xenobiotics from the CNS. We also measured the effect of the well-known Pgp substrate verapamil and the P2X7 blocker JNJ-47965567 (JNJ), all of them tested at 10 μM. The Pgp substrate verapamil<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> up-regulated the ATPase activity of Pgp, measured as the variation in luminescence (R.L.U., <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Surprisingly, JNJ-47965567 strongly activated Pgp ATPase, too, meaning that it is likely to be an important substrate of the efflux pump. This was not reported yet in the literature, although <i>ex vivo</i> radioligand assays in rat brains demonstrated the capacity of JNJ-47965567 to endure in the CNS for at least 2 h,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> with a continuous decrease in concentration during the time.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Unlike JNJ-47965567, compounds <b>6</b> and <b>31</b> did not affect Pgp ATPase activity in statistical significance (<i>P</i> = 0.09 and 0.16, respectively, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Considering that human and rat P-glycoprotein activities are usually comparable,<a onclick="showRef(event, 'ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64">(62−64)</a> our data suggest that our compounds could persist in the CNS similar to or even better than JNJ-47965567 despite its enhancing activity on the Pgp.</div><figure id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compounds <b>6</b> and <b>31</b> on Pgp ATPase activity compared with those of the Pgp substrate verapamil and the P2X7 blocker JNJ-47965567 (JNJ). Data are presented as the mean ± S.E.M. of triplicates of three individual experiments. *<i>P</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Computational Study</h3><div class="NLM_p">Finally, we wanted to predict the binding pose of compound <b>6</b>, being the most potent P2X7 ligand discovered in this work. Most of the antagonists developed so far act in a highly lipophilic allosteric binding pocket located between neighboring subunits in the extracellular domain (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). We ran docking experiments in this binding site using the model described by Bin Dayel and co-workers (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_004.mp4" class="ext-link">Video S1</a>, Supporting Information).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The majority of the poses obtained placed the dichloroaryl core deep into the pocket, interacting in a presumably π–π stacking with phenylalanines 95 (F95), 103 (F103), and 293 (F293), as previously described for Calmidazolium.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Besides, all the antagonists crystallized in the pdP2X7 show their most lipophilic moiety in this vestibule.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The purine core, instead, is placed among tyrosine 295 (Y295) and 298 (Y298) as well as isoleucine 310 (I310) and methionine 105 (M105). The top area of the binding pocket is defined by the presence of phenylalanines 88 (F88) and 108 (F108), which suggests a halogen-aromatic interaction of the chlorine at C6 with these residues (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). This would explain why the compounds with polar groups at this position lose their activity. Moreover, the replacement of the chloride with a bulkier iodine at C6 reduces the potency, considering that the distance between halogen and F88/F108 is about 3.5 Å.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Noteworthily, many residues of this pocket have shown an essential contribution for receptor blockade in mutagenesis experiments.<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9,11)</a> Further investigation is needed to validate this <i>in silico</i> prediction and the potential involvement of these residues in ligand binding.</div><figure id="fig8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0010.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lateral (A) and top (B) views of the ribbon-like representation of P2X7. The predicted binding site of compound <b>6</b> is indicated by the black frame. The residues defining the binding pocket are shown in C. The protein model was provided by Dayel et al.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> with permission (crystal templates PDB IDs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1U">5U1U</a>,<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1V">5U1V</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1W">5U1W</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1X">5U1X</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1Y">5U1Y</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite efforts carried out by Big Pharma and Academia in the last decade, no P2X7 antagonists have reached clinical trials for the treatment of NDDs. Only JNJ-54175446 (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) drew attention for the potential treatment of a CNS disease, that is, major depression.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> Indeed, the few candidates blocking P2X7 studied in clinical trials have focused on peripheral disorders.<a onclick="showRef(event, 'ref49 ref50 ref66'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref66">(49,50,66)</a> This fact evidences the critical role that pharmacokinetics properties play in the selection of a drug candidate for NDDs besides high potency, selectivity, and an interspecies blocking effect. Most of the studies reported in literature to find a proper P2X7 antagonist for NDDs have focused only on pharmacological potency. When a head compound was selected, it commonly lacked an adequate pharmacokinetic profile to penetrate the CNS, forcing medicinal chemists to rethink all the design programs. Such is the case of the adamantine series, which showed a good P2X7 antagonist effect but a mediocre pharmacokinetic profile (for instance, <i>t</i><sub>1/2</sub> = 0.22 h).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p">In this work, we have paid attention to brain penetration, starting from the molecular design. First, we selected well-known scaffolds that are present in drugs with recognized CNS activity. Then, we corroborated that the target compounds fulfilled Lipinski’s rule of five. These preliminary considerations guided us to synthesize and study the pharmacological scope of novel non-nucleotide purine derivatives as potential antagonists of P2X7. The purine scaffold of these novel compounds has been linked to a lipophilic group, that is, a substituted benzene, through a small spacer, namely, a carbonyl, a sulfonyl, and an ethanoyl moiety. All the data obtained through the pharmacological assays revealed that these features fit the structural properties necessary to inhibit the P2X7 but that more investigation is needed to fully define them. The most potent compound of our series, <b>6</b>, belongs to the family that possesses an ethanoyl group as the spacer. Only compound <b>31</b>, which bears a sulfonyl spacer and a theophylline core in its structure, showed a certain blockade. All its derivatives lose their inhibitory potency, and we consider that it might interact differently with P2X7 than purinylethanones. Compound <b>6</b> (2-(6-chloro-9<i>H</i>-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one), which we have named ITH15004, has a chlorine at C6, which can be replaced by other halogens such as iodine. However, this results in a decrease in potency. Substitution of the chlorine with a phenyl, like in <b>14</b>, might be permitted, but adding some polar substituent to increase compound solubility was an issue that led to contradictory data in this work. Also, the insertion of smaller halogens such as fluorine or non-voluminous alkyl chains at this position has not been tested yet as well as the effect of substituents at position 8 of the purine core. Small substituents at C2 are accepted with a decrease in potency, but a reduction in BBB-permeation is expected as happened for compound <b>16</b> in PAMPA. The removal of the chlorine at C2′ at the aryl group of the ethanoyl derivatives seems detrimental to blockade. This might be due to lipophilic interactions with V12 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), one of the residues responsible for P2X7 inhibition with other antagonists.<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9,11)</a></div><div class="NLM_p">Compound <b>6</b> (ITH15004) elicits a concentration-dependent blockade of BzATP-evoked [Ca<sup>2+</sup>]<sub>c</sub> transients in hP2X7-HEK293 cells, with an IC<sub>50</sub> of 13.7 μM, and blocks by 63% at 10 μM the BzATP-induced YO-PRO-1 uptake in the same cellular model. At 100 μM, it also decreases by 47% the ATP (300 μM)-activated currents in <i>Xenopus laevis</i> oocytes expressing hP2X7. It was also shown to be P2X7-selective as it did not block rat P2X1, P2X2, or P2X4 but rat P2X7. Compound <b>6</b> also blocked mouse P2X7, halving the ATP-induced IL-1β release in LPS-primed MPMs, and exhibits a high lipophilic membrane permeability in the PAMPA, suggesting that it can permeate BBB and gain access to the brain.</div><div class="NLM_p">Although the potency of compound <b>6</b> is in the micromolar range, its pharmacodynamic profile and BBB permeability suggest that this non-nucleotide purine derivative could serve as the starting point to design and synthesize new P2X7 blockers with moderate potency. This is relevant in the context of drug side effects and safety, which can be compromised with highly potent compounds that target P2X7 in the low nanomolar range. Moreover, it was observed that the complete removal of P2X7 in a mouse model of multiple sclerosis caused an exacerbation of the disease, probably due to P2X7-dependent changes in lymphocytic homeostasis,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> which could also be affected by a chronic administration of a potent antagonist. Hence, we consider that a modulation of P2X7 by a chronic administration of a mild potent antagonist could potentially lead to better results. This could presume a point in favor for compounds <b>6</b> and <b>31</b> that confirmed the success of our chemical design, aimed at developing a P2X7 antagonist with improved pharmacokinetic profile and high BBB permeability rate. These features represent a fundamental issue that affects the development of agents targeting the CNS, such as the well-known P2X7 antagonist JNJ-47965567, which was never included in a clinical trial. Although it was demonstrated that it reaches the CNS,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> we have observed for the first time that it also increases the Pgp ATPase activity, which could jeopardize its positive effects on CNS disorders. Pursuing this hypothesis is out of the scope of this work, but it underlines the necessity of a deeper focus on the pharmacokinetic parameters of potential new CNS drugs, as we have intended.</div><div class="NLM_p last">In conclusion, in this work, we have designed and synthesized a novel series of non-nucleotide purine derivatives that show a certain effect as the P2X7 antagonist when an ethanoyl moiety is used as a spacer according to our designed model (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Most of them have high lipophilicity, being adequate to target the CNS. ITH15004 was the best antagonist of the series and could be used as a tool for further <i>in vitro</i> and <i>in vivo</i> studies in neurodegenerative diseases where chronic administration and P2X7 modulation might be preferred. Future studies should be addressed to further explore the structure–activity relationships of this scaffold and evaluate other important features such as metabolism and CNS stability, without affecting its gained selectivity and good BBB permeability.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32346" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32346" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedures and Materials</h3><div class="NLM_p last">Solvents and starting materials were used as supplied by Sigma-Aldrich, Merck KGaA (Madrid, Spain), unless otherwise indicated. Anhydrous and inert conditions for specific reactions were obtained using a Schlenk line (vacuum purges and Ar atm), and solvents were dried and freshly distilled over its corresponding adsorbent. Reactions were controlled by TLC (silica gel plates from Sigma-Aldrich, Merck KGaA). Detection was made with a UV light lamp at a wavelength of 254 nm. Flash normal-phase CC (CC) was carried out on an Isolera One (Biotage) using silica gel pre-packaged cartridges unless otherwise indicated. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained in a spectrometer Bruker AVANCE 300 MHz and presented in ppm using the residual signal of the proton of the corresponding deuterated solvent as the internal standard. MS spectra were obtained in an ABSciex QSTAR spectrometer under the high-resolution configuration with electrospray as the ionization source. Melting points were obtained in an apparatus Stuart SMP-10 and are uncorrected. X-ray diffractions for selected compounds were performed using a Bruker D8 Kappa series apparatus, with radiation of graphite monochromated Mo Kα at a λ = 0.71073 Å. Full details of data collection and refinement have been described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">Supporting Information</a>. CIF files have been deposited in the Cambridge Crystallographic Data Centre (CCDC) with the codes CCDC2023914 for the compound <b>19</b> X ray structure and CCDC2023913 for the compound <b>31</b> X ray structure. The tested compounds did not present potential PAINS activity according to screening in <a href="http://zinc15.docking.org/patterns/home" class="extLink">http://zinc15.docking.org/patterns/home</a>.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The purity of the tested compounds was determined by elemental organic analysis on a station LECO-CHNS-932 or by HPLC-UV with a Varian Prostar analytical liquid chromatographer. Values of C, H, and N from elemental analyses data were within 0.4% of the calculated values for each final compound. The purity of all tested compounds is >95%.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Preparation of Synthetic Precursors</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 6-Methoxypurine (<b>3</b>)</h4><div class="NLM_p last">Metallic Na (200 mg, 9.1 mmol) was slowly added to MeOH (10 mL) in a flask under dry and inert conditions. After 30 min of stirring at rt, 6-chloropurine (350 mg, 2.3 mmol) was added. The mixture was heated to 60 °C and stirred for 2 h. The solvent was then evaporated under reduced pressure, and the crude was purified by filtration through a silica plug (gradient of methanol in CH<sub>2</sub>Cl<sub>2</sub>, 0/100 to 20/80). The filtrate was evaporated under vacuum obtaining a white powder that corresponded to <b>3</b> in quantitative yield. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.49 (s, 1H, H2), 8.27 (s, 1H, H8), 4.18 (s, 3H, CH<sub>3</sub>).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 6-Chloro-9-(tetrahydro-2<i>H</i>-pyran-2-yl)purine (<b>7</b>)</h4><div class="NLM_p last">6-chloropurine (1.5 g, 9.7 mmol) and <i>p</i>-toluenesulfonic acid (PTSA, 33 mg, 0.19 mmol) were suspended in dry EtOAc (16 mL) in dry and inert conditions. The mixture was heated up to 50 °C, and 3,4-dihydropyran (DHP, 992 μL, 11 mmol) was added dropwise over 5 min. The reaction was stirred at 50 °C for 64 h. Then, aqueous ammonia was added until pH = 8. The mixture was diluted with EtOAc (10 mL) and water (10 mL). Then, the organic layer was separated, washed again with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the solvent was evaporated under reduced pressure. The crude was purified by column chromatography (gradient of EtOAc in hexane, 18/82 to 100/0), giving compound <b>7</b> as a transparent oil that solidified upon standing (1.45 g, 62%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.75 (s, 1H, H2), 8.34 (s, 1H, H8), 5.80 (dd, <i>J</i> = 10.2 Hz, 2.6 Hz, 1H, CHO), 4.20 (dd, <i>J</i> = 12.8, 3.0 Hz, 1H, CH<sub>2</sub>O), 3.79 (td, <i>J</i> = 11.4, 3.1 Hz, 1H, CH<sub>2</sub>O), 2.28–1.96 and 1.94–1.63 (2m, 6H, (C<i>H</i><sub>2</sub>)<sub>3</sub>CH<sub>2</sub>O).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 6-Phenyl-9-(tetrahydro-2<i>H</i>-pyran-2-yl)purine (<b>8</b>)</h4><div class="NLM_p last">Intermediate <b>7</b> (138 mg, 0.58 mmol) was dissolved in freshly distilled toluene (6 mL) under dry and inert conditions. K<sub>2</sub>CO<sub>3</sub> (116 mg, 0.84 mmol) and phenylboronic acid (102 mg, 0.84 mmol) were added, and the mixture was sonicated for 5 min under Ar bubbling. Tetrakis(triphenylphosphine)palladium(0) (33 mg, 29 μmol) was added, and the reaction was refluxed overnight. After 15 h, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (gradient of EtOAc in hexane, 18/82 to 100/0), obtaining <b>8</b> as a transparent oil that solidified upon standing (117 mg, 72%). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 9.01–8.92 (m, 3H, H2′ and H2), 8.65 (s, 1H, H8), 7.63–7.52 (m, 3H, H3′, H4′), 5.90 (dd, <i>J</i> = 10.9, 2.4 Hz, 1H, CHO), 4.17–4.07 (m, 1H, CH<sub>2</sub>O), 3.82 (td, <i>J</i> = 11.5, 3.1 Hz, 1H, CH<sub>2</sub>O), 2.45–2.23, 2.20–2.08, 1.99–1.81, 1.79–1.60 (4m, 6H, (C<i>H</i><sub>2</sub>)<sub>3</sub>CH<sub>2</sub>O).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 6-Phenylpurine (<b>9</b>)</h4><div class="NLM_p last">Intermediate <b>8</b> (117 mg, 0.42 mmol) was suspended in MeOH (4 mL). Acetyl chloride (8.3 μL, 0.12 mmol) was added, and the reaction was stirred at rt for 72 h. Then, the solvent was evaporated under reduced pressure, and the residue was washed with water (2 × 4 mL) and concentrated under vacuum, giving <b>9</b> as a white powder (69 mg, 84%). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 9.04–8.94 (m, 2H, H2′), 8.93 (s, 1H, H2), 8.56 (s, 1H, H8), 7.65–7.52 (m, 3H, H3′, H4′).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 6-Chloro-2-fluoropurine (<b>10</b>)</h4><div class="NLM_p last">Following the procedure described by Kim et al.,<a onclick="showRef(event, 'ref6900'); return false;" href="javascript:void(0);" class="ref ref6900">(69)</a> 2-amino-6-chloropurine (100 mg, 0.59 mmol) was added to a solution of hydrofluoric acid in pyridine (70%, 1.5 mL) at −50 °C. The reaction was allowed to warm up to −30 °C, and <i>tert</i>-butyl nitrite (105 μL, 0.88 mmol) was added. The reaction was stirred at −30 °C for 20 min; then, it was quenched by adding water and ice (4 mL). The mixture was extracted with CHCl<sub>3</sub> (5 × 3 mL), and the organic fractions were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. After solvent evaporation under vacuum, the residue was purified by column chromatography (gradient of MeOH in DCM, 1/99 to 8/92), giving <b>10</b> as a white solid (43 mg, 42%). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.60 (s, 1H, H8).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Chloro-6-iodopurine (<b>11</b>)</h4><div class="NLM_p last">Following the procedure described by Tobrman et al.,<a onclick="showRef(event, 'ref7000'); return false;" href="javascript:void(0);" class="ref ref7000">(70)</a> 2,6-dichloropurine (100 mg, 0.53 mmol) was suspended in hydriodic acid (1 mL) at 0 °C. After 5 h of stirring, the reaction was diluted with water (2 mL) and NH<sub>4</sub>OH was added until pH = 9. The mixture was decanted overnight, then filtered, washed with water (1 mL), and dried under vacuum, obtaining <b>11</b> as a yellowish powder (123 mg, 83%). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.60 (s, 1H, H8).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-Chloro-1-(2,4-dichlorophenyl)propan-1-one (<b>21</b>)</h4><div class="NLM_p last">AlCl<sub>3</sub> (252 mg, 1.9 mmol) was suspended in 1,3-dichlorobenzene (920 μL, 8 mmol) under dry and inert conditions. 3-Chloropropanoyl chloride (150 μL, 1.6 mmol) was added dropwise to the mixture, which was subsequently heated up to 60 °C and stirred for 4 h. Then, the mixture was cooled down to 0 °C and water (2 mL) was slowly added to quench the reaction. The mixture was extracted with EtOAc (3 × 3 mL), and the combined organic fraction was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The residue was purified by CC (gradient of EtOAc in hexane, 2/98 to 20/80). After solvent evaporation under vacuum, intermediate <b>21</b> was obtained as a clear amber oil (307 mg, 82%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.52 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.46 (d, <i>J</i> = 2.0 Hz, H3′), 7.34 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H, H5′), 3.88 (t, <i>J</i> = 6.6 Hz, 2H, CH<sub>2</sub>CO), 3.76 (t, <i>J</i> = 6.6 Hz, 1H, CH<sub>2</sub>CO), 3.44 (t, <i>J</i> = 6.5 Hz, 1H, CH<sub>2</sub>Cl), 2.87 (t, <i>J</i> = 6.6 Hz, 1H, CH<sub>2</sub>Cl).</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2,6-Dichloropurin-9-ium Chloride</h4><div class="NLM_p last">2,6-Dichloropurine (100 mg, 0.53 mmol) was dissolved in a 3 M solution of HCl in cyclopentylmethylether (1 mL) under dry and inert conditions. The reaction was stirred at rt for 24 h and filtered. The resulting solid was washed with diethyl ether (2 × 1 mL) and dried under vacuum, yielding <b>12</b> as a yellowish powder (84 mg, 70%). <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O): δ 8.64 (s, 1H, H8).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-Chloro-9-methyl-1,9-dihydro-6<i>H</i>-purin-6-one (<b>39</b>)</h4><div class="NLM_p last">Following the procedure described by Tumma et al.,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> 2,6-dichloropurin-9-ium chloride (84 mg, 0.37 mmol) and basic alumina (38 mg) were suspended in MeOH (2 mL). The reaction was heated up to 70 °C and stirred for 24 h. The reaction was interrupted by solvent evaporation under reduced pressure, and the residue was purified by CC (gradient of MeOH in CH<sub>2</sub>Cl<sub>2</sub>, 2/98 to 16/84), yielding <b>39</b> as a white powder (26 mg, 38%). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.32 (s, 1H, H8), 4.15 (s, 3H, CH<sub>3</sub>).</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure for the Synthesis of 2-Chlorobenzamides <b>2</b>, <b>4</b>, and <b>28</b></h3><div class="NLM_p">The 6-substituted purine or theobromine (1 equiv) was dissolved in freshly distilled THF (0.1 M) under dry and inert conditions. DMAP (0.05 equiv) and TEA (2 equiv) were injected, and the mixture was cooled down to 0 °C. 2-Chlorobenzoyl chloride (1 equiv) was added dropwise for 30 min, and the mixture was allowed to reach rt while stirring. After the reaction was completed (4–6 h for purines, 24 h at rt plus 24 h at 70 °C when theobromine was used as the substrate, TLC), the solvent was evaporated under reduced pressure, EtOAc (20 mL) and water (20 mL) were added to the crude, and the two layers were separated. The aqueous layer was extracted again with EtOAc (10 mL), and the combined organic fraction was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. The solvent was concentrated under reduced pressure, and the residue was purified by trituration in hexane several times to yield a pure product.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (6-Chloro-9<i>H</i>-purin-9-yl)(2-Chlorophenyl)methanone (<b>2</b>)</h4><div class="NLM_p last">6-Chloropurine (227 mg, 1.5 mmol), 2-chlorobenzenesulfonyl chloride (186 μL, 1.5 mmol), DMAP (9 mg, 73.7 μmol), and TEA (410 μL, 3 mmol) in THF (15 mL) yielded <b>2</b> as a white powder (337 mg, 78%).<sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 9.02 (s, 1H, H2), 8.61 (s, 1H, H8), 7.88–7.52 (m, 4H, Ar). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub>6</sub>): δ 164.0, 154.1, 152.1, 151.9, 145.5, 134.4, 133.7, 133.6, 132.3, 131.3, 131.0, 128.4. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>12</sub>H<sub>6</sub>Cl<sub>2</sub>N<sub>4</sub>O (<i>m</i>/<i>z</i>) 292.9991 [M + H]<sup>+</sup>; found, 292.9994. mp 133–135 °C. Anal. Calcd for C<sub>12</sub>H<sub>6</sub>Cl<sub>2</sub>N<sub>4</sub>O: C, 49.17; H, 2.06; N, 19.12. Found: C, 48.78; H, 2.40; N, 19.50.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (2-Chlorophenyl)(6-methoxy-9<i>H</i>-purin-9-yl)methanone (<b>4</b>)</h4><div class="NLM_p last">6-Methoxypurine (<b>3</b>, 100 mg, 0.67 mmol), 2-chlorobenzenesulfonyl chloride (84.5 μL, 0.67 mmol), DMAP (4 mg, 33.3 μmol), and TEA (177 μL, 1.3 mmol) in THF (6.5 mL) yielded <b>4</b> as a white powder (102 mg, 53%). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.74 (s, 1H, H2), 8.34 (s, 1H, H8), 7.80–7.52 (m, 4H, Ar), 4.15 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub><i>6</i></sub>): δ 164.6, 162.3, 154.3, 152.3, 145.5, 142.1, 134.4, 134.1, 132.2, 131.1, 130.9, 128.4, 123.4, 54.8. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>9</sub>ClN<sub>4</sub>O<sub>2</sub> (<i>m</i>/<i>z</i>) 311.0306 [M + Na]<sup>+</sup>; found, 311.0302 [M + Na]<sup>+</sup>. mp 169–171 °C. Anal. Calcd for C<sub>13</sub>H<sub>9</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 54.09; H, 3.14; N, 19.41. Found: C, 54.00; H, 3.06; N, 18.95.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(2-Chlorobenzoyl)-3,7-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>28</b>)</h4><div class="NLM_p last">Theobromine (3,7-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione, 200 mg, 1.1 mmol), 2-chlorobenzoyl chloride (141 μL, 1.1 mmol), DMAP (7 mg, 57.3 μmol), and TEA (309 μL, 2.2 mmol) in THF (11 mL) yielded <b>28</b> as a white powder (196 mg, 55%). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.01 (d, <i>J</i> = 7.9 Hz, 1H, H6′), 7.95 (s, 1H, H8), 7.70–7.60 (m, 2H, Ar), 7.48 (t, <i>J</i> = 7.4 Hz, 1H, Ar), 3.97 (s, 1H, N7CH<sub>3</sub>), 3.47 (s, 1H, N3CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub><i>6</i></sub>): δ 167.8, 154.6, 151.2, 150.8, 144.5, 135.5, 134.9, 133.6, 132.6, 132.6, 128.4, 108.1, 33.8. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>14</sub>H<sub>11</sub>ClN<sub>4</sub>O<sub>3</sub> (<i>m/z</i>) 341.0411 [M + Na]<sup>+</sup>; found, 341.0398. mp 182–183 °C. Anal. Calcd for C<sub>14</sub>H<sub>11</sub>ClN<sub>4</sub>O<sub>3</sub>: C, 52.76; H, 3.48; N, 17.58. Found: C, 52.66; H, 3.38; N, 17.56.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedure for the Preparation of Purinyl/Xanthinyl-2,4-dichlorophenylethanones/propanones <b>6</b>, <b>12–18</b>, <b>20</b>, <b>22</b>, <b>29</b>, and <b>30</b></h3><div class="NLM_p">Method A. The purine derivative used as the starting material (1 equiv) was dissolved in dry DMF (0.05 M) under dry and inert conditions and cooled down to 0 °C. NaH (60% dispersion in mineral oil, 1.2 equiv) was added, and the resulting mixture was stirred at rt for 30 min.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(71)</a> The corresponding 2-chloro-1-arylethan-1-one (1.5 equiv), dissolved in dry DMF (1 mL), was added dropwise at 0 °C over 45 min. The reaction was allowed to reach rt. After completion (15–40 h, TLC), the solvent was evaporated under vacuum and the residue was dissolved in EtOAc (30 mL) and water (20 mL). The layers were decanted, and the aqueous phase was extracted with EtOAc (2 × 10 mL). The combined organic fraction was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the solvent was evaporated under reduced pressure. The crude was purified by CC or trituration. Method B. The purine or xanthine derivative used as the starting material (1 equiv), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (1.2 equiv), Bu<sub>4</sub>NHSO<sub>4</sub> (0.05 equiv), and K<sub>2</sub>CO<sub>3</sub> (1 equiv) were dissolved in dry DMF (0.2 M) under dry and inert conditions. The mixture was then heated up to 150 °C in a sealed tube. After completion (1–6 h, TLC), the solvent was evaporated under vacuum, and the residue was retrieved with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and washed with water (2 × 4 mL). The organic fraction was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The crude was eventually purified by CC.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-(6-Chloro-9<i>H</i>-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one (<b>6</b>)</h4><div class="NLM_p last">Following method A, 6-chloropurine (100 mg, 0.65 mmol), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (224 mg, 0.97 mmol), and NaH (60% dispersion in mineral oil, 31 mg, 776 μmol) in dry DMF (11 mL) yielded <b>6</b> as a white powder (50 mg, 45%) after purification by CC (gradient of EtOAc in hexane, 16/84 to 100/0). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.71 (s, 1H, H2), 8.55 (s, 1H, H8), 8.03 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.73 (d, <i>J</i> = 2.0 Hz, 1H, H3′), 7.63 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H, H5′), 6.01 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone<i>-d</i><sub><i>6</i></sub>): δ 193.4, 153.6, 152.8, 151.0, 148.3, 139.4, 134.9, 133.9, 132.7, 132.2, 131.8, 128.8, 53.2. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>7</sub>Cl<sub>3</sub>N<sub>4</sub>O (<i>m/z</i>) 340.9758 [M + H]<sup>+</sup>; found, 340.9759. mp 166–168 °C. Anal. Calcd for C<sub>13</sub>H<sub>7</sub>Cl<sub>3</sub>N<sub>4</sub>O: C, 45.71; H, 2.07; N, 16.40. Found: C, 45.69; H, 1.89; N, 16.50.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-(6-Chloro-9<i>H</i>-purin-9-yl)-1-(4-chlorophenyl)ethan-1-one (<b>12</b>)</h4><div class="NLM_p last">Following method A, 6-chloropurine (100 mg, 0.65 mmol), 2-chloro-1-(4-chlorophenyl)ethan-1-one (183 mg, 0.97 mmol), and NaH (60% dispersion in mineral oil, 31 mg, 796 μmol) in dry DMF (10 mL) yielded <b>12</b> as a white powder (95 mg, 48%) after purification by CC (gradient of acetone in hexane, 10/90 to 80/20). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.69 (s, 1H, H2), 8.53 (s, 1H, H8), 8.20 (d, <i>J</i> = 8.6 Hz, 2H, H2′), 7.68 (d, <i>J</i> = 8.6 Hz, 2H, H3′), 6.12 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub>6</sub>): δ 191.6, 153.8, 152.7, 150.9, 148.5, 141.0, 134.0, 132.2, 131.0, 130.3, 50.8. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>4</sub>O (<i>m/z</i>) 307.0147 [M + H]<sup>+</sup>; found, 307.0161. mp 217 °C (dec.). Anal. Calcd for C<sub>13</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>4</sub>O: C, 50.84; H, 2.63; N, 18.24. Found: C, 50.77; H, 2.78; N, 18.26.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-(6-Chloro-9<i>H</i>-purin-9-yl)-1-(4-fluorophenyl)ethan-1-one (<b>13</b>)</h4><div class="NLM_p last">Following method A, 6-chloropurine (100 mg, 0.65 mmol), 2-chloro-1-(4-fluorophenyl)ethan-1-one (167 mg, 0.97 mmol), and NaH (60% dispersion in mineral oil, 31 mg, 796 μmol) in dry DMF (10 mL) yielded <b>13</b> as a white powder (156 mg, 83%) after purification by CC (gradient of EtOAc in hexane, 12/88 to 100/0). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.69 (s, 1H, H2), 8.54 (s, 1H, H8), 8.27 (ddd, <i>J</i> = 8.9, 4.6, 1.7 Hz, 2H, H2′), 7.46–7.34 (m, 2H, H3′), 6.12 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone<i>-d</i><sub><i>6</i></sub>): δ 191.0, 167.1 (d, <i>J</i> = 253.3 Hz), 153.6, 152.5, 150.8, 148.4, 132.1 (d, <i>J</i> = 9.8 Hz), 131.9, 131.9, 116.9 (d, <i>J</i> = 21.9 Hz), 50.6. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>8</sub>ClFN<sub>4</sub>O (<i>m/z</i>) 291.0443 [M + H]<sup>+</sup>; found, 291.0454. mp 162–165 °C. Anal. Calcd for C<sub>13</sub>H<sub>8</sub>ClFN<sub>4</sub>O: C, 53.72; H, 2.77; N, 19.27. Found: C, 53.86; H, 2.93; N, 19.37.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-(2,4-Dichlorophenyl)-2-(6-phenyl-9<i>H</i>-purin-9-yl)ethan-1-one (<b>14</b>)</h4><div class="NLM_p last">Following method A, 6-phenylpurine (<b>9</b>, 55 mg, 0.28 mmol), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>, 97 mg, 0.42 mmol), and NaH (60% dispersion in mineral oil, 13 mg, 336 μmol) in dry DMF (7 mL) yielded <b>14</b> as a yellowish powder (55 mg, 41%) after purification by CC (gradient of EtOAc in hexane, 15/85 to 100/0). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 9.04–8.98 (m, 2H, C6Ar), 8.94 (s, 1H, H2), 8.56 (s, 1H, H8), 8.04 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.73 (d, <i>J</i> = 2.0 Hz, 1H, H3′), 7.68–7.51 (m, 4H, C6Ar, H5′), 5.99 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone<i>-d</i><sub><i>6</i></sub>): δ 194.0, 154.4, 154.1, 153.1, 147.3, 139.3, 137.0, 135.2, 133.8, 132.6, 131.9, 131.7, 131.5, 130.8, 129.4, 128.8, 52.7. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>19</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O (<i>m/z</i>) 383.0460 [M + H]<sup>+</sup>; found, 383.0465. mp 160–162 °C. Anal. Calcd for C<sub>19</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O: C, 59.55; H, 3.16; N, 14.62. Found: C, 59.58; H, 3.43; N, 14.48.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 1-(2,4-Dichlorophenyl)-2-(6-methoxy-9<i>H</i>-purin-9-yl)ethan-1-one (<b>15</b>)</h4><div class="NLM_p last">Following method A, 6-methoxypurine (<b>3</b>, 100 mg, 0.67 mmol), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>, 223 mg, 1.0 mmol), and NaH (60% dispersion in mineral oil, 32 mg, 799 μmol) in dry DMF (11 mL) yielded <b>15</b> as a yellowish powder (53 mg, 24%) after purification by CC (gradient of acetone in hexane, 12/88 to 80/20). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.47 (s, 1H, H2), 8.25 (s, 1H, H8), 7.99 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.71 (d, <i>J</i> = 2.1 Hz, 1H, H3′), 7.61 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H, H5′), 5.89 (s, 2H, CH<sub>2</sub>), 4.15 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone<i>-d</i><sub><i>6</i></sub>): δ 194.0, 161.9, 153.7, 152.7, 144.7, 139.1, 135.2, 133.6, 132.5, 131.6, 128.7, 121.8, 54.4, 52.8. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> (<i>m/z</i>) 337.0253 [M + H]<sup>+</sup>; found, 337.0256. mp 158 °C (dec). Anal. Calcd for C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>: C, 49.87; H, 2.99; N, 16.62. Found: C, 50.01; H, 3.11; N, 16.38.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(2,6-Dichloro-9<i>H</i>-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one (<b>16</b>)</h4><div class="NLM_p last">Following method A, 2,6-dichloropurine (100 mg, 0.53 mmol), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>, 183 mg, 0.79 mmol), and NaH (60% dispersion in mineral oil, 25 mg, 635 μmol) in dry DMF (18 mL) yielded <b>16</b> as a yellowish powder (65 mg, 40%) after purification by CC (gradient of EtOAc in hexane, 12/88 to 100/0) and trituration in diethyl ether. <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.57 (s, 1H, H8), 8.05 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.73 (d, <i>J</i> = 2.0 Hz, 1H, H3′), 7.63 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H, H3′), 6.01 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone<i>-d</i><sub><i>6</i></sub>): δ 192.9, 155.2, 153.1, 151.7, 149.3, 139.6, 134.6, 134.1, 132.9, 131.9, 131.6, 128.9, 53.4. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>6</sub>Cl<sub>4</sub>N<sub>4</sub>O (<i>m/z</i>) 374.9368 [M + H]<sup>+</sup>; found, 374.9374. Mp 136–138 °C. Anal. calcd for C<sub>13</sub>H<sub>6</sub>Cl<sub>4</sub>N<sub>4</sub>O: C, 41.53; H, 1.61; N, 14.90. Found: C, 41.78; H, 1.93; N, 14.81.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-(6-Chloro-2-fluoro-9<i>H</i>-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one (<b>17</b>)</h4><div class="NLM_p last">Following method A, 6-chloro-2-fluoropurine (<b>10</b>, 42 mg, 0.24 mmol), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>, 82 mg, 0.36 mmol), and NaH (60% dispersion in mineral oil, 15 mg, 365 μmol) in dry DMF (4 mL) yielded <b>17</b> as a yellow oil (34 mg, 39%) after purification by CC (gradient of acetone in hexane, 6/94 to 50/50). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.55 (s, 1H, H8), 8.04 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.73 (d, <i>J</i> = 2.0 Hz, 1H, H3′), 7.63 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H, H5′), 5.98 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub>6</sub>): δ 191.9, 157.9 (d, <i>J</i> = 214.9 Hz), 154.7 (d, <i>J</i> = 17.3 Hz), 151.4 (d, <i>J</i> = 18.1 Hz), 148.2 (d, <i>J</i> = 3.0 Hz), 138.5, 133.6, 133.0, 131.8, 130.8, 130.1 (d, <i>J</i> = 6.8 Hz), 127.8, 52.3. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>6</sub>Cl<sub>3</sub>FN<sub>4</sub>O (<i>m/z</i>) 358.9663 [M + H]<sup>+</sup>; found, 358.9657. mp 134 °C. HPLC-UV (λ = 260 nm): purity 98%.</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-(2-Chloro-6-iodo-9<i>H</i>-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one (<b>18</b>)</h4><div class="NLM_p last">Following method A, 2-chloro-6-iodopurine (<b>11</b>, 69 mg, 0.25 mmol), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>, 85 mg, 0.37 mmol), and NaH (60% dispersion in mineral oil, 15 mg, 369 μmol) in dry DMF (4 mL) yielded <b>18</b> as a yellowish powder (30 mg, 28%) after purification by trituration in diethyl ether. <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.55 (s, 1H, H8), 8.04 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.73 (d, <i>J</i> = 2.1 Hz, 1H, H3′), 7.63 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H, H5′), 5.97 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone<i>-d</i><sub><i>6</i></sub>): δ 191.9, 151.7, 150.1, 147.5, 138.5, 138.0, 133.5, 133.0, 131.8, 130.8, 127.8, 121.7, 52.2. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>6</sub>Cl<sub>3</sub>IN<sub>4</sub>O (<i>m/z</i>) 466.8724 [M + H]<sup>+</sup>; found, 466.8721. mp 214–215 °C (dec). HPLC-UV (λ = 284 nm): purity 100%.</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-(2-Amino-6-chloro-9<i>H</i>-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one (<b>20</b>)</h4><div class="NLM_p last">Following method B, 6-chloropurin-2-amine (100 mg, 0.53 mmol), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>, 145 mg, 0.65 mmol), Bu<sub>4</sub>NHSO<sub>4</sub> (10 mg, 29 μmol), and K<sub>2</sub>CO<sub>3</sub> (81 mg, 0.59 mmol) in dry DMF (3 mL) yielded <b>20</b> as a brown powder (15 mg, 10%) after 30 h of reaction time at 80 °C and purification by CC (gradient of MeOH in CH<sub>2</sub>Cl<sub>2</sub>, 1/99 to 8/92) and trituration in cold EtOAc. <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.03 (s, 1H, H8), 7.96 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.70 (d, <i>J</i> = 2.0 Hz, 1H, H3′), 7.60 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H, H5′), 6.17 (br, 2H, NH<sub>2</sub>), 5.69 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone<i>-d</i><sub><i>6</i></sub>): δ 194.1, 161.1, 155.6, 151.3, 144.3, 139.2, 135.3, 133.7, 132.6, 131.6, 128.8, 125.1, 52.6. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>8</sub>Cl<sub>3</sub>N<sub>5</sub>O (<i>m/z</i>) 355.9867 [M + H]<sup>+</sup>; found, 355.9873. mp 208–209 °C (dec). HPLC-UV (λ = 306 nm), purity 99%.</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-(6-Chloro-9<i>H</i>-purin-9-yl)-1-(2,4-dichlorophenyl)propan-1-one (<b>22</b>)</h4><div class="NLM_p last">Following method A, 6-chloropurine (75 mg, 0.49 mmol), intermediate <b>21</b> (174 mg, 0.73 mmol), and NaH (60% dispersion in mineral oil, 23 mg, 586 μmol) in dry DMF (10 mL) yielded <b>22</b> as a white powder (40 mg, 23%) after purification by CC (gradient of EtOAc in hexane, 20/80 to 100/0). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.70 (s, 1H, H2), 8.55 (s, 1H, H8), 7.72 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.58 (d, <i>J</i> = 2.1 Hz, 1H, H3′), 7.48 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H, H5′), 4.80 (t, <i>J</i> = 6.3 Hz, 2H, NCH<sub>2</sub>), 3.81 (t, <i>J</i> = 6.3 Hz, 2H, CH<sub>2</sub>CO). <sup>13</sup>C NMR (75.4 MHz, acetone<i>-d</i><sub><i>6</i></sub>): δ 198.3, 152.3, 151.4, 149.7, 147.2, 137.2, 136.6, 131.9, 131.5, 130.9, 130.3, 127.5, 41.3, 39.1. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>14</sub>H<sub>9</sub>Cl<sub>3</sub>N<sub>4</sub>O (<i>m/z</i>) 354.9914 [M + H]<sup>+</sup>; found, 354.9919. mp 140 °C (dec). HPLC-UV (λ = 256 nm), purity 99%.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 1-[2-(2,4-Dichlorophenyl)-2-oxoethyl]-3,7-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>29</b>)</h4><div class="NLM_p last">Following method B, theobromine (3,7-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione, 70 mg, 0.39 mmol), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>, 104 mg, 0.47 mmol), Bu<sub>4</sub>NHSO<sub>4</sub> (7 mg, 19 μmol), and K<sub>2</sub>CO<sub>3</sub> (54 mg, 0.39 mmol) in dry DMF (2 mL) yielded <b>29</b> as a brown powder (36 mg, 25%) after purification by CC (gradient of MeOH in EtOAc, 0/100 to 4/96) and trituration in diethyl ether. <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.89 (s, 1H, H8), 7.86 (d, <i>J</i> = 8.3 Hz, 2H, H6′), 7.67 (d, <i>J</i> = 2.0 Hz, 1H, H3′), 7.58 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H, H5′), 5.28 (s, 2H, CH<sub>2</sub>), 3.99 (s, 3H, N7CH<sub>3</sub>), 3.51 (s, 3H, N3CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub>6</sub>): δ 195.4, 155.3 152.0, 150.2, 143.9, 138.4, 136.6, 133.1, 132.1, 131.3, 128.6, 50.2, 33.8. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>15</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub> (<i>m/z</i>) 367.0359 [M + H]<sup>+</sup>; found, 367.0367. mp 196 °C (dec.). Anal. Calcd for C<sub>15</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub>: C, 49.07; H, 3.29; N, 15.26. Found: C, 49.05; H, 3.39; N, 15.19.</div></div><div id="sec4_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 9-[2-(2,4-Dichlorophenyl)-2-oxoethyl]-1,3-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>30</b>)</h4><div class="NLM_p last">Following method B, theophylline (1,3-dimethyl-3,9-dihydro-1<i>H</i>-purine-2,6-dione, 70 mg, 0.39 mmol), 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>, 104 mg, 0.47 mmol), Bu<sub>4</sub>NHSO<sub>4</sub> (7 mg, 19 μmol), and K<sub>2</sub>CO<sub>3</sub> (54 mg, 0.39 mmol) in dry DMF (2 mL) yielded <b>30</b> as a white powder (65 mg, 46%) after purification by CC (gradient of MeOH in EtOAc, 1/99 to 10/90) and trituration in diethyl ether. <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.04–7.94 (m, 2H, H8, H6′), 7.69 (d, <i>J</i> = 2.1 Hz, 1H, H3′), 7.62 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H, H5′), 5.87 (s, 2H, CH<sub>2</sub>), 3.53 (s, 3H, N3CH<sub>3</sub>), 3.26 (s, 3H, N1CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub>6</sub>): δ 194.1, 156.2, 152.4, 149.7, 144.0, 139.1, 135.6, 133.5, 132.7, 131.5, 128.8, 107.7, 55.8, 28.0. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>15</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub> (<i>m/z</i>) 367.0359 [M + H]<sup>+</sup>; found, 367.0368. mp 198–199 °C. HPLC-UV (λ = 260 nm), purity 97%.</div></div><div id="sec4_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-[2-Chloro-6-(methylamino)-9<i>H</i>-purin-9-yl]-1-(2,4-dichlorophenyl)ethan-1-one (<b>19</b>)</h4><div class="NLM_p last">2-Chloro-<i>N</i>-methylpurin-6-amine (60 mg, 0.33 mmol), Bu<sub>4</sub>NHSO<sub>4</sub> (5.5 mg, 16 μmol), and KOH (18 mg, 0.33 mmol) were suspended in dry DMF (2 mL) under dry and inert conditions. 2-Chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>, 80 mg, 0.36 mmol) was dissolved in dry DMF (0.5 mL) and added dropwise to the reaction at 0 °C over 45 min. The reaction was stirred at rt for 26 h and then it was diluted with cold water (6 mL) and EtOAc (7 mL). The mixture was stirred for 30 min after which the two layers were separated. The aqueous fraction was extracted with EtOAc (3 × 3 mL), and the combined organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. The crude was purified by CC (gradient of EtOAc in hexane, 18/82 to 100/0). After solvent evaporation, the solid was triturated with diethyl ether, furnishing <b>19</b> as a white solid (27 mg, 22%). The compound was recrystallized in EtOAc by slow evaporation to obtain crystals for X-ray diffraction (experimental details in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">Supporting Information</a>). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.02 (s, 1H, H8), 7.98 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 7.70 (d, <i>J</i> = 2.1 Hz, 1H, H3′), 7.61 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H, H5′), 7.24 (br s, 1H, NH), 5.75 (s, 2H, CH<sub>2</sub>), 3.12 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone<i>-d</i><sub><i>6</i></sub>): δ 193.9, 157.1, 154.3, 142.4, 139.1, 135.1, 133.6, 132.5, 131.5, 128.6, 119.2, 52.5, 27.7. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>14</sub>H<sub>10</sub>Cl<sub>3</sub>N<sub>5</sub>O (<i>m/z</i>) 370.0023 [M + H]<sup>+</sup>; found, 370.0041. mp 213 °C (dec). Anal. Calcd for C<sub>14</sub>H<sub>10</sub>Cl<sub>3</sub>N<sub>5</sub>O·H<sub>2</sub>O: C, 43.27; H, 3.11; N, 18.02. Found: C, 43.33; H, 2.80; N, 17.99.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> General Procedure for the Synthesis of Sulfonamides <b>23–27</b> and <b>31–38</b></h3><div class="NLM_p">Method A. The purine derivative (1 equiv) was dissolved in freshly distilled CH<sub>2</sub>Cl<sub>2</sub> and THF (1:1, 0.1 M) under dry and inert conditions. DMAP (0.2 equiv) and TEA (2 equiv) were added, and the mixture was cooled down to 0 °C. 2-Chlorobenzenesulfonyl chloride (2 equiv) was added dropwise for 30 min. The mixture was stirred at rt, and after completion (2–4 h, TLC), the solvent was removed under reduced pressure. The crude was dissolved in EtOAc (30 mL) and water (20 mL), and the two layers were separated. The aqueous layer was extracted again with EtOAc (10 mL), and the combined organic fraction was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. The solvent was evaporated under reduced pressure and the residue purified by CC or trituration to yield the pure product. Method B. Theophylline (1,3-dimethyl-3,9-dihydro-1<i>H</i>-purine-2,6-dione, 1 equiv) was suspended in freshly distilled THF (0.05 M) in dry and inert conditions. The mixture was cooled down to 0 °C and NaH (60% dispersion in mineral oil, 1.2 equiv) was added, allowing the reaction to stir at rt for 30 min. The corresponding arylsulfonyl chloride derivative (1.2 equiv) was dissolved in dry THF (1 mL) and added to the reaction dropwise at 0 °C for 15 min. The reaction was stirred at rt, and after completion (4–48 h, TLC), the solvent was evaporated under reduced pressure. The residue was dissolved in EtOAc (30 mL) and water (30 mL). The layers were separated, and the aqueous layer was extracted once again with EtOAc (20 mL). The combined organic fraction was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. The solvent was evaporated under reduced pressure, and the residue was purified by CC to yield the pure product.</div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 6-Chloro-9-[(2-chlorophenyl)sulfonyl]-9<i>H</i>-Purine (<b>23</b>)</h4><div class="NLM_p last">Following method A, 6-chloropurine (100 mg, 0.65 mmol), 2-chlorobenzenesulfonyl chloride (176 μL, 1.3 mmol), DMAP (16 mg, 129 μmol), and TEA (180 μL, 1.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/THF (6.5 mL) yielded <b>23</b> as a white powder (165 mg, 77%) after trituration with cold MeOH. <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 9.05 (s, 1H, H2), 8.70 (s, 1H, H8), 8.60 (dd, <i>J</i> = 7.9, 1.9 Hz, 1H, H6′), 7.93–7.74 (m, 2H, H4′, H5′), 7.67 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H, H3′). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub>6</sub>): δ 154.2, 152.1, 151.4, 145.5, 138.3, 134.6, 134.5, 133.4, 133.1, 129.1. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>11</sub>H<sub>6</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S (<i>m/z</i>) 328.9661 [M + H]<sup>+</sup>; found, 328.9663. mp 172 °C (dec). Anal. Calcd for C<sub>11</sub>H<sub>6</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S: C, 40.14; H, 1.84; N, 17.02; S, 9.74. Found: C, 40.12; H, 2.06; N, 16.66; S, 9.75.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2,6-Dichloro-9-[(2-chlorophenyl)sulfonyl]-9<i>H</i>-purine (<b>24</b>)</h4><div class="NLM_p last">Following method A, 2,6-dichloropurine (100 mg, 0.53 mmol), 2-chlorobenzenesulfonyl chloride (144 μL, 1.1 mmol), DMAP (13 mg, 106 μmol), and TEA (147 μL, 1.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/THF (5.3 mL) yielded <b>24</b> as a white powder (90 mg, 47%) after purification by CC (gradient of EtOAc in hexane, 0/100 to 50/50). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 9.07 (s, 1H, H8), 8.58 (dd, <i>J</i> = 8.0, 1.9 Hz, 1H, H6′), 7.95–7.75 (m, 2H, H4′, H5′), 7.70 (dd, <i>J</i> = 7.9, 1.2 Hz, 1H, H3′). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub><i>6</i></sub>): δ 154.7, 153.0, 152.8, 146.2, 138.6, 134.8, 134.4, 133.7, 133.6, 132.9, 129.3. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>11</sub>H<sub>5</sub>Cl<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S (<i>m/z</i>) 362.9271 [M + H]<sup>+</sup>; found, 362.9285. Mp 156 °C (dec). Anal. Calcd for C<sub>11</sub>H<sub>5</sub>Cl<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S: C, 36.34; H, 1.39; N, 15.41; S, 8.82. Found: C, 36.06; H, 1.58; N, 15.20; S, 9.14.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 9-[(2-Chlorophenyl)sulfonyl]-6-methoxy-9<i>H</i>-purine (<b>25</b>)</h4><div class="NLM_p last">Following method A, 6-methoxypurine (<b>3</b>, 90 mg, 0.60 mmol), 2-chlorobenzenesulfonyl chloride (163 μL, 1.2 mmol), DMAP (15 mg, 120 μmol), and TEA (167 μL, 1.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/THF (6 mL) yielded <b>25</b> as a white powder (72 mg, 37%) after purification by trituration with cold MeOH. <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.76 (s, 1H, H2), 8.57 (dd, <i>J</i> = 7.9, 1.9 Hz, 1H, H6′), 8.43 (s, 1H, H8), 7.85–7.77 (m, 2H, H4′, H5′), 7.66 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H, H3′), 4.13 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub><i>6</i></sub>): δ 162.2, 154.5, 151.5, 142.3, 138.0, 134.9, 134.6, 133.2, 133.1, 129.0, 122.6, 54.9. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>12</sub>H<sub>9</sub>ClN<sub>4</sub>O<sub>3</sub>S (<i>m/z</i>) 346.9976 [M + Na]<sup>+</sup>; found, 346.9980. mp 158 °C (dec). Anal. Calcd for C<sub>12</sub>H<sub>9</sub>ClN<sub>4</sub>O<sub>3</sub>S: C, 44.38; H, 2.79; N, 17.25; S, 9.87. Found: C, 44.48; H, 2.99; N, 16.94; S, 9.93.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 6-Chloro-9-[(2-chlorophenyl)sulfonyl]-9<i>H</i>-purin-2-amine (<b>26</b>)</h4><div class="NLM_p last">Following method A, 6-chloropurin-2-amine (100 mg, 0.59 mmol), 2-chlorobenzenesulfonyl chloride (161 μL, 1.2 mmol), DMAP (14 mg, 118 μmol), and TEA (164 μL, 1.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/THF (6 mL) yielded <b>26</b> as a white powder (102 mg, 50%) after purification by CC (gradient of EtOAc in hexane, 12/88 to 85/15). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.51–8.42 (m, 2H, H8, H6′), 7.84 (td, <i>J</i> = 7.7, 1.7 Hz, 1H, H5′), 7.77–7.62 (m, 2H, H3′, H4′), 6.52 (br s, 2H, NH<sub>2</sub>). <sup>13</sup>C NMR (75.4 MHz, CDCl<sub>3</sub>): δ 161.8, 153.5, 152.5, 140.8, 137.9, 135.0, 134.7, 133.3, 133.2, 128.9, 125.1. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>11</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S (<i>m/z</i>) 343.9770 [M + H]<sup>+</sup> and 365.9589 [M + Na]<sup>+</sup>; found, 343.9765 and 365.9573. mp 200 °C (dec). Anal. Calcd for C<sub>11</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S: C, 38.39; H, 2.05; N, 20.35; S, 9.32. Found: C, 38.66; H, 2.37; N, 19.91; S, 9.23.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-Chloro-9-[(2-chlorophenyl)sulfonyl]-<i>N</i>-methyl-9<i>H</i>-purin-6-amine (<b>27</b>)</h4><div class="NLM_p last">Following method A, 2-chloro-<i>N</i>-methylpurin-6-amine (100 mg, 0.54 mmol), 2-chlorobenzenesulfonyl chloride (148 μL, 1.1 mmol), DMAP (13 mg, 118 μmol), and TEA (152 μL, 1.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/THF (6 mL) yielded <b>27</b> as a white powder (94 mg, 48%) after purification by CC (gradient of EtOAc in hexane, 12/88 to 100/0). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.55–8.46 (m, 2H, H8, H6′), 7.91–7.71 (m, 2H, H5′, H4′), 7.67 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H, H3′), 7.55 (br s, 1H, NH), 3.07 (d, <i>J</i> = 4.4 Hz, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, DMSO-<i>d</i><sub>6</sub>): δ 155.4, 154.9, 147.9, 139.6, 137.4, 133.2, 133.1, 132.4, 131.3, 126.2, 118.4, 27.2. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>12</sub>H<sub>9</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S (<i>m/z</i>) 357.9926 [M + H]<sup>+</sup>; found, 357.9932. mp 235 °C (dec). HPLC-UV (λ = 260 nm), purity 96%.</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 7-[(2-Chlorophenyl)sulfonyl]-1,3-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>31</b>)</h4><div class="NLM_p last">Following method B, theophylline (60 mg, 0.33 mmol), 2-chlorobenzenesulfonyl chloride (55 μL, 0.40 mmol), and NaH (60% dispersion in mineral oil, 16 mg, 0.4 mmol) in THF (5.5 mL) yielded <b>31</b> as a white powder (82 mg, 69%) after purification by CC (gradient of EtOAc in hexane, 12/88 to 100/0). The compound was recrystallized in CH<sub>2</sub>Cl<sub>2</sub> and acetone by slow evaporation to obtain crystals for X-ray diffraction (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">Supporting Information</a>). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.70 (s, 1H, H8), 8.60 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H, H6′), 7.88–7.84, 7.76–7.66 (2m, 3H, Ar), 3.52 (s, 3H, N3CH<sub>3</sub>), 3.16 (s, 3H, N1CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, CDCl<sub>3</sub>): δ 153.6, 152.0, 151.8, 151.3, 145.4, 138.0, 136.1, 134.6, 133.3, 132.8, 128.6, 28.5. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>11</sub>ClN<sub>4</sub>O<sub>4</sub>S (<i>m/z</i>) 377.0081 [M + Na]<sup>+</sup>; found, 377.0070. mp 212 °C (dec). HPLC-UV (λ = 287 nm), purity 100%.</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 7-[(2,4-Dichlorophenyl)sulfonyl]-1,3-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>32</b>)</h4><div class="NLM_p last">Following method B, theophylline (100 mg, 0.55 mmol), 2,4-dichlorobenzenesulfonyl chloride (163 mg, 0.67 mmol), and NaH (60% dispersion in mineral oil, 27 mg, 0.67 mmol) in THF (11 mL) yielded <b>32</b> as a white powder (160 mg, 74%) after purification by CC (gradient of EtOAc in hexane, 12/88 to 95/5). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.59 (d, <i>J</i> = 9.2 Hz, 1H, H6′), 8.43 (s, 1H, H8), 7.61–7.47 (m, 2H, H3′, H5′), 3.60 (s, 3H, N3CH<sub>3</sub>), 3.30 (s, 3H, N1CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, CDCl<sub>3</sub>): δ 152.9, 151.2, 150.6, 144.0, 142.9, 136.2, 133.9, 132.0, 131.7, 127.9, 105.7, 30.3, 28.6. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>4</sub>S (<i>m/z</i>) 410.9692 [M + Na]<sup>+</sup>; found, 410.9687. mp 206–208 °C. Anal. Calcd for C<sub>13</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>4</sub>S: C, 40.12; H, 2.59; N, 14.40; S, 8.24. Found: C, 40.19; H, 2.71; N, 14.22; S, 8.25.</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 7-[(2-Chloro-4-fluorophenyl)sulfonyl]-1,3-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>33</b>)</h4><div class="NLM_p last">Following method B, theophylline (100 mg, 0.55 mmol), 2-chloro-4-fluorobenzenesulfonyl chloride (97 μL, 0.67 mmol), and NaH (60% dispersion in mineral oil, 27 mg, 0.67 mmol) in THF (11 mL) yielded <b>33</b> as a white powder (112 mg, 54%) after purification by CC (gradient of EtOAc in hexane, 12/88 to 100/0). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.69 (dd, <i>J</i> = 9.0, 5.7 Hz, 1H, H6′), 8.43 (s, 1H, H8), 7.34–7.20 (m, 2H, H3′, H5′), 3.60 (s, 3H, N3CH<sub>3</sub>), 3.29 (s, 3H, N1CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, CDCl<sub>3</sub>): δ 166,4 (d<i>, J</i> = 263.9 Hz), 153.0, 151.3, 150.6, 144.0, 138.0 (d, <i>J</i> = 10.6 Hz), 135.2 (d, <i>J</i> = 11.3 Hz), 134.3, 129.8, 119.6 (d, <i>J</i> = 25.6 Hz), 115.1 (d, <i>J</i> = 21.9 Hz), 105.8, 30.3, 28.6. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>10</sub>ClFN<sub>4</sub>O<sub>4</sub>S (<i>m/z</i>) 394.9987 [M + Na]<sup>+</sup>; found, 394.9980. mp 220–222 °C. Anal. Calcd for C<sub>13</sub>H<sub>10</sub>ClFN<sub>4</sub>O<sub>4</sub>S: C, 41.89; H, 2.70; N, 15.03; S, 8.60. Found: C, 41.85; H, 2.82; N, 14.85; 8.72.</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 7-([2-Chloro-4-(trifluoromethyl)phenyl]sulfonyl)-1,3-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>34</b>)</h4><div class="NLM_p last">Following method B, theophylline (100 mg, 0.55 mmol), 2-chloro-4-(trifluoromethyl)benzenesulfonyl chloride (186 mg, 0.67 mmol), and NaH (60% dispersion in mineral oil, 27 mg, 0.67 mmol) in THF (11 mL) yielded <b>34</b> as a white powder (177 mg, 75%) after purification by CC (gradient of EtOAc in hexane, 15/85 to 100/0). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.80 (d, <i>J</i> = 8.4 Hz, 1H, H6′), 8.46 (s, 1H, H8), 7.84 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H, H5′), 7.75 (d, <i>J</i> = 1.7 Hz, 1H, H3′), 3.60 (s, 3H, N3CH<sub>3</sub>), 3.28 (s, 3H, N1CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, CDCl<sub>3</sub>): δ 153.0, 151.2, 150.6, 144.0, 138.0 (q, <i>J</i> = 31.7 Hz), 136.92, 136.1, 133.9, 129.0 (q, <i>J</i> = 3.8 Hz), 124.4 (q, <i>J</i> = 3.8 Hz), 122.2 (d, <i>J</i> = 273.7 Hz), 105.8, 30.4, 28.6. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>14</sub>H<sub>10</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (<i>m/z</i>) 444.9955 [M + Na]<sup>+</sup>; found, 444.9954. mp 210 °C (dec). Anal. Calcd for C<sub>14</sub>H<sub>10</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S: C, 39.77; H, 2.38; N, 13.25; S, 7.58. Found: C, 39.93; H, 2.55; N, 12.99; S, 7.76.</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 7-[(2,4-Difluorophenyl)sulfonyl]-1,3-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>35</b>)</h4><div class="NLM_p last">Following method B, theophylline (100 mg, 0.55 mmol), 2,4-difluorobenzenesulfonyl chloride (141 mg, 0.67 mmol), and NaH (60% dispersion in mineral oil, 27 mg, 0.67 mmol) in THF (11 mL) yielded <b>35</b> as a white powder (142 mg, 72%) after purification by CC (gradient of EtOAc in hexane, 10/90 to 80/20). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.48 (ddd, <i>J</i> = 9.0, 8.1, 5.9 Hz, 1H, H6′), 8.37 (d, <i>J</i> = 1.2 Hz, 1H, H8), 7.16 (dddd, <i>J</i> = 8.9, 7.6, 2.4, 1.1 Hz, 1H, H5′), 6.93 (ddd, <i>J</i> = 10.4, 8.2, 2.4 Hz, 1H, H3′), 3.60 (s, 3H, N3CH<sub>3</sub>), 3.31 (s, 3H, N1CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, CDCl<sub>3</sub>): δ 167.8 (dd, <i>J</i> = 12.1, 262.4 Hz), 160.5 (dd, <i>J</i> = 12.8, 261.6 Hz), 153.0, 151.3, 150.6, 143.0, 135.8 (d, <i>J</i> = 11.31 Hz), 120.8 (dd, <i>J</i> = 3.8, 12.1 Hz), 112.7 (dd, <i>J</i> = 3.8, 22.6 Hz), 105.9 (dd, <i>J</i> = 24.9, 26.4 Hz), 105.8, 30.3, 28.6. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>10</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub>S (<i>m/z</i>) 379.0283 [M + Na]<sup>+</sup>; found, 379.0269. Mp 194 °C (dec). Anal. Calcd for C<sub>13</sub>H<sub>10</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub>S: C, 43.82; H, 2.83; N, 15.72; S, 9.00. Found: C, 43.83; H, 2.96; N, 15.63; S, 9.12.</div></div><div id="sec4_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 7-[(4-Fluoro-2-methylphenyl)sulfonyl]-1,3-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>36</b>)</h4><div class="NLM_p last">Following method B, theophylline (100 mg, 0.55 mmol), 4-fluoro-2-methylbenzenesulfonyl chloride (97 μL, 0.67 mmol), and NaH (60% dispersion in mineral oil, 27 mg, 0.67 mmol) in THF (11 mL) yielded <b>36</b> as a white powder (152 mg, 78%) after purification by CC (gradient of EtOAc in hexane, 10/90 to 80/20). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.57 (dd, <i>J</i> = 9.0, 5.5 Hz, 1H, H6′), 8.38 (s, 1H, H8), 7.17 (ddd, <i>J</i> = 9.5, 7.6, 2.6 Hz, 1H, H5′), 6.99 (dd, <i>J</i> = 9.0, 2.6, 1H, H3′), 3.59 (s, 3H, N3CH<sub>3</sub>), 3.30 (s, 3H, N1CH<sub>3</sub>), 2.51 (s, 3H, C2′CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, CDCl<sub>3</sub>): δ 166.6 (d, <i>J</i> = 263.1 Hz), 153.0, 151.3, 150.6, 142.7, 142.2 (d, <i>J</i> = 9.8 Hz), 137.1 (d, <i>J</i> = 10.6 Hz), 130.3 (d, <i>J</i> = 3.0 Hz), 119.7 (d, <i>J</i> = 22.6 Hz), 114.1 (d, <i>J</i> = 21.9 Hz), 106.1, 30.3, 28.6, 20.4 (d, <i>J</i> = 1.1 Hz). HRMS (ESI<sup>+</sup>) mass calcd for C<sub>14</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>4</sub>S (<i>m/z</i>) 375.0533 [M + Na]<sup>+</sup>; found, 375.0535. mp 216–218 °C (dec). Anal. Calcd for C<sub>14</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>4</sub>S: C, 47.72; H, 3.72; N, 15.90; S, 9.10. Found: C, 47.63; H, 3.83; N, 15.64; S, 9.18.</div></div><div id="sec4_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 7-[(2,5-Dichlorophenyl)sulfonyl]-1,3-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>37</b>)</h4><div class="NLM_p last">Following method B, theophylline (100 mg, 0.55 mmol), 2,5-dichlorobenzenesulfonyl chloride (163 mg, 0.67 mmol), and NaH (60% dispersion in mineral oil, 27 mg, 0.67 mmol) in THF (11 mL) yielded <b>37</b> as a white powder (157 mg, 73%) after purification by CC (gradient of EtOAc in hexane, 15/85 to 100/0). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.62 (d, <i>J</i> = 2.5 Hz, 1H, H6′), 8.43 (s, 1H, H8), 7.60 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H, H4′), 7.42 (d, <i>J</i> = 8.6 Hz, 1H, H3′), 3.59 (s, 3H, N3CH<sub>3</sub>), 3.30 (s, 3H, N1CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, CDCl<sub>3</sub>): δ 152.8, 151.3, 150.5, 144.0, 136.4, 134.9, 134.8, 133.8, 132.8, 131.1, 105.8, 30.3, 28.6. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>4</sub>S (<i>m/z</i>) 410.9692 [M + Na]<sup>+</sup>; found, 410.9686. mp 222 °C (dec). Anal. Calcd for C<sub>13</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>4</sub>S: C, 40.12; H, 2.59; N, 14.40; S, 8.24. Found: C, 40.34; H, 2.78; N, 14.23; S, 8.52.</div></div><div id="sec4_5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 7-[(4-Fluorophenyl)sulfonyl]-1,3-dimethyl-3,7-dihydro-1<i>H</i>-purine-2,6-dione (<b>38</b>)</h4><div class="NLM_p last">Following method B, theophylline (100 mg, 0.55 mmol), 4-fluorobenzenesulfonyl chloride (130 mg, 0.67 mmol), and NaH (60% dispersion in mineral oil, 27 mg, 0.67 mmol) in THF (11 mL) yielded <b>38</b> as a white powder (152 mg, 81%) after purification by CC (gradient of EtOAc in hexane, 10/90 to 100/0). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.42–8.21 (m, 3H, H2′, H8), 7.36–7.20 (m, 2H, H3′), 3.57 (s, 3H, N3CH<sub>3</sub>), 3.36 (s, 3H, N1CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, CDCl<sub>3</sub>): δ 166.9 (d, <i>J</i> = 260.13), 153.1, 151.3, 150.8, 142.2, 133.0 (d, <i>J</i> = 10.6 Hz), 132.4 (d, <i>J</i> = 3.1 Hz), 117.1 (d, <i>J</i> = 22.6 Hz), 106.1, 30.3, 28.7. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>11</sub>FN<sub>4</sub>O<sub>4</sub>S (<i>m/z</i>) 361.0377 [M + Na]<sup>+</sup> and 699.0862 [2M + Na]<sup>+</sup>; found, 361.0366 and 699.0841. mp 223 °C (dec). Anal. Calcd for C<sub>13</sub>H<sub>11</sub>FN<sub>4</sub>O<sub>4</sub>S: C, 46.15; H, 3.28; N, 16.56; S, 9.48. Found: C, 46.05; H, 3.41; N, 16.45; S, 9.21.</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Synthesis of 2-Chloro-1-(2-chlorobenzyl)-9-methyl-1,9-dihydro-6<i>H</i>-purin-6-one (<b>40</b>)</h3><div class="NLM_p last">Following the procedure described by Szarek et al.,<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(72)</a> NaHCO<sub>3</sub> (35 mg, 0.42 mmol) was added to a solution of intermediate <b>39</b> (24 mg, 0.13 mmol) in DMF (1 mL). The reaction was stirred at rt for 30 min. 1-Chloro-2-(chloromethyl)benzene (40 μL, 0.31 mmol) was added dropwise, and the mixture was heated up to 75 °C and stirred overnight. The solvent was evaporated under reduced pressure, and the residue was suspended in water (3 mL) and extracted with EtOAc (3 × 2 mL). The combined organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the solvent was evaporated under reduced pressure. Purification was performed by CC (gradient of EtOAc in hexane, 15/85 to 80/20), giving <b>40</b> as a brownish powder (10 mg, 32%). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.44 (s, 1H, H8), 7.51 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H, H3′), 7.35 (m, 2H, H4′, H5′), 7.08 (dd, <i>J</i> = 7.6, 1.9 Hz, 1H, H6′), 5.77 (s, 2H, CH<sub>2</sub>), 4.07 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (75.4 MHz, acetone-<i>d</i><sub><i>6</i></sub>): δ 161.4, 153.8, 152.3, 143.8, 133.5, 132.8, 129.9, 129.8, 129.7, 127.6, 120.3, 54.4, 45.0. HRMS (ESI<sup>+</sup>) mass calcd for C<sub>13</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>4</sub>O (<i>m/z</i>) 309.0304 [M + H]<sup>+</sup>; found, 309.0308. mp 146–149 °C. HPLC-UV (λ = 250 nm): purity 95%.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> HEK293-hP2X7 Cell Culture</h3><div class="NLM_p last">The human embryonic kidney cell line that stably expresses the human P2X7 isoform A (hP2X7-HEK293) was generously donated by Francesco di Virgilio’s group. HEK293-hP2X7 cells were kept in 75 cm<sup>2</sup> flasks under DMEM-F12 culture medium enriched with 50 units/mL of penicillin and 50 μg/mL of streptomycin, 10% FBS bovine serum, and 0.2 mg/mL of geneticin (G-418 sulfate, Roche Diagnostics GmbH, Mannheim, Germany), which was used as a selection reagent. Cells were allowed to grow up to 95% confluence in an incubator with a constant atmosphere of 5% CO<sub>2</sub>, saturated humidity, and at a temperature of 37 °C. For culture plating, they were dissociated from the flask using Trypsin–EDTA 0.05%, counted, and seeded in 96-well black, clear-bottomed plates (Conning Inc. Kennebunk ME, USA) at a different density depending on the experiment. Experiments were performed 24–48 h after plating.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> YO-PRO-1 Uptake</h3><div class="NLM_p last">hP2X7-HEK293 cells were seeded at a density of 400,000 cells/well. After 48 h, the culture medium was harvested and the cells were incubated with Mg<sup>2+</sup>-free Krebs-HEPES buffer containing (in mM) 144 NaCl, 5.9 KCl, 11 glucose, 10 HEPES, and 0.2 CaCl<sub>2</sub> at pH 7.4. Test groups were incubated with the compounds for 20 min; then, the YOPRO-1 probe (2 μM) was applied, and subsequently, the cells were stimulated with BzATP (30 μM). Changes in the fluorescence (excitation at 485 nm and emission at 520 nm) were measured for 25 min using a fluorescence plate reader (Fluostar, BMG Labtech, Offenburg, Germany). Responses of each well were normalized with respect to the maximum (<i>F</i><sub>max</sub>) and the minimum (<i>F</i><sub>min</sub>) fluorescence values obtained by adding 0.5% Triton X-100 and then 2 M MnCl<sub>2</sub>. Data were calculated with the formula <i>F</i> = (<i>F</i><sub><i>x</i></sub> – <i>F</i><sub>0</sub>)/(<i>F</i><sub>max</sub> – <i>F</i><sub>min</sub>), where <i>F</i><sub><i>x</i></sub> is the maximum fluorescence obtained and F<sub>0</sub> is the averaged fluorescence before Bz-ATP injection.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Fura-2 Calcium Measurements</h3><div class="NLM_p last">hP2X7-HEK293 cells were seeded at a density of 50,000 cells/well and after 24–48 h were loaded with 8 μM Fura-2-AM (Invitrogen or Biotium, USA) for 1 h at 37 °C. After incubation, the loading medium was washed with Tyrode solution without Mg<sup>2+</sup> (in mM): 137 NaCl, 10 HEPES, 2 CaCl<sub>2</sub>, 4 KCl, and 10 glucose at pH 7.4, for 15–30 min. Test molecules were incubated during this period. Fura-2 calcium measurements were carried out with a fluorescence multi-well plate reader (Fluostar Optima, BMG, Germany). Cells were alternatively illuminated by 340 and 380 nm wavelength lights, and the emitted fluorescence was detected through a 520/10 nm filter for both excitation wavelengths. After a few cycles of basal fluorescence recording, the P2X7 agonist BzATP was injected to get a final concentration of 100 μM. Fluorescence was transformed to [Ca<sup>2+</sup>]<sub>c</sub> with Grynkiewitz’s equation.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(73)</a> Each experimental condition was performed in triplicate and averaged. Blockade is expressed as a percentage of the maximum [Ca<sup>2+</sup>]<sub>c</sub> increase elicited by BzATP in control Tyrode-only wells.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Electrophysiological Measurements</h3><div class="NLM_p last">cDNA of human His-P2X7 was synthesized (GeneArt String DNA fragment, Life Technologies/Thermo Fisher Scientific Inc.) and cloned together with the poly-A tail from the pNKS2 vector<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(74)</a> into a modified pUC19 vector. Rat P2X7 cDNA was present in pSGem,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(75)</a> and rat P2X1 and P2X2 subunits were present in pNKS2.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(74)</a> Capped cRNAs were formed from linearized templates using the mMESSAGE mMACHINE Kit (Ambion, Austin, Texas, USA). Oocytes were kindly donated by Prof. Luis Pardo, MPI for Experimental Medicine, Göttingen or from EcoCyte Bioscience, Dortmund, Germany), injected with 50 nL of cRNA (0.5 mg/mL for rP2X1, rP2X4 and hP2X7; 0.1 mg/mL for rP2X2; 25 μg/mL for rP2X7), and incubated for 1–2 days at 16–18 °C before recordings were performed as described<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(76)</a> in a low divalent-cation solution (90 mM NaCl, 1 mM KCl, 0.5 mM CaCl<sub>2</sub>, 5 mM HEPES). Current responses to ATP (300 μM for hP2X7, 30 μM for rP2X4 and rP2X7, and 10 μM for rP2X2 and rP2X1) were measured by TEVC at −70 mV using a Turbo Tec 05X Amplifier (NPI Electronic, Tamm, Germany) and Cell Works software. A rapid exchange of solution, about 300 ms, was reached with a 50 μL oocyte chamber with a funnel shape, combined with a fast solution flow (150 μL/s), fed through a manifold built immediately above the oocyte. Compounds were directly diluted in the recording chamber and incubated for 3 min without perfusion. ATP pulses were applied for 2 s (3 s for rP2X7 subtype) followed by 58 s of perfusion at 4-min intervals. Data were shown as means ± S.E.M. from at least three oocytes from two different frogs.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Isolation of MPMs</h3><div class="NLM_p last">Elicited MPMs were obtained from twelve (<i>n</i> = 12) 6–8 week-old C57BL/6 male mice. Twenty-four hours before macrophages extraction, mice were injected intraperitoneally with 1 mL of 3.8% Brewer’s thioglycolate medium in order to attract circulating macrophages to the peritoneal cavity. The day after, the mice were euthanized by cervical dislocation and the abdominal skin was retracted to expose the peritoneal wall. The highest efforts were made to mitigate animal suffering according to the EU Council Directive guidelines. All experiments with animals were carried out in accordance with the ARRIVE guidelines, the International Council for Laboratory Animal Science and the European Union 2010/63/EU Guidelines. The experimental protocol was approved by the Institutional Ethical Committee for Animal Research at the Universidad Autónoma de Madrid (UAM). Ten milliliters of cold sterile PBS were injected in the peritoneal cavity with a 20-G needle, and the peritoneal content was collected by aspirating the fluid with the same syringe and needle. The peritoneal exudate cells were centrifuged at 4 °C for 10 min at 1000 rpm, and the cell pellet was resuspended in 1 mL of cold DMEM high glucose (Gibco) supplemented with 10% FBS (Gibco), 100 U/mL penicillin/streptomycin (Lonza). Cells were counted with a Neubauer chamber, and the cell concentration was adjusted to 1–3 × 10<sup>6</sup> cells/mL. Macrophages were seeded in 24-well plates at a density of 3 × 10<sup>5</sup> cells/well and primed with 1 μg/mL LPS (<i>Escherichia coli</i> 026:B6 serotype; Sigma-Aldrich) in DMEM high glucose +10% SBF for 4 h. The LPS-containing medium was removed and fresh DMEM without FBS containing the different compounds was added for 15 min. ATP 5 mM (Sigma-Aldrich) was then added for 30 min. Cell supernatants were collected and frozen at −20 °C for IL-1β detection.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> IL-1β detection</h3><div class="NLM_p last">IL-1β (pg/mL) was detected in the collected cell supernatants using a specific ELISA kit. Supernatant samples were obtained from the treated MPMs and subjected to the ELISA analysis according to the supplier recommendations (R&D systems).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Parallel Artificial Membrane Permeability Assay</h3><div class="NLM_p last">The lipophilic membrane was prepared by dissolving porcine brain polar lipid extract (Avanti, Merck) in dodecane (Sigma-Aldrich) at a concentration of 20 mg/mL and injecting 4 μL of it on the membrane of each well of a 96-well Multiscreen Filter Plate (Reference: MAIPNTR10, Millipore, Merck). Compound solutions were prepared at 100 μM in PBS at pH 7.4 (Sigma-Aldrich, Merck). The blank solution contained 1% of DMSO. Each well was then filled with 180 μL of compounds or blank solution, whereas the corresponding wells of the acceptor Multiscreen 96-well tray (MAMCS9610, Millipore, Merck) were filled with an equal amount of PBS at pH 7.4. The filter plate was inserted in the acceptor tray and incubated at rt for 4 h. A volume of 150 μL of acceptor plate solutions was transferred to a UV-transparent 96-well plate (MSCPNUV40, Millipore, Merck) together with compound solutions at initial and equilibrium concentrations (100 μM and 50 μM, respectively). Compound absorption spectra were recorded by a SPECTROstar Nano Microplate Reader (BMG Labtech, Orterberg, Germany) and corrected by blank absorption spectra. Concentrations and permeability values were calculated with the following equations<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_m001.gif" alt="" id="_i72" /></img></span><span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_m002.gif" alt="" id="_i73" /></img></span><span class="NLM_disp-formula" id="ueq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_m003.gif" alt="" id="_i74" /></img></span>where <i>V</i> is the solution volume (180 μL); <i>a</i> is the membrane area in cm<sup>2</sup>; <i>t</i> is the time of incubation in seconds; <i>C</i><sub>0</sub> is the starting concentration of compound solutions; <i>A</i><sub>0</sub> is the measured absorbance of compound solutions at starting concentration; <i>A</i><sub>eq</sub> is the measured absorbance of the solution with concentration at equilibrium point, that is, when the compound completely permeates the membrane; and <i>A</i><sub>ac</sub> is the measured absorbance of solutions in the acceptor plate. For each compound, the wavelength at maximum absorbance was considered for calculations (240 nm for JNJ-47965567; 264 nm for <b>6</b>, <b>16</b>, <b>23</b>, <b>29</b>, <b>30</b>, and <b>40</b>; 274 nm for theophylline, <b>17</b>, and <b>24</b>; 284 nm for verapamil and <b>31</b>; 365 nm for piroxicam). All data are presented as mean ± S.E.M. of triplicates of three individual experiments performed in three different days.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Pgp ATP-ase Activity Measurements</h3><div class="NLM_p last">Human P-glycoprotein ATPase activity was measured using the luminescence-based Pgp-glo Assay System (Promega, Madison, WI, USA). The assay was performed according to manufacturer’s protocol (freely available at Promega webpage). Compounds were tested at 10 μM, and MgATP was incubated for 1.5 h. Data were acquired using a microplate luminometer (Orion II, Berthold Technologies GmbH& Co. KG, Germany) and processed according to the manufacturer’s protocol. Briefly, basal relative luminescence unit (R.L.U) variation was calculated as the R.L.U. difference of Na<sub>3</sub>VO<sub>4</sub>-treated wells and non-treated wells R.L.U. Compounds R.L.U. variation was calculated as the R.L.U. difference of Na<sub>3</sub>VO<sub>4</sub>-treated wells and compound-treated wells.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Data Analysis</h3><div class="NLM_p last">The statistically significant differences were analyzed by the one sample <i>t</i>-test or the one-way analysis of variance (ANOVA), followed by the Dunnett post hoc test, using Prism 5.0 (Graph Pad) under a Mac OS X-operated computer. Groups of data were considered statistically different when <i>p</i> < 0.05.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Molecular Docking</h3><div class="NLM_p last">The ligand was docked with the consent of Dr. Ralf Schmid in the homology model of the hP2X7 published by Dayel et al<i>.</i><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Molecules’ 3D conformations were generated using Open Babel.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(77)</a> The ligand was docked in two previously described allosteric binding pockets of hP2X7<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> and in the orthosteric binding pocket using a squared grid with a side of 22–26 Å. Docking was performed using AutodockTools and Autodock Vina<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(78)</a> and represented using UCSF Chimera.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(79)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02145" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56627" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56627" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02145?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02145</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Scheme for the synthesis of <b>14</b>, summary of pharmacological data of the tested compounds, NMR spectra, current inhibition in rat P2X7 by <b>6</b>, HPLC, and X-ray (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">PDB coordinates for the computational model used, modified from the protein model by Dayel et al.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> with permission (crystal templates PDB IDs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1U">5U1U</a>,<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1V">5U1V</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1W">5U1W</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1X">5U1X</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1Y">5U1Y</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_003.txt" class="ext-link">TXT</a>)</p></li><li><p class="inline">Compound <b>6</b> pose at the P2X7 binding site (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_004.mp4" class="ext-link">MP4</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf">jm0c02145_si_001.pdf (7.56 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_002.csv">jm0c02145_si_002.csv (3.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_003.txt">jm0c02145_si_003.txt (737.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_004.mp4">jm0c02145_si_004.mp4 (3.66 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02145" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64408" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64408" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonio G. García</span> - <span class="hlFld-Affiliation affiliation">Instituto-Fundación
Teófilo Hernando and Departamento de Farmacología, Facultad
de Medicina, Universidad Autónoma
de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Instituto
de Investigación Sanitaria, Hospital
Universitario de La Princesa, C/ Diego de León, 62—1a Planta, 28006 Madrid, Spain</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f2939595b287939fdc9781"><span class="__cf_email__" data-cfemail="39585e5e794c5854175c4a">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cristóbal de los Ríos</span> - <span class="hlFld-Affiliation affiliation">Instituto-Fundación
Teófilo Hernando and Departamento de Farmacología, Facultad
de Medicina, Universidad Autónoma
de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Instituto
de Investigación Sanitaria, Hospital
Universitario de La Princesa, C/ Diego de León, 62—1a Planta, 28006 Madrid, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6456-7589" title="Orcid link">http://orcid.org/0000-0002-6456-7589</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#086b7a617b7c676a6964266c6d64677b7a61677b4861667e267d6965266d7b"><span class="__cf_email__" data-cfemail="8ae9f8e3f9fee5e8ebe6a4eeefe6e5f9f8e3e5f9cae3e4fca4ffebe7a4eff9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesco Calzaferri</span> - <span class="hlFld-Affiliation affiliation">Instituto-Fundación
Teófilo Hernando and Departamento de Farmacología, Facultad
de Medicina, Universidad Autónoma
de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4781-2925" title="Orcid link">http://orcid.org/0000-0002-4781-2925</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paloma Narros-Fernández</span> - <span class="hlFld-Affiliation affiliation">Instituto-Fundación
Teófilo Hernando and Departamento de Farmacología, Facultad
de Medicina, Universidad Autónoma
de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Instituto
de Investigación Sanitaria, Hospital
Universitario de La Princesa, C/ Diego de León, 62—1a Planta, 28006 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ricardo de Pascual</span> - <span class="hlFld-Affiliation affiliation">Instituto-Fundación
Teófilo Hernando and Departamento de Farmacología, Facultad
de Medicina, Universidad Autónoma
de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonio M.G. de Diego</span> - <span class="hlFld-Affiliation affiliation">Instituto-Fundación
Teófilo Hernando and Departamento de Farmacología, Facultad
de Medicina, Universidad Autónoma
de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Annette Nicke</span> - <span class="hlFld-Affiliation affiliation">Walther
Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-Universität München, 80336 Munich, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Javier Egea</span> - <span class="hlFld-Affiliation affiliation">Instituto-Fundación
Teófilo Hernando and Departamento de Farmacología, Facultad
de Medicina, Universidad Autónoma
de Madrid, C/ Arzobispo Morcillo 4, 28029 Madrid, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Instituto
de Investigación Sanitaria, Hospital
Universitario de La Princesa, C/ Diego de León, 62—1a Planta, 28006 Madrid, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4704-3019" title="Orcid link">http://orcid.org/0000-0003-4704-3019</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86838" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86838" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work has been supported by the following grants: EU Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie, Grant Agreement N. 766124 to AGG and AN, and Ministerio de Economía y Competitividad, Spain, Grant Number SAF2016-78892R to AGG; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID: 335447717, SFB 1328 (TP15) to A.N.; Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain, Grant Numbers PI16/01041 and PI19/01724 (Co-funded by FEDER) to CdlR; Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain, Grant Numbers PI16/00735 and PI19/00082 (Co-funded by FEDER) to J.E. We thank Fundación Teófilo Hernando for continuous support. We thank Prof. Francesco de Virgilio and his research group for the generous donation of hP2X7-HEK293 cells. We thank Prof. Luis Pardo for the generous donation of <i>X. laevis</i> oocytes. We thank Dr. Ralf Schmid for permission to use the homology model of hP2X7. We thank Dr. Eva M. Garcia-Frutos (ICMM, CSIC, Spain) for X-ray diffraction crystal preparation. We thank Dr. Juan Felipe Franco-Gonzalez (CIB, CSIC, Spain) for assistance with computational docking analyses.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">amyloid β peptide</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">ALS</td><td class="NLM_def"><p class="first last">amyothrophic lateral sclerosis</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">BBG</td><td class="NLM_def"><p class="first last">brilliant blue G</p></td></tr><tr><td class="NLM_term">CC</td><td class="NLM_def"><p class="first last">column chromatography</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco-modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">IL-1β</td><td class="NLM_def"><p class="first last">interleukin 1β</p></td></tr><tr><td class="NLM_term">MPMs</td><td class="NLM_def"><p class="first last">mouse peritoneal macrophages</p></td></tr><tr><td class="NLM_term">NDDs</td><td class="NLM_def"><p class="first last">neurodegenerative diseases</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">P2X</td><td class="NLM_def"><p class="first last">type 2 ionotropic purinergic receptor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 79 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiLuca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, J.</span></span> <span> </span><span class="NLM_article-title">The Cost of Brain Diseases: a Burden or a Challenge?</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1208</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2014.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.neuron.2014.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=24945765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCju7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=1205-1208&author=M.+DiLucaauthor=J.+Olesen&title=The+Cost+of+Brain+Diseases%3A+a+Burden+or+a+Challenge%3F&doi=10.1016%2Fj.neuron.2014.05.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Cost of Brain Diseases: A Burden or a Challenge?</span></div><div class="casAuthors">DiLuca, Monica; Olesen, Jes</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1205-1208</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Brain diseases represent a considerable social and economic burden in Europe.  With yearly costs of about 800 billion euros and an estd. 179 million people afflicted in 2010, brain diseases are an unquestionable emergency and a grand challenge for neuroscientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlTAjvSGNAV7Vg90H21EOLACvtfcHk0ljDZyPc2xIyNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCju7rL&md5=853d1eec0a4175cb42d9b639ec2cebc4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2014.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2014.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DDiLuca%26aufirst%3DM.%26aulast%3DOlesen%26aufirst%3DJ.%26atitle%3DThe%2520Cost%2520of%2520Brain%2520Diseases%253A%2520a%2520Burden%2520or%2520a%2520Challenge%253F%26jtitle%3DNeuron%26date%3D2014%26volume%3D82%26spage%3D1205%26epage%3D1208%26doi%3D10.1016%2Fj.neuron.2014.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gustavsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allgulander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faravelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fratiglioni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gannon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennum, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karampampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobelt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljungcrantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maercker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscarelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musayev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norwood, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preisig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliatti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvador-Carulla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlehofer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhausen, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stovner, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallat, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Bergh, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Os, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittchen, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Group, C. D.</span></span> <span> </span><span class="NLM_article-title">Cost of Disorders of the Brain in Europe 2010</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2011.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.euroneuro.2011.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=21924589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12itr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=718-779&author=A.+Gustavssonauthor=M.+Svenssonauthor=F.+Jacobiauthor=C.+Allgulanderauthor=J.+Alonsoauthor=E.+Beghiauthor=R.+Dodelauthor=M.+Ekmanauthor=C.+Faravelliauthor=L.+Fratiglioniauthor=B.+Gannonauthor=D.+H.+Jonesauthor=P.+Jennumauthor=A.+Jordanovaauthor=L.+J%C3%B6nssonauthor=K.+Karampampaauthor=M.+Knappauthor=G.+Kobeltauthor=T.+Kurthauthor=R.+Liebauthor=M.+Lindeauthor=C.+Ljungcrantzauthor=A.+Maerckerauthor=B.+Melinauthor=M.+Moscarelliauthor=A.+Musayevauthor=F.+Norwoodauthor=M.+Preisigauthor=M.+Pugliattiauthor=J.+Rehmauthor=L.+Salvador-Carullaauthor=B.+Schlehoferauthor=R.+Simonauthor=H.-C.+Steinhausenauthor=L.+J.+Stovnerauthor=J.-M.+Vallatauthor=P.+V.+den+Berghauthor=J.+van+Osauthor=P.+Vosauthor=W.+Xuauthor=H.-U.+Wittchenauthor=B.+J%C3%B6nssonauthor=J.+Olesenauthor=C.+D.+Group&title=Cost+of+Disorders+of+the+Brain+in+Europe+2010&doi=10.1016%2Fj.euroneuro.2011.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cost of disorders of the brain in Europe 2010</span></div><div class="casAuthors">Gustavsson, Anders; Svensson, Mikael; Jacobi, Frank; Allgulander, Christer; Alonso, Jordi; Beghi, Ettore; Dodel, Richard; Ekman, Mattias; Faravelli, Carlo; Fratiglioni, Laura; Gannon, Brenda; Jones, David Hilton; Jennum, Poul; Jordanova, Albena; Joensson, Linus; Karampampa, Korinna; Knapp, Martin; Kobelt, Gisela; Kurth, Tobias; Lieb, Roselind; Linde, Mattias; Ljungcrantz, Christina; Maercker, Andreas; Melin, Beatrice; Moscarelli, Massimo; Musayev, Amir; Norwood, Fiona; Preisig, Martin; Pugliatti, Maura; Rehm, Juergen; Salvador-Carulla, Luis; Schlehofer, Brigitte; Simon, Roland; Steinhausen, Hans-Christoph; Stovner, Lars Jacob; Vallat, Jean-Michel; Van den Bergh, Peter; van Os, Jim; Vos, Pieter; Xu, Weili; Wittchen, Hans-Ulrich; Joensson, Bengt; Olesen, Jes</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">718-779</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background: The spectrum of disorders of the brain is large, covering hundreds of disorders that are listed in either the mental or neurol. disorder chapters of the established international diagnostic classification systems.  These disorders have a high prevalence as well as short- and long-term impairments and disabilities.  Therefore they are an emotional, financial and social burden to the patients, their families and their social network.  In a 2005 landmark study, we estd. for the first time the annual cost of 12 major groups of disorders of the brain in Europe and gave a conservative est. of (euro sign)386 billion for the year 2004.  This est. was limited in scope and conservative due to the lack of sufficiently comprehensive epidemiol. and/or economic data on several important diagnostic groups.  We are now in a position to substantially improve and revise the 2004 ests.  In the present report we cover 19 major groups of disorders, 7 more than previously, of an increased range of age groups and more cost items.  We therefore present much improved cost ests.  Our revised ests. also now include the new EU member states, and hence a population of 514 million people.  Aims: To est. the no. of persons with defined disorders of the brain in Europe in 2010, the total cost per person related to each disease in terms of direct and indirect costs, and an est. of the total cost per disorder and country.  Methods: The best available ests. of the prevalence and cost per person for 19 groups of disorders of the brain (covering well over 100 specific disorders) were identified via a systematic review of the published literature.  Together with the twelve disorders included in 2004, the following range of mental and neurol. groups of disorders is covered: addictive disorders, affective disorders, anxiety disorders, brain tumor, childhood and adolescent disorders (developmental disorders), dementia, eating disorders, epilepsy, mental retardation, migraine, multiple sclerosis, neuromuscular disorders, Parkinson's disease, personality disorders, psychotic disorders, sleep disorders, somatoform disorders, stroke, and traumatic brain injury.  Epidemiol. panels were charged to complete the literature review for each disorder in order to est. the 12-mo prevalence, and health economic panels were charged to est. best cost-ests.  A cost model was developed to combine the epidemiol. and economic data and est. the total cost of each disorder in each of 30 European countries (EU27 + Iceland, Norway and Switzerland).  The cost model was populated with national statistics from Eurostat to adjust all costs to 2010 values, converting all local currencies to Euro, imputing costs for countries where no data were available, and aggregating country ests. to purchasing power parity adjusted ests. for the total cost of disorders of the brain in Europe 2010.  Results: The total cost of disorders of the brain was estd. at (euro sign)798 billion in 2010.  Direct costs constitute the majority of costs (37% direct healthcare costs and 23% direct non-medical costs) whereas the remaining 40% were indirect costs assocd. with patients' prodn. losses.  On av., the estd. cost per person with a disorder of the brain in Europe ranged between (euro sign)285 for headache and (euro sign)30,000 for neuromuscular disorders.  The European per capita cost of disorders of the brain was (euro sign)1550 on av. but varied by country.  The cost (in billion (euro sign)PPP 2010) of the disorders of the brain included in this study was as follows: addiction: (euro sign)65.7; anxiety disorders: (euro sign)74.4; brain tumor: (euro sign)5.2; child/adolescent disorders: (euro sign)21.3; dementia: (euro sign)105.2; eating disorders: (euro sign)0.8; epilepsy: (euro sign)13.8; headache: (euro sign)43.5; mental retardation: (euro sign)43.3; mood disorders: (euro sign)113.4; multiple sclerosis: (euro sign)14.6; neuromuscular disorders: (euro sign)7.7; Parkinson's disease: (euro sign)13.9; personality disorders: (euro sign)27.3; psychotic disorders: (euro sign)93.9; sleep disorders: (euro sign)35.4; somatoform disorder: (euro sign)21.2; stroke: (euro sign)64.1; traumatic brain injury: (euro sign)33.0.  It should be noted that the revised est. of those disorders included in the previous 2004 report constituted (euro sign)477 billion, by and large confirming our previous study results after considering the inflation and population increase since 2004.  Further, our results were consistent with administrative data on the health care expenditure in Europe, and comparable to previous studies on the cost of specific disorders in Europe.  Our ests. were lower than comparable ests. from the US.  Discussion: This study was based on the best currently available data in Europe and our model enabled extrapolation to countries where no data could be found.  Still, the scarcity of data is an important source of uncertainty in our ests. and may imply over- or underestimations in some disorders and countries.  Even though this review included many disorders, diagnoses, age groups and cost items that were omitted in 2004, there are still remaining disorders that could not be included due to limitations in the available data.  We therefore consider our est. of the total cost of the disorders of the brain in Europe to be conservative.  In terms of the health economic burden outlined in this report, disorders of the brain likely constitute the no. one economic challenge for European health care, now and in the future.  Data presented in this report should be considered by all stakeholder groups, including policy makers, industry and patient advocacy groups, to reconsider the current science, research and public health agenda and define a coordinated plan of action of various levels to address the assocd. challenges.  Recommendations: Political action is required in light of the present high cost of disorders of the brain.  Funding of brain research must be increased; care for patients with brain disorders as well as teaching at medical schools and other health related educations must be quant. and qual. improved, including psychol. treatments.  The current move of the pharmaceutical industry away from brain related indications must be halted and reversed.  Continued research into the cost of the many disorders not included in the present study is warranted.  It is essential that not only the EU but also the national governments forcefully support these initiatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_5YCk7AoEdrVg90H21EOLACvtfcHk0ljCwnyozKEwog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12itr7E&md5=8f1a90ef1c8e218bcb974ab5839fce6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2011.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2011.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DGustavsson%26aufirst%3DA.%26aulast%3DSvensson%26aufirst%3DM.%26aulast%3DJacobi%26aufirst%3DF.%26aulast%3DAllgulander%26aufirst%3DC.%26aulast%3DAlonso%26aufirst%3DJ.%26aulast%3DBeghi%26aufirst%3DE.%26aulast%3DDodel%26aufirst%3DR.%26aulast%3DEkman%26aufirst%3DM.%26aulast%3DFaravelli%26aufirst%3DC.%26aulast%3DFratiglioni%26aufirst%3DL.%26aulast%3DGannon%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DD.%2BH.%26aulast%3DJennum%26aufirst%3DP.%26aulast%3DJordanova%26aufirst%3DA.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DL.%26aulast%3DKarampampa%26aufirst%3DK.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DKobelt%26aufirst%3DG.%26aulast%3DKurth%26aufirst%3DT.%26aulast%3DLieb%26aufirst%3DR.%26aulast%3DLinde%26aufirst%3DM.%26aulast%3DLjungcrantz%26aufirst%3DC.%26aulast%3DMaercker%26aufirst%3DA.%26aulast%3DMelin%26aufirst%3DB.%26aulast%3DMoscarelli%26aufirst%3DM.%26aulast%3DMusayev%26aufirst%3DA.%26aulast%3DNorwood%26aufirst%3DF.%26aulast%3DPreisig%26aufirst%3DM.%26aulast%3DPugliatti%26aufirst%3DM.%26aulast%3DRehm%26aufirst%3DJ.%26aulast%3DSalvador-Carulla%26aufirst%3DL.%26aulast%3DSchlehofer%26aufirst%3DB.%26aulast%3DSimon%26aufirst%3DR.%26aulast%3DSteinhausen%26aufirst%3DH.-C.%26aulast%3DStovner%26aufirst%3DL.%2BJ.%26aulast%3DVallat%26aufirst%3DJ.-M.%26aulast%3Dden%2BBergh%26aufirst%3DP.%2BV.%26aulast%3Dvan%2BOs%26aufirst%3DJ.%26aulast%3DVos%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWittchen%26aufirst%3DH.-U.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DB.%26aulast%3DOlesen%26aufirst%3DJ.%26aulast%3DGroup%26aufirst%3DC.%2BD.%26atitle%3DCost%2520of%2520Disorders%2520of%2520the%2520Brain%2520in%2520Europe%25202010%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2011%26volume%3D21%26spage%3D718%26epage%3D779%26doi%3D10.1016%2Fj.euroneuro.2011.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Virgilio, F.</span></span> <span> </span><span class="NLM_article-title">P2X Receptors and Inflammation</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">866</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.2174/0929867322666141210155311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.2174%2F0929867322666141210155311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=25524252" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=866-877&author=F.+Virgilio&title=P2X+Receptors+and+Inflammation&doi=10.2174%2F0929867322666141210155311"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F0929867322666141210155311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666141210155311%26sid%3Dliteratum%253Aachs%26aulast%3DVirgilio%26aufirst%3DF.%26atitle%3DP2X%2520Receptors%2520and%2520Inflammation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D866%26epage%3D877%26doi%3D10.2174%2F0929867322666141210155311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calzaferri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diego, A. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Méndez-López, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano-Abad, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ríos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandía, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, A. G.</span></span> <span> </span><span class="NLM_article-title">The Purinergic P2X7 Receptor as a Potential Drug Target to Combat Neuroinflammation in Neurodegenerative Diseases</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2465</span>, <span class="refDoi"> DOI: 10.1002/med.21710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fmed.21710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=32677086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVKlurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=2427-2465&author=F.+Calzaferriauthor=C.+Ruiz-Ruizauthor=A.+M.+G.+Diegoauthor=R.+Pascualauthor=I.+M%C3%A9ndez-L%C3%B3pezauthor=M.+F.+Cano-Abadauthor=V.+Maneuauthor=C.+R%C3%ADosauthor=L.+Gand%C3%ADaauthor=A.+G.+Garc%C3%ADa&title=The+Purinergic+P2X7+Receptor+as+a+Potential+Drug+Target+to+Combat+Neuroinflammation+in+Neurodegenerative+Diseases&doi=10.1002%2Fmed.21710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases</span></div><div class="casAuthors">Calzaferri, Francesco; Ruiz-Ruiz, Cristina; de Diego, Antonio M. G.; de Pascual, Ricardo; Mendez-Lopez, Iago; Cano-Abad, Maria F.; Maneu, Victoria; de los Rios, Cristobal; Gandia, Luis; Garcia, Antonio G.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2427-2465</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review of the purinergic P2X7 receptors (P2X7Rs)are gatekeepers of inflammation, they could be developed as drug targets for NDDs.  Herein, we review this challenging hypothesis and comment on the numerous studies that have investigated P2X7Rs, emphasizing their mol. structure and functions, as well as their role in inflammation.  Then, we elaborate on research undertaken in the field of medicinal chem. to det. potential P2X7R antagonists.  Subsequently, we review the state of neuroinflammation and P2X7R expression in the brain, in animal models and patients suffering from AD, Parkinson's disease, amyotrophic lateral sclerosis, Huntington disease, multiple sclerosis, and retinal degeneration.  Next, we summarize the in vivo studies testing the hypothesis that by mitigating neuroinflammation, P2X7R blockers afford neuroprotection, increasing neuroplasticity and neuronal repair in animal models of NDDs.  Finally, we reviewed previous and ongoing CTs investigating compds. directed toward targets assocd. with NDDs; we propose that CTs with P2X7R antagonists should be initiated.  Despite the high expectations for putative P2X7Rs antagonists in various central nervous system diseases, the field is moving forward at a relatively slow pace, presumably due to the complexity of P2X7Rs.  A better pharmacol. approach to combat NDDs would be a dual strategy, combining P2X7R antagonism with drugs targeting a selective pathway in a given NDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6K9cEDPmFNLVg90H21EOLACvtfcHk0ljCwnyozKEwog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVKlurbM&md5=61c929af816b30378efcdb9a89e8b56a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fmed.21710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21710%26sid%3Dliteratum%253Aachs%26aulast%3DCalzaferri%26aufirst%3DF.%26aulast%3DRuiz-Ruiz%26aufirst%3DC.%26aulast%3DDiego%26aufirst%3DA.%2BM.%2BG.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DM%25C3%25A9ndez-L%25C3%25B3pez%26aufirst%3DI.%26aulast%3DCano-Abad%26aufirst%3DM.%2BF.%26aulast%3DManeu%26aufirst%3DV.%26aulast%3DR%25C3%25ADos%26aufirst%3DC.%26aulast%3DGand%25C3%25ADa%26aufirst%3DL.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DA.%2BG.%26atitle%3DThe%2520Purinergic%2520P2X7%2520Receptor%2520as%2520a%2520Potential%2520Drug%2520Target%2520to%2520Combat%2520Neuroinflammation%2520in%2520Neurodegenerative%2520Diseases%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D2427%26epage%3D2465%26doi%3D10.1002%2Fmed.21710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Surprenant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassendren, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buell, G.</span></span> <span> </span><span class="NLM_article-title">The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7)</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">738</span>, <span class="refDoi"> DOI: 10.1126/science.272.5262.735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1126%2Fscience.272.5262.735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=8614837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK28Xislamt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1996&pages=735-738&author=A.+Surprenantauthor=F.+Rassendrenauthor=E.+Kawashimaauthor=R.+A.+Northauthor=G.+Buell&title=The+Cytolytic+P2Z+Receptor+for+Extracellular+ATP+Identified+as+a+P2X+Receptor+%28P2X7%29&doi=10.1126%2Fscience.272.5262.735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The cytolytic P2Z receptor for extracellular ATP identified as a P2x receptor (P2X7)</span></div><div class="casAuthors">Surprenant, A.; Rassendren, F.; Kawashima, E.; North, R. A.; Buell, G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">5262</span>),
    <span class="NLM_cas:pages">735-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The P2Z receptor is responsible for ATP (ATP)-dependent lysis of macrophages through the formation of membrane pores permeable to large mols.  Other ATP-gated channels, the P2x receptors, are permeable only to small cations.  Here, an ATP receptor, the P2X7 receptor, was cloned from rat brain and exhibited both these properties.  This protein is homologous to other P2x receptors but has a unique carboxyl-terminal domain that was required for the lytic actions of ATP.  Thus, the P2X7 (or P2Z) receptor is a bifunctional mol. that could function in both fast synaptic transmission and the ATP-mediated lysis of antigen-presenting cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3JbVuyrvX37Vg90H21EOLACvtfcHk0ljCwnyozKEwog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislamt74%253D&md5=6417dd3fc96249f798858c369330f83a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.272.5262.735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.272.5262.735%26sid%3Dliteratum%253Aachs%26aulast%3DSurprenant%26aufirst%3DA.%26aulast%3DRassendren%26aufirst%3DF.%26aulast%3DKawashima%26aufirst%3DE.%26aulast%3DNorth%26aufirst%3DR.%2BA.%26aulast%3DBuell%26aufirst%3DG.%26atitle%3DThe%2520Cytolytic%2520P2Z%2520Receptor%2520for%2520Extracellular%2520ATP%2520Identified%2520as%2520a%2520P2X%2520Receptor%2520%2528P2X7%2529%26jtitle%3DScience%26date%3D1996%26volume%3D272%26spage%3D735%26epage%3D738%26doi%3D10.1126%2Fscience.272.5262.735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denlinger, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisette, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watters, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubyak, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertics, P. J.</span></span> <span> </span><span class="NLM_article-title">Cutting Edge: the Nucleotide Receptor P2X7 Contains Multiple Protein- and Lipid-Interaction Motifs Including a Potential Binding Site for Bacterial Lipopolysaccharide</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.167.4.1871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.4049%2Fjimmunol.167.4.1871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=11489964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFeqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2001&pages=1871-1876&author=L.+C.+Denlingerauthor=P.+L.+Fisetteauthor=J.+A.+Sommerauthor=J.+J.+Wattersauthor=U.+Prabhuauthor=G.+R.+Dubyakauthor=R.+A.+Proctorauthor=P.+J.+Bertics&title=Cutting+Edge%3A+the+Nucleotide+Receptor+P2X7+Contains+Multiple+Protein-+and+Lipid-Interaction+Motifs+Including+a+Potential+Binding+Site+for+Bacterial+Lipopolysaccharide&doi=10.4049%2Fjimmunol.167.4.1871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide</span></div><div class="casAuthors">Denlinger, Loren C.; Fisette, Philip L.; Sommer, Julie A.; Watters, Jyoti J.; Prabhu, Usha; Dubyak, George R.; Proctor, Richard A.; Bertics, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1871-1876</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The nucleotide receptor P2X7 has been shown to modulate LPS-induced macrophage prodn. of numerous inflammatory mediators.  Although the C-terminal portion of P2X7 is thought to be essential for multiple receptor functions, little is known regarding the structural motifs that lie within this region.  We show here that the P2X7 C-terminal domain contains several apparent protein-protein and protein-lipid interaction motifs with potential importance to macrophage signaling and LPS action.  Surprisingly, P2X7 also contains a conserved LPS-binding domain.  In this report, we demonstrate that peptides derived from this P2X7 sequence bind LPS in vitro.  Moreover, these peptides neutralize the ability of LPS to activate the extracellular signal-regulated kinases (ERK1, ERK2) and to promote the degrdn. of the inhibitor of κB-α isoform (IκB-α) in RAW 264.7 macrophages.  Collectively, these data suggest that the C-terminal domain of P2X7 may directly coordinate several signal transduction events related to macrophage function and LPS action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPpdlIBLcb2rVg90H21EOLACvtfcHk0ljiNN6lH6nGow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFeqt7g%253D&md5=d189a60c471a8939babd7714591f3434</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.167.4.1871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.167.4.1871%26sid%3Dliteratum%253Aachs%26aulast%3DDenlinger%26aufirst%3DL.%2BC.%26aulast%3DFisette%26aufirst%3DP.%2BL.%26aulast%3DSommer%26aufirst%3DJ.%2BA.%26aulast%3DWatters%26aufirst%3DJ.%2BJ.%26aulast%3DPrabhu%26aufirst%3DU.%26aulast%3DDubyak%26aufirst%3DG.%2BR.%26aulast%3DProctor%26aufirst%3DR.%2BA.%26aulast%3DBertics%26aufirst%3DP.%2BJ.%26atitle%3DCutting%2520Edge%253A%2520the%2520Nucleotide%2520Receptor%2520P2X7%2520Contains%2520Multiple%2520Protein-%2520and%2520Lipid-Interaction%2520Motifs%2520Including%2520a%2520Potential%2520Binding%2520Site%2520for%2520Bacterial%2520Lipopolysaccharide%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D167%26spage%3D1871%26epage%3D1876%26doi%3D10.4049%2Fjimmunol.167.4.1871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adinolfi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemoli, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idzko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panther, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Virgilio, F.</span></span> <span> </span><span class="NLM_article-title">The P2X7 Receptor: a Key Player in IL-1 Processing and Release</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">3877</span>– <span class="NLM_lpage">3883</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.176.7.3877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.4049%2Fjimmunol.176.7.3877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=16547218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1ertL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=3877-3883&author=D.+Ferrariauthor=C.+Pizziraniauthor=E.+Adinolfiauthor=R.+M.+Lemoliauthor=A.+Curtiauthor=M.+Idzkoauthor=E.+Pantherauthor=F.+Di+Virgilio&title=The+P2X7+Receptor%3A+a+Key+Player+in+IL-1+Processing+and+Release&doi=10.4049%2Fjimmunol.176.7.3877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The P2X7 Receptor: A Key Player in IL-1 Processing and Release</span></div><div class="casAuthors">Ferrari, Davide; Pizzirani, Cinzia; Adinolfi, Elena; Lemoli, Roberto M.; Curti, Antonio; Idzko, Marco; Panther, Elisabeth; Di Virgilio, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3877-3883</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Human interleukin 1 (IL-1) family proteins are key mediators of the host response to infections, injury, and immunol. challenges.  The mechanism by which IL-1 activates proinflammatory responses in target cells, and the plasma membrane receptors involved, are fairly well known.  This has led to the development of innovative drugs that block IL-1 downstream to its synthesis and secretion.  On the contrary, the mechanism of IL-1 and other IL-1 family members (e.g., IL-18) maturation and release is incompletely understood.  Accruing evidence points to a plasma membrane receptor for extracellular ATP, the P2X7 receptor, as a key player in both processes.  A deeper understanding of the mechanism by which the P2X7 receptor triggers IL-1 maturation and exteriorization may suggest novel avenues for the treatment of inflammatory diseases and provide a deeper insight in the fundamental mechanism of protease activation and cellular export of proteins lacking a leader sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_AAKnLXk6DbVg90H21EOLACvtfcHk0ljiNN6lH6nGow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1ertL4%253D&md5=c64da9cb2a04420486b508cc6afd3a03</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.7.3877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.7.3877%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DD.%26aulast%3DPizzirani%26aufirst%3DC.%26aulast%3DAdinolfi%26aufirst%3DE.%26aulast%3DLemoli%26aufirst%3DR.%2BM.%26aulast%3DCurti%26aufirst%3DA.%26aulast%3DIdzko%26aufirst%3DM.%26aulast%3DPanther%26aufirst%3DE.%26aulast%3DDi%2BVirgilio%26aufirst%3DF.%26atitle%3DThe%2520P2X7%2520Receptor%253A%2520a%2520Key%2520Player%2520in%2520IL-1%2520Processing%2520and%2520Release%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D3877%26epage%3D3883%26doi%3D10.4049%2Fjimmunol.176.7.3877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piccini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasiglie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubartelli, A.</span></span> <span> </span><span class="NLM_article-title">ATP is Released by Monocytes Stimulated with Pathogen-Sensing Receptor Ligands and Induces IL-1beta and IL-18 Secretion in an Autocrine Way</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">8067</span>– <span class="NLM_lpage">8072</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709684105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1073%2Fpnas.0709684105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=18523012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1elsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=8067-8072&author=A.+Picciniauthor=S.+Cartaauthor=S.+Tassiauthor=D.+Lasiglieauthor=G.+Fossatiauthor=A.+Rubartelli&title=ATP+is+Released+by+Monocytes+Stimulated+with+Pathogen-Sensing+Receptor+Ligands+and+Induces+IL-1beta+and+IL-18+Secretion+in+an+Autocrine+Way&doi=10.1073%2Fpnas.0709684105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1β and IL-18 secretion in an autocrine way</span></div><div class="casAuthors">Piccini, Alessandra; Carta, Sonia; Tassi, Sara; Lasiglie, Denise; Fossati, Gianluca; Rubartelli, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8067-8072</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">IL-1β and IL-18 are crucial mediators of inflammation, and a defective control of their release may cause serious diseases.  Yet, the mechanisms regulating IL-1β and IL-18 secretion are partially undefined.  Both cytokines are produced as inactive cytoplasmic precursors.  Processing to the active form is mediated by caspase-1, which is in turn activated by the multiprotein complex inflammasome.  Here, the authors show that in primary human monocytes microbial components acting on different pathogen-sensing receptors and the danger-assocd. mol. uric acid are all competent to induce maturation and secretion of IL-1β and IL-18 through a process that involves as a first event the extracellular release of endogenous ATP.  ATP release is followed by autocrine stimulation of the purinergic receptors P2X7.  Indeed, antagonists of the P2X7 receptor (P2X7R), or treatment with apyrase, prevent IL-1β and IL-18 maturation and secretion triggered by the different stimuli.  At variance, blocking P2X7R activity has no effects on IL-1β secretion by monocytes carrying a mutated inflammasome that does not require exogenous ATP for activation.  P2X7R engagement is followed by K+ efflux and activation of phospholipase A2.  Both events are required for processing and secretion induced by all of the stimuli.  Thus, stimuli acting on different pathogen-sensing receptors converge on a common pathway where ATP externalization is the first step in the cascade of events leading to inflammasome activation and IL-1β and IL-18 secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwcfFNCJ8BPLVg90H21EOLACvtfcHk0ljiNN6lH6nGow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1elsLs%253D&md5=56a17ac4ddb6d5565c10db31957fc19f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709684105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709684105%26sid%3Dliteratum%253Aachs%26aulast%3DPiccini%26aufirst%3DA.%26aulast%3DCarta%26aufirst%3DS.%26aulast%3DTassi%26aufirst%3DS.%26aulast%3DLasiglie%26aufirst%3DD.%26aulast%3DFossati%26aufirst%3DG.%26aulast%3DRubartelli%26aufirst%3DA.%26atitle%3DATP%2520is%2520Released%2520by%2520Monocytes%2520Stimulated%2520with%2520Pathogen-Sensing%2520Receptor%2520Ligands%2520and%2520Induces%2520IL-1beta%2520and%2520IL-18%2520Secretion%2520in%2520an%2520Autocrine%2520Way%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D8067%26epage%3D8072%26doi%3D10.1073%2Fpnas.0709684105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karasawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawate, T.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Subtype-Specific Inhibition of the P2X7 Receptor</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e22153</span> <span class="refDoi"> DOI: 10.7554/elife.22153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.7554%2FeLife.22153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=27935479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslentLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=A.+Karasawaauthor=T.+Kawate&title=Structural+Basis+for+Subtype-Specific+Inhibition+of+the+P2X7+Receptor&doi=10.7554%2Felife.22153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for subtype-specific inhibition of the P2X7 receptor</span></div><div class="casAuthors">Karasawa, Akira; Kawate, Toshimitsu</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e22153/1-e22153/17</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">The P2X7 receptor is a non-selective cation channel activated by extracellular ATP (ATP).  Chronic activation of P2X7 underlies many health problems such as pathol. pain, yet we lack effective antagonists due to poorly understood mechanisms of inhibition.  Here we present crystal structures of a mammalian P2X7 receptor complexed with five structurally-unrelated antagonists.  Unexpectedly, these drugs all bind to an allosteric site distinct from the ATP-binding pocket in a groove formed between two neighboring subunits.  This novel drug-binding pocket accommodates a diversity of small mols. mainly through hydrophobic interactions.  Functional assays propose that these compds. allosterically prevent narrowing of the drug-binding pocket and the turret-like architecture during channel opening, which is consistent with a site of action distal to the ATP-binding pocket.  These novel mechanistic insights will facilitate the development of P2X7-specific drugs for treating human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeIo_gt316wbVg90H21EOLACvtfcHk0lgBQgn06UfAoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslentLrE&md5=76fcd0704f055ebb98c500c731da71b1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7554%2FeLife.22153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.22153%26sid%3Dliteratum%253Aachs%26aulast%3DKarasawa%26aufirst%3DA.%26aulast%3DKawate%26aufirst%3DT.%26atitle%3DStructural%2520Basis%2520for%2520Subtype-Specific%2520Inhibition%2520of%2520the%2520P2X7%2520Receptor%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26doi%3D10.7554%2Felife.22153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bidula, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, L.</span></span> <span> </span><span class="NLM_article-title">Mapping a Novel Positive Allosteric Modulator Binding Site in the Central Vestibule Region of Human P2X7</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3231</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-39771-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1038%2Fs41598-019-39771-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=30824738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BB3cfpsFWitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=3231&author=S.+M.+Bidulaauthor=B.+A.+Cromerauthor=S.+Walpoleauthor=J.+Anguloauthor=L.+Stokes&title=Mapping+a+Novel+Positive+Allosteric+Modulator+Binding+Site+in+the+Central+Vestibule+Region+of+Human+P2X7&doi=10.1038%2Fs41598-019-39771-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping a novel positive allosteric modulator binding site in the central vestibule region of human P2X7</span></div><div class="casAuthors">Bidula Stefan M; Walpole Samuel; Angulo Jesus; Stokes Leanne; Cromer Brett A; Cromer Brett A</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">P2X7 receptors are important in the regulation of inflammatory responses and immune responses to intracellular pathogens such as Mycobacterium tuberculosis and Toxoplasma gondii.  Enhancement of P2X7 receptor responses may be useful in pathogen clearance particularly in individuals with defective microbial killing mechanisms.  Ginsenosides from Panax ginseng have been discovered to act as positive allosteric modulators of P2X7.  Here we describe a novel modulator binding site identified by computational docking located in the central vestibule of P2X7 involving S60, D318, and L320 in the lower body β-sheets lining the lateral portals.  Potentiation of ATP-mediated responses by ginsenosides CK and Rd caused enhanced ionic currents, Ca(2+) influx and YOPRO-1 uptake in stably transfected HEK-293 cells (HEK-hP2X7) plus enhanced cell death responses.  Potentiation of ATP responses by CK and Rd was markedly reduced by mutations S59A, S60A, D318L and L320A supporting the proposed allosteric modulator binding site.  Furthermore, mutation of the conserved residues S60 and D318 led to alterations in P2X7 response and a higher sensitivity to ATP in the absence of modulators suggesting residues in the connecting rods play an important role in regulating P2X7 gating.  Identification of this novel binding site location in the central vestibule may also be relevant for structurally similar channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtbLKZwETEnuqrn-c4Of3KfW6udTcc2eZH09PhgBjXT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfpsFWitA%253D%253D&md5=ae11ec0dad23ef1b10374e48cace7fbe</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-39771-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-39771-5%26sid%3Dliteratum%253Aachs%26aulast%3DBidula%26aufirst%3DS.%2BM.%26aulast%3DCromer%26aufirst%3DB.%2BA.%26aulast%3DWalpole%26aufirst%3DS.%26aulast%3DAngulo%26aufirst%3DJ.%26aulast%3DStokes%26aufirst%3DL.%26atitle%3DMapping%2520a%2520Novel%2520Positive%2520Allosteric%2520Modulator%2520Binding%2520Site%2520in%2520the%2520Central%2520Vestibule%2520Region%2520of%2520Human%2520P2X7%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D3231%26doi%3D10.1038%2Fs41598-019-39771-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dayel, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R.</span></span> <span> </span><span class="NLM_article-title">Mapping the Site of Action of Human P2X7 Receptor Antagonists AZ11645373, Brilliant Blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit Allosteric Pocket</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1124/mol.119.116715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1124%2Fmol.119.116715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31263019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCqsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2019&pages=355-363&author=A.+B.+Dayelauthor=R.+J.+Evansauthor=R.+Schmid&title=Mapping+the+Site+of+Action+of+Human+P2X7+Receptor+Antagonists+AZ11645373%2C+Brilliant+Blue+G%2C+KN-62%2C+Calmidazolium%2C+and+ZINC58368839+to+the+Intersubunit+Allosteric+Pocket&doi=10.1124%2Fmol.119.116715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the site of action of human P2X7 receptor antagonists AZ11645373, brilliant blue G, KN-62, calmidazolium, and ZINC58368839 to the Intersubunit allosteric pocket</span></div><div class="casAuthors">Dayel, Anfal Bin; Evans, Richard J.; Schmid, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-363</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The P2X7 receptor is a trimeric ligand-gated ion channel activated by ATP.  It is implicated in the cellular response to trauma/disease and considered to have significant therapeutic potential.  Using chimeras and point mutants we have mapped the binding site of the P2X7R-selective antagonist AZ11645373 to the known allosteric binding pocket at the interface between two subunits, in proximity to, but sepd. from the ATP binding site.  Our structural model of AZ11645373 binding is consistent with effects of mutations on antagonist sensitivity, and the proposed binding mode explains variation in antagonist sensitivity between the human and rat P2X7 receptors.  We have also detd. the site of action for the P2X7R-selective antagonists ZINC58368839, brilliant blue G, KN-62, and calmidazolium.  The effect of intersubunit allosteric pocket "signature mutants" F88A, T90V, D92A, F103A, and V312A on antagonist sensitivity suggests that ZINC58368839 comprises a binding mode similar to AZ11645373 and other previously characterized antagonists.  For the larger antagonists, brilliant blue G, KN-62, and calmidazolium, our data imply an overlapping but distinct binding mode involving the central upper vestibule of the receptor in addn. to the intersubunit allosteric pocket.  Our work explains the site of action for a series of P2X7R antagonists and establishes "signature mutants" for P2X7R binding-mode characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV___L68o7D7Vg90H21EOLACvtfcHk0lgBQgn06UfAoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCqsb%252FM&md5=979f15602e1ab0d78f1d25c123d79f2b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fmol.119.116715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.119.116715%26sid%3Dliteratum%253Aachs%26aulast%3DDayel%26aufirst%3DA.%2BB.%26aulast%3DEvans%26aufirst%3DR.%2BJ.%26aulast%3DSchmid%26aufirst%3DR.%26atitle%3DMapping%2520the%2520Site%2520of%2520Action%2520of%2520Human%2520P2X7%2520Receptor%2520Antagonists%2520AZ11645373%252C%2520Brilliant%2520Blue%2520G%252C%2520KN-62%252C%2520Calmidazolium%252C%2520and%2520ZINC58368839%2520to%2520the%2520Intersubunit%2520Allosteric%2520Pocket%26jtitle%3DMol.%2520Pharmacol.%26date%3D2019%26volume%3D96%26spage%3D355%26epage%3D363%26doi%3D10.1124%2Fmol.119.116715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caseley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muench, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishwick, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.-H.</span></span> <span> </span><span class="NLM_article-title">Docking of Competitive Inhibitors to the P2X7 Receptor Family Reveals Key Differences Responsible for Changes in Response Between Rat and Human</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3164</span>– <span class="NLM_lpage">3167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2015.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=26099538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVejtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3164-3167&author=E.+A.+Caseleyauthor=S.+P.+Muenchauthor=S.+A.+Baldwinauthor=K.+Simmonsauthor=C.+W.+Fishwickauthor=L.-H.+Jiang&title=Docking+of+Competitive+Inhibitors+to+the+P2X7+Receptor+Family+Reveals+Key+Differences+Responsible+for+Changes+in+Response+Between+Rat+and+Human&doi=10.1016%2Fj.bmcl.2015.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Docking of competitive inhibitors to the P2X7 receptor family reveals key differences responsible for changes in response between rat and human</span></div><div class="casAuthors">Caseley, Emily A.; Muench, Stephen P.; Baldwin, Stephen A.; Simmons, Katie; Fishwick, Colin W.; Jiang, Lin-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3164-3167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The P2X7 receptor is a calcium permeable cationic channel activated by extracellular ATP, playing a role in chronic pain, osteoporosis and arthritis.  A no. of potential lead compds. are inactive against the rat isoform, despite good activity against the human homolog, making animal model studies problematic.  Here we have produced P2X7 models and docked three structurally distinct inhibitors using in silico approaches and show they have a similar mode of binding in which Phe95 plays a key role by forming pi-stacking interactions.  Importantly this residue is replaced by Leu in the rat P2X7 receptor resulting in a significantly reduced binding affinity.  This work provides new insights into binding of P2X7 inhibitors and shows the structural difference in human and rat P2X7 receptors which results in a difference in affinity.  Such information is useful both for the rational design of inhibitors based on these scaffolds and also the way in which these compds. are tested in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouJ81BAAXBurVg90H21EOLACvtfcHk0liUzjuQf8PO8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVejtL%252FM&md5=4af63cdf4b5861d4b8c2ca1ecd6605a1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DCaseley%26aufirst%3DE.%2BA.%26aulast%3DMuench%26aufirst%3DS.%2BP.%26aulast%3DBaldwin%26aufirst%3DS.%2BA.%26aulast%3DSimmons%26aufirst%3DK.%26aulast%3DFishwick%26aufirst%3DC.%2BW.%26aulast%3DJiang%26aufirst%3DL.-H.%26atitle%3DDocking%2520of%2520Competitive%2520Inhibitors%2520to%2520the%2520P2X7%2520Receptor%2520Family%2520Reveals%2520Key%2520Differences%2520Responsible%2520for%2520Changes%2520in%2520Response%2520Between%2520Rat%2520and%2520Human%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3164%26epage%3D3167%26doi%3D10.1016%2Fj.bmcl.2015.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parvathenani, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tertyshnikova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posmantur, R.</span></span> <span> </span><span class="NLM_article-title">P2X7 Mediates Superoxide Production in Primary Microglia and is Up-Regulated in a Transgenic Mouse Model of Alzheimer’s Disease</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">13309</span>– <span class="NLM_lpage">13317</span>, <span class="refDoi"> DOI: 10.1074/jbc.m209478200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1074%2Fjbc.M209478200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=12551918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislGru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=13309-13317&author=L.+K.+Parvathenaniauthor=S.+Tertyshnikovaauthor=C.+R.+Grecoauthor=S.+B.+Robertsauthor=B.+Robertsonauthor=R.+Posmantur&title=P2X7+Mediates+Superoxide+Production+in+Primary+Microglia+and+is+Up-Regulated+in+a+Transgenic+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1074%2Fjbc.m209478200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 Mediates Superoxide Production in Primary Microglia and Is Up-regulated in a Transgenic Mouse Model of Alzheimer's Disease</span></div><div class="casAuthors">Parvathenani, Lav K.; Tertyshnikova, Svetlana; Greco, Corinne R.; Roberts, Susan B.; Robertson, Barbara; Posmantur, Rand</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">13309-13317</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Primary rat microglia stimulated with either ATP or 2'- and 3'-O-(4-benzoylbenzoyl)-ATP (BzATP) release copious amts. of superoxide (O2•-).  ATP and BzATP stimulate O2•- prodn. through purinergic receptors, primarily the P2X7 receptor.  O2•- is produced through the activation of the NADPH oxidase.  Although both p42/44 MAPK and p38 MAPK were activated rapidly in cells stimulated with BzATP, only pharmacol. inhibition of p38 MAPK attenuated O2•- prodn.  Furthermore, an inhibitor of phosphatidylinositol 3-kinase attenuated O2•- prodn. to a greater extent than an inhibitor of p38 MAPK.  Both ATP and BzATP stimulated microglia-induced cortical cell death indicating this pathway may contribute to neurodegeneration.  Consistent with this hypothesis, P2X7 receptor was specifically up-regulated around β-amyloid plaques in a mouse model of Alzheimer's disease (Tg2576).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU2RQIXjn6I7Vg90H21EOLACvtfcHk0liUzjuQf8PO8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislGru7o%253D&md5=b2222cd7a8f22f3b491c2c97f1f54109</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M209478200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M209478200%26sid%3Dliteratum%253Aachs%26aulast%3DParvathenani%26aufirst%3DL.%2BK.%26aulast%3DTertyshnikova%26aufirst%3DS.%26aulast%3DGreco%26aufirst%3DC.%2BR.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DRobertson%26aufirst%3DB.%26aulast%3DPosmantur%26aufirst%3DR.%26atitle%3DP2X7%2520Mediates%2520Superoxide%2520Production%2520in%2520Primary%2520Microglia%2520and%2520is%2520Up-Regulated%2520in%2520a%2520Transgenic%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D13309%26epage%3D13317%26doi%3D10.1074%2Fjbc.m209478200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Frailes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Lauro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Diego-Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebastian-Serrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Hernandez, M.</span></span> <span> </span><span class="NLM_article-title">Amyloid Peptide Induced Neuroinflammation Increases the P2X7 Receptor Expression in Microglial Cells, Impacting on Its Functionality</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">143</span>, <span class="refDoi"> DOI: 10.3389/fncel.2019.00143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3389%2Ffncel.2019.00143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31031598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=143&author=C.+Martinez-Frailesauthor=C.+Di+Lauroauthor=C.+Bianchiauthor=L.+de+Diego-Garciaauthor=A.+Sebastian-Serranoauthor=L.+Boscaauthor=M.+Diaz-Hernandez&title=Amyloid+Peptide+Induced+Neuroinflammation+Increases+the+P2X7+Receptor+Expression+in+Microglial+Cells%2C+Impacting+on+Its+Functionality&doi=10.3389%2Ffncel.2019.00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid peptide induced neuroinflammation increases the P2X7 receptor expression in microglial cells, impacting on its functionality</span></div><div class="casAuthors">Martinez-Frailes, Carlos; Di Lauro, Caterina; Bianchi, Carolina; de Diego-Garcia, Laura; Sebastian-Serrano, Alvaro; Bosca, Lisardo; Diaz-Hernandez, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">143</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Alzheimer disease is a neurodegenerative disease characterized by the presence of senile plaques composed of amyloid-β (Aβ) peptide, neurofibrillary tangles, neuronal loss and neuroinflammation.  Previous works have revealed that extracellular ATP, through its selective receptor P2X7 (P2X7R), is essential to neuroinflammation and neurotoxicity induced by Aβ.  P2X7R is upregulated on microglial cells around the senile plaques.  This upregulation progressively rises with age and is parallel with an accumulation of senile plaques and also correlates with the synaptic toxicity detected both in animal models reproducing AD and human patients of AD.  Furthermore, the late onset of the first AD-assocd. symptoms suggests that aging assocd.-changes may be relevant to the disease progression.  Thus, microglia motility and its capacity to respond to exogenous ATP stimulus decrease with aging.  To evaluate whether the P2X7R age related-changes on microglia cells may be relevant to the AD progression, we generated a new transgenic mouse model crossing an Aβ peptide mouse model, J20 mice and the P2X7R reporter mice P2X7REGFP.  Our results indicate that neuroinflammation induced by Ab peptide causes changes in the P2X7R distribution pattern, increasing it s expression in microglial cells at advanced and late stages, when microgliosis occurs, but not in the early stages, in the absence of microgliosis.  In addn., we found that P2X7R activation promotes microglial cells migration to senile plaques but decreases their phagocytic capacity.  Moreover, we found a significant redn. of P2X7R transcription on neuronal cells at the early and advanced stages, but not at the late stages.  Since previous studies have reported that either pharmacol. inhibition or selective downregulation of P2X7R significantly improve behavioral alterations and reduce the incidence and size of senile plaques in the early and advanced stages of AD, the results presented here provide new evidence, indicating that this therapeutic approach could be also efficient in the late stages of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9sWfRgDcePbVg90H21EOLACvtfcHk0liUzjuQf8PO8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKms7o%253D&md5=0935599fb6c9a7d85ba46babe28bc5bb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2019.00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2019.00143%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Frailes%26aufirst%3DC.%26aulast%3DDi%2BLauro%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3Dde%2BDiego-Garcia%26aufirst%3DL.%26aulast%3DSebastian-Serrano%26aufirst%3DA.%26aulast%3DBosca%26aufirst%3DL.%26aulast%3DDiaz-Hernandez%26aufirst%3DM.%26atitle%3DAmyloid%2520Peptide%2520Induced%2520Neuroinflammation%2520Increases%2520the%2520P2X7%2520Receptor%2520Expression%2520in%2520Microglial%2520Cells%252C%2520Impacting%2520on%2520Its%2520Functionality%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D143%26doi%3D10.3389%2Ffncel.2019.00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Hernandez, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Villafuertes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León-Otegui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hontecillas-Prieto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Puerto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trejo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gualix, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miras-Portugal, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Hernandez, M.</span></span> <span> </span><span class="NLM_article-title">In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease through GSK3β and secretases</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1816</span>– <span class="NLM_lpage">1828</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2011.09.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.neurobiolaging.2011.09.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22048123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFaksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=1816-1828&author=J.+I.+Diaz-Hernandezauthor=R.+Gomez-Villafuertesauthor=M.+Le%C3%B3n-Oteguiauthor=L.+Hontecillas-Prietoauthor=A.+Del+Puertoauthor=J.+L.+Trejoauthor=J.+J.+Lucasauthor=J.+J.+Garridoauthor=J.+Gualixauthor=M.+T.+Miras-Portugalauthor=M.+Diaz-Hernandez&title=In+vivo+P2X7+inhibition+reduces+amyloid+plaques+in+Alzheimer%E2%80%99s+disease+through+GSK3%CE%B2+and+secretases&doi=10.1016%2Fj.neurobiolaging.2011.09.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases</span></div><div class="casAuthors">Diaz-Hernandez, Juan Ignacio; Gomez-Villafuertes, Rosa; Leon-Otegui, Miriam; Hontecillas-Prieto, Lourdes; del Puerto, Ana; Trejo, Jose Luis; Lucas, Jose Javier; Garrido, Juan Jose; Gualix, Javier; Miras-Portugal, Maria Teresa; Diaz-Hernandez, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1816-1828</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">β-Amyloid (Aβ) peptide prodn. from amyloid precursor protein (APP) is essential in the formation of the β-amyloid plaques characteristic of Alzheimer's disease.  However, the extracellular signals that maintain the balance between nonpathogenic and pathol. forms of APP processing, mediated by α-secretase and β-secretase resp., remain poorly understood.  In the present work, we describe regulation of the processing of APP via the ATP receptor P2X7R.  In 2 different cellular lines, the inhibition of either native or overexpressed P2X7R increased α-secretase activity through inhibition of glycogen synthase kinase 3 (GSK-3).  In vivo inhibition of the P2X7R in J20 mice, transgenic for mutant human APP, induced a significant decrease in the no. of hippocampal amyloid plaques.  This redn. correlated with a decrease in glycogen synthase kinase 3 activity in J20 mice, increasing the proteolytic processing of APP through an increase in α-secretase activity.  The in vivo findings presented here demonstrate for the first time the therapeutic potential of P2X7R antagonism in the treatment of familiar Alzheimer's disease (FAD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquJ7Scs2MZhbVg90H21EOLACvtfcHk0licS68XuRc3dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFaksrY%253D&md5=a455fc370ac113fffea9029fbc44c055</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2011.09.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2011.09.040%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz-Hernandez%26aufirst%3DJ.%2BI.%26aulast%3DGomez-Villafuertes%26aufirst%3DR.%26aulast%3DLe%25C3%25B3n-Otegui%26aufirst%3DM.%26aulast%3DHontecillas-Prieto%26aufirst%3DL.%26aulast%3DDel%2BPuerto%26aufirst%3DA.%26aulast%3DTrejo%26aufirst%3DJ.%2BL.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26aulast%3DGarrido%26aufirst%3DJ.%2BJ.%26aulast%3DGualix%26aufirst%3DJ.%26aulast%3DMiras-Portugal%26aufirst%3DM.%2BT.%26aulast%3DDiaz-Hernandez%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520P2X7%2520inhibition%2520reduces%2520amyloid%2520plaques%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520through%2520GSK3%25CE%25B2%2520and%2520secretases%26jtitle%3DNeurobiol.%2520Aging%26date%3D2012%26volume%3D33%26spage%3D1816%26epage%3D1828%26doi%3D10.1016%2Fj.neurobiolaging.2011.09.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durrenberger, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünblatt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monoranu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dexter, D. T.</span></span> <span> </span><span class="NLM_article-title">Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study</span>. <i>Parkinsons Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">214714</span>, <span class="refDoi"> DOI: 10.1155/2012/214714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1155%2F2012%2F214714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22548201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BC38rpsVGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=214714&author=P.+F.+Durrenbergerauthor=E.+Gr%C3%BCnblattauthor=F.+S.+Fernandoauthor=C.+M.+Monoranuauthor=J.+Evansauthor=P.+Riedererauthor=R.+Reynoldsauthor=D.+T.+Dexter&title=Inflammatory+Pathways+in+Parkinson%E2%80%99s+Disease%3B+A+BNE+Microarray+Study&doi=10.1155%2F2012%2F214714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study</span></div><div class="casAuthors">Durrenberger Pascal F; Grunblatt Edna; Fernando Francesca S; Monoranu Camelia Maria; Evans Jordan; Riederer Peter; Reynolds Richard; Dexter David T</div><div class="citationInfo"><span class="NLM_cas:title">Parkinson's disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214714</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The aetiology of Parkinson's disease (PD) is yet to be fully understood but it is becoming more and more evident that neuronal cell death may be multifactorial in essence.  The main focus of PD research is to better understand substantia nigra homeostasis disruption, particularly in relation to the wide-spread deposition of the aberrant protein α-synuclein.  Microarray technology contributed towards PD research with several studies to date and one gene, ALDH1A1 (Aldehyde dehydrogenase 1 family, member A1), consistently reappeared across studies including the present study, highlighting dopamine (DA) metabolism dysfunction resulting in oxidative stress and most probably leading to neuronal cell death.  Neuronal cell death leads to increased inflammation through the activation of astrocytes and microglia.  Using our dataset, we aimed to isolate some of these pathways so to offer potential novel neuroprotective therapeutic avenues.  To that effect our study has focused on the upregulation of P2X7 (purinergic receptor P2X, ligand-gated ion channel, 7) receptor pathway (microglial activation) and on the NOS3 (nitric oxide synthase 3) pathway (angiogenesis).  In summary, although the exact initiator of striatal DA neuronal cell death remains to be determined, based on our analysis, this event does not remain without consequence.  Extracellular ATP and reactive astrocytes appear to be responsible for the activation of microglia which in turn release proinflammatory cytokines contributing further to the parkinsonian condition.  In addition to tackling oxidative stress pathways we also suggest to reduce microglial and endothelial activation to support neuronal outgrowth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJPAiA5hY20hFwe7cAcrfPfW6udTcc2eb9kIFUsDlaHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rpsVGrsw%253D%253D&md5=3086796fc740f8a890a6831979ac4b2c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1155%2F2012%2F214714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F214714%26sid%3Dliteratum%253Aachs%26aulast%3DDurrenberger%26aufirst%3DP.%2BF.%26aulast%3DGr%25C3%25BCnblatt%26aufirst%3DE.%26aulast%3DFernando%26aufirst%3DF.%2BS.%26aulast%3DMonoranu%26aufirst%3DC.%2BM.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DRiederer%26aufirst%3DP.%26aulast%3DReynolds%26aufirst%3DR.%26aulast%3DDexter%26aufirst%3DD.%2BT.%26atitle%3DInflammatory%2520Pathways%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%253B%2520A%2520BNE%2520Microarray%2520Study%26jtitle%3DParkinsons%2520Dis.%26date%3D2012%26volume%3D2012%26spage%3D214714%26doi%3D10.1155%2F2012%2F214714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-T.</span></span> <span> </span><span class="NLM_article-title">Extracellular ATP Mediates Necrotic Cell Swelling in SN4741 Dopaminergic Neurons Through P2X7 Receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">37350</span>– <span class="NLM_lpage">37358</span>, <span class="refDoi"> DOI: 10.1074/jbc.m707915200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1074%2Fjbc.M707915200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=17962183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGjtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=37350-37358&author=D.-J.+Junauthor=J.+Kimauthor=S.-Y.+Jungauthor=R.+Songauthor=J.-H.+Nohauthor=Y.-S.+Parkauthor=S.-H.+Ryuauthor=J.-H.+Kimauthor=Y.-Y.+Kongauthor=J.-M.+Chungauthor=K.-T.+Kim&title=Extracellular+ATP+Mediates+Necrotic+Cell+Swelling+in+SN4741+Dopaminergic+Neurons+Through+P2X7+Receptors&doi=10.1074%2Fjbc.m707915200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular ATP Mediates Necrotic Cell Swelling in SN4741 Dopaminergic Neurons through P2X7 Receptors</span></div><div class="casAuthors">Jun, Dong-Jae; Kim, Jaeyoon; Jung, Sang-Yong; Song, Ran; Noh, Ji-Hyun; Park, Yong-Soo; Ryu, Sung-Ho; Kim, Joung-Hun; Kong, Young-Yun; Chung, Jun-Mo; Kim, Kyong-Tai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">37350-37358</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Extracellular ATP has recently been identified as an important regulator of cell death in response to pathol. insults.  When SN4741 cells, which are dopaminergic neurons derived from the substantia nigra of transgenic mouse embryos, are exposed to ATP, cell death occurs.  This cell death is assocd. with prominent cell swelling, loss of ER integrity, the formation of many large cytoplasmic vacuoles, and subsequent cytolysis and DNA release.  In addn., the cleavage of caspase-3, a hallmark of apoptosis, is induced by ATP treatment.  However, caspase inhibitors do not overcome ATP-induced cell death, indicating that both necrosis and apoptosis are assocd. with ATP-induced cell death and suggesting that a necrotic event might override the apoptotic process.  In this study we also found that P2X7 receptors (P2X7Rs) are abundantly expressed in SN4741 cells, and both ATP-induced swelling and cell death are reversed by pretreatment with the P2X7Rs antagonist, KN62, or by knock-down of P2X7Rs with small interfering RNAs.  Therefore, extracellular ATP release from injured tissues may act as an accelerating factor in necrotic SN4741 dopaminergic cell death via P2X7Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFFDWZ-00b77Vg90H21EOLACvtfcHk0licS68XuRc3dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGjtrzO&md5=499d267c28421155c676226cd3e1eccf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M707915200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M707915200%26sid%3Dliteratum%253Aachs%26aulast%3DJun%26aufirst%3DD.-J.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DS.-Y.%26aulast%3DSong%26aufirst%3DR.%26aulast%3DNoh%26aufirst%3DJ.-H.%26aulast%3DPark%26aufirst%3DY.-S.%26aulast%3DRyu%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DKong%26aufirst%3DY.-Y.%26aulast%3DChung%26aufirst%3DJ.-M.%26aulast%3DKim%26aufirst%3DK.-T.%26atitle%3DExtracellular%2520ATP%2520Mediates%2520Necrotic%2520Cell%2520Swelling%2520in%2520SN4741%2520Dopaminergic%2520Neurons%2520Through%2520P2X7%2520Receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D37350%26epage%3D37358%26doi%3D10.1074%2Fjbc.m707915200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carmo, M. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, A. P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, A. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pliássova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeira, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canas, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, G. M.</span></span> <span> </span><span class="NLM_article-title">The P2X7 Receptor Antagonist Brilliant Blue G Attenuates Contralateral Rotations in a Rat Model of Parkinsonism Through a Combined Control of Synaptotoxicity, Neurotoxicity and Gliosis</span>. <i>Neuropharmacol</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.01.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.neuropharm.2014.01.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=24508709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Wku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2014&pages=142-152&author=M.+R.+S.+Carmoauthor=A.+P.+F.+Menezesauthor=A.+C.+L.+Nunesauthor=A.+Pli%C3%A1ssovaauthor=A.+P.+Roloauthor=C.+M.+Palmeiraauthor=R.+A.+Cunhaauthor=P.+M.+Canasauthor=G.+M.+Andrade&title=The+P2X7+Receptor+Antagonist+Brilliant+Blue+G+Attenuates+Contralateral+Rotations+in+a+Rat+Model+of+Parkinsonism+Through+a+Combined+Control+of+Synaptotoxicity%2C+Neurotoxicity+and+Gliosis&doi=10.1016%2Fj.neuropharm.2014.01.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis</span></div><div class="casAuthors">Carmo, Marta R. S.; Menezes, Ana Paula F.; Nunes, Ana Carla L.; Pliassova, Anna; Rolo, Anabela P.; Palmeira, Carlos M.; Cunha, Rodrigo A.; Canas, Paula M.; Andrade, Geanne M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">142-152</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) involves an initial loss of striatal dopaminergic terminals evolving into a degeneration of dopaminergic neurons in the substantia nigra (SN), which can be modeled by 6-hydroxydopamine (6-OHDA) administration.  Since ATP is a danger signal acting through its P2X7 receptors (P2X7R), we now tested if a blood-brain barrier-permeable P2X7R antagonist, Brilliant Blue G (BBG), controlled the 6-OHDA-induced PD-like features in rats.  BBG (45 mg/kg) attenuated the 6-OHDA-induced: 1) increase of contralateral rotations in the apomorphine test, an effect mimicked by another P2X7R antagonist A438079 applied intra-cerebroventricularly; 2) short-term memory impairment in the passive avoidance and cued version of the Morris Water maze; 3) redn. of dopamine content in the striatum and SN; 4) microgliosis and astrogliosis in the striatum.  To grasp the mechanism of action of BBG, we used in vitro models exploring synaptotoxicity (striatal synaptosomes) and neurotoxicity (dopamine-differentiated neuroblastoma SH-SY5Y cells).  P2X7R were present in striatal dopaminergic terminals, and BBG (100 nM) prevented the 6-OHDA-induced synaptosomal dysfunction.  P2X7R were also co-localized with tyrosine hydroxylase in SH-SY5Y cells, where BBG (100 nM) attenuated the 6-OHDA-induced neurotoxicity.  This suggests that P2X7R contribute to PD pathogenesis through a triple impact on synaptotoxicity, gliosis and neurotoxicity, highlighting the therapeutic potential of P2X7R antagonists in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpri1wRg8e8HLVg90H21EOLACvtfcHk0lhamB5R-AnI7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Wku7k%253D&md5=be760e2f1bb8da76d1782f3fe0665007</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.01.045%26sid%3Dliteratum%253Aachs%26aulast%3DCarmo%26aufirst%3DM.%2BR.%2BS.%26aulast%3DMenezes%26aufirst%3DA.%2BP.%2BF.%26aulast%3DNunes%26aufirst%3DA.%2BC.%2BL.%26aulast%3DPli%25C3%25A1ssova%26aufirst%3DA.%26aulast%3DRolo%26aufirst%3DA.%2BP.%26aulast%3DPalmeira%26aufirst%3DC.%2BM.%26aulast%3DCunha%26aufirst%3DR.%2BA.%26aulast%3DCanas%26aufirst%3DP.%2BM.%26aulast%3DAndrade%26aufirst%3DG.%2BM.%26atitle%3DThe%2520P2X7%2520Receptor%2520Antagonist%2520Brilliant%2520Blue%2520G%2520Attenuates%2520Contralateral%2520Rotations%2520in%2520a%2520Rat%2520Model%2520of%2520Parkinsonism%2520Through%2520a%2520Combined%2520Control%2520of%2520Synaptotoxicity%252C%2520Neurotoxicity%2520and%2520Gliosis%26jtitle%3DNeuropharmacol%26date%3D2014%26volume%3D81%26spage%3D142%26epage%3D152%26doi%3D10.1016%2Fj.neuropharm.2014.01.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrazoli, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, H. D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nascimento, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira-Giacomelli, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwindt, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britto, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, H.</span></span> <span> </span><span class="NLM_article-title">Brilliant Blue G, But Not Fenofibrate, Treatment Reverts Hemiparkinsonian Behavior and Restores Dopamine Levels in an Animal Model of Parkinson’s Disease</span>. <i>Cell Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.3727/096368917x695227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3727%2F096368917X695227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=28403913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnt1Klsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=669-677&author=E.+G.+Ferrazoliauthor=H.+D.+N.+de+Souzaauthor=I.+C.+Nascimentoauthor=%C3%81.+Oliveira-Giacomelliauthor=T.+T.+Schwindtauthor=L.+R.+Brittoauthor=H.+Ulrich&title=Brilliant+Blue+G%2C+But+Not+Fenofibrate%2C+Treatment+Reverts+Hemiparkinsonian+Behavior+and+Restores+Dopamine+Levels+in+an+Animal+Model+of+Parkinson%E2%80%99s+Disease&doi=10.3727%2F096368917x695227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Brilliant Blue G, But Not Fenofibrate, Treatment Reverts Hemiparkinsonian Behavior and Restores Dopamine Levels in an Animal Model of Parkinson's Disease</span></div><div class="casAuthors">Ferrazoli Eneas G; de Souza Hellio D N; Nascimento Isis C; Oliveira-Giacomelli Agatha; Schwindt Telma T; Britto Luiz R; Ulrich Henning</div><div class="citationInfo"><span class="NLM_cas:title">Cell transplantation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">669-677</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson's disease (PD) is a neurodegenerative disorder, characterized by the loss of dopaminergic neurons in the substantia nigra and their projections to the striatum.  Several processes have been described as potential inducers of the dopaminergic neuron death, such as inflammation, oxidative stress, and mitochondrial dysfunction.  However, the death of dopaminergic neurons seems to be multifactorial, and its cause remains unclear.  ATP-activating purinergic receptors influence various physiological functions in the CNS, including neurotransmission.  Purinergic signaling is also involved in pathological scenarios, where ATP is extensively released and promotes sustained purinergic P2X7 receptor (P2X7R) activation and consequent induction of cell death.  This effect occurs, among other factors, by oxidative stress and during the inflammatory response.  On the other hand, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) is involved in energy metabolism and mitochondrial biogenesis.  Expression and activity upregulation of this protein has been related with reduction of oxidative stress and neuroprotection.  Therefore, P2X7R and PGC-1α are potential targets in the treatment of PD.  Here hemiparkinsonism was induced by unilateral stereotactic injection of 6-OHDA in a rat model.  After 7 days, the establishment of PD was confirmed and followed by treatment with the P2X7R antagonist Brilliant Blue G (BBG) or PGC-1α agonist fenofibrate.  BBG, but not fenofibrate, reverted hemiparkinsonian behavior accompanied by an increase in tyrosine hydroxylase immunoreactivity in the substantia nigra.  Our results suggest that the P2X7R may be a therapeutic target in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxS5Q_1W1J1TAyhZbj3lKdfW6udTcc2eZiKnTpzoKANbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnt1Klsg%253D%253D&md5=c457be4238ee10d3b97e14ae2f8de38d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3727%2F096368917X695227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3727%252F096368917X695227%26sid%3Dliteratum%253Aachs%26aulast%3DFerrazoli%26aufirst%3DE.%2BG.%26aulast%3Dde%2BSouza%26aufirst%3DH.%2BD.%2BN.%26aulast%3DNascimento%26aufirst%3DI.%2BC.%26aulast%3DOliveira-Giacomelli%26aufirst%3D%25C3%2581.%26aulast%3DSchwindt%26aufirst%3DT.%2BT.%26aulast%3DBritto%26aufirst%3DL.%2BR.%26aulast%3DUlrich%26aufirst%3DH.%26atitle%3DBrilliant%2520Blue%2520G%252C%2520But%2520Not%2520Fenofibrate%252C%2520Treatment%2520Reverts%2520Hemiparkinsonian%2520Behavior%2520and%2520Restores%2520Dopamine%2520Levels%2520in%2520an%2520Animal%2520Model%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DCell%2520Transplant.%26date%3D2017%26volume%3D26%26spage%3D669%26epage%3D677%26doi%3D10.3727%2F096368917x695227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzaferri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. G.</span></span> <span> </span><span class="NLM_article-title">P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">93</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2020.00093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3389%2Ffnmol.2020.00093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=32595451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlOltbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=93&author=C.+Ruiz-Ruizauthor=F.+Calzaferriauthor=A.+G.+Garcia&title=P2X7+Receptor+Antagonism+as+a+Potential+Therapy+in+Amyotrophic+Lateral+Sclerosis&doi=10.3389%2Ffnmol.2020.00093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 receptor antagonism as a potential therapy in amyotrophic lateral sclerosis</span></div><div class="casAuthors">Ruiz-Ruiz, Cristina; Calzaferri, Francesco; Garcia, Antonio G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">This review focuses on the purinergic ionotropic receptor P2X7 (P2X7R) as a potential target for developing drugs that delay the onset and/or disease progression in patients with amyotrophic lateral sclerosis (ALS).  Description of clin. and genetic ALS features is followed by an anal. of advantages and drawbacks of transgenic mouse models of disease based on mutations in a bunch of proteins, particularly Cu/Zn superoxide dismutase (SOD1), TAR-DNA binding protein-43 (TDP-43), Fused in Sarcoma/Translocated in Sarcoma (FUS), and Chromosome 9 open reading frame 72 (C9orf72).  Though of limited value, these models are however crit. to study the proof of concept of new compds., before reaching clin. trials.  The authors also provide a description of ALS pathogenesis including protein aggregation, calcium-dependent excitotoxicity, dysfunction of calcium-binding proteins, ultrastructural mitochondrial alterations, disruption of mitochondrial calcium handling, and overprodn. of reactive oxygen species (ROS).  Understanding disease pathogenic pathways may ease the identification of new drug targets.  Subsequently, neuroinflammation linked with P2X7Rs in ALS pathogenesis is described in order to understand the rationale of placing the use of P2X7R antagonists as a new therapeutic pharmacol. approach to ALS.  This is the basis for the hypothesis that a P2X7R blocker could mitigate the neuroinflammatory state, indirectly leading to neuroprotection and higher motoneuron survival in ALS patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA9x1VgsfP-7Vg90H21EOLACvtfcHk0lhamB5R-AnI7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlOltbjK&md5=27333c993e8771e3036baf3adc2b4d06</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2020.00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2020.00093%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz-Ruiz%26aufirst%3DC.%26aulast%3DCalzaferri%26aufirst%3DF.%26aulast%3DGarcia%26aufirst%3DA.%2BG.%26atitle%3DP2X7%2520Receptor%2520Antagonism%2520as%2520a%2520Potential%2520Therapy%2520in%2520Amyotrophic%2520Lateral%2520Sclerosis%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2020%26volume%3D13%26spage%3D93%26doi%3D10.3389%2Ffnmol.2020.00093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yiangou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrenberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessell, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banati, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span> <span> </span><span class="NLM_article-title">COX-2, CB2 and P2X7-Immunoreactivities are Increased in Activated Microglial Cells/Macrophages of Multiple Sclerosis and Amyotrophic Lateral Sclerosis Spinal Cord</span>. <i>BMC Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1186/1471-2377-6-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1186%2F1471-2377-6-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=16512913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BD287mvFCitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=12&author=Y.+Yiangouauthor=P.+Facerauthor=P.+Durrenbergerauthor=I.+P.+Chessellauthor=A.+Naylorauthor=C.+Bountraauthor=R.+R.+Banatiauthor=P.+Anand&title=COX-2%2C+CB2+and+P2X7-Immunoreactivities+are+Increased+in+Activated+Microglial+Cells%2FMacrophages+of+Multiple+Sclerosis+and+Amyotrophic+Lateral+Sclerosis+Spinal+Cord&doi=10.1186%2F1471-2377-6-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord</span></div><div class="casAuthors">Yiangou Yiangos; Facer Paul; Durrenberger Pascal; Chessell Iain P; Naylor Alan; Bountra Chas; Banati Richard R; Anand Praveen</div><div class="citationInfo"><span class="NLM_cas:title">BMC neurology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  While multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are primarily inflammatory and degenerative disorders respectively, there is increasing evidence for shared cellular mechanisms that may affect disease progression, particularly glial responses.  Cyclooxygenase 2 (COX-2) inhibition prolongs survival and cannabinoids ameliorate progression of clinical disease in animal models of ALS and MS respectively, but the mechanism is uncertain.  Therefore, three key molecules known to be expressed in activated microglial cells/macrophages, COX-2, CB2 and P2X7, which plays a role in inflammatory cascades, were studied in MS and ALS post-mortem human spinal cord.  METHODS:  Frozen human post mortem spinal cord specimens, controls (n = 12), ALS (n = 9) and MS (n = 19), were available for study by immunocytochemistry and Western blotting, using specific antibodies to COX-2, CB2 and P2X7, and markers of microglial cells/macrophages (CD 68, ferritin).  In addition, autoradiography for peripheral benzodiazepine binding sites was performed on some spinal cord sections using [3H] (R)-PK11195, a marker of activated microglial cells/macrophages.  Results of immunostaining and Western blotting were quantified by computerized image and optical density analysis respectively.  RESULTS:  In control spinal cord, few small microglial cells/macrophages-like COX-2-immunoreactive cells, mostly bipolar with short processes, were scattered throughout the tissue, whilst MS and ALS specimens had significantly greater density of such cells with longer processes in affected regions, by image analysis.  Inflammatory cell marker CD68-immunoreactivity, [3H] (R)-PK11195 autoradiography, and double-staining against ferritin confirmed increased production of COX-2 by activated microglial cells/macrophages.  An expected 70-kDa band was seen by Western blotting which was significantly increased in MS spinal cord.  There was good correlation between the COX-2 immunostaining and optical density of the COX-2 70-kDa band in the MS group (r = 0.89, P = 0.0011, n = 10).  MS and ALS specimens also had significantly greater density of P2X7 and CB2-immunoreactive microglial cells/macrophages in affected regions.  CONCLUSION:  It is hypothesized that the known increase of lesion-associated extracellular ATP contributes via P2X7 activation to release IL-1 beta which in turn induces COX-2 and downstream pathogenic mediators.  Selective CNS-penetrant COX-2 and P2X7 inhibitors and CB2 specific agonists deserve evaluation in the progression of MS and ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTre1M4-XAP9f6xYuD7tu2XfW6udTcc2eY7JuAbCbnjhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287mvFCitA%253D%253D&md5=33b344093a3cdbab389d158bf731e597</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2F1471-2377-6-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2377-6-12%26sid%3Dliteratum%253Aachs%26aulast%3DYiangou%26aufirst%3DY.%26aulast%3DFacer%26aufirst%3DP.%26aulast%3DDurrenberger%26aufirst%3DP.%26aulast%3DChessell%26aufirst%3DI.%2BP.%26aulast%3DNaylor%26aufirst%3DA.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBanati%26aufirst%3DR.%2BR.%26aulast%3DAnand%26aufirst%3DP.%26atitle%3DCOX-2%252C%2520CB2%2520and%2520P2X7-Immunoreactivities%2520are%2520Increased%2520in%2520Activated%2520Microglial%2520Cells%252FMacrophages%2520of%2520Multiple%2520Sclerosis%2520and%2520Amyotrophic%2520Lateral%2520Sclerosis%2520Spinal%2520Cord%26jtitle%3DBMC%2520Neurol.%26date%3D2006%26volume%3D6%26spage%3D12%26doi%3D10.1186%2F1471-2377-6-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cervetto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattaroli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoli, M.</span></span> <span> </span><span class="NLM_article-title">Motor Neuron Dysfunction in a Mouse Model of ALS: Gender-Dependent Effect of P2X7 Antagonism</span>. <i>Toxicol</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2013.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.tox.2013.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=23583883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVWhtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2013&pages=69-77&author=C.+Cervettoauthor=D.+Frattaroliauthor=G.+Mauraauthor=M.+Marcoli&title=Motor+Neuron+Dysfunction+in+a+Mouse+Model+of+ALS%3A+Gender-Dependent+Effect+of+P2X7+Antagonism&doi=10.1016%2Fj.tox.2013.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Motor neuron dysfunction in a mouse model of ALS: Gender-dependent effect of P2X7 antagonism</span></div><div class="casAuthors">Cervetto, Chiara; Frattaroli, Daniela; Maura, Guido; Marcoli, Manuela</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">69-77</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative progressive currently untreatable disease, characterized by selective motor neuron degeneration; the incidence and prevalence of ALS are greater in men than in women.  Although some important mechanisms that might contribute to the death of motor neurons have been identified, the mechanisms underlying disease pathophysiol. are still uncertain.  In particular, the mechanisms underlying the role of gender in ALS and whether treatments should take into account sexual dimorphism remain only partially understood.  Recently, the P2X7 receptor for ATP was reported to display neurotoxic potential in motor neuron disorders, and antagonism of the receptor has been suggested to be helpful in these disorders.  Studying transgenic mice with superoxide dismutase 1 gene mutations, widely used as model for ALS, may provide a better understanding of pathogenic mechanisms and of toxicity towards motor neurons, also possibly helping to understand whether treatments for ALS should take into account sexual dimorphism.The aim of the work was (1) investigating on gender-dependence of disease progression in the std. model for ALS - the transgenic mouse bearing superoxide dismutase 1 gene mutations - and (2) assessing if a P2X7 receptor antagonist treatment should take into account sexual dimorphism.  We evaluated if gender affect the disease course, the motor performance, the wt. loss and the lifespan in mice overexpressing mutant superoxide dismutase 1.  We measured motor impairment, motor strength and coordination by rotarod and grip strength testing.  Further, we assessed if a treatment with the P2X7 receptor antagonist Brilliant Blue G - a dye that can cross the blood-brain barrier, has low toxicity, and has exhibited therapeutic effects in animal models of neurodegenerative diseases - impact on the disease progression, in male and female ALS mice.  We found that (1) the onset and the disease progression, and the survival were dependent on gender: male performed worst than female, lost body wt. and died before; (2) treatment with the P2X7 receptor antagonist Brilliant Blue G ameliorated the disease progression.  The treatment effect was gender-dependent: amelioration was greater in male than in female.  In conclusion, we suggest that not only pathogenetic mechanism of motor neuron toxicity but also the drug treatment effectiveness may depend on gender; sexual dimorphism should be considered when investigating on ALS treatment efficacy in the ALS animal model.  Our findings also point on the potential relevance of P2X7 receptor antagonism for ALS treatment, and highlight the importance of adopting a sex-specific approach to searching for treatment of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppk8x0xfmJsLVg90H21EOLACvtfcHk0liiMWyLCLGiTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVWhtro%253D&md5=530b1f3a994923f49d7311847c94319d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2013.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2013.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DCervetto%26aufirst%3DC.%26aulast%3DFrattaroli%26aufirst%3DD.%26aulast%3DMaura%26aufirst%3DG.%26aulast%3DMarcoli%26aufirst%3DM.%26atitle%3DMotor%2520Neuron%2520Dysfunction%2520in%2520a%2520Mouse%2520Model%2520of%2520ALS%253A%2520Gender-Dependent%2520Effect%2520of%2520P2X7%2520Antagonism%26jtitle%3DToxicol%26date%3D2013%26volume%3D311%26spage%3D69%26epage%3D77%26doi%3D10.1016%2Fj.tox.2013.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dongol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthbertson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraghty, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sophocleous, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerbury, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluyter, R.</span></span> <span> </span><span class="NLM_article-title">The P2X7 Receptor Antagonist JNJ-47965567 Administered Thrice Weekly from Disease Onset Does not Alter Progression of Amyotrophic Lateral Sclerosis in SOD1(G93A) Mice</span>. <i>Purinergic Signal.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1007/s11302-020-09692-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1007%2Fs11302-020-09692-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=32170537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltFSjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=109-122&author=D.+Lyauthor=A.+Dongolauthor=P.+Cuthbertsonauthor=T.+V.+Guyauthor=N.+J.+Geraghtyauthor=R.+A.+Sophocleousauthor=L.+Sinauthor=B.+J.+Turnerauthor=D.+Watsonauthor=J.+J.+Yerburyauthor=R.+Sluyter&title=The+P2X7+Receptor+Antagonist+JNJ-47965567+Administered+Thrice+Weekly+from+Disease+Onset+Does+not+Alter+Progression+of+Amyotrophic+Lateral+Sclerosis+in+SOD1%28G93A%29+Mice&doi=10.1007%2Fs11302-020-09692-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice.</span></div><div class="casAuthors">Ly, Diane; Dongol, Anjila; Cuthbertson, Peter; Guy, Thomas V.; Geraghty, Nicholas J.; Sophocleous, Reece A.; Sin, Lucia; Turner, Bradley J.; Watson, Debbie; Yerbury, Justin J.; Sluyter, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-122</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The ATP-gated P2X7 ion channel has emerging roles in amyotrophic lateral sclerosis (ALS) progression.  Therefore, the current study aimed to det. whether the CNS-penetrant P2X7 antagonist, JNJ-47965567, could ameliorate ALS progression in SOD1G93A mice.  A flow cytometric assay revealed that JNJ-47965567 impaired ATP-induced cation dye uptake in a concn.-dependent manner in murine J774 macrophages.  Female and male SOD1G93A mice were injected i.p. with JNJ-47965567 (30 mg/kg) or 2-(hydroxypropyl)-beta-cyclodextrin (vehicle control) three times a week from disease onset until end stage, when tissues were collected and studied.  JNJ-47965567 did not impact wt. loss, clin. score, motor (rotarod) coordination or survival compared to control mice.  NanoString anal. revealed altered spinal cord gene expression in JNJ-47965567 mice compared to control mice, but such differences were not confirmed by quant. PCR.  Flow cytometric analyses revealed no differences between treatments in the frequencies or activation status of T cell or dendritic cell subsets in lymphoid tissues or in the concns. of serum cytokines.  Notably, serum IL-27, IFNbetaand IL-10 were present in relatively high concns. compared to other cytokines in both groups.  In conclusion, JNJ-47965567 administered thrice weekly from disease onset did not alter disease progression or mol. and cellular parameters in SOD1G93A mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ2BFtzdZIAbVg90H21EOLACvtfcHk0liiMWyLCLGiTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltFSjurg%253D&md5=8c6e7a8b9740851014d14f34cd4b22e8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11302-020-09692-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-020-09692-4%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DD.%26aulast%3DDongol%26aufirst%3DA.%26aulast%3DCuthbertson%26aufirst%3DP.%26aulast%3DGuy%26aufirst%3DT.%2BV.%26aulast%3DGeraghty%26aufirst%3DN.%2BJ.%26aulast%3DSophocleous%26aufirst%3DR.%2BA.%26aulast%3DSin%26aufirst%3DL.%26aulast%3DTurner%26aufirst%3DB.%2BJ.%26aulast%3DWatson%26aufirst%3DD.%26aulast%3DYerbury%26aufirst%3DJ.%2BJ.%26aulast%3DSluyter%26aufirst%3DR.%26atitle%3DThe%2520P2X7%2520Receptor%2520Antagonist%2520JNJ-47965567%2520Administered%2520Thrice%2520Weekly%2520from%2520Disease%2520Onset%2520Does%2520not%2520Alter%2520Progression%2520of%2520Amyotrophic%2520Lateral%2520Sclerosis%2520in%2520SOD1%2528G93A%2529%2520Mice%26jtitle%3DPurinergic%2520Signal.%26date%3D2020%26volume%3D16%26spage%3D109%26epage%3D122%26doi%3D10.1007%2Fs11302-020-09692-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narcisse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scemes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosnan, C. F.</span></span> <span> </span><span class="NLM_article-title">The Cytokine IL-1beta Transiently Enhances P2X7 Receptor Expression and Function in Human Astrocytes</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1002/glia.20110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fglia.20110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=15472991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BD2crpsF2kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=245-258&author=L.+Narcisseauthor=E.+Scemesauthor=Y.+Zhaoauthor=S.+C.+Leeauthor=C.+F.+Brosnan&title=The+Cytokine+IL-1beta+Transiently+Enhances+P2X7+Receptor+Expression+and+Function+in+Human+Astrocytes&doi=10.1002%2Fglia.20110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes</span></div><div class="casAuthors">Narcisse Leontine; Scemes Eliana; Zhao Yongmei; Lee Sunhee C; Brosnan Celia F</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-58</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">Extracellular nucleotide di- and triphosphates such as ATP and ADP mediate their effects through purinergic P2 receptors belonging to either the metabotropic P2Y or the ionotropic P2X receptor family.  The P2X7R is a unique member of the P2X family, which forms a pore in response to ligand stimulation, regulating cell permeability, cytokine release, and/or apoptosis.  This receptor is also unique in that its affinity for the ligand benzoyl-benzoyl ATP (BzATP) is at least 10-fold greater than that of ATP.  Primary human fetal astrocytes in culture express low-levels of P2X7R mRNA and protein, and BzATP induces only a slight influx in intracellular calcium [Ca2+]i, with little demonstrable effect on gene expression or pore formation in these cells.  We now show that, following treatment with the proinflammatory cytokine IL-1beta, BzATP induces a robust rise in [Ca2+]i with agonist and antagonist profiles indicative of the P2X7R.  IL-1beta also induced the formation of membrane pores as evidenced by the uptake of YO-PRO-1 (375 Da).  Quantitative real-time PCR demonstrated transient upregulation of P2X7R mRNA in IL-1beta-treated cells, while FACS analysis indicated a similar upregulation of P2X7R protein at the cell membrane.  In multiple sclerosis lesions, immunoreactivity for the P2X7R was demonstrated on reactive astrocytes in autopsy brain tissues.  In turn, P2X7R stimulation increased the production of IL-1-induced nitric oxide synthase activity by astrocytes in culture.  These studies suggest that signaling via the P2X7R may modulate the astrocytic response to inflammation in the human central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTisPFlwsWFEa-9TkgmBqTqfW6udTcc2eY7JuAbCbnjhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpsF2kug%253D%253D&md5=67358b4c1409471f1bf905c560c11f27</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fglia.20110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.20110%26sid%3Dliteratum%253Aachs%26aulast%3DNarcisse%26aufirst%3DL.%26aulast%3DScemes%26aufirst%3DE.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DBrosnan%26aufirst%3DC.%2BF.%26atitle%3DThe%2520Cytokine%2520IL-1beta%2520Transiently%2520Enhances%2520P2X7%2520Receptor%2520Expression%2520and%2520Function%2520in%2520Human%2520Astrocytes%26jtitle%3DGlia%26date%3D2005%26volume%3D49%26spage%3D245%26epage%3D258%26doi%3D10.1002%2Fglia.20110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guile, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkinshaw, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Antagonists of the P2X(7) Receptor. From Lead Identification to Drug Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3123</span>– <span class="NLM_lpage">3141</span>, <span class="refDoi"> DOI: 10.1021/jm801528x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801528x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFWnsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3123-3141&author=S.+D.+Guileauthor=L.+Alcarazauthor=T.+N.+Birkinshawauthor=K.+C.+Bowersauthor=M.+R.+Ebdenauthor=M.+Furberauthor=M.+J.+Stocks&title=Antagonists+of+the+P2X%287%29+Receptor.+From+Lead+Identification+to+Drug+Development&doi=10.1021%2Fjm801528x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of the P2X7 Receptor. From Lead Identification to Drug Development</span></div><div class="casAuthors">Guile, Simon D.; Alcaraz, Lilian; Birkinshaw, Timothy N.; Bowers, Keith C.; Ebden, Mark R.; Furber, Mark; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3123-3141</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3KAnZB1iwlLVg90H21EOLACvtfcHk0li3h8LNqDQGUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFWnsbw%253D&md5=00684268474169015a967ad8daabec15</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm801528x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801528x%26sid%3Dliteratum%253Aachs%26aulast%3DGuile%26aufirst%3DS.%2BD.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBirkinshaw%26aufirst%3DT.%2BN.%26aulast%3DBowers%26aufirst%3DK.%2BC.%26aulast%3DEbden%26aufirst%3DM.%2BR.%26aulast%3DFurber%26aufirst%3DM.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DAntagonists%2520of%2520the%2520P2X%25287%2529%2520Receptor.%2520From%2520Lead%2520Identification%2520to%2520Drug%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3123%26epage%3D3141%26doi%3D10.1021%2Fjm801528x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murgia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rippa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Virgilio, F.</span></span> <span> </span><span class="NLM_article-title">Oxidized ATP. An Irreversible Inhibitor of the Macrophage Purinergic P2Z Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">8199</span>– <span class="NLM_lpage">8203</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(18)53082-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2FS0021-9258%2818%2953082-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=8463330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK3sXit1Kgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=8199-8203&author=M.+Murgiaauthor=S.+Hanauauthor=P.+Pizzoauthor=M.+Rippaauthor=F.+Di+Virgilio&title=Oxidized+ATP.+An+Irreversible+Inhibitor+of+the+Macrophage+Purinergic+P2Z+Receptor&doi=10.1016%2Fs0021-9258%2818%2953082-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2z receptor</span></div><div class="casAuthors">Murgia, Marta; Hanau, Stefania; Pizzo, Paola; Rippa, Mario; Di Virgilio, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8199-203</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The effects of oxidized ATP (oATP) on responses triggered by extracellular ATP (ATPe) were investigated in the mouse macrophage-like cell line J774.  ATPe induced in this cell line two kinds of responses mediated by two different P2 purinergic receptors: 1) an early permeabilization of the plasma membrane to extracellular hydrophilic markers of Mr ≤900 mediated by P2Z receptors; and 2) a fast mobilization of Ca2+ from intracellular stores mediated by P2Y receptors.  Low oATP concns. (100 μM) completely blocked the first response without affecting the second.  ATPe-dependent cell swelling, vacuolization, and lysis were also inhibited.  Antagonism developed slowly, as an incubation at 37° for at least 2 h in the presence of oATP was needed and was irreversible, thus suggesting that the inhibitory action was due to covalent modification of the receptor.  The rate of hydrolysis of exogenous ATP was slightly decreased by oATP, indicating a minor blocking effect of this compd. on plasma membrane ecto-ATPases in the concn. range tested.  These observations suggest that oATP may be a potentially very useful tool for isolation and characterization of the P2Z purinergic receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxT6uQQf5BrbVg90H21EOLACvtfcHk0li3h8LNqDQGUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit1Kgurs%253D&md5=c85fbd67af69bdc020809d3e0f71dcd4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2953082-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252953082-9%26sid%3Dliteratum%253Aachs%26aulast%3DMurgia%26aufirst%3DM.%26aulast%3DHanau%26aufirst%3DS.%26aulast%3DPizzo%26aufirst%3DP.%26aulast%3DRippa%26aufirst%3DM.%26aulast%3DDi%2BVirgilio%26aufirst%3DF.%26atitle%3DOxidized%2520ATP.%2520An%2520Irreversible%2520Inhibitor%2520of%2520the%2520Macrophage%2520Purinergic%2520P2Z%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D8199%26epage%3D8203%26doi%3D10.1016%2Fs0021-9258%2818%2953082-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotrina, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedergaard, M.</span></span> <span> </span><span class="NLM_article-title">Systemic Administration of an Antagonist of the ATP-Sensitive Receptor P2X7 Improves Recovery after Spinal Cord Injury</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">12489</span>– <span class="NLM_lpage">12493</span>, <span class="refDoi"> DOI: 10.1073/pnas.0902531106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1073%2Fpnas.0902531106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19666625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpslCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=12489-12493&author=W.+Pengauthor=M.+L.+Cotrinaauthor=X.+Hanauthor=H.+Yuauthor=L.+Bekarauthor=L.+Blumauthor=T.+Takanoauthor=G.-F.+Tianauthor=S.+A.+Goldmanauthor=M.+Nedergaard&title=Systemic+Administration+of+an+Antagonist+of+the+ATP-Sensitive+Receptor+P2X7+Improves+Recovery+after+Spinal+Cord+Injury&doi=10.1073%2Fpnas.0902531106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic administration of an antagonist of the ATP-sensitive receptor P2x7 improves recovery after spinal cord injury</span></div><div class="casAuthors">Peng, Weiguo; Cotrina, Maria L.; Han, Xiaoning; Yu, Hongmei; Bekar, Lane; Blum, Livnat; Takano, Takahiro; Tian, Guo-Feng; Goldman, Steven A.; Nedergaard, Maiken</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">12489-12493, S12489/1-S12489/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Traumatic spinal cord injury is characterized by an immediate, irreversible loss of tissue at the lesion site, as well as a secondary expansion of tissue damage over time.  Although secondary injury should, in principle, be preventable, no effective treatment options currently exist for patients with acute spinal cord injury (SCI).  Excessive release of ATP by the traumatized tissue, followed by activation of high-affinity P2X7 receptors, has previously been implicated in secondary injury, but no clin. relevant strategy by which to antagonize P2X7 receptors has yet, to the best of our knowledge, been reported.  Here we have tested the neuroprotective effects of a systemically administered P2X7R antagonist, Brilliant blue G (BBG), in a wt.-drop model of thoracic SCI in rats.  Administration of BBG 15 min after injury reduced spinal cord anat. damage and improved motor recovery without evident toxicity.  Moreover, BBG treatment directly reduced local activation of astrocytes and microglia, as well as neutrophil infiltration.  These observations suggest that BBG not only protected spinal cord neurons from purinergic excitotoxicity, but also reduced local inflammatory responses.  Importantly, BBG is a deriv. of a commonly used blue food color (FD&C blue No. 1), which crosses the blood-brain barrier.  Systemic administration of BBG may thus comprise a readily feasible approach by which to treat traumatic SCI in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Yf3jpAKlxbVg90H21EOLACvtfcHk0lgxW-Rp0YQIlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpslCisbc%253D&md5=2a6f8aa6f802c71540c74c74fdcc1809</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0902531106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0902531106%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DCotrina%26aufirst%3DM.%2BL.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DBekar%26aufirst%3DL.%26aulast%3DBlum%26aufirst%3DL.%26aulast%3DTakano%26aufirst%3DT.%26aulast%3DTian%26aufirst%3DG.-F.%26aulast%3DGoldman%26aufirst%3DS.%2BA.%26aulast%3DNedergaard%26aufirst%3DM.%26atitle%3DSystemic%2520Administration%2520of%2520an%2520Antagonist%2520of%2520the%2520ATP-Sensitive%2520Receptor%2520P2X7%2520Improves%2520Recovery%2520after%2520Spinal%2520Cord%2520Injury%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D12489%26epage%3D12493%26doi%3D10.1073%2Fpnas.0902531106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lambrecht, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friebe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windscheif, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungardt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bäumert, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spatz-Kümbel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutschler, E.</span></span> <span> </span><span class="NLM_article-title">PPADS, a Novel Functionally Selective Antagonist of P2 Purinoceptor-Mediated Responses</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>217</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(92)90877-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2F0014-2999%2892%2990877-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1330591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK38XltVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=1992&pages=217-219&author=G.+Lambrechtauthor=T.+Friebeauthor=U.+Grimmauthor=U.+Windscheifauthor=E.+Bungardtauthor=C.+Hildebrandtauthor=H.+G.+B%C3%A4umertauthor=G.+Spatz-K%C3%BCmbelauthor=E.+Mutschler&title=PPADS%2C+a+Novel+Functionally+Selective+Antagonist+of+P2+Purinoceptor-Mediated+Responses&doi=10.1016%2F0014-2999%2892%2990877-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses</span></div><div class="casAuthors">Lambrecht, Guenter; Friebe, Thomas; Grimm, Ulrike; Windscheif, Ursula; Bungardt, Edwin; Hildebrandt, Caren; Baeumert, Hans G.; Spatz-Kuembel, Gerhard; Mutschler, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">217-19</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">PPADS (pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid) has been characterized as a novel antagonist which selectively blocks P2 purinoceptor-mediated responses in rabbit vas deferens at pre- and postjunctional sites.  PPADS did not interact with α1-adrenoceptors, muscarinic M2 and M3 receptors, histamine H1 and adenosine A1 receptors.  Thus, PPADS is a novel and useful pharmacol. tool to study cotransmission in tissues where ATP and coexisting neurotransmitters act in concert.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlvJYA0GOQO7Vg90H21EOLACvtfcHk0lgxW-Rp0YQIlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltVCqurk%253D&md5=9cc352930fb06540bff8ea1007b9e819</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2892%2990877-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252892%252990877-7%26sid%3Dliteratum%253Aachs%26aulast%3DLambrecht%26aufirst%3DG.%26aulast%3DFriebe%26aufirst%3DT.%26aulast%3DGrimm%26aufirst%3DU.%26aulast%3DWindscheif%26aufirst%3DU.%26aulast%3DBungardt%26aufirst%3DE.%26aulast%3DHildebrandt%26aufirst%3DC.%26aulast%3DB%25C3%25A4umert%26aufirst%3DH.%2BG.%26aulast%3DSpatz-K%25C3%25BCmbel%26aufirst%3DG.%26aulast%3DMutschler%26aufirst%3DE.%26atitle%3DPPADS%252C%2520a%2520Novel%2520Functionally%2520Selective%2520Antagonist%2520of%2520P2%2520Purinoceptor-Mediated%2520Responses%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1992%26volume%3D217%26spage%3D217%26epage%3D219%26doi%3D10.1016%2F0014-2999%2892%2990877-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gargett, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. S.</span></span> <span> </span><span class="NLM_article-title">The Isoquinoline Derivative KN-62 a Potent Antagonist of the P2Z-Receptor of Human Lymphocytes</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0701081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1038%2Fsj.bjp.0701081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=9113369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK2sXjtVGrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1997&pages=1483-1490&author=C.+E.+Gargettauthor=J.+S.+Wiley&title=The+Isoquinoline+Derivative+KN-62+a+Potent+Antagonist+of+the+P2Z-Receptor+of+Human+Lymphocytes&doi=10.1038%2Fsj.bjp.0701081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes</span></div><div class="casAuthors">Gargett, Caroline E.; Wiley, James S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1483-1490</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Extracellular ATP is an agonist for a P2Z receptor on human lymphocytes which mediates opening of a cation-selective ion channel, activation of phospholipase D, and shedding of the adhesion mol., L-selectin, from the cell surface.  The isoquinolinesulfonamides, KN-62, (1-[N, O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine), a selective antagonist of Ca2+/calmodulin-dependent protein kinase II (CaMKII), and KN-04, (N-[1-[N-methyl-p-(5 isoquinoline sulfonyl)benzyl]-2-(4 phenylpiperazine)ethyl]-5-isoquinolinesulfonamide) an inactive analog, were used to investigate the possible role of CaMKII in these diverse effects of extracellular ATP.  KN-62 potently antagonized ATP-stimulated Ba2+ influx into fura-2 loaded human lymphocytes with an IC50 of 12.7 nM and complete inhibition of the flux at a concn. of 500 nM.  Similarly, KN-62 inhibited ATP-stimulated ethidium+ uptake, measured by time resolved flow cytometry, with an IC50 of 13.1 nM and complete inhibition of the flux at 500 nM.  KN-04 antagonized ATP-stimulated Ba2+ influx with an IC50 of 17.3 nM.  Similarly, KN-04 inhibited ATP-stimulated ethidium+ uptake with an IC50 of 37.2 nM.  Both fluxes were completely inhibited at 500 nM KN-04.  ATP-stimulated phospholipase D activity, measured in [3H]-oleic acid-labeled lymphocytes by the transphosphatidylation reaction, was antagonized by KN-62 and KN-04, with 50% inhibition at 5.9 and 9.7 nM, resp.  Both KN-62 and KN-04 inhibited ATP-stimulated shedding of L-selectin, measured by flow cytometric anal. of cell surface L-selectin, with IC50 values of 31.5 and 78.7 nM, resp.  Neither of the isoquinolinesulfonamides (500 nM) inhibited phorbol ester- or ionomycin-stimulated phospholipase D activity or phorbol ester-induced shedding of L-selectin.  The inhibitory effect of KN-62 or KN-04 on P2Z-mediated responses was slow in onset (5 min) and only partially reversed by washing the cells.  Both KN-62 and KN-04 (at 500 nM) had no effect on UTP-stimulated Ca2+ transients in fura-2 loaded human neutrophils, a response which is mediated by the P2Y2 receptor.  Thus, KN-62 and KN-04 are potent antagonists of the P2Z receptor and at nanomolar concns. inhibit all known responses mediated by the P2Z receptor of human lymphocytes.  In contrast, KN-62 and KN-04 had no effect on responses mediated by the P2Y2 receptor of neutrophils.  Moreover, since KN-62 and KN-04 are almost equipotent, the P2Z-mediated responses do not involve CaMKII, but indicate that the isoquinolinesulfonamides are potent and direct inhibitors of the P2Z-receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0JeOmP3i4hbVg90H21EOLACvtfcHk0limG-C0xbcYWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtVGrs78%253D&md5=e64ed73e3517f2a1d6caf22c5230979e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0701081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0701081%26sid%3Dliteratum%253Aachs%26aulast%3DGargett%26aufirst%3DC.%2BE.%26aulast%3DWiley%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520Isoquinoline%2520Derivative%2520KN-62%2520a%2520Potent%2520Antagonist%2520of%2520the%2520P2Z-Receptor%2520of%2520Human%2520Lymphocytes%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D120%26spage%3D1483%26epage%3D1490%26doi%3D10.1038%2Fsj.bjp.0701081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship Studies of Pyrimidine-2,4-dione Derivatives as Potent P2X7 Receptor Antagonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.10.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.ejmech.2015.10.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=26547056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyhtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2015&pages=180-193&author=J.-H.+Parkauthor=G.-E.+Leeauthor=S.-D.+Leeauthor=H.+Koauthor=Y.-C.+Kim&title=Structure-Activity+Relationship+Studies+of+Pyrimidine-2%2C4-dione+Derivatives+as+Potent+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.ejmech.2015.10.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists</span></div><div class="casAuthors">Park, Jin-Hee; Lee, Ga-Eun; Lee, So-Deok; Ko, Hyojin; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">180-193</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As an optimization strategy, the flexible structure of KN-62, a known P2X7 receptor antagonist, was converted into conformationally constrained derivs. using pyrimidine-2,4-dione as the core skeleton.  Various modifications at the 4-position of the piperazine moiety of the new lead compd. were performed to improve P2X7 receptor antagonistic activities, which were evaluated in HEK293 cells stably expressing the human P2X7 receptor (EtBr uptake assay) and in THP-1 cells (IL-1β ELISA assay).  According to the results, polycycloalkyl acyl or di-halogenated benzoyl substituents were much more favorable than the original Ph group of KN-62.  Among these compds., I and adamantyl carbonyl derivs. showed potent antagonistic effects, with IC50 values ranging from 10 to 30 nM.  In addn., the in vitro adsorption, distribution, metab., excretion, and toxicity (ADMET) profile of I was detd. to be in acceptable ranges in terms of metabolic stability and cytotoxicity.  These results suggest that pyrimidine-2,4-dione derivs. may be promising novel P2X7 receptor antagonists for the development of anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz1HGQYz3nQrVg90H21EOLACvtfcHk0limG-C0xbcYWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyhtb7J&md5=04245371468145d95704d2bd721bb142</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.10.036%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DG.-E.%26aulast%3DLee%26aufirst%3DS.-D.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DStructure-Activity%2520Relationship%2520Studies%2520of%2520Pyrimidine-2%252C4-dione%2520Derivatives%2520as%2520Potent%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D106%26spage%3D180%26epage%3D193%26doi%3D10.1016%2Fj.ejmech.2015.10.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationships of Novel, Substituted 5,6-dihydrodibenzo[a,g]quinolizinium P2X7 Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.11.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2008.11.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19110420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2itb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=954-958&author=G.+E.+Leeauthor=H.-S.+Leeauthor=S.+D.+Leeauthor=J.-H.+Kimauthor=W.-K.+Kimauthor=Y.-C.+Kim&title=Synthesis+and+Structure-Activity+Relationships+of+Novel%2C+Substituted+5%2C6-dihydrodibenzo%5Ba%2Cg%5Dquinolizinium+P2X7+Antagonists&doi=10.1016%2Fj.bmcl.2008.11.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of novel, substituted 5,6-dihydrodibenzo[a,g]quinolizinium P2X7 antagonists</span></div><div class="casAuthors">Lee, Ga Eun; Lee, Ho-Sung; Lee, So Deok; Kim, Jung-Ho; Kim, Won-Ki; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">954-958</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Iminium quaternary protoberberine alkaloids (QPA) have been found to be novel P2X7 antagonists.  To assess their structure-activity relationships, these compds. were modified at their R1 and R2 groups and assayed for their ability to inhibit the 2'(3')-O-(4-benzoylbenzoyl)-ATP (BzATP)-induced uptake of fluorescent ethidium by HEK-293 cells stably expressing the human P2X7 receptor, and their ability to inhibit BzATP-induced IL-1β release by differentiated THP-1 cells.  Compds. I (R1 = Et) and I (R1 = allyl), and esp. compd. II (R1 = Et, R2 = 2-nitro-4,5-dimethoxybenzyl) had potent inhibitory efficacy as P2X7 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEth-82I2_jLVg90H21EOLACvtfcHk0lhSgOvG-xjECQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2itb0%253D&md5=4b2b38a38cf59d4ca688811ee7224b0f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.11.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.11.088%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DG.%2BE.%26aulast%3DLee%26aufirst%3DH.-S.%26aulast%3DLee%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DW.-K.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationships%2520of%2520Novel%252C%2520Substituted%25205%252C6-dihydrodibenzo%255Ba%252Cg%255Dquinolizinium%2520P2X7%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D954%26epage%3D958%26doi%3D10.1016%2Fj.bmcl.2008.11.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reekie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barron, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werry, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and Pharmacological Evaluation of a Novel Series of Adamantyl Cyanoguanidines as P2X7 Receptor Antagonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.02.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.ejmech.2017.02.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=28279849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFymu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=433-439&author=J.+O%E2%80%99Brien-Brownauthor=A.+Jacksonauthor=T.+A.+Reekieauthor=M.+L.+Barronauthor=E.+L.+Werryauthor=P.+Schiaviniauthor=M.+McDonnellauthor=L.+Munozauthor=S.+Wilkinsonauthor=B.+Nollauthor=S.+Wangauthor=M.+Kassiou&title=Discovery+and+Pharmacological+Evaluation+of+a+Novel+Series+of+Adamantyl+Cyanoguanidines+as+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.ejmech.2017.02.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists</span></div><div class="casAuthors">O'Brien-Brown, James; Jackson, Alexander; Reekie, Tristan A.; Barron, Melissa L.; Werry, Eryn L.; Schiavini, Paolo; McDonnell, Michelle; Munoz, Lenka; Wilkinson, Shane; Noll, Benjamin; Wang, Shudong; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">433-439</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Here we report adamantyl cyanoguanidine compds. based on hybrids of the adamantyl amide scaffold reported by AstraZeneca and cyanoguanidine scaffold reported by Abbott Labs.  Compd. 27 displayed five-fold greater inhibitory potency than the lead compd. 2 in both pore-formation and interleukin-1β release assays, while 35-treated mice displayed an antidepressant phenotype in behavioral studies.  This SAR study provides a proof of concept for hybrid compds., which will help in the further development of P2X7R antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDxomOTDTbzbVg90H21EOLACvtfcHk0lhSgOvG-xjECQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFymu7g%253D&md5=b7376e07daebfe826167802febe47f8d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.02.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.02.060%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien-Brown%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DA.%26aulast%3DReekie%26aufirst%3DT.%2BA.%26aulast%3DBarron%26aufirst%3DM.%2BL.%26aulast%3DWerry%26aufirst%3DE.%2BL.%26aulast%3DSchiavini%26aufirst%3DP.%26aulast%3DMcDonnell%26aufirst%3DM.%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DWilkinson%26aufirst%3DS.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520Pharmacological%2520Evaluation%2520of%2520a%2520Novel%2520Series%2520of%2520Adamantyl%2520Cyanoguanidines%2520as%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D130%26spage%3D433%26epage%3D439%26doi%3D10.1016%2Fj.ejmech.2017.02.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merriman, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shum, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabol, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirtz-Brugger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of Novel 4,5-Diarylimidazolines as Potent P2X7 Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.10.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2004.10.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=15603968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFanu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=435-438&author=G.+H.+Merrimanauthor=L.+Maauthor=P.+Shumauthor=D.+McGarryauthor=F.+Volzauthor=J.+S.+Sabolauthor=A.+Grossauthor=Z.+Zhaoauthor=D.+Rampeauthor=L.+Wangauthor=F.+Wirtz-Bruggerauthor=B.+A.+Harrisauthor=D.+Macdonald&title=Synthesis+and+SAR+of+Novel+4%2C5-Diarylimidazolines+as+Potent+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2004.10.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists</span></div><div class="casAuthors">Merriman, Gregory H.; Ma, Liang; Shum, Patrick; McGarry, Daniel; Volz, Frank; Sabol, Jeffrey S.; Gross, Alexandre; Zhao, Zhicheng; Rampe, David; Wang, Lin; Wirtz-Brugger, Friederike; Harris, Bruce A.; Macdonald, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435-438</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 4,5-diarylimidazoline libraries were prepd. using high-throughput solid-phase and microwave techniques.  The compds., e.g., I, were evaluated as P2X7 antagonists and their SAR is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo80lFJGWZNXrVg90H21EOLACvtfcHk0lhSgOvG-xjECQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFanu7bP&md5=fd6134b90dc1a22ae66543e375fdc37f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.10.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.10.052%26sid%3Dliteratum%253Aachs%26aulast%3DMerriman%26aufirst%3DG.%2BH.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DShum%26aufirst%3DP.%26aulast%3DMcGarry%26aufirst%3DD.%26aulast%3DVolz%26aufirst%3DF.%26aulast%3DSabol%26aufirst%3DJ.%2BS.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DRampe%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWirtz-Brugger%26aufirst%3DF.%26aulast%3DHarris%26aufirst%3DB.%2BA.%26aulast%3DMacdonald%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520Novel%25204%252C5-Diarylimidazolines%2520as%2520Potent%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D435%26epage%3D438%26doi%3D10.1016%2Fj.bmcl.2004.10.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationships of Pyrazolodiazepine Derivatives as Human P2X7 Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6053</span>– <span class="NLM_lpage">6058</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2009.09.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19800793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GmurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6053-6058&author=J.-Y.+Leeauthor=J.+Yuauthor=W.+J.+Choauthor=H.+Koauthor=Y.-C.+Kim&title=Synthesis+and+Structure-Activity+Relationships+of+Pyrazolodiazepine+Derivatives+as+Human+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2009.09.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists</span></div><div class="casAuthors">Lee, Ju-Yeon; Yu, Juan; Cho, Won Je; Ko, Hyojin; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6053-6058</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Screening of library compds. has yielded pyrazolodiazepine derivs. with P2X7 receptor antagonist activity.  To explore the structure-activity relationships (SAR) of these pyrazolodiazepines as human P2X7 receptor antagonists, derivs. were synthesized by substitutions at positions 4 and 6 of the pyrazolodiazepine skeleton.  Using a 2'(3')-O-(4-benzoylbenzoyl)ATP (BzATP)-induced fluorescent ethidium uptake assay, the activities of these derivs. were tested in HEK-293 cells stably expressing human P2X7 receptors.  Moreover, the effect of these derivs. was assessed by measuring their effect on IL-1β release induced by BzATP-induced activation of differentiated THP-1 cells.  A 2-phenethyl pyrazolodiazepine deriv. with a 1-methyl-1H-3-indolyl ester group at position 6 had fivefold greater activity than the deriv. with a 5-isoquinolinyl ester group.  Moreover, a benzyl moiety at the 4-position had fivefold greater activity than a bicyclic moiety.  The stereochem. effect at C-6 showed a preference for the (R)-isomer.  Among the series of active derivs., I exhibited activity similar to that of the pos. control, KN-62, as shown by the inhibitory effects of IL-1β release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodk4lmKyYRoLVg90H21EOLACvtfcHk0lju2gMNmgr-cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GmurzE&md5=db9d429514bae8e8a6155196960973c5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.053%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.-Y.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DW.%2BJ.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationships%2520of%2520Pyrazolodiazepine%2520Derivatives%2520as%2520Human%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6053%26epage%3D6058%26doi%3D10.1016%2Fj.bmcl.2009.09.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7410</span>– <span class="NLM_lpage">7430</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01690</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01690" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyitLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7410-7430&author=J.-H.+Parkauthor=D.+R.+Williamsauthor=J.-H.+Leeauthor=S.-D.+Leeauthor=J.-H.+Leeauthor=H.+Koauthor=G.-E.+Leeauthor=S.+Kimauthor=J.-M.+Leeauthor=A.+Abdelrahmanauthor=C.+E.+M%C3%BCllerauthor=D.-W.+Jungauthor=Y.-C.+Kim&title=Potent+Suppressive+Effects+of+1-Piperidinylimidazole+Based+Novel+P2X7+Receptor+Antagonists+on+Cancer+Cell+Migration+and+Invasion&doi=10.1021%2Facs.jmedchem.5b01690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion</span></div><div class="casAuthors">Park, Jin-Hee; Williams, Darren R.; Lee, Ji-Hyung; Lee, So-Deok; Lee, Je-Heon; Ko, Hyojin; Lee, Ga-Eun; Kim, Sujin; Lee, Jeong-Min; Abdelrahman, Aliaa; Muller, Christa E.; Jung, Da-Woon; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7410-7430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The P2X7 receptor (P2X7R) has been reported as a key mediator in inflammatory processes and cancer invasion/metastasis.  In this study, we report the discovery of novel P2X7R antagonists and their functional activities as potential antimetastatic agents.  Modifications of the hydantoin core-skeleton and the side chain substituents of the P2X7R antagonist 7 were performed.  The structure-activity relationships (SAR) and optimization demonstrated the importance of the sulfonyl group at the R1 position and the substituted position and overall size of R2 for P2X7R antagonism.  The optimized novel analogs displayed potent P2X7 receptor antagonism (IC50 = 0.11-112 nM) along with significant suppressive effects on IL-1β release (IC50 = 0.32-210 nM).  Moreover, representative antagonists (12g, 13k, and 17d) with imidazole and uracil core skeletons significantly inhibited the invasion of MDA-MB-231 triple neg. breast cancer cells and cancer cell migration in a zebrafish xenograft model, suggesting the potential therapeutic application of these novel P2X7 antagonists to block metastatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCjP9mbj45cbVg90H21EOLACvtfcHk0lju2gMNmgr-cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyitLjP&md5=14aaace65aac1eb7f159f6e18d4fd725</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01690%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DWilliams%26aufirst%3DD.%2BR.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DS.-D.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DG.-E.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.-M.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJung%26aufirst%3DD.-W.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DPotent%2520Suppressive%2520Effects%2520of%25201-Piperidinylimidazole%2520Based%2520Novel%2520P2X7%2520Receptor%2520Antagonists%2520on%2520Cancer%2520Cell%2520Migration%2520and%2520Invasion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7410%26epage%3D7430%26doi%3D10.1021%2Facs.jmedchem.5b01690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, W. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationships of Quinolinone and Quinoline-Based P2X7 Receptor Antagonists and Their anti-Sphere Formation Activities in Glioblastoma Cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.ejmech.2018.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=29649742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1Kgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=462-481&author=S.-H.+Kwakauthor=S.+Shinauthor=J.-H.+Leeauthor=J.-K.+Shimauthor=M.+Kimauthor=S.-D.+Leeauthor=A.+Leeauthor=J.+Baeauthor=J.-H.+Parkauthor=A.+Abdelrahmanauthor=C.+E.+M%C3%BCllerauthor=S.+K.+Choauthor=S.-G.+Kangauthor=M.+A.+Baeauthor=J.+Y.+Yangauthor=H.+Koauthor=W.+A.+Goddardauthor=Y.-C.+Kim&title=Synthesis+and+Structure-Activity+Relationships+of+Quinolinone+and+Quinoline-Based+P2X7+Receptor+Antagonists+and+Their+anti-Sphere+Formation+Activities+in+Glioblastoma+Cells&doi=10.1016%2Fj.ejmech.2018.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells</span></div><div class="casAuthors">Kwak, Seung-Hwa; Shin, Seungheon; Lee, Ji-Hyun; Shim, Jin-Kyoung; Kim, Minjeong; Lee, So-Deok; Lee, Aram; Bae, Jinsu; Park, Jin-Hee; Abdelrahman, Aliaa; Muller, Christa E.; Cho, Steve K.; Kang, Seok-Gu; Bae, Myung Ae; Yang, Jung Yoon; Ko, Hyojin; Goddard, William A., III; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">462-481</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A compd. library of quinolinone derivs. identified compd. I [R2 = C6H5(CH2)2CO] as a new P2X7 receptor antagonist was screened.  To optimize its activity, structure-activity relationships (SAR) at three different positions, R1, R2 and R3, of the quinolinone scaffold I [R1 = C(O)2H, C(O)2CH3, CONHCH3, etc.; R2 = (adamantan-1-yl)carbonyl, C6H5CO, C6H5(CH2)2CO, etc.; R3 = 4-F, 4-OCH3, 4-C2H5, etc.] were assessed .  SAR anal. suggested that a carboxylic acid Et ester group at the R1 position, an adamantyl carboxamide group at R2 and a 4-methoxy substitution at the R3 position are the best substituents for the antagonism of P2X7R activity.  However, because most of the quinolinone derivs. showed low inhibitory effects in an IL-1β ELISA assay, the core structure was further modified to a quinoline skeleton with chloride or substituted Ph groups.  The optimized antagonists with the quinoline scaffold included 2-chloro-5-adamantyl-quinoline deriv. II and 2-(4-hydroxymethylphenyl)-5-adamantyl-quinoline deriv. III (R4 = C6H4CH2OH), with IC50 values of 4 and 3nM, resp.  In contrast to the quinolinone derivs., the antagonistic effects of the quinoline compds. II and III (R4 = C6H4CH2OH) were paralleled by their ability to inhibit the release of the pro-inflammatory cytokine, IL-1β, from LPS/IFN-γ/BzATP-stimulated THP-1cells (IC50 of 7 and 12nM, resp.).  In addn., potent P2X7R antagonists significantly inhibited the sphere size of TS15-88 glioblastoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6WGfJxxJ4t7Vg90H21EOLACvtfcHk0lhXuJSqoeOLTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1Kgsb0%253D&md5=f0bd8ff36450d00af3aa950fe1d37b5f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DS.-H.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DShim%26aufirst%3DJ.-K.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DS.-D.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DBae%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DCho%26aufirst%3DS.%2BK.%26aulast%3DKang%26aufirst%3DS.-G.%26aulast%3DBae%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BY.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DGoddard%26aufirst%3DW.%2BA.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationships%2520of%2520Quinolinone%2520and%2520Quinoline-Based%2520P2X7%2520Receptor%2520Antagonists%2520and%2520Their%2520anti-Sphere%2520Formation%2520Activities%2520in%2520Glioblastoma%2520Cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D462%26epage%3D481%26doi%3D10.1016%2Fj.ejmech.2018.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goutopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanabal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seenisamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayadevan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chekler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriraman, V.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR Development of Quinoline Analogs as Novel P2X7 Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1660</span>– <span class="NLM_lpage">1664</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2019.04.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31031055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVOktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1660-1664&author=Y.+Xiaoauthor=S.+Karraauthor=A.+Goutopoulosauthor=N.+T.+Morseauthor=S.+Zhangauthor=M.+Dhanabalauthor=H.+Tianauthor=J.+Seenisamyauthor=J.+Jayadevanauthor=R.+Caldwellauthor=J.+Potnickauthor=M.+Bleichauthor=E.+Cheklerauthor=B.+Shererauthor=V.+Sriraman&title=Synthesis+and+SAR+Development+of+Quinoline+Analogs+as+Novel+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2019.04.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR development of quinoline analogs as novel P2X7 receptor antagonists</span></div><div class="casAuthors">Xiao, Yufang; Karra, Srinivasa; Goutopoulos, Andreas; Morse, Noune Tahmassian; Zhang, Susan; Dhanabal, Mohanraj; Tian, Hui; Seenisamy, Jeyaprakashnarayanan; Jayaadevan, Jayashankaran; Caldwell, Richard; Potnick, Justin; Bleich, Matthew; Chekler, Eugene; Sherer, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1660-1664</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The P2X7 receptor (P2X7R) plays an important role in diverse conditions assocd. with tissue damage and inflammation, suggesting that the human P2X7R (hP2X7R) is an attractive therapeutic target.  In the present study, the synthesis and structure-activity relationship (SAR) of a novel series of quinoline derivs. as P2X7R antagonists are described herein.  These compds. exhibited mechanistic activity (YO PRO) in an engineered HEK293 expressing hP2X7R as well as a functional response (IL-1β) in human THP-1 (hTHP-1) cellular assays.  Compd. I was identified as the most promising compd. in this series with excellent cellular potency, low liver microsomal clearance, good permeability and low efflux ratio.  In addn., this compd. also displayed good pharmacokinetic properties and acceptable brain permeability (Kp,uu of 0.37).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbtcX1ZlznvrVg90H21EOLACvtfcHk0lhXuJSqoeOLTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVOktLc%253D&md5=348c4bedb949191227b38730e4c5b1ae</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.033%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKarra%26aufirst%3DS.%26aulast%3DGoutopoulos%26aufirst%3DA.%26aulast%3DMorse%26aufirst%3DN.%2BT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DDhanabal%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DSeenisamy%26aufirst%3DJ.%26aulast%3DJayadevan%26aufirst%3DJ.%26aulast%3DCaldwell%26aufirst%3DR.%26aulast%3DPotnick%26aufirst%3DJ.%26aulast%3DBleich%26aufirst%3DM.%26aulast%3DChekler%26aufirst%3DE.%26aulast%3DSherer%26aufirst%3DB.%26aulast%3DSriraman%26aufirst%3DV.%26atitle%3DSynthesis%2520and%2520SAR%2520Development%2520of%2520Quinoline%2520Analogs%2520as%2520Novel%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1660%26epage%3D1664%26doi%3D10.1016%2Fj.bmcl.2019.04.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faria, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Hiller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resende, J. A. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diogo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Ranke, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Luna Martins, D.</span></span> <span> </span><span class="NLM_article-title">Arylboronic Acids Inhibit P2X7 Receptor Function and the Acute Inflammatory Response</span>. <i>J. Bioenerg. Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1007/s10863-019-09802-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1007%2Fs10863-019-09802-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31256283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yktr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=277-290&author=R.+X.+Fariaauthor=N.+de+Jesus+Hillerauthor=J.+P.+Sallesauthor=J.+A.+L.+C.+Resendeauthor=R.+T.+Diogoauthor=N.+L.+von+Rankeauthor=M.+L.+Belloauthor=C.+R.+Rodriguesauthor=H.+C.+Castroauthor=D.+de+Luna+Martins&title=Arylboronic+Acids+Inhibit+P2X7+Receptor+Function+and+the+Acute+Inflammatory+Response&doi=10.1007%2Fs10863-019-09802-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response</span></div><div class="casAuthors">Faria, Robson Xavier; de Jesus Hiller, Noemi; Salles, Juliana Pimenta; Resende, Jackson Antonio Lamounier Camargos; Diogo, Roberta Tosta; von Ranke, Natalia Lidmar; Bello, Murilo Lamim; Rodrigues, Carlos Rangel; Castro, Helena Carla; de Luna Martins, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bioenergetics and Biomembranes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-290</span>CODEN:
                <span class="NLM_cas:coden">JBBID4</span>;
        ISSN:<span class="NLM_cas:issn">0145-479X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The P2X7 receptor (P2X7R) is an ion channel which is activated by interactions with the extracellular ATP mols.  The mol. complex P2X7R/ATP induces conformational changes in the protein subunits, opening a pore in the ion channel macromol. structure.  Currently, the P2X7R has been studied as a potential therapeutic target of anti-inflammatory drugs.  Based on this, a series of eight boronic acids (NO) analogs were evaluated on the biol. effect of this pharmacophoric group on the human and murine P2X7R.  The boronic acids derivs. NO-01 and NO-12 inhibited in vitro human and murine P2X7R function.  These analogs compds. showed effect better than compd. BBG and similar to inhibitor A740003 for inhibiting dye uptake, in vitro IL-1β release and ATP-induced paw edema in vivo.  In both, in vitro and in vivo assays the compd. NO-01 showed to be the hit compd. in the present series of the arylboronic acids analogs.  The mol. docking suggests that the NO derivs. bind into the upper body domain of the P2X7 pore and that the main intermol. interaction with the two most active NO derivs. occur with the residues Phe 95, 103 and 293 by hydrophobic interactions and with Leu97, Gln98 and Ser101 by hydrogen bonds..  These results indicate that the boronic acid deriv. NO-01 shows the lead compd. characteristics to be used as a scaffold structure to the development of new P2X7R inhibitors with anti-inflammatory action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRTu0LGKMrfLVg90H21EOLACvtfcHk0lgsoag4EaKecQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yktr%252FI&md5=890cbcd9a93fff4b98c68d8c73778772</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10863-019-09802-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10863-019-09802-x%26sid%3Dliteratum%253Aachs%26aulast%3DFaria%26aufirst%3DR.%2BX.%26aulast%3Dde%2BJesus%2BHiller%26aufirst%3DN.%26aulast%3DSalles%26aufirst%3DJ.%2BP.%26aulast%3DResende%26aufirst%3DJ.%2BA.%2BL.%2BC.%26aulast%3DDiogo%26aufirst%3DR.%2BT.%26aulast%3Dvon%2BRanke%26aufirst%3DN.%2BL.%26aulast%3DBello%26aufirst%3DM.%2BL.%26aulast%3DRodrigues%26aufirst%3DC.%2BR.%26aulast%3DCastro%26aufirst%3DH.%2BC.%26aulast%3Dde%2BLuna%2BMartins%26aufirst%3DD.%26atitle%3DArylboronic%2520Acids%2520Inhibit%2520P2X7%2520Receptor%2520Function%2520and%2520the%2520Acute%2520Inflammatory%2520Response%26jtitle%3DJ.%2520Bioenerg.%2520Biomembr.%26date%3D2019%26volume%3D51%26spage%3D277%26epage%3D290%26doi%3D10.1007%2Fs10863-019-09802-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzaga, D. T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Ranke, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinho, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, C. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leme, R. P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mafra, J. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, L. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelz, L. V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boechat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faria, R. X.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Biological Evaluation, and Molecular Modeling Studies of New Thiadiazole Derivatives as Potent P2X7 Receptor Inhibitors</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">261</span>, <span class="refDoi"> DOI: 10.3389/fchem.2019.00261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3389%2Ffchem.2019.00261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31134177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKisbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=261&author=D.+T.+G.+Gonzagaauthor=F.+H.+Oliveiraauthor=N.+L.+von+Rankeauthor=G.+Q.+Pinhoauthor=J.+P.+Sallesauthor=M.+L.+Belloauthor=C.+R.+Rodriguesauthor=H.+C.+Castroauthor=H.+de+Souzaauthor=C.+R.+C.+Reisauthor=R.+P.+P.+Lemeauthor=J.+C.+M.+Mafraauthor=L.+C.+S.+Pinheiroauthor=L.+V.+B.+Hoelzauthor=N.+Boechatauthor=R.+X.+Faria&title=Synthesis%2C+Biological+Evaluation%2C+and+Molecular+Modeling+Studies+of+New+Thiadiazole+Derivatives+as+Potent+P2X7+Receptor+Inhibitors&doi=10.3389%2Ffchem.2019.00261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation, and molecular modeling studies of new thiadiazole derivatives as potent P2X7 receptor inhibitors</span></div><div class="casAuthors">Gonzaga, Daniel T. G.; Oliveira, Felipe H.; von Ranke, N. L.; Pinho, G. Q.; Salles, Juliana P.; Bello, Murilo L.; Rodrigues, Carlos R.; Castro, Helena C.; de Souza, Hellen V. C. M.; Reis, Caroline R. C.; Leme, Rennan P. P.; Mafra, Joao C. M.; Pinheiro, Luiz C. S.; Hoelz, Lucas V. B.; Boechat, Nubia; Faria, Robson X.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">261</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Twenty new 2-(1H-pyrazol-1-yl)-1,3,4-thiadiazole analogs were synthesized to develop P2X7 receptor (P2X7R) inhibitors.  P2X7R inhibition in vitro was evaluated in mouse peritoneal macrophages, HEK-293 cells transfected with hP2X7R (dye uptake assay), and THP-1 cells (IL-1β release assay).  The 1-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-pyrazol-5-amine derivs. 9b, 9c, and 9f, and 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-(4-fluorophenyl)-1,3,4-thiadiazole (11c) showed inhibitory effects with IC50 values ranging from 16 to 122 nM for reduced P2X7R-mediated dye uptake and 20 to 300 nM for IL-1β release.  In addn., the in vitro ADMET profile of the four most potent derivs. was detd. to be in acceptable ranges concerning metabolic stability and cytotoxicity.  Mol. docking and mol. dynamics simulation studies of the mol. complexes human P2X7R/9f and murine P2X7R/9f indicated the putative intermol. interactions.  Compd. 9f showed affinity mainly for the Arg268, Lys377, and Asn266 residues.  These results suggest that 2-(1H-pyrazol-1-yl)-1,3,4-thiadiazole analogs may be promising novel P2X7R inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryovcXZRpZIrVg90H21EOLACvtfcHk0lgsoag4EaKecQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKisbnL&md5=645c4a32b5a1e66887a6aa773f81ba10</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2019.00261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2019.00261%26sid%3Dliteratum%253Aachs%26aulast%3DGonzaga%26aufirst%3DD.%2BT.%2BG.%26aulast%3DOliveira%26aufirst%3DF.%2BH.%26aulast%3Dvon%2BRanke%26aufirst%3DN.%2BL.%26aulast%3DPinho%26aufirst%3DG.%2BQ.%26aulast%3DSalles%26aufirst%3DJ.%2BP.%26aulast%3DBello%26aufirst%3DM.%2BL.%26aulast%3DRodrigues%26aufirst%3DC.%2BR.%26aulast%3DCastro%26aufirst%3DH.%2BC.%26aulast%3Dde%2BSouza%26aufirst%3DH.%26aulast%3DReis%26aufirst%3DC.%2BR.%2BC.%26aulast%3DLeme%26aufirst%3DR.%2BP.%2BP.%26aulast%3DMafra%26aufirst%3DJ.%2BC.%2BM.%26aulast%3DPinheiro%26aufirst%3DL.%2BC.%2BS.%26aulast%3DHoelz%26aufirst%3DL.%2BV.%2BB.%26aulast%3DBoechat%26aufirst%3DN.%26aulast%3DFaria%26aufirst%3DR.%2BX.%26atitle%3DSynthesis%252C%2520Biological%2520Evaluation%252C%2520and%2520Molecular%2520Modeling%2520Studies%2520of%2520New%2520Thiadiazole%2520Derivatives%2520as%2520Potent%2520P2X7%2520Receptor%2520Inhibitors%26jtitle%3DFront.%2520Chem.%26date%3D2019%26volume%3D7%26spage%3D261%26doi%3D10.3389%2Ffchem.2019.00261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Medrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly-Roberts, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florjancic, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namovic, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltynek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, W. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in Vitro Activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine P2X(7) Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3297</span>– <span class="NLM_lpage">3300</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2011.04.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=21536435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsVOgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3297-3300&author=A.+Perez-Medranoauthor=D.+L.+Donnelly-Robertsauthor=A.+S.+Florjancicauthor=D.+W.+Nelsonauthor=T.+Liauthor=M.+T.+Namovicauthor=S.+Peddiauthor=C.+R.+Faltynekauthor=M.+F.+Jarvisauthor=W.+A.+Carroll&title=Synthesis+and+in+Vitro+Activity+of+N-benzyl-1-%282%2C3-dichlorophenyl%29-1H-tetrazol-5-amine+P2X%287%29+Antagonists&doi=10.1016%2Fj.bmcl.2011.04.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine as P2X7 antagonists</span></div><div class="casAuthors">Perez-Medrano, Arturo; Donnelly-Roberts, Diana L.; Florjancic, Alan S.; Nelson, Derek W.; Li, Tongmei; Namovic, Marian T.; Peddi, Sridhar; Faltynek, Connie R.; Jarvis, Michael F.; Carroll, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3297-3300</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis and biol. evaluation of a novel class of substituted N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine derivs. resulted in the identification of potent P2X7 antagonists.  These compds. were assayed for activity at both the human and rat P2X7 receptors.  On the benzyl moiety, a variety of functional groups were tolerated, including both electron-withdrawing and electron-donating substituents.  Ortho-substitution on the benzyl group provided the greatest potency.  The ortho-substituted analogs showed approx. 2.5-fold greater potency at human compared to rat P2X7 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp91q681OLzurVg90H21EOLACvtfcHk0lgsoag4EaKecQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsVOgsL4%253D&md5=1bdcd33feb9fb3cd1b39e15d199b5d9a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Medrano%26aufirst%3DA.%26aulast%3DDonnelly-Roberts%26aufirst%3DD.%2BL.%26aulast%3DFlorjancic%26aufirst%3DA.%2BS.%26aulast%3DNelson%26aufirst%3DD.%2BW.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DNamovic%26aufirst%3DM.%2BT.%26aulast%3DPeddi%26aufirst%3DS.%26aulast%3DFaltynek%26aufirst%3DC.%2BR.%26aulast%3DJarvis%26aufirst%3DM.%2BF.%26aulast%3DCarroll%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%2520and%2520in%2520Vitro%2520Activity%2520of%2520N-benzyl-1-%25282%252C3-dichlorophenyl%2529-1H-tetrazol-5-amine%2520P2X%25287%2529%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3297%26epage%3D3300%26doi%3D10.1016%2Fj.bmcl.2011.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00089</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00089" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=671-676&author=B.+M.+Savallauthor=D.+Wuauthor=M.+De+Angelisauthor=N.+I.+Carruthersauthor=H.+Aoauthor=Q.+Wangauthor=B.+Lordauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Synthesis%2C+SAR%2C+and+Pharmacological+Characterization+of+Brain+Penetrant+P2X7+Receptor+Antagonists&doi=10.1021%2Facsmedchemlett.5b00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists</span></div><div class="casAuthors">Savall, Brad M.; Wu, Duncan; De Angelis, Meri; Carruthers, Nicholas I.; Ao, Hong; Wang, Qi; Lord, Brian; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-676</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and SAR of 1,2,3-triazolopiperidines, e.g., I, as a novel series of potent, brain penetrant P2X7 antagonists was described.  Initial efforts yielded a series of potent human P2X7R antagonists with moderate to weak rodent potency, some CYP inhibition, poor metabolic stability, and low soly.  Further work in this series, which focused on the SAR of the N-linked heterocycle, not only increased the potency at the human P2X7R but also provided compds. with good potency at the rat P2X7R.  These efforts eventually delivered a potent rat and human P2X7R antagonist with good physicochem. properties, an excellent pharmacokinetic profile, good partitioning into the CNS, and demonstrated in vivo target engagement after oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfae7yM_oV1bVg90H21EOLACvtfcHk0lirEkN6DENtGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGisbo%253D&md5=11d93747bb8b71d0ca108a3946e3a758</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00089%26sid%3Dliteratum%253Aachs%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%252C%2520SAR%252C%2520and%2520Pharmacological%2520Characterization%2520of%2520Brain%2520Penetrant%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D671%26epage%3D676%26doi%3D10.1021%2Facsmedchemlett.5b00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beswick, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billinton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collis, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonfria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejeune, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livermore, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medhurst, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingsby, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, J. G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, D. S.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structure-Activity Relationships of a Series of Pyroglutamic Acid Amide Antagonists of the P2X7 Receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5080</span>– <span class="NLM_lpage">5084</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2010.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=20673717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5080-5084&author=M.+H.+Abdiauthor=P.+J.+Beswickauthor=A.+Billintonauthor=L.+J.+Chambersauthor=A.+Charltonauthor=S.+D.+Collinsauthor=K.+L.+Collisauthor=D.+K.+Deanauthor=E.+Fonfriaauthor=R.+J.+Gleaveauthor=C.+L.+Lejeuneauthor=D.+G.+Livermoreauthor=S.+J.+Medhurstauthor=A.+D.+Michelauthor=A.+P.+Mosesauthor=L.+Pageauthor=S.+Patelauthor=S.+A.+Romanauthor=S.+Sengerauthor=B.+Slingsbyauthor=J.+G.+A.+Steadmanauthor=A.+J.+Stevensauthor=D.+S.+Walter&title=Discovery+and+Structure-Activity+Relationships+of+a+Series+of+Pyroglutamic+Acid+Amide+Antagonists+of+the+P2X7+Receptor&doi=10.1016%2Fj.bmcl.2010.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor</span></div><div class="casAuthors">Abdi, Muna H.; Beswick, Paul J.; Billinton, Andy; Chambers, Laura J.; Charlton, Andrew; Collins, Sue D.; Collis, Katharine L.; Dean, David K.; Fonfria, Elena; Gleave, Robert J.; Lejeune, Clarisse L.; Livermore, David G.; Medhurst, Stephen J.; Michel, Anton D.; Moses, Andrew P.; Page, Lee; Patel, Sadhana; Roman, Shilina A.; Senger, Stefan; Slingsby, Brian; Steadman, Jon G. A.; Stevens, Alexander J.; Walter, Daryl S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5080-5084</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A computational lead-hopping exercise identified compd. 4 (I) as a structurally distinct P2X7 receptor antagonist.  Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogs of 4 were investigated and compd. 31 was identified as a potent P2X7 antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDVRhpk7pAFrVg90H21EOLACvtfcHk0lirEkN6DENtGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehsbbE&md5=7ffef75090b4baf3bba946701ec9dd8f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DAbdi%26aufirst%3DM.%2BH.%26aulast%3DBeswick%26aufirst%3DP.%2BJ.%26aulast%3DBillinton%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DL.%2BJ.%26aulast%3DCharlton%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DS.%2BD.%26aulast%3DCollis%26aufirst%3DK.%2BL.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DFonfria%26aufirst%3DE.%26aulast%3DGleave%26aufirst%3DR.%2BJ.%26aulast%3DLejeune%26aufirst%3DC.%2BL.%26aulast%3DLivermore%26aufirst%3DD.%2BG.%26aulast%3DMedhurst%26aufirst%3DS.%2BJ.%26aulast%3DMichel%26aufirst%3DA.%2BD.%26aulast%3DMoses%26aufirst%3DA.%2BP.%26aulast%3DPage%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DRoman%26aufirst%3DS.%2BA.%26aulast%3DSenger%26aufirst%3DS.%26aulast%3DSlingsby%26aufirst%3DB.%26aulast%3DSteadman%26aufirst%3DJ.%2BG.%2BA.%26aulast%3DStevens%26aufirst%3DA.%2BJ.%26aulast%3DWalter%26aufirst%3DD.%2BS.%26atitle%3DDiscovery%2520and%2520Structure-Activity%2520Relationships%2520of%2520a%2520Series%2520of%2520Pyroglutamic%2520Acid%2520Amide%2520Antagonists%2520of%2520the%2520P2X7%2520Receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5080%26epage%3D5084%26doi%3D10.1016%2Fj.bmcl.2010.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honore, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly-Roberts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namovic, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusa, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvin, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medrano, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltynek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, M. F.</span></span> <span> </span><span class="NLM_article-title">A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">1376</span>– <span class="NLM_lpage">1385</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.111559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1124%2Fjpet.106.111559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=16982702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2006&pages=1376-1385&author=P.+Honoreauthor=D.+Donnelly-Robertsauthor=M.+T.+Namovicauthor=G.+Hsiehauthor=C.+Z.+Zhuauthor=J.+P.+Mikusaauthor=G.+Hernandezauthor=C.+Zhongauthor=D.+M.+Gauvinauthor=P.+Chandranauthor=R.+Harrisauthor=A.+P.+Medranoauthor=W.+Carrollauthor=K.+Marshauthor=J.+P.+Sullivanauthor=C.+R.+Faltynekauthor=M.+F.+Jarvis&title=A-740003+%5BN-%281-%7B%5B%28cyanoimino%29%285-quinolinylamino%29+methyl%5Damino%7D-2%2C2-dimethylpropyl%29-2-%283%2C4-dimethoxyphenyl%29acetamide%5D%2C+a+Novel+and+Selective+P2X7+Receptor+Antagonist%2C+Dose-Dependently+Reduces+Neuropathic+Pain+in+the+Rat&doi=10.1124%2Fjpet.106.111559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat</span></div><div class="casAuthors">Honore, Prisca; Donnelly-Roberts, Diana; Namovic, Marian T.; Hsieh, Gin; Zhu, Chang Z.; Mikusa, Joe P.; Hernandez, Gricelda; Zhong, Chengmin; Gauvin, Donna M.; Chandran, Prasant; Harris, Richard; Medrano, Arturo Perez; Carroll, William; Marsh, Kennan; Sullivan, James P.; Faltynek, Connie R.; Jarvis, Michael F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1376-1385</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">ATP-sensitive P2X7 receptors are localized on cells of immunol. origin including glial cells in the central nervous system.  Activation of P2X7 receptors leads to rapid changes in intracellular calcium concns., release of the proinflammatory cytokine interleukin-1β (IL-1β), and following prolonged agonist exposure, cytolytic plasma membrane pore formation.  P2X7 knockout mice show reduced inflammation as well as decreased nociceptive sensitivity following peripheral nerve injury.  A-740003 (N-(1-{[(cyanoimino)(5-quinolinylamino) methyl] amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) is a novel competitive antagonist of P2X7 receptors (IC50 values = 40 nM for human and 18 nM for rat) as measured by agonist-stimulated changes in intracellular calcium concns.  A-740003 showed weak or no activity (IC50 > 10 μM) at other P2 receptors and an array of other neurotransmitter and peptide receptors, ion channels, reuptake sites, and enzymes.  A-740003 potently blocked agonist-evoked IL-1β release (IC50 = 156 nM) and pore formation (IC50 = 92 nM) in differentiated human THP-1 cells.  Systemic administration of A-740003 produced dose-dependent antinociception in a spinal nerve ligation model (ED50 = 19 mg/kg i.p.) in the rat.  A-740003 also attenuated tactile allodynia in two other models of neuropathic pain, chronic constriction injury of the sciatic nerve and vincristine-induced neuropathy.  In addn., A-740003 effectively reduced thermal hyperalgesia obsd. following intraplantar administration of carrageenan or complete Freund's adjuvant (ED50 = 38-54 mg/kg i.p.).  A-740003 was ineffective in attenuating acute thermal nociception in normal rats and did not alter motor performance at analgesic doses.  These data demonstrate that selective blockade of P2X7 receptors in vivo produces significant antinociception in animal models of neuropathic and inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKvrIcS3OJT7Vg90H21EOLACvtfcHk0ljzUE6TjfmG4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltLrP&md5=a7d3bfa9cfc728ab7730ec7b351ecb1d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.111559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.111559%26sid%3Dliteratum%253Aachs%26aulast%3DHonore%26aufirst%3DP.%26aulast%3DDonnelly-Roberts%26aufirst%3DD.%26aulast%3DNamovic%26aufirst%3DM.%2BT.%26aulast%3DHsieh%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DC.%2BZ.%26aulast%3DMikusa%26aufirst%3DJ.%2BP.%26aulast%3DHernandez%26aufirst%3DG.%26aulast%3DZhong%26aufirst%3DC.%26aulast%3DGauvin%26aufirst%3DD.%2BM.%26aulast%3DChandran%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DMedrano%26aufirst%3DA.%2BP.%26aulast%3DCarroll%26aufirst%3DW.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DFaltynek%26aufirst%3DC.%2BR.%26aulast%3DJarvis%26aufirst%3DM.%2BF.%26atitle%3DA-740003%2520%255BN-%25281-%257B%255B%2528cyanoimino%2529%25285-quinolinylamino%2529%2520methyl%255Damino%257D-2%252C2-dimethylpropyl%2529-2-%25283%252C4-dimethoxyphenyl%2529acetamide%255D%252C%2520a%2520Novel%2520and%2520Selective%2520P2X7%2520Receptor%2520Antagonist%252C%2520Dose-Dependently%2520Reduces%2520Neuropathic%2520Pain%2520in%2520the%2520Rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D319%26spage%3D1376%26epage%3D1385%26doi%3D10.1124%2Fjpet.106.111559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly-Roberts, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namovic, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidyanathan, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Medrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, M. F.</span></span> <span> </span><span class="NLM_article-title">[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a Novel, potent, and selective antagonist radioligand for P2X7 receptors</span>. <i>Neuropharmacol</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.neuropharm.2008.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=18602931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252Fksl2luw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2009&pages=223-229&author=D.+L.+Donnelly-Robertsauthor=M.+T.+Namovicauthor=B.+Surberauthor=S.+X.+Vaidyanathanauthor=A.+Perez-Medranoauthor=Y.+Wangauthor=W.+A.+Carrollauthor=M.+F.+Jarvis&title=%5B3H%5DA-804598+%28%5B3H%5D2-cyano-1-%5B%281S%29-1-phenylethyl%5D-3-quinolin-5-ylguanidine%29+is+a+Novel%2C+potent%2C+and+selective+antagonist+radioligand+for+P2X7+receptors&doi=10.1016%2Fj.neuropharm.2008.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors</span></div><div class="casAuthors">Donnelly-Roberts Diana L; Namovic Marian T; Surber Bruce; Vaidyanathan Srirajan X; Perez-Medrano Arturo; Wang Ying; Carroll William A; Jarvis Michael F</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-9</span>
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    </div><div class="casAbstract">ATP-sensitive P2X7 receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.  Activation of P2X7 receptors leads to rapid changes in intracellular calcium concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.  Data from gene knockout studies and recently described selective antagonists indicate a role for P2X7 receptor activation in inflammation and pain.  While several species selective P2X7 antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.  A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.  A-804598 was tritiated ([3H]A-804598; 8.1Ci/mmol) and utilized to study recombinant rat P2X7 receptors expressed in 1321N1 cells. [3H]A-804598 labeled a single class of high affinity binding sites (Kd=2.4 nM and apparent Bmax=0.56 pmol/mg).  No specific binding was observed in untransfected 1321N1 cells.  The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05).  These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQY3sRlI5qwG8ERNNga7KD-fW6udTcc2ebU1ROv1WLvBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252Fksl2luw%253D%253D&md5=3d983a02c52691e211b092e7036b9982</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly-Roberts%26aufirst%3DD.%2BL.%26aulast%3DNamovic%26aufirst%3DM.%2BT.%26aulast%3DSurber%26aufirst%3DB.%26aulast%3DVaidyanathan%26aufirst%3DS.%2BX.%26aulast%3DPerez-Medrano%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCarroll%26aufirst%3DW.%2BA.%26aulast%3DJarvis%26aufirst%3DM.%2BF.%26atitle%3D%255B3H%255DA-804598%2520%2528%255B3H%255D2-cyano-1-%255B%25281S%2529-1-phenylethyl%255D-3-quinolin-5-ylguanidine%2529%2520is%2520a%2520Novel%252C%2520potent%252C%2520and%2520selective%2520antagonist%2520radioligand%2520for%2520P2X7%2520receptors%26jtitle%3DNeuropharmacol%26date%3D2009%26volume%3D56%26spage%3D223%26epage%3D229%26doi%3D10.1016%2Fj.neuropharm.2008.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrovian, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soyode-Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepassi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=207-223&author=C.+C.+Chrovianauthor=A.+Soyode-Johnsonauthor=A.+A.+Petersonauthor=C.+F.+Gelinauthor=X.+Dengauthor=C.+A.+Dvorakauthor=N.+I.+Carruthersauthor=B.+Lordauthor=I.+Fraserauthor=L.+Aluisioauthor=K.+J.+Coeauthor=B.+Scottauthor=T.+Koudriakovaauthor=F.+Schoetensauthor=K.+Sepassiauthor=D.+J.+Gallacherauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=A+Dipolar+Cycloaddition+Reaction+To+Access+6-Methyl-4%2C5%2C6%2C7-tetrahydro-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-c%5Dpyridines+Enables+the+Discovery+Synthesis+and+Preclinical+Profiling+of+a+P2X7+Antagonist+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b01279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate</span></div><div class="casAuthors">Chrovian, Christa C.; Soyode-Johnson, Akinola; Peterson, Alexander A.; Gelin, Christine F.; Deng, Xiaohu; Dvorak, Curt A.; Carruthers, Nicholas I.; Lord, Brian; Fraser, Ian; Aluisio, Leah; Coe, Kevin J.; Scott, Brian; Koudriakova, Tatiana; Schoetens, Freddy; Sepassi, Kia; Gallacher, David J.; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">207-223</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A single pot dipolar cycloaddn. reaction/Cope elimination sequence was developed to access novel 1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridine P2X7 antagonists that contain a synthetically challenging chiral center.  The structure-activity relationships of the new compds. are described.  Two of these compds., (S)-(2-fluoro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone (I) and (S)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone (II), were found to have robust P2X7 receptor occupancy at low doses in rat with ED50 values of 0.06 and 0.07 mg/kg, resp.  Compd. II had notable soly. compared to I and showed good tolerability in preclin. species.  Compd. II was chosen as a clin. candidate for advancement into phase I clin. trials to assess safety and tolerability in healthy human subjects prior to the initiation of proof of concept studies for the treatment of mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0Y2r79JhbbVg90H21EOLACvtfcHk0ljYI7ciBQf2NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrnN&md5=a97dfbda53f249894c7e4ef409601c95</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01279%26sid%3Dliteratum%253Aachs%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DSoyode-Johnson%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%2BA.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DSepassi%26aufirst%3DK.%26aulast%3DGallacher%26aufirst%3DD.%2BJ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DA%2520Dipolar%2520Cycloaddition%2520Reaction%2520To%2520Access%25206-Methyl-4%252C5%252C6%252C7-tetrahydro-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-c%255Dpyridines%2520Enables%2520the%2520Discovery%2520Synthesis%2520and%2520Preclinical%2520Profiling%2520of%2520a%2520P2X7%2520Antagonist%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D207%26epage%3D223%26doi%3D10.1021%2Facs.jmedchem.7b01279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceusters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenden, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span> <span> </span><span class="NLM_article-title">4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4572</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Wms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4559-4572&author=M.+A.+Letavicauthor=B.+M.+Savallauthor=B.+D.+Allisonauthor=L.+Aluisioauthor=J.+I.+Andresauthor=M.+De+Angelisauthor=H.+Aoauthor=D.+A.+Beauchampauthor=P.+Bonaventureauthor=S.+Bryantauthor=N.+I.+Carruthersauthor=M.+Ceustersauthor=K.+J.+Coeauthor=C.+A.+Dvorakauthor=I.+C.+Fraserauthor=C.+F.+Gelinauthor=T.+Koudriakovaauthor=J.+Liangauthor=B.+Lordauthor=T.+W.+Lovenbergauthor=M.+A.+Otienoauthor=F.+Schoetensauthor=D.+M.+Swansonauthor=Q.+Wangauthor=A.+D.+Wickendenauthor=A.+Bhattacharya&title=4-Methyl-6%2C7-dihydro-4H-triazolo%5B4%2C5-c%5Dpyridine-Based+P2X7+Receptor+Antagonists%3A+Optimization+of+Pharmacokinetic+Properties+Leading+to+the+Identification+of+a+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b00408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate</span></div><div class="casAuthors">Letavic, Michael A.; Savall, Brad M.; Allison, Brett D.; Aluisio, Leah; Andres, Jose Ignacio; De Angelis, Meri; Ao, Hong; Beauchamp, Derek A.; Bonaventure, Pascal; Bryant, Stewart; Carruthers, Nicholas I.; Ceusters, Marc; Coe, Kevin J.; Dvorak, Curt A.; Fraser, Ian C.; Gelin, Christine F.; Koudriakova, Tatiana; Liang, Jimmy; Lord, Brian; Lovenberg, Timothy W.; Otieno, Monicah A.; Schoetens, Freddy; Swanson, Devin M.; Wang, Qi; Wickenden, Alan D.; Bhattacharya, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4559-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and preclin. characterization of novel 4-(R)-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridines that are potent and selective brain penetrant P2X7 antagonists are described.  Optimization efforts based on previously disclosed unsubstituted 6,7-dihydro-4H-triazolo[4,5-c]pyridines, Me substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazines, and several other series lead to the identification of a series of 4-(R)-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridines that are selective P2X7 antagonists with potency at the rodent and human P2X7 ion channels.  These novel P2X7 antagonists have suitable physicochem. properties, and several analogs have an excellent pharmacokinetic profile, good partitioning into the CNS and show robust in vivo target engagement after oral dosing.  Improvements in metabolic stability led to the identification of JNJ-54175446 (I) as a candidate for clin. development.  The drug discovery efforts and strategies that resulted in the identification of the clin. candidate are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkx8e5Sq5aYbVg90H21EOLACvtfcHk0lgmJidh9doaGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Wms7Y%253D&md5=5b5465d8f64d527da6647997efe34aee</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00408%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DAllison%26aufirst%3DB.%2BD.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBeauchamp%26aufirst%3DD.%2BA.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DBryant%26aufirst%3DS.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DCeusters%26aufirst%3DM.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWickenden%26aufirst%3DA.%2BD.%26aulast%3DBhattacharya%26aufirst%3DA.%26atitle%3D4-Methyl-6%252C7-dihydro-4H-triazolo%255B4%252C5-c%255Dpyridine-Based%2520P2X7%2520Receptor%2520Antagonists%253A%2520Optimization%2520of%2520Pharmacokinetic%2520Properties%2520Leading%2520to%2520the%2520Identification%2520of%2520a%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4559%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.7b00408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">US National Library of Medicine</span>. <a href="https://clinicaltrials.gov/" class="extLink">https://clinicaltrials.gov/</a>, (accessed Jan 15, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+National+Library+of+Medicine.+https%3A%2F%2Fclinicaltrials.gov%2F%2C+%28accessed+Jan+15%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Recourt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevets, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nueten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanhai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebenga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuiker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravenstijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gerven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, P.</span></span> <span> </span><span class="NLM_article-title">Characterisation of the Pharmacodynamic Effects of the P2X7 Receptor Antagonist JNJ-54175446 Using an Oral Dexamphetamine Challenge Model in Healthy Males in a Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1030</span>– <span class="NLM_lpage">1042</span>, <span class="refDoi"> DOI: 10.1177/0269881120914206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1177%2F0269881120914206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=32248747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1aitbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=1030-1042&author=K.+Recourtauthor=J.+van+der+Aartauthor=G.+Jacobsauthor=M.+de+Kamauthor=W.+Drevetsauthor=L.+van+Nuetenauthor=K.+Kanhaiauthor=P.+Siebengaauthor=R.+Zuikerauthor=P.+Ravenstijnauthor=M.+Timmersauthor=J.+van+Gervenauthor=P.+de+Boer&title=Characterisation+of+the+Pharmacodynamic+Effects+of+the+P2X7+Receptor+Antagonist+JNJ-54175446+Using+an+Oral+Dexamphetamine+Challenge+Model+in+Healthy+Males+in+a+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C+Multiple+Ascending+Dose+Trial&doi=10.1177%2F0269881120914206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial</span></div><div class="casAuthors">Recourt, Kasper; van der Aart, Jasper; Jacobs, Gabriel; de Kam, Marieke; Drevets, Wayne; van Nueten, Luc; Kanhai, Kawita; Siebenga, Pieter; Zuiker, Rob; Ravenstijn, Paulien; Timmers, Maarten; van Gerven, Joop; de Boer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1030-1042</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">First report of pharmacodynamic (PD) effects of selective, potent and brain-penetrant P2X7 receptor (P2X7R) antagonist JNJ-54175446.  Activation of P2X7R, an ATP-gated ion channel, leads to prodn. of pro-inflammatory cytokines which is linked to neuroinflammation and pathogenesis of mood disorders.  Previous studies with JNJ-54175446 showed its peripheral target engagement by assessing ex vivo lipopolysaccharide (LPS)-stimulated cytokine prodn and blood-brain barrier penetration.  Objectives of this double-blind, placebo-controlled, translational study were to assess safety and tolerability of administering multiple doses of JNJ-54175446 and to explore its PD effects using dexamphetamine challenge.  Subjects were randomised to either JNJ-54175446(50-450 mg) or placebo and underwent baseline oral 20 mg dexamphetamine challenge followed by 11 consecutive days q.d. dosing with JNJ-54175446/placebo and randomised crossover dexamphetamine/placebo challenge.  At all doses tested, JNJ-54175446 was well tolerated and suppressed ex vivo LPS-induced release of cytokines.  At doses ≥100 mg, JNJ-54175446 attenuated dexamphetamine-induced increases in locomotion and enhanced mood-elevating effects of dexamphetamine, suggesting that dose twice as high is needed to obtain central PD response compared to dose needed for max. peripheral occupancy.  Obsd. pharmacol. profile of JNJ-54175446 in dexamphetamine challenge paradigm is compatible with potential mood-modulating effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5ioGr5SHM87Vg90H21EOLACvtfcHk0lgmJidh9doaGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1aitbnF&md5=4cf8fc3621e3c1476113a2ae197cf3e0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F0269881120914206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881120914206%26sid%3Dliteratum%253Aachs%26aulast%3DRecourt%26aufirst%3DK.%26aulast%3Dvan%2Bder%2BAart%26aufirst%3DJ.%26aulast%3DJacobs%26aufirst%3DG.%26aulast%3Dde%2BKam%26aufirst%3DM.%26aulast%3DDrevets%26aufirst%3DW.%26aulast%3Dvan%2BNueten%26aufirst%3DL.%26aulast%3DKanhai%26aufirst%3DK.%26aulast%3DSiebenga%26aufirst%3DP.%26aulast%3DZuiker%26aufirst%3DR.%26aulast%3DRavenstijn%26aufirst%3DP.%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%26aulast%3Dde%2BBoer%26aufirst%3DP.%26atitle%3DCharacterisation%2520of%2520the%2520Pharmacodynamic%2520Effects%2520of%2520the%2520P2X7%2520Receptor%2520Antagonist%2520JNJ-54175446%2520Using%2520an%2520Oral%2520Dexamphetamine%2520Challenge%2520Model%2520in%2520Healthy%2520Males%2520in%2520a%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Multiple%2520Ascending%2520Dose%2520Trial%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2020%26volume%3D34%26spage%3D1030%26epage%3D1042%26doi%3D10.1177%2F0269881120914206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keystone, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Team, D. C. S.</span></span> <span> </span><span class="NLM_article-title">Clinical Evaluation of the Efficacy of the P2X7 Purinergic Receptor Antagonist AZD9056 on the Signs and Symptoms of Rheumatoid Arthritis in Patients with Active Disease Despite Treatment with Methotrexate or Sulphasalazine</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1630</span>– <span class="NLM_lpage">1635</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2011-143578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1136%2Fannrheumdis-2011-143578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22966146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1SqurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2012&pages=1630-1635&author=E.+C.+Keystoneauthor=M.+M.+Wangauthor=M.+Laytonauthor=S.+Hollisauthor=I.+B.+McInnesauthor=D.+C.+S.+Team&title=Clinical+Evaluation+of+the+Efficacy+of+the+P2X7+Purinergic+Receptor+Antagonist+AZD9056+on+the+Signs+and+Symptoms+of+Rheumatoid+Arthritis+in+Patients+with+Active+Disease+Despite+Treatment+with+Methotrexate+or+Sulphasalazine&doi=10.1136%2Fannrheumdis-2011-143578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine</span></div><div class="casAuthors">Keystone, Edward C.; Wang, Millie M.; Layton, Mark; Hollis, Sally; McInnes, Iain B.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1630-1635</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: The P2X7 purinergic receptor antagonist AZD9056 was evaluated in a phase IIa study and subsequently in a phase IIb study to assess the effects of orally administered AZD9056 on the signs/symptoms of rheumatoid arthritis (RA), with American College of Rheumatol. 20% response criteria (ACR20) as the primary outcome.  Methods: Both studies were randomized, double-blind, placebo-controlled, parallel-group studies in patients with RA receiving methotrexate or sulphasalazine.  Phase IIa was an ascending-dose trial in two cohorts (n=75) using AZD9056 administered daily over 4 wk.  Phase IIb included an open-label etanercept treatment group.  Patients were randomized to receive treatment for 6 mo with 50, 100, 200 or 400 mg AZD9056 (oral, once a day) or matching placebo (oral, once a day), or s.c. etanercept (50 mg once a week).  Results: In phase IIa, 65% of AZD9056 recipients at 400 mg/day responded at the ACR20 level compared with 27% of placebo-treated patients.  A significant redn. in swollen and tender joint count was obsd. in the actively treated group compared with placebo, whereas no effect on acute-phase response was obsd.  Of 385 randomized patients in the phase IIb study, 383 received treatment.  AZD9056 (all doses) had no clin. or statistically significant effect on RA relative to placebo as measured by the proportion of patients meeting the ACR20 criteria at 6 mo and further supported by secondary end points.  In both studies AZD9056 was well tolerated up to 400 mg/day.  Conclusions: AZD9056 does not have significant efficacy in the treatment of RA, and the P2X7 receptor does not appear to be a therapeutically useful target in RA.  Trial registration no. ClinicalTrials.gov NCT00520572.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzCebkc5d0gLVg90H21EOLACvtfcHk0li1DGTZjO2tJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1SqurzL&md5=97ca48663327aa8578f11001fa96d8c0</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2011-143578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2011-143578%26sid%3Dliteratum%253Aachs%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DWang%26aufirst%3DM.%2BM.%26aulast%3DLayton%26aufirst%3DM.%26aulast%3DHollis%26aufirst%3DS.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DTeam%26aufirst%3DD.%2BC.%2BS.%26atitle%3DClinical%2520Evaluation%2520of%2520the%2520Efficacy%2520of%2520the%2520P2X7%2520Purinergic%2520Receptor%2520Antagonist%2520AZD9056%2520on%2520the%2520Signs%2520and%2520Symptoms%2520of%2520Rheumatoid%2520Arthritis%2520in%2520Patients%2520with%2520Active%2520Disease%2520Despite%2520Treatment%2520with%2520Methotrexate%2520or%2520Sulphasalazine%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2012%26volume%3D71%26spage%3D1630%26epage%3D1635%26doi%3D10.1136%2Fannrheumdis-2011-143578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombel, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutgeerts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelsang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braddock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinisch, W.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn’s Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study</span>. <i>Inflamm. Bowel Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2247</span>– <span class="NLM_lpage">2253</span>, <span class="refDoi"> DOI: 10.1097/MIB.0000000000000514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1097%2FMIB.0000000000000514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=26197451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FltVSqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2247-2253&author=A.+Eserauthor=J.+F.+Colombelauthor=P.+Rutgeertsauthor=S.+Vermeireauthor=H.+Vogelsangauthor=M.+Braddockauthor=T.+Perssonauthor=W.+Reinisch&title=Safety+and+Efficacy+of+an+Oral+Inhibitor+of+the+Purinergic+Receptor+P2X7+in+Adult+Patients+with+Moderately+to+Severely+Active+Crohn%E2%80%99s+Disease%3A+A+Randomized+Placebo-controlled%2C+Double-blind%2C+Phase+IIa+Study&doi=10.1097%2FMIB.0000000000000514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study</span></div><div class="casAuthors">Eser Alexander; Colombel Jean-Frederic; Rutgeerts Paul; Vermeire Severine; Vogelsang Harald; Braddock Martin; Persson Tore; Reinisch Walter</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2247-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9056 is a selective orally active inhibitor of the purinergic receptor P2X7, which is a key player in the generation and secretion of several proinflammatory cytokines involved in the pathogenesis of Crohn's disease (CD).  The aim of this phase IIa study was to assess the efficacy and safety of AZD9056 for the treatment of moderately to severely active CD.  METHODS:  We conducted a placebo-controlled, multicenter, double-blind phase IIa study in patients with moderately to severely active CD as defined by a CD Activity Index (CDAI) of at least 220.  Patients were randomized in a 2:1 mode either to 200 mg of AZD9056 administered orally as a tablet once daily for 28 days or matching placebo.  Primary endpoint was the change in CDAI from baseline at day 28, and secondary endpoints included clinical remission (CDAI < 150) and CDAI 70 response and improvement in the quality of life measures Short Form 36 and Inflammatory Bowel Disease Questionnaire.  Changes in serum C-reactive protein and fecal calprotectin were assessed.  RESULTS:  In total, 34 patients were enrolled, 24 to AZD9056 and 10 to placebo.  The CDAI dropped in AZD9056-treated subjects from a baseline mean of 311 to 242 and from 262 to 239 in placebo-treated subjects (P = 0.049).  Remission and response rates were numerically higher with AZD9056 versus placebo, (n = 5, 24% versus n = 1, 11%, P = 0.43 and n = 11, 52% versus n = 2, 22%, P = 0.13, respectively).  Marked decrease in disease activity was observed for the CDAI subcomponents, pain and general well-being.  Apart from a statistically significant improvement in the Mental Component Score of Short Form 36 for AZD9056 versus placebo (P = 0.017), no other differences in measurements of quality of life could be observed.  There was no decrease in concentrations of serum C-reactive protein and fecal calprotectin during treatment.  AZD9056 was well-tolerated, and no serious adverse events were reported.  CONCLUSIONS:  Our data suggest that the purinergic receptor P2X7 antagonist AZD9056 has the potential to improve symptoms in patients with moderate-to-severe CD combined with a beneficial risk profile.  Although the lack in change of inflammatory biomarkers questions its anti-inflammatory potential, the results obtained in this study rather suggest P2X7 antagonism for the treatment of chronic abdominal pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHjK0qgS5fO0g6wdEZmT2rfW6udTcc2eaGqzmiEKqD4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FltVSqtA%253D%253D&md5=8ade69d316c57adae49fb595e35ab2f7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1097%2FMIB.0000000000000514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMIB.0000000000000514%26sid%3Dliteratum%253Aachs%26aulast%3DEser%26aufirst%3DA.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DRutgeerts%26aufirst%3DP.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DVogelsang%26aufirst%3DH.%26aulast%3DBraddock%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DT.%26aulast%3DReinisch%26aufirst%3DW.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520an%2520Oral%2520Inhibitor%2520of%2520the%2520Purinergic%2520Receptor%2520P2X7%2520in%2520Adult%2520Patients%2520with%2520Moderately%2520to%2520Severely%2520Active%2520Crohn%25E2%2580%2599s%2520Disease%253A%2520A%2520Randomized%2520Placebo-controlled%252C%2520Double-blind%252C%2520Phase%2520IIa%2520Study%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2015%26volume%3D21%26spage%3D2247%26epage%3D2253%26doi%3D10.1097%2FMIB.0000000000000514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchilibon, S.</span></span> <span> </span><span class="NLM_article-title">Molecular Recognition at Purine and Pyrimidine Nucleotide (P2) Receptors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.2174/1568026043450961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.2174%2F1568026043450961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=15078212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVeju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=805-819&author=K.+Jacobsonauthor=S.+Costanziauthor=M.+Ohnoauthor=B.+Joshiauthor=P.+Besadaauthor=B.+Xuauthor=S.+Tchilibon&title=Molecular+Recognition+at+Purine+and+Pyrimidine+Nucleotide+%28P2%29+Receptors&doi=10.2174%2F1568026043450961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition at purine and pyrimidine nucleotide (P2) receptors</span></div><div class="casAuthors">Jacobson, Kenneth A.; Costanzi, Stefano; Ohno, Michihiro; Joshi, Bhalchandra V.; Besada, Pedro; Xu, Bin; Tchilibon, Susanna</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">805-819</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In comparison to other classes of cell surface receptors, the medicinal chem. at P2X (ligand-gated ion channels) and P2Y (G protein-coupled) nucleotide receptors has been relatively slow to develop.  Recent effort to design selective agonists and antagonists based on a combination of library screening, empirical modification of known ligands, and rational design have led to the introduction of potent antagonists of the P2X1 (derivs. of pyridoxal phosphates and suramin), P2X3 (A-317491), P2X7 (derivs. of the isoquinoline KN-62), P2Y1 (nucleotide analogs MRS 2179 and MRS 2279), P2Y2 (thiouracil derivs. such as AR-C126313), and P2Y12 (nucleotide/nucleoside analogs AR-C69931X and AZD6140) receptors.  A variety of native agonist ligands (ATP, ADP, UTP, UDP, and UDP-glucose) are currently the subject of structural modification efforts to improve selectivity.  MRS2365 is a selective agonist for P2Y1 receptors.  The dinucleotide INS 37217 potently activates the P2Y2 receptor.  UTP-γ-S and UDP-β-S are selective agonists for P2Y2/P2Y4 and P2Y6 receptors, resp.  The current knowledge of the structures of P2X and P2Y receptors, is derived mainly from mutagenesis studies.  Site-directed mutagenesis has shown that ligand recognition in the human P2Y1 receptor involves individual residues of both the TMs (3, 5, 6, and 7), as well as EL 2 and 3.  The binding of the neg.-charged phosphate moiety is dependent on pos. charged lysine and arginine residues near the exofacial side of TMs 3 and 7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmJE-OmgZig7Vg90H21EOLACvtfcHk0lhZQqwfgnn0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVeju70%253D&md5=7fe4929a95451294ba6852c46326d2e7</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F1568026043450961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026043450961%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DK.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DOhno%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DB.%26aulast%3DBesada%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DTchilibon%26aufirst%3DS.%26atitle%3DMolecular%2520Recognition%2520at%2520Purine%2520and%2520Pyrimidine%2520Nucleotide%2520%2528P2%2529%2520Receptors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D805%26epage%3D819%26doi%3D10.2174%2F1568026043450961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soltani
Rad, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrouz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asrari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalafi-Nezhad, A.</span></span> <span> </span><span class="NLM_article-title">A Simple and Regioselective One-Pot Procedure for the Direct N-Acylation of Some Purine and Pyrimidine Nucleobases via Carboxylic Acids Using Cyanuric Chloride</span>. <i>Monatsh. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">1933</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1007/s00706-014-1270-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1007%2Fs00706-014-1270-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1yksrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2014&pages=1933-1940&author=M.+N.+Soltani%0ARadauthor=S.+Behrouzauthor=Z.+Asrariauthor=A.+Khalafi-Nezhad&title=A+Simple+and+Regioselective+One-Pot+Procedure+for+the+Direct+N-Acylation+of+Some+Purine+and+Pyrimidine+Nucleobases+via+Carboxylic+Acids+Using+Cyanuric+Chloride&doi=10.1007%2Fs00706-014-1270-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A simple and regioselective one-pot procedure for the direct N-acylation of some purine and pyrimidine nucleobases via carboxylic acids using cyanuric chloride</span></div><div class="casAuthors">Soltani Rad, Mohammad Navid; Behrouz, Somayeh; Asrari, Zeinab; Khalafi-Nezhad, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Monatshefte fuer Chemie</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1933-1940</span>CODEN:
                <span class="NLM_cas:coden">MOCMB7</span>;
        ISSN:<span class="NLM_cas:issn">0026-9247</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A facile and selective one-pot N-acylation of nucleobases via carboxylic acids using cyanuric chloride (2,4,6-trichloro-1,3,5-triazine) is described.  In this protocol, the reaction of diverse carboxylic acids with pyrimidine and/or purine nucleobases is efficiently achieved in the presence of cyanuric chloride and NaH/Et3N in DMF/MeCN (1:1, vol./vol.) to afford the corresponding N-acyl nucleobases in good yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqORc1JzfkbXLVg90H21EOLACvtfcHk0lhZQqwfgnn0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1yksrfL&md5=550d913665a837b7437fb971bf8b011a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs00706-014-1270-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00706-014-1270-1%26sid%3Dliteratum%253Aachs%26aulast%3DSoltani%2BRad%26aufirst%3DM.%2BN.%26aulast%3DBehrouz%26aufirst%3DS.%26aulast%3DAsrari%26aufirst%3DZ.%26aulast%3DKhalafi-Nezhad%26aufirst%3DA.%26atitle%3DA%2520Simple%2520and%2520Regioselective%2520One-Pot%2520Procedure%2520for%2520the%2520Direct%2520N-Acylation%2520of%2520Some%2520Purine%2520and%2520Pyrimidine%2520Nucleobases%2520via%2520Carboxylic%2520Acids%2520Using%2520Cyanuric%2520Chloride%26jtitle%3DMonatsh.%2520Chem.%26date%3D2014%26volume%3D145%26spage%3D1933%26epage%3D1940%26doi%3D10.1007%2Fs00706-014-1270-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tumma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. V.</span></span> <span> </span><span class="NLM_article-title">N-Alkylation of 2,6-Dichloropurine Hydrochloride with a Variety of Alcohols over Alumina Catalyst</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1856</span>– <span class="NLM_lpage">1866</span>, <span class="refDoi"> DOI: 10.1080/00397910903162791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1080%2F00397910903162791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFCntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=1856-1866&author=H.+Tummaauthor=N.+Nagarajuauthor=K.+V.+Reddy&title=N-Alkylation+of+2%2C6-Dichloropurine+Hydrochloride+with+a+Variety+of+Alcohols+over+Alumina+Catalyst&doi=10.1080%2F00397910903162791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">N-Alkylation of 2,6-Dichloropurine Hydrochloride with a Variety of Alcohols over Alumina Catalyst</span></div><div class="casAuthors">Tumma, Harikrishna; Nagaraju, N.; Reddy, K. Vijayakumar</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1856-1866</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">2,6-Dichloropurine hydrochloride reacts with various types of alcs. using different alumina catalysts and converts into its N-9-alkyl-2-chloro-6-hydroxy-9H-purine products to an extent of 49-74%.  The product selectivity depends on the stability of carbocation generated from the alc.  More stable carbocation formulates both N-7 and N-9-alkyl-2,6-dichloropurine products, whereas the less stable carbocation results in exclusively N-9-alkyl-2-chloro-6-hydroxy-9H-purine.  The catalytic activity of alumina prepd. using the sol-gel method has larger Brunauer, Emmett, and Teller (BET) surface area and hence shows significantly greater catalytic activity than the com. available alumina samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNw2OE3l1pfrVg90H21EOLACvtfcHk0lhZQqwfgnn0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFCntbc%253D&md5=68fdb430d196ba1ce8b2dcce4567c56d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F00397910903162791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910903162791%26sid%3Dliteratum%253Aachs%26aulast%3DTumma%26aufirst%3DH.%26aulast%3DNagaraju%26aufirst%3DN.%26aulast%3DReddy%26aufirst%3DK.%2BV.%26atitle%3DN-Alkylation%2520of%25202%252C6-Dichloropurine%2520Hydrochloride%2520with%2520a%2520Variety%2520of%2520Alcohols%2520over%2520Alumina%2520Catalyst%26jtitle%3DSynth.%2520Commun.%26date%3D2010%26volume%3D40%26spage%3D1856%26epage%3D1866%26doi%3D10.1080%2F00397910903162791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakx, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutot, M.</span></span> <span> </span><span class="NLM_article-title">A Fast and Reproducible Cell- and 96-Well Plate-Based Method for the Evaluation of P2X7 Receptor Activation Using YO-PRO-1 Fluorescent Dye</span>. <i>J. Microbiol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e64</span> <span class="refDoi"> DOI: 10.14440/jbm.2017.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.14440%2Fjbm.2017.136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&author=P.+Ratauthor=E.+Olivierauthor=C.+Tanterauthor=A.+Wakxauthor=M.+Dutot&title=A+Fast+and+Reproducible+Cell-+and+96-Well+Plate-Based+Method+for+the+Evaluation+of+P2X7+Receptor+Activation+Using+YO-PRO-1+Fluorescent+Dye&doi=10.14440%2Fjbm.2017.136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.14440%2Fjbm.2017.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14440%252Fjbm.2017.136%26sid%3Dliteratum%253Aachs%26aulast%3DRat%26aufirst%3DP.%26aulast%3DOlivier%26aufirst%3DE.%26aulast%3DTanter%26aufirst%3DC.%26aulast%3DWakx%26aufirst%3DA.%26aulast%3DDutot%26aufirst%3DM.%26atitle%3DA%2520Fast%2520and%2520Reproducible%2520Cell-%2520and%252096-Well%2520Plate-Based%2520Method%2520for%2520the%2520Evaluation%2520of%2520P2X7%2520Receptor%2520Activation%2520Using%2520YO-PRO-1%2520Fluorescent%2520Dye%26jtitle%3DJ.%2520Microbiol.%2520Methods%26date%3D2017%26volume%3D4%26doi%3D10.14440%2Fjbm.2017.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helliwell, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ShioukHuey, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molero, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, L.</span></span> <span> </span><span class="NLM_article-title">Selected Ginsenosides of the Protopanaxdiol Series are Novel Positive Allosteric Modulators of P2X7 Receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">3326</span>– <span class="NLM_lpage">3340</span>, <span class="refDoi"> DOI: 10.1111/bph.13123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1111%2Fbph.13123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=25752193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaqt7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=3326-3340&author=R.+M.+Helliwellauthor=C.+O.+ShioukHueyauthor=K.+Dhunaauthor=J.+C.+Moleroauthor=J.-M.+Yeauthor=C.+C.+Xueauthor=L.+Stokes&title=Selected+Ginsenosides+of+the+Protopanaxdiol+Series+are+Novel+Positive+Allosteric+Modulators+of+P2X7+Receptors&doi=10.1111%2Fbph.13123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Selected ginsenosides of the protopanaxdiol series are novel positive allosteric modulators of P2X7 receptors</span></div><div class="casAuthors">Helliwell, R. M.; ShioukHuey, C. O.; Dhuna, K.; Molero, J. C.; Ye, J.-M.; Xue, C. C.; Stokes, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3326-3340</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The P2X7 receptor is an ATP-gated ion channel predominantly expressed in immune cells and plays a key role in inflammatory processes.  Ginseng is a well-known Chinese herb with both pro- and anti-inflammatory properties and many of its actions have been ascribed to constituent ginsenosides.  We screened a no. of ginsenoside compds. for pharmacol. activity at P2X7 receptors, that might contribute to the reported immunomodulatory actions of ginseng.  Exptl. Approach : We used several assays to measure responses of P2X7 receptors, ATP-mediated dye uptake, intracellular calcium measurement and whole-cell patch-clamp recordings.  HEK-293 cells stably expressing human P2X7 receptors were used in addn. to mouse macrophages endogenously expressing P2X7 receptors.  Key Results : Four ginsenosides of the protopanaxdiol series, Rb1, Rh2, Rd and the metabolite compd. K (CK) potentiated the dye uptake responses of P2X7 receptors, whereas other ginsenosides tested were ineffective (1-10 μM).  The potentiation was rapid in onset, required a threshold concn. of ATP (>50 μM) and had an EC50 of 1.08 μM.  CK markedly enhanced ATP-activated P2X7 currents, probably via an extracellular site of action.  One of the consequences of this potentiation effect is a sustained rise in intracellular Ca2+ that could account for the decrease in cell viability in mouse macrophages after a combination of 500 μM ATP and 10 μM CK that are non-toxic when applied alone.  Conclusions and Implications : This study identifies selected ginsenosides as novel potent allosteric modulators of P2X7 channels that may account for some of the reported immune modulatory actions of protopanaxdiol ginsenosides in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreyTdb5rbxbrVg90H21EOLACvtfcHk0lgESZy4ORhutQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaqt7rL&md5=cd14c1318acff8b717a1db3ea17fbfaa</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1111%2Fbph.13123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13123%26sid%3Dliteratum%253Aachs%26aulast%3DHelliwell%26aufirst%3DR.%2BM.%26aulast%3DShioukHuey%26aufirst%3DC.%2BO.%26aulast%3DDhuna%26aufirst%3DK.%26aulast%3DMolero%26aufirst%3DJ.%2BC.%26aulast%3DYe%26aufirst%3DJ.-M.%26aulast%3DXue%26aufirst%3DC.%2BC.%26aulast%3DStokes%26aufirst%3DL.%26atitle%3DSelected%2520Ginsenosides%2520of%2520the%2520Protopanaxdiol%2520Series%2520are%2520Novel%2520Positive%2520Allosteric%2520Modulators%2520of%2520P2X7%2520Receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D3326%26epage%3D3340%26doi%3D10.1111%2Fbph.13123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jo, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasakawa, C.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms Regulating NLRP3 Inflammasome Activation</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1038/cmi.2015.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1038%2Fcmi.2015.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=26549800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Gms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=148-159&author=E.-K.+Joauthor=J.+K.+Kimauthor=D.-M.+Shinauthor=C.+Sasakawa&title=Molecular+Mechanisms+Regulating+NLRP3+Inflammasome+Activation&doi=10.1038%2Fcmi.2015.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms regulating NLRP3 inflammasome activation</span></div><div class="casAuthors">Jo, Eun-Kyeong; Kim, Jin Kyung; Shin, Dong-Min; Sasakawa, Chihiro</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-159</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">Inflammasomes are multi-protein signaling complexes that trigger the activation of inflammatory caspases and the maturation of interleukin-1β.  Among various inflammasome complexes, the NLRP3 inflammasome is best characterized and has been linked with various human autoinflammatory and autoimmune diseases.  Thus, the NLRP3 inflammasome may be a promising target for anti-inflammatory therapies.  In this review, we summarize the current understanding of the mechanisms by which the NLRP3 inflammasome is activated in the cytosol.  We also describe the binding partners of NLRP3 inflammasome complexes activating or inhibiting the inflammasome assembly.  Our knowledge of the mechanisms regulating NLRP3 inflammasome signaling and how these influence inflammatory responses offers further insight into potential therapeutic strategies to treat inflammatory diseases assocd. with dysregulation of the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBv_NNzcwFLVg90H21EOLACvtfcHk0lij9rIplNcu6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Gms7s%253D&md5=90c508a823912cf69f86cefac7aaaaec</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2015.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2015.95%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DE.-K.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DShin%26aufirst%3DD.-M.%26aulast%3DSasakawa%26aufirst%3DC.%26atitle%3DMolecular%2520Mechanisms%2520Regulating%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2016%26volume%3D13%26spage%3D148%26epage%3D159%26doi%3D10.1038%2Fcmi.2015.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barberà-Cremades, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baroja-Mazo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Virgilio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrín, P.</span></span> <span> </span><span class="NLM_article-title">P2X7 Receptor-Stimulation Causes Fever via PGE2 and IL-1beta Release</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2951</span>– <span class="NLM_lpage">2962</span>, <span class="refDoi"> DOI: 10.1096/fj.12-205765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1096%2Ffj.12-205765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22490780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFartL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2951-2962&author=M.+Barber%C3%A0-Cremadesauthor=A.+Baroja-Mazoauthor=A.+I.+Gomezauthor=F.+Machadoauthor=F.+Di+Virgilioauthor=P.+Pelegr%C3%ADn&title=P2X7+Receptor-Stimulation+Causes+Fever+via+PGE2+and+IL-1beta+Release&doi=10.1096%2Ffj.12-205765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release</span></div><div class="casAuthors">Barbera-Cremades, Maria; Baroja-Mazo, Alberto; Gomez, Ana I.; Machado, Francisco; Di Virgilio, Francesco; Pelegrin, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2951-2962, 10.1096/fj.12-205765</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Prostaglandins (PGs) are important lipid mediators involved in the development of inflammatory assocd. pain and fever.  PGE2 is a well-established endogenous pyrogen activated by proinflammatory cytokine interleukin (IL)-1β.  P2X7 receptors (P2X7Rs) expressed by inflammatory cells are stimulated by the danger signal extracellular ATP to activate the inflammasome and release IL-1β.  Here we show that P2X7R activation is required for the release of PGE2 and other autacoids independent of inflammasome activation, with an ATP EC50 for PGE2 and IL-1β release of 1.58 and 1.23 mM, resp.  Furthermore, lack of P2X7R or specific antagonism of P2X7R decreased the febrile response in mice triggered after i.p. LPS or IL-1β inoculation.  Accordingly, LPS inoculation caused i.p. ATP accumulation.  Therefore, P2X7R antagonists emerge as novel therapeutics for the treatment for acute inflammation, pain and fever, with wider anti-inflammatory activity than currently used cyclooxygenase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkUeT1_7VD3rVg90H21EOLACvtfcHk0lij9rIplNcu6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFartL%252FO&md5=6f6acbbafe803ea4d74b9ed343efd5a8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1096%2Ffj.12-205765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.12-205765%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%25C3%25A0-Cremades%26aufirst%3DM.%26aulast%3DBaroja-Mazo%26aufirst%3DA.%26aulast%3DGomez%26aufirst%3DA.%2BI.%26aulast%3DMachado%26aufirst%3DF.%26aulast%3DDi%2BVirgilio%26aufirst%3DF.%26aulast%3DPelegr%25C3%25ADn%26aufirst%3DP.%26atitle%3DP2X7%2520Receptor-Stimulation%2520Causes%2520Fever%2520via%2520PGE2%2520and%2520IL-1beta%2520Release%26jtitle%3DFASEB%2520J.%26date%3D2012%26volume%3D26%26spage%3D2951%26epage%3D2962%26doi%3D10.1096%2Ffj.12-205765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">High Throughput Artificial Membrane Permeability Assay for Blood-Brain Barrier</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/s0223-5234(03)00012-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2FS0223-5234%2803%2900012-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=12667689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=223-232&author=L.+Diauthor=E.+H.+Kernsauthor=K.+Fanauthor=O.+J.+McConnellauthor=G.+T.+Carter&title=High+Throughput+Artificial+Membrane+Permeability+Assay+for+Blood-Brain+Barrier&doi=10.1016%2Fs0223-5234%2803%2900012-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput artificial membrane permeability assay for blood-brain barrier</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Fan, Kristi; McConnell, Oliver J.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The recent advances in high throughput screening for biol. activities and combinatorial chem. have greatly expanded the no. of drug candidates.  Rapid screening for BBB penetration potential early in drug discovery programs provides important information for compd. selection and guidance of synthesis for desirable CNS properties.  In this paper, we discuss a modification of the parallel artificial membrane permeation assay (PAMPA) for the prediction of blood-brain barrier penetration (PAMPA-BBB).  The assay was developed with 30 structurally diverse com. drugs and validated with 14 Wyeth Research compds.  The PAMPA-BBB assay has the advantages of: predicting passive blood-brain barrier penetration with high success, high throughput, low cost, and reproducibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCg9Ka4mziLVg90H21EOLACvtfcHk0ljU1krP5gv3Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D&md5=d228d5808ba8df23deed92c5e2bf3863</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900012-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900012-6%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DFan%26aufirst%3DK.%26aulast%3DMcConnell%26aufirst%3DO.%2BJ.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DHigh%2520Throughput%2520Artificial%2520Membrane%2520Permeability%2520Assay%2520for%2520Blood-Brain%2520Barrier%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D223%26epage%3D232%26doi%3D10.1016%2Fs0223-5234%2803%2900012-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.-d.</span></span> <span> </span><span class="NLM_article-title">Photoaffinity Substrates for P-Glycoprotein</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(92)90665-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2F0006-2952%2892%2990665-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1346496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK38Xht1Shtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=89-93&author=W.+T.+Beckauthor=X.-d.+Qian&title=Photoaffinity+Substrates+for+P-Glycoprotein&doi=10.1016%2F0006-2952%2892%2990665-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity substrates for P-glycoprotein</span></div><div class="casAuthors">Beck, William T.; Qian, Xiao Dong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-93</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review with 42 refs.  A variety of compds. can inhibit the function of P-glycoprotein (Pgp) by binding to it and preventing the efflux of anticancer drug substrates.  While the mol. architecture of the drug binding site(s) in Pgp is not known, it is clear that modulators in general appear to conform to some general phys.-chem. rules.  In this paper, the authors discuss the basic concepts of drug recognition by Pgp as currently understood.  The authors also examine the compds. used to photoaffinity label this protein and discuss their utility in identifying drug binding sites.  Finally, the authors show that a photoaffinity analog of daunorubicin, [3H]azidobenzoyl-daunorubicin ([3H]AB-DNR), is a good affinity labeling reagent for Pgp.  A finding of interest is that vinblastine and verapamil compete more effectively than daunorubicin for [3H]AB-DNR binding to Pgp, suggesting that vinblastine and verapamil have similar structural features not shared by daunorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUsQxdfkM8xbVg90H21EOLACvtfcHk0ljU1krP5gv3Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xht1Shtrk%253D&md5=7fcd989f8728521a5d6920a27da8ef15</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2892%2990665-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252892%252990665-6%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DW.%2BT.%26aulast%3DQian%26aufirst%3DX.-d.%26atitle%3DPhotoaffinity%2520Substrates%2520for%2520P-Glycoprotein%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1992%26volume%3D43%26spage%3D89%26epage%3D93%26doi%3D10.1016%2F0006-2952%2892%2990665-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoblock, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neff, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenden, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Characterization of a Novel Centrally Permeable P2X7 Receptor Antagonist: JNJ-47965567</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1111/bph.12314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1111%2Fbph.12314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=23889535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2ntrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=624-640&author=A.+Bhattacharyaauthor=Q.+Wangauthor=H.+Aoauthor=J.+R.+Shoblockauthor=B.+Lordauthor=L.+Aluisioauthor=I.+Fraserauthor=D.+Nepomucenoauthor=R.+A.+Neffauthor=N.+Weltyauthor=T.+W.+Lovenbergauthor=P.+Bonaventureauthor=A.+D.+Wickendenauthor=M.+A.+Letavic&title=Pharmacological+Characterization+of+a+Novel+Centrally+Permeable+P2X7+Receptor+Antagonist%3A+JNJ-47965567&doi=10.1111%2Fbph.12314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567</span></div><div class="casAuthors">Bhattacharya, Anindya; Wang, Qi; Ao, Hong; Shoblock, James R.; Lord, Brian; Aluisio, Leah; Fraser, Ian; Nepomuceno, Diane; Neff, Robert A.; Welty, Natalie; Lovenberg, Timothy W.; Bonaventure, Pascal; Wickenden, Alan D.; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">624-640</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : An increasing body of evidence suggests that the purinergic receptor P2X, ligand-gated ion channel, 7 (P2X7) in the CNS may play a key role in neuropsychiatry, neurodegeneration and chronic pain.  In this study, we characterized JNJ-47965567, a centrally permeable, high-affinity, selective P2X7 antagonist.  Exptl. Approach : We have used a combination of in vitro assays (calcium flux, radioligand binding, electrophysiol., IL-1β release) in both recombinant and native systems.  Target engagement of JNJ-47965567 was demonstrated by ex vivo receptor binding autoradiog. and in vivo blockade of Bz-ATP induced IL-1β release in the rat brain.  Finally, the efficacy of JNJ-47965567 was tested in std. models of depression, mania and neuropathic pain.  Key Results : JNJ-47965567 is potent high affinity (pKi 7.9 ± 0.07), selective human P2X7 antagonist, with no significant obsd. speciation.  In native systems, the potency of the compd. to attenuate IL-1β release was 6.7 ± 0.07 (human blood), 7.5 ± 0.07 (human monocytes) and 7.1 ± 0.1 (rat microglia).  JNJ-47965567 exhibited target engagement in rat brain, with a brain EC50 of 78 ± 19 ng·mL-1 (P2X7 receptor autoradiog.) and functional block of Bz-ATP induced IL-1β release.  JNJ-47965567 (30 mg·kg-1) attenuated amphetamine-induced hyperactivity and exhibited modest, yet significant efficacy in the rat model of neuropathic pain.  No efficacy was obsd. in forced swim test.  Conclusion and Implications : JNJ-47965567 is centrally permeable, high affinity P2X7 antagonist that can be used to probe the role of central P2X7 in rodent models of CNS pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS_bU7fI8KzLVg90H21EOLACvtfcHk0ljU1krP5gv3Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2ntrnI&md5=29d3bc1d3ecedda01f3d33b53d96c289</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1111%2Fbph.12314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12314%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DShoblock%26aufirst%3DJ.%2BR.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DNepomuceno%26aufirst%3DD.%26aulast%3DNeff%26aufirst%3DR.%2BA.%26aulast%3DWelty%26aufirst%3DN.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DWickenden%26aufirst%3DA.%2BD.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DPharmacological%2520Characterization%2520of%2520a%2520Novel%2520Centrally%2520Permeable%2520P2X7%2520Receptor%2520Antagonist%253A%2520JNJ-47965567%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D624%26epage%3D640%26doi%3D10.1111%2Fbph.12314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rech, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sales, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velter, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenden, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1021/ml400040v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400040v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVahtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=419-422&author=M.+A.+Letavicauthor=B.+Lordauthor=F.+Bischoffauthor=N.+A.+Hawrylukauthor=S.+Pietersauthor=J.+C.+Rechauthor=Z.+Salesauthor=A.+I.+Velterauthor=H.+Aoauthor=P.+Bonaventureauthor=V.+Contrerasauthor=X.+Jiangauthor=K.+L.+Mortonauthor=B.+Scottauthor=Q.+Wangauthor=A.+D.+Wickendenauthor=N.+I.+Carruthersauthor=A.+Bhattacharya&title=Synthesis+and+Pharmacological+Characterization+of+Two+Novel%2C+Brain+Penetrating+P2X7+Antagonists&doi=10.1021%2Fml400040v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists</span></div><div class="casAuthors">Letavic, Michael A.; Lord, Brian; Bischoff, Francois; Hawryluk, Natalie A.; Pieters, Serge; Rech, Jason C.; Sales, Zachary; Velter, Adriana I.; Ao, Hong; Bonaventure, Pascal; Contreras, Victor; Jiang, Xiaohui; Morton, Kirsten L.; Scott, Brian; Wang, Qi; Wickenden, Alan D.; Carruthers, Nicholas I.; Bhattacharya, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-422</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and preclin. characterization of two novel, brain penetrating P2X7 compds. will be described.  Both compds. are shown to be high potency P2X7 antagonists in human, rat, and mouse cell lines and both were shown to have high brain concns. and robust receptor occupancy in rat.  Compd. I is of particular interest as a probe compd. for the preclin. assessment of P2X7 blockade in animal models of neuro-inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFnpKdjd4_XLVg90H21EOLACvtfcHk0liAi287NGFTAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVahtbw%253D&md5=7c1d0561aad7338b75840181756c9295</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fml400040v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400040v%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBischoff%26aufirst%3DF.%26aulast%3DHawryluk%26aufirst%3DN.%2BA.%26aulast%3DPieters%26aufirst%3DS.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DSales%26aufirst%3DZ.%26aulast%3DVelter%26aufirst%3DA.%2BI.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DContreras%26aufirst%3DV.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DMorton%26aufirst%3DK.%2BL.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWickenden%26aufirst%3DA.%2BD.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DBhattacharya%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Characterization%2520of%2520Two%2520Novel%252C%2520Brain%2520Penetrating%2520P2X7%2520Antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D419%26epage%3D422%26doi%3D10.1021%2Fml400040v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span> <span> </span><span class="NLM_article-title">Interspecies Comparison of Putative Ligand Binding Sites of Human, Rat and Mouse P-Glycoprotein</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2018.06.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.ejps.2018.06.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=29936088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Kms7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2018&pages=134-143&author=S.+Jainauthor=M.+Granditsauthor=G.+F.+Ecker&title=Interspecies+Comparison+of+Putative+Ligand+Binding+Sites+of+Human%2C+Rat+and+Mouse+P-Glycoprotein&doi=10.1016%2Fj.ejps.2018.06.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Interspecies comparison of putative ligand binding sites of human, rat and mouse P-glycoprotein</span></div><div class="casAuthors">Jain, Sankalp; Grandits, Melanie; Ecker, Gerhard F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prior to the clin. phases of testing, safety, efficacy and pharmacokinetic profiles of lead compds. are evaluated in animal studies.  These tests are primarily performed in rodents, such as mouse and rats.  In order to reduce the no. of animal expts., computational models that predict the outcome of these studies and thus aid in prioritization of preclin. candidates are heavily needed.  However, although computational models for human off-target interactions with decent quality are available, they cannot easily be transferred to rodents due to lack of resp. data.  In this study, we assess the transferability of human P-glycoprotein activity data for development of in silico models to predict in vivo effects in rats and mouse using a structure-based approach.  P-glycoprotein (P-gp) is an ATP-dependent efflux transporter that transports xenobiotic compds. such as toxins and drugs out of cells and has a broad substrate and inhibitor specificity.  Being mostly expressed at barriers, it influences the bioavailability of drugs and thus contributes also to toxicity.  Comparison of the binding site interaction profiles of human, rat and mouse P-gp derived from docking studies with a set of common inhibitors suggests that the inhibitors share potentially similar binding modes.  These findings encourage the use of in vitro human P-gp data for predicting in vivo effects in rodents and thus contributes to the 3Rs (Replace, Reduce and Refine) of animal expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql3AvJfNmhRbVg90H21EOLACvtfcHk0liAi287NGFTAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Kms7bM&md5=c52c06b5a6ce21fafabc41008c6eae56</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2018.06.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2018.06.022%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%26aulast%3DGrandits%26aufirst%3DM.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26atitle%3DInterspecies%2520Comparison%2520of%2520Putative%2520Ligand%2520Binding%2520Sites%2520of%2520Human%252C%2520Rat%2520and%2520Mouse%2520P-Glycoprotein%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D122%26spage%3D134%26epage%3D143%26doi%3D10.1016%2Fj.ejps.2018.06.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinan, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryan, J. F.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein Inhibition Increases the Brain Distribution and Antidepressant-Like Activity of Escitalopram in Rodents</span>. <i>Neuropsychopharmacol</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2209</span>– <span class="NLM_lpage">2219</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1038%2Fnpp.2013.120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCqur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=2209-2219&author=F.+E.+O%E2%80%99Brienauthor=R.+M.+O%E2%80%99Connorauthor=G.+Clarkeauthor=T.+G.+Dinanauthor=B.+T.+Griffinauthor=J.+F.+Cryan&title=P-Glycoprotein+Inhibition+Increases+the+Brain+Distribution+and+Antidepressant-Like+Activity+of+Escitalopram+in+Rodents&doi=10.1038%2Fnpp.2013.120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein Inhibition Increases the Brain Distribution and Antidepressant-Like Activity of Escitalopram in Rodents</span></div><div class="casAuthors">O'Brien, Fionn E.; O'Connor, Richard M.; Clarke, Gerard; Dinan, Timothy G.; Griffin, Brendan T.; Cryan, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite the clin. prevalence of the antidepressant escitalopram, over 30% of escitalopram-treated patients fail to respond to treatment.  Recent gene assocn. studies have highlighted a potential link between the drug efflux transporter P-glycoprotein (P-gp) and response to escitalopram.  The present studies investigated pharmacokinetic and pharmacodynamic interactions between P-gp and escitalopram.  In vitro bidirectional transport studies revealed that escitalopram is a transported substrate of human P-gp.  Microdialysis-based pharmacokinetic studies demonstrated that administration of the P-gp inhibitor cyclosporin A resulted in increased brain levels of escitalopram without altering plasma escitalopram levels in the rat, thereby showing that P-gp restricts escitalopram transport across the blood-brain barrier (BBB) in vivo.  The tail suspension test (TST) was carried out to elucidate the pharmacodynamic impact of P-gp inhibition on escitalopram effect in a mouse model of antidepressant activity.  Pre-treatment with the P-gp inhibitor verapamil enhanced the response to escitalopram in the TST.  Taken together, these data indicate that P-gp may restrict the BBB transport of escitalopram in humans, potentially resulting in subtherapeutic brain concns. in certain patients.  Moreover, by verifying that increasing escitalopram delivery to the brain by P-gp inhibition results in enhanced antidepressant-like activity, we suggest that adjunctive treatment with a P-gp inhibitor may represent a beneficial approach to augment escitalopram therapy in depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLDTWggs2-TLVg90H21EOLACvtfcHk0ljtsa14v-KAWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCqur%252FF&md5=f34540814671ef20080a7deb1ecb681d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.120%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DF.%2BE.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BM.%26aulast%3DClarke%26aufirst%3DG.%26aulast%3DDinan%26aufirst%3DT.%2BG.%26aulast%3DGriffin%26aufirst%3DB.%2BT.%26aulast%3DCryan%26aufirst%3DJ.%2BF.%26atitle%3DP-Glycoprotein%2520Inhibition%2520Increases%2520the%2520Brain%2520Distribution%2520and%2520Antidepressant-Like%2520Activity%2520of%2520Escitalopram%2520in%2520Rodents%26jtitle%3DNeuropsychopharmacol%26date%3D2013%26volume%3D38%26spage%3D2209%26epage%3D2219%26doi%3D10.1038%2Fnpp.2013.120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshitomi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">Species Differences of Inhibitory Effects on P-Glycoprotein-Mediated Drug Transport</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1609</span>– <span class="NLM_lpage">1618</span>, <span class="refDoi"> DOI: 10.1002/jps.20787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fjps.20787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=17094122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1CisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=1609-1618&author=N.+Suzuyamaauthor=M.+Katohauthor=T.+Takeuchiauthor=S.+Yoshitomiauthor=T.+Higuchiauthor=S.+Asashiauthor=T.+Yokoi&title=Species+Differences+of+Inhibitory+Effects+on+P-Glycoprotein-Mediated+Drug+Transport&doi=10.1002%2Fjps.20787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Species differences of inhibitory effects on P-glycoprotein-mediated drug transport</span></div><div class="casAuthors">Suzuyama, Naoto; Katoh, Miki; Takeuchi, Toshiyuki; Yoshitomi, Sumie; Higuchi, Tomoaki; Asashi, Satoru; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1609-1618</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Previously, we clarified the species differences in P-glycoprotein (P-gp)-mediated drug transport activity using human MDR1, monkey MDR1, canine MDR1, rat MDR1a, rat MDR1b, mouse mdr1a, and mouse mdr1b transfected LLC-PK1 cell lines.  However, the species differences in the inhibitory effects on P-gp-mediated drug transport have not been clarified yet.  The purpose of the present study was to evaluate the species differences in the inhibitory effects of typical P-gp inhibitors, quinidine and verapamil, on P-gp-mediated drug transport using MDR1 transfected cell lines.  The transcellular transport of [3H] daunorubicin, [3H] digoxin, and [mebmt-β-3H] cyclosporin A across monolayers of the MDR1 transfected cells were measured in the presence or absence of P-gp inhibitors.  On daunorubicin transport, the relative IC50 value (quinidine IC50/verapamil IC50) of human P-gp was 5.25 and those from other species ranged from 0.89 to 10.70.  The transport of digoxin and cyclosporin A also showed different relative IC50 values among human, monkey, canine, rat, and mouse P-gps.  The present study revealed that species differences in the inhibitory effects on P-gp-mediated drug transport should not be disregarded among human, monkey, canine, rat, and mouse.  This study will provide useful information for predicting drug interactions mediated by P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3shbk_L6sQbVg90H21EOLACvtfcHk0ljtsa14v-KAWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1CisL8%253D&md5=789ae2c96c2400cd5830e07c7fe0194f</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fjps.20787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20787%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuyama%26aufirst%3DN.%26aulast%3DKatoh%26aufirst%3DM.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DYoshitomi%26aufirst%3DS.%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DAsashi%26aufirst%3DS.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DSpecies%2520Differences%2520of%2520Inhibitory%2520Effects%2520on%2520P-Glycoprotein-Mediated%2520Drug%2520Transport%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2007%26volume%3D96%26spage%3D1609%26epage%3D1618%26doi%3D10.1002%2Fjps.20787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirimulla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegesna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, M.</span></span> <span> </span><span class="NLM_article-title">Halogen Interactions in Protein-Ligand Complexes: Implications of Halogen Bonding for Rational Drug Design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2781</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1021/ci400257k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci400257k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cisr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=2781-2791&author=S.+Sirimullaauthor=J.+B.+Baileyauthor=R.+Vegesnaauthor=M.+Narayan&title=Halogen+Interactions+in+Protein-Ligand+Complexes%3A+Implications+of+Halogen+Bonding+for+Rational+Drug+Design&doi=10.1021%2Fci400257k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen Interactions in Protein-Ligand Complexes: Implications of Halogen Bonding for Rational Drug Design</span></div><div class="casAuthors">Sirimulla, Suman; Bailey, Jake B.; Vegesna, Rahulsimham; Narayan, Mahesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2781-2791</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Halogen bonding interactions between halogenated ligands and proteins were examd. using the crystal structures deposited to date in the PDB.  The data was analyzed as a function of halogen bonding to main chain Lewis bases, viz. oxygen of backbone carbonyl and backbone amide nitrogen.  This anal. also examd. halogen bonding to side-chain Lewis bases (O, N, and S) and to the electron-rich arom. amino acids.  All interactions were restricted to van der Waals radii with resp. atoms.  The data reveals that while fluorine and chlorine have strong tendencies favoring interactions with the backbone Lewis bases at glycine, the trend is not restricted to the achiral amino acid backbone for larger halogens.  Halogen side-chain interactions are not restricted to amino acids contg. O, N, and S as Lewis bases.  Electron-rich arom. amino acids host a high frequency of halogen bonds as does Leu.  A closer examn. of the latter hydrophobic side chain reveals that the "propensity of interactions" of halogen ligands at this oily residue is an outcome of strong classical halogen bonds with Lewis bases in the vicinity.  Finally, an examn. of Θ1 (C-X···O and C-X···N) and Θ2 (X···O-Z and X···N-Z) angles reveals that very few ligands adopt classical halogen bonding angles, suggesting that steric and other factors may influence these angles.  The data is discussed in the context of ligand design for pharmaceutical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wcnZDXmkYrVg90H21EOLACvtfcHk0ljtsa14v-KAWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cisr3O&md5=a73378681587e3ac13143452ecb78882</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fci400257k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400257k%26sid%3Dliteratum%253Aachs%26aulast%3DSirimulla%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DJ.%2BB.%26aulast%3DVegesna%26aufirst%3DR.%26aulast%3DNarayan%26aufirst%3DM.%26atitle%3DHalogen%2520Interactions%2520in%2520Protein-Ligand%2520Complexes%253A%2520Implications%2520of%2520Halogen%2520Bonding%2520for%2520Rational%2520Drug%2520Design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D2781%26epage%3D2791%26doi%3D10.1021%2Fci400257k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishaq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mebus, C. A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">720</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.3899/jrheum.110874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3899%2Fjrheum.110874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22382341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVOnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=720-727&author=T.+C.+Stockauthor=B.+J.+Bloomauthor=N.+Weiauthor=S.+Ishaqauthor=W.+Parkauthor=X.+Wangauthor=P.+Guptaauthor=C.+A.+Mebus&title=Efficacy+and+Safety+of+CE-224%2C535%2C+an+Antagonist+of+P2X7+Receptor%2C+in+Treatment+of+Patients+with+Rheumatoid+Arthritis+Inadequately+Controlled+by+Methotrexate&doi=10.3899%2Fjrheum.110874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate</span></div><div class="casAuthors">Stock, Thomas C.; Bloom, Bradley J.; Wei, Nathan; Ishaq, Saliha; Park, Won; Wang, Xin; Gupta, Pankaj; Mebus, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">720-727</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">To evaluate efficacy and safety of CE-224,535, a selective P2X7 receptor antagonist, vs. placebo, in patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX).  In our phase IIA study (ClinicalTrials.gov no. NCT00628095; A6341009), patients aged ≥ 18 years with active RA were randomized to receive either CE-224,535 (500 mg bid) or placebo for 12 wk; all patients continued a stable background dose of ≥ 7.5 mg MTX.  The American College of Rheumatol. 20% (ACR20) response rate (primary efficacy endpoint) was not significantly different from placebo for CE-224,535 (34.0% vs 36.2%; p = 0.591) at Week 12, or at any timepoint over the 12-wk treatment period.  There was no significant difference at Week 12 for the ACR20 response rate following subgroup analyses by age, sex, baseline disease activity, baseline duration of disease, geog. region, or concomitant use of steroids.  ACR50/ACR70 response rates and change from baseline in Disease Activity Score 28-joint C-reactive protein (DAS28-3-CRP) and Health Assessment Questionnaire-Disability Index for CE-224,535 were not significant at Week 12 vs. placebo.  Treatment-emergent adverse events (AE) were reported by 62.3% (CE-224,535) and 55.3% (placebo) of patients; the most common AE were nausea (11.3%, CE-224,535; 4.3%, placebo) and diarrhea (7.5%, CE-224,535; 4.3%, placebo).  The proportion of patients discontinuing due to an AE was 9.4% (CE-224,535) and 6.4% (placebo); no deaths were reported.  Serious AE occurred in 3.8% (CE-224,535) and 2.1% (placebo) of patients; none was considered treatment-related.  CE-224,535 was not efficacious, compared with placebo, for the treatment of RA in patients with an inadequate response to MTX.  CE-224,535 demonstrated an acceptable safety and tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorblWg-aNBNLVg90H21EOLACvtfcHk0lja5viR17LtfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVOnsro%253D&md5=dc919436c3c6e7f3f624c57b77c5dbb2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.110874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.110874%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DWei%26aufirst%3DN.%26aulast%3DIshaq%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMebus%26aufirst%3DC.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520CE-224%252C535%252C%2520an%2520Antagonist%2520of%2520P2X7%2520Receptor%252C%2520in%2520Treatment%2520of%2520Patients%2520with%2520Rheumatoid%2520Arthritis%2520Inadequately%2520Controlled%2520by%2520Methotrexate%26jtitle%3DJ.%2520Rheumatol.%26date%3D2012%26volume%3D39%26spage%3D720%26epage%3D727%26doi%3D10.3899%2Fjrheum.110874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosnan, C. F.</span></span> <span> </span><span class="NLM_article-title">Exacerbation of Experimental Autoimmune Encephalomyelitis in P2X7R-/- Mice: Evidence for Loss of Apoptotic Activity in Lymphocytes</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">3115</span>– <span class="NLM_lpage">3126</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.176.5.3115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.4049%2Fjimmunol.176.5.3115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=16493071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1eru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=3115-3126&author=L.+Chenauthor=C.+F.+Brosnan&title=Exacerbation+of+Experimental+Autoimmune+Encephalomyelitis+in+P2X7R-%2F-+Mice%3A+Evidence+for+Loss+of+Apoptotic+Activity+in+Lymphocytes&doi=10.4049%2Fjimmunol.176.5.3115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Exacerbation of Experimental Autoimmune Encephalomyelitis in P2X7R-/- Mice: Evidence for Loss of Apoptotic Activity in Lymphocytes</span></div><div class="casAuthors">Chen, Lanfen; Brosnan, Celia F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3115-3126</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The purinergic receptor P2X7R is a nucleotide-gated ion channel that has been proposed to function as a major regulator of inflammation.  Here, the authors examd. the role of this receptor in regulating inflammation in the CNS by detg. the effects of the loss of this receptor (P2X7R-/-) on exptl. autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis.  They show here that P2X7R-/- mice developed more severe clin. and pathol. expression of EAE than wild type (WT) controls and that spleen and lymph node cells from P2X7R-/- mice proliferated more vigorously to antigen in vitro.  Bone marrow (BM) radiation chimeras revealed that enhanced susceptibility to EAE was detected in chimeric mice of WT host engrafted with P2X7R-/- BM cells, indicating that the genotype of the BM cells regulated disease susceptibility.  Coculture of P2X7R-/- macrophages with WT lymphocytes and vice versa showed that enhanced proliferative activity resided within the P2X7R-/- lymphocyte population and correlated with reduced levels of IFN-γ and NO and apoptosis of lymphocytes.  MRNA and protein for IFN-γ were also reduced in the CNS of P2X7R-/- mice with EAE.  FACS anal. of cells isolated from the CNS showed fewer annexin V/propidium iodide-pos. lymphocytes in the CNS of P2X7R-/- mice early in the disease, and TUNEL staining of inflamed CNS tissues supported this result.  Thus, enhanced susceptibility of P2X7R-/- mice to EAE reflects a loss of apoptotic activity in lymphocytes, supporting an important role for this receptor in lymphocyte homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBCtaLZPgUpLVg90H21EOLACvtfcHk0lja5viR17LtfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1eru7w%253D&md5=ab8255f6409f17328596b64350300444</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.5.3115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.5.3115%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBrosnan%26aufirst%3DC.%2BF.%26atitle%3DExacerbation%2520of%2520Experimental%2520Autoimmune%2520Encephalomyelitis%2520in%2520P2X7R-%252F-%2520Mice%253A%2520Evidence%2520for%2520Loss%2520of%2520Apoptotic%2520Activity%2520in%2520Lymphocytes%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D3115%26epage%3D3126%26doi%3D10.4049%2Fjimmunol.176.5.3115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiessling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">The Ecstasy and Agony of Assay Interference Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2165</span>– <span class="NLM_lpage">2168</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00229</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00229" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtl2lsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2165-2168&author=C.+Aldrichauthor=C.+Bertozziauthor=G.+I.+Georgauthor=L.+Kiesslingauthor=C.+Lindsleyauthor=D.+Liottaauthor=K.+M.+Merzauthor=A.+Schepartzauthor=S.+Wang&title=The+Ecstasy+and+Agony+of+Assay+Interference+Compounds&doi=10.1021%2Facs.jmedchem.7b00229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The Ecstasy and Agony of Assay Interference Compounds</span></div><div class="casAuthors">Aldrich, Courtney; Bertozzi, Carolyn; Georg, Gunda I.; Kiessling, Laura; Lindsley, Craig; Liotta, Dennis; Merz, Kenneth M.; Schepartz, Alanna; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2165-2168</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ecstasy of discovering a new hit from screening can lead to a highly productive research effort to discover new bioactive compds.  However, in too many cases this ecstasy is followed by the agony of realizing that the compds. are not active against the desired target.  Many of these false hits are Pan Assay INterference compds. (PAINS) 1 or colloidal aggregators.  Whether the screen is conducted in silico or in the lab. and whether screening libraries, natural products, or drugs are used, all discovery efforts that rely on some form of screening to identify bioactivity are susceptible to this phenomenon.  Studies that omit crit. controls against exptl. artifacts caused by PAINS may waste years of research effort as useless compds. are progressed.  The American Chem. Society (ACS) is eager to alert the scientific community to this problem and to recommend protocols that will eliminate the publication of research articles based on compds. with artificial activity.  This editorial aims to summarize relevant concepts and to set the framework by which relevant ACS journals will address this issue going forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJUf5u51VEpbVg90H21EOLACvtfcHk0lja5viR17LtfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtl2lsLY%253D&md5=64bf087659a47fe7769208217ef8c989</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00229%26sid%3Dliteratum%253Aachs%26aulast%3DAldrich%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DC.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DKiessling%26aufirst%3DL.%26aulast%3DLindsley%26aufirst%3DC.%26aulast%3DLiotta%26aufirst%3DD.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DSchepartz%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DThe%2520Ecstasy%2520and%2520Agony%2520of%2520Assay%2520Interference%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2165%26epage%3D2168%26doi%3D10.1021%2Facs.jmedchem.7b00229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6900"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6900'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit6900"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddileti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">2-Substitution of Adenine Nucleotide Analogues Containing a Bicyclo[3.1.0]hexane Ring System Locked in a Northern Conformation: Enhanced Potency as P2Y1 Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4987</span>, <span class="refDoi"> DOI: 10.1021/jm030127+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030127%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6900/cit6900&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVWqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4974-4987&author=H.+S.+Kimauthor=M.+Ohnoauthor=B.+Xuauthor=H.+O.+Kimauthor=Y.+Choiauthor=X.+D.+Jiauthor=S.+Maddiletiauthor=V.+E.+Marquezauthor=T.+K.+Hardenauthor=K.+A.+Jacobson&title=2-Substitution+of+Adenine+Nucleotide+Analogues+Containing+a+Bicyclo%5B3.1.0%5Dhexane+Ring+System+Locked+in+a+Northern+Conformation%3A+Enhanced+Potency+as+P2Y1+Receptor+Antagonists&doi=10.1021%2Fjm030127%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6900R"><div class="casContent"><span class="casTitleNuber">6900</span><div class="casTitle"><span class="NLM_cas:atitle">2-Substitution of Adenine Nucleotide Analogues Containing a Bicyclo[3.1.0]hexane Ring System Locked in a Northern Conformation: Enhanced Potency as P2Y1 Receptor Antagonists</span></div><div class="casAuthors">Kim, Hak Sung; Ohno, Michihiro; Xu, Bin; Kim, Hea Ok; Choi, Yongseok; Ji, Xiao D.; Maddileti, Savitri; Marquez, Victor E.; Harden, T. Kendall; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4974-4987</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Preference for the northern (N) ring conformation of the ribose moiety of adenine nucleotide 3',5'-bisphosphate antagonists of P2Y1 receptors was established by using a ring-constrained Methanocarba (a bicyclo[3.1.0]hexane) ring as a ribose substitute (Nandanan et al. J. Med. Chem. 2000, 43, 829-842).  We have now combined the ring-constrained (N)-Methanocarba modification with other functionalities at the 2-position of the adenine moiety.  A new synthetic route to this series of bisphosphate derivs. was introduced, consisting of phosphorylation of the pseudo-ribose moiety prior to coupling with the adenine base.  The activity of the newly synthesized analogs was detd. by measuring antagonism of 2-methylthio-ADP-stimulated phospholipase C (PLC) activity in 1321N1 human astrocytoma cells expressing the recombinant human P2Y1 receptor and by using the radiolabeled antagonist [3H]2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine 3',5'-bisphosphate (I) in a newly developed binding assay in Sf9 cell membranes.  Within the series of 2-halo analogs, the most potent mol. at the hP2Y1 receptor was an (N)-methanocarba N6-methyl-2-iodo analog II, which displayed a Ki value in competition for binding of [3H]I of 0.79 nM and a KB value of 1.74 nM for inhibition of PLC.  Thus, II is the most potent antagonist selective for the P2Y1 receptor yet reported.  The 2-iodo group was substituted with trimethyltin, thus providing a parallel synthetic route for the introduction of an iodo group in this high-affinity antagonist.  The (N)-methanocarba-2-methylthio, 2-methylseleno, 2-hexyl, 2-(1-hexenyl), and 2-(1-hexynyl) analogs bound less well, exhibiting micro-molar affinity at P2Y1 receptors.  An enzymic method of synthesis of the 3',5'-bisphosphate from the corresponding 3'-monophosphate, suitable for the prepn. of a radio-phosphorylated analog, was explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8otZqmpOhbVg90H21EOLACvtfcHk0lja5viR17LtfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVWqtbw%253D&md5=ddcf40be66d691b6d64b6f696d83bb12</span></div><a href="/servlet/linkout?suffix=cit6900&amp;dbid=16384&amp;doi=10.1021%2Fjm030127%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030127%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DOhno%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DH.%2BO.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DX.%2BD.%26aulast%3DMaddileti%26aufirst%3DS.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DHarden%26aufirst%3DT.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3D2-Substitution%2520of%2520Adenine%2520Nucleotide%2520Analogues%2520Containing%2520a%2520Bicyclo%255B3.1.0%255Dhexane%2520Ring%2520System%2520Locked%2520in%2520a%2520Northern%2520Conformation%253A%2520Enhanced%2520Potency%2520as%2520P2Y1%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4974%26epage%3D4987%26doi%3D10.1021%2Fjm030127%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7000"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7000'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit7000"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tobrman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, D.</span></span> <span> </span><span class="NLM_article-title">Magnesiation of Chloro-iodopurines: an Efficient Approach to New Purine Derivatives</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1294</span>, <span class="refDoi"> DOI: 10.1021/ol053013w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol053013w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7000/cit7000&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFamtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=1291-1294&author=T.+Tobrmanauthor=D.+Dvorak&title=Magnesiation+of+Chloro-iodopurines%3A+an+Efficient+Approach+to+New+Purine+Derivatives&doi=10.1021%2Fol053013w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7000R"><div class="casContent"><span class="casTitleNuber">7000</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Magnesiation of Chloro-iodopurines: An Efficient Approach to New Purine Derivatives</span></div><div class="casAuthors">Tobrman, Tomas; Dvorak, Dalimil</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1291-1294</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">I (R = CMe2, CH2Ph) undergo a selective I/Mg exchange reaction with iPrMgCl at -80 °C.  The reaction course at 0 °C is different.  Magnesiation of I (R = CMe2) proceeds with the migration of magnesium to the 8 position of the purine nuclei.  In the case of I (R = CH2Ph), substitution of iodine with an alkyl group from the Grignard reagent accompanied with a Cl/Mg exchange reaction takes place, and 6-alkyl-2-magnesiated purines (II) are formed.  Thus prepd. Grignard reagents afford the corresponding alcs. by the reaction with aldehydes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWL41kOV9j0bVg90H21EOLACvtfcHk0ljPGCgEAJSOog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFamtrc%253D&md5=c0034eebb93cf92a465c5f8554db6d6a</span></div><a href="/servlet/linkout?suffix=cit7000&amp;dbid=16384&amp;doi=10.1021%2Fol053013w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol053013w%26sid%3Dliteratum%253Aachs%26aulast%3DTobrman%26aufirst%3DT.%26aulast%3DDvorak%26aufirst%3DD.%26atitle%3DMagnesiation%2520of%2520Chloro-iodopurines%253A%2520an%2520Efficient%2520Approach%2520to%2520New%2520Purine%2520Derivatives%26jtitle%3DOrg.%2520Lett.%26date%3D2006%26volume%3D8%26spage%3D1291%26epage%3D1294%26doi%3D10.1021%2Fol053013w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span>; <span class="NLM_string-name">Grether, U.</span>; <span class="NLM_string-name">Kimbara, A.</span>; <span class="NLM_string-name">Nettekoven, M.</span>; <span class="NLM_string-name">Roever, S.</span>; <span class="NLM_string-name">Rogers-Evans, M.</span>; <span class="NLM_string-name">Schulz-Gasch, T.</span></span> <span> </span><span class="NLM_article-title">Purine Derivatives as CB2 Receptor Agonists</span>. <span class="NLM_patent">WO 2014177490 A1</span>, Nov.6, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Bendels&author=U.+Grether&author=A.+Kimbara&author=M.+Nettekoven&author=S.+Roever&author=M.+Rogers-Evans&author=T.+Schulz-Gasch&title=Purine+Derivatives+as+CB2+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBendels%26aufirst%3DS.%26atitle%3DPurine%2520Derivatives%2520as%2520CB2%2520Receptor%2520Agonists%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szarek, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakawa, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activity of Nucleoside Analogs Involving Modifications in the Carbohydrate Ring</span>. <i>Can. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2149</span>– <span class="NLM_lpage">2161</span>, <span class="refDoi"> DOI: 10.1139/v85-354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1139%2Fv85-354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaL2MXmtFGksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1985&pages=2149-2161&author=W.+A.+Szarekauthor=B.+M.+Pintoauthor=M.+Iwakawa&title=Synthesis+and+Biological+Activity+of+Nucleoside+Analogs+Involving+Modifications+in+the+Carbohydrate+Ring&doi=10.1139%2Fv85-354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activity of nucleoside analogs involving modifications in the carbohydrate ring</span></div><div class="casAuthors">Szarek, Walter A.; Pinto, B. Mario; Iwakawa, Masaharu</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2149-61</span>CODEN:
                <span class="NLM_cas:coden">CJCHAG</span>;
        ISSN:<span class="NLM_cas:issn">0008-4042</span>.
    </div><div class="casAbstract">The synthesis of a variety of nucleoside analogs involving modifications in the carbohydrate ring is described.  In particular, 6-substituted purin-9-yl derivs. of 1-oxa-4-thiacyclohexane and 1,4-dioxacyclohexane have been synthesized.  A no. of 6-chloropurin-9-yl derivs. of substituted 1-oxa-4-thiacyclohexane have also been derived from the parent compds. by way of a Pummerer rearrangement.  A route to nucleoside analogs of 1-oxa-4-thiacyclohexane from naturally occurring nucleosides is illustrated for the case of inosine.  A route to nucleoside analogs in which the carbohydrate moiety is replaced by an acyclic moiety bearing α,β-unsatd. esters is also illustrated for the case of uridine.  The results of biol. screening of these analogs and others previously synthesized against leukemia L-1210 cells in vitro are presented; some of these compds. showed marginal antitumor activity.  The screening results of selected compds. against the human HeLa cell line in vitro are also presented; none of the compds. that were tested showed significant inhibitory activity of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZRqxcJClXlLVg90H21EOLACvtfcHk0ljPGCgEAJSOog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXmtFGksro%253D&md5=06bb3a22b740b4f7affea942da0b0f58</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1139%2Fv85-354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fv85-354%26sid%3Dliteratum%253Aachs%26aulast%3DSzarek%26aufirst%3DW.%2BA.%26aulast%3DPinto%26aufirst%3DB.%2BM.%26aulast%3DIwakawa%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520Nucleoside%2520Analogs%2520Involving%2520Modifications%2520in%2520the%2520Carbohydrate%2520Ring%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D1985%26volume%3D63%26spage%3D2149%26epage%3D2161%26doi%3D10.1139%2Fv85-354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grynkiewicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poenie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsien, R. Y.</span></span> <span> </span><span class="NLM_article-title">A New Generation of Ca2+ Indicators with Greatly Improved Fluorescence Properties</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">3440</span>– <span class="NLM_lpage">3450</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(19)83641-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2FS0021-9258%2819%2983641-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=3838314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaL2MXitVSmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=3440-3450&author=G.+Grynkiewiczauthor=M.+Poenieauthor=R.+Y.+Tsien&title=A+New+Generation+of+Ca2%2B+Indicators+with+Greatly+Improved+Fluorescence+Properties&doi=10.1016%2Fs0021-9258%2819%2983641-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A new generation of calcium indicators with greatly improved fluorescence properties</span></div><div class="casAuthors">Grynkiewicz, Grzegorz; Poenie, Martin; Tsien, Roger Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3440-50</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">A new family of highly fluorescent indicators has been synthesized for biochem. studies of the physiol. role of cytosolic free Ca2+.  The compds. combine an 8-coordinate tetracarboxylate chelating site with stilbene chromophores.  Incorporation of the ethylenic linkage of the stilbene into a heterocyclic ring enhances the quantum efficiency and photochem. stability of the fluorophore.  Compared to their widely used predecessor, quin2, the new dyes offer up to 30-fold brighter fluorescence, major changes in wavelength not just intensity upon Ca2+ binding, slightly lower affinities for Ca2+, slightly longer wavelengths of excitation, and considerably improved selectivity for Ca2+ over other divalent cations.  These properties, particularly the wavelength sensitivity to Ca2+, should make these dyes the preferred fluorescent indicators for many intracellular applications, esp. in single cells, adherent cell layers, or bulk tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWLBb9bdhjwrVg90H21EOLACvtfcHk0ljPGCgEAJSOog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXitVSmu7s%253D&md5=b78f3fc8d29fe8bae7cb8a6f2170d8d1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2983641-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252983641-4%26sid%3Dliteratum%253Aachs%26aulast%3DGrynkiewicz%26aufirst%3DG.%26aulast%3DPoenie%26aufirst%3DM.%26aulast%3DTsien%26aufirst%3DR.%2BY.%26atitle%3DA%2520New%2520Generation%2520of%2520Ca2%252B%2520Indicators%2520with%2520Greatly%2520Improved%2520Fluorescence%2520Properties%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D3440%26epage%3D3450%26doi%3D10.1016%2Fs0021-9258%2819%2983641-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongs, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalzing, G.</span></span> <span> </span><span class="NLM_article-title">A vector for the Synthesis of cRNAs Encoding Myc Epitope-Tagged Proteins in Xenopus Laevis Oocytes</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1016/0378-1119(95)00226-v</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2F0378-1119%2895%2900226-V" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=7543868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK2MXns1CqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1995&pages=213-217&author=S.+Gloorauthor=O.+Pongsauthor=G.+Schmalzing&title=A+vector+for+the+Synthesis+of+cRNAs+Encoding+Myc+Epitope-Tagged+Proteins+in+Xenopus+Laevis+Oocytes&doi=10.1016%2F0378-1119%2895%2900226-v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A vector for the synthesis of cRNAs encoding Myc epitope-tagged proteins in Xenopus laevis oocytes</span></div><div class="casAuthors">Gloor, Sergio; Pongs, Olaf; Schmalzing, Guenther</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-17</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We describe a plasmid, pNKS2-myc, designed for convenient in-frame fusion of an antibody-specific epitope sequence to the N terminus of a desired cDNA and subsequent synthesis of transcripts that direct the synthesis of the tagged polypeptide in Xenopus laevis (Xl) oocytes.  Plasmid pNKS2-myc contains an SP6 promoter, followed by the translation initiation sequence of the Na,K-pump β3 subunit of Xl and the sequence encoding an epitope derived from the human c-myc proto-oncogene product.  Appropriate restriction sites allow one to insert virtually any desired cDNA fragment directly behind the epitope-specific sequence and before a long poly(A) tail.  After linearization with EcoRI or NotI, polyadenylated cRNA can be synthesized that is efficiently translated in Xl oocytes.  The utility of pNKS2-myc is demonstrated by cloning cDNAs coding for Na,K-pump subunits into this vector and injecting the corresponding cRNAs into oocytes.  The tagged mouse β1 and β2 subunit isoforms could be purified from detergent exts. of these cells by immunopptn. with a generally available monoclonal antibody (mAb) to the tag, 9E10, as well as with specific mAb that recognize individual β subunit isoforms.  Under native conditions, endogenous and coexpressed exogenous α1 subunits (the catalytic subunit of the Na,K-pump) were co-pptd., indicating that the N-terminal addn. of the decapeptide epitope has no adverse effect on the folding of β subunits nor on their assembly with α subunits.  Furthermore, the Myc-specific mAb likewise pptd. a Myc-tagged Na,K-pump α1 subunit together with any of the co-synthesized β subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTAkcR9G9iabVg90H21EOLACvtfcHk0liJZ_NQVV623A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXns1CqtbY%253D&md5=1a5b393899fc11d5790465500fdcad94</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2F0378-1119%2895%2900226-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-1119%252895%252900226-V%26sid%3Dliteratum%253Aachs%26aulast%3DGloor%26aufirst%3DS.%26aulast%3DPongs%26aufirst%3DO.%26aulast%3DSchmalzing%26aufirst%3DG.%26atitle%3DA%2520vector%2520for%2520the%2520Synthesis%2520of%2520cRNAs%2520Encoding%2520Myc%2520Epitope-Tagged%2520Proteins%2520in%2520Xenopus%2520Laevis%2520Oocytes%26jtitle%3DGene%26date%3D1995%26volume%3D160%26spage%3D213%26epage%3D217%26doi%3D10.1016%2F0378-1119%2895%2900226-v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuan, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez-Klaka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Górecki, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrell-Lagnado, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, F.</span></span> <span> </span><span class="NLM_article-title">A Functional P2X7 Splice Variant with an Alternative Transmembrane Domain 1 Escapes Gene Inactivation in P2X7 Knock-out Mice</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">25813</span>– <span class="NLM_lpage">25822</span>, <span class="refDoi"> DOI: 10.1074/jbc.m109.033134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1074%2Fjbc.M109.033134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19546214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWhtr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=25813-25822&author=A.+Nickeauthor=Y.-H.+Kuanauthor=M.+Masinauthor=J.+Rettingerauthor=B.+Marquez-Klakaauthor=O.+Benderauthor=D.+C.+G%C3%B3reckiauthor=R.+D.+Murrell-Lagnadoauthor=F.+Soto&title=A+Functional+P2X7+Splice+Variant+with+an+Alternative+Transmembrane+Domain+1+Escapes+Gene+Inactivation+in+P2X7+Knock-out+Mice&doi=10.1074%2Fjbc.m109.033134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A Functional P2X7 Splice Variant with an Alternative Transmembrane Domain 1 Escapes Gene Inactivation in P2X7 Knock-out Mice</span></div><div class="casAuthors">Nicke, Annette; Kuan, Yung-Hui; Masin, Marianela; Rettinger, Juergen; Marquez-Klaka, Benjamin; Bender, Olaf; Gorecki, Dariusz C.; Murrell-Lagnado, Ruth D.; Soto, Florentina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">25813-25822</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The ATP-activated P2X7 receptor channel is involved in immune function and inflammatory pain and represents an important drug target.  Here the authors describe a new P2X7 splice variant (P2X7(k)), contg. an alternative intracellular N terminus and first transmembrane domain encoded by a novel exon 1 in the rodent P2rx7 gene.  Whole cell patch clamp recordings of the rat isoform expressed in HEK293 cells revealed an 8-fold higher sensitivity to the agonist Bz-ATP and much slower deactivation kinetics when compared with the P2X7(a) receptor.  Permeability measurements in Xenopus oocytes show a high permeability for N-methyl-D-glucamine immediately upon activation, suggesting that the P2X7(k) channel is constitutively dilated upon opening.  The rates of agonist-induced dye uptake and membrane blebbing in HEK cells were also increased.  PCR analyses and biochem. anal. by SDS-PAGE and BN-PAGE indicate that the P2X7(k) variant escapes gene deletion in one of the available P2X7-/- mice strains and is strongly expressed in the spleen.  Taken together, the authors describe a novel P2X7 isoform with distinct functional properties that contributes to the diversity of P2X7 receptor signaling.  Its presence in one of the P2X7-/- strains has important implications for the understanding of the role of this receptor in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWSNK2OAuzmLVg90H21EOLACvtfcHk0liJZ_NQVV623A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWhtr%252FO&md5=d8b22d751bce21e574abc90ce8136a58</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.033134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.033134%26sid%3Dliteratum%253Aachs%26aulast%3DNicke%26aufirst%3DA.%26aulast%3DKuan%26aufirst%3DY.-H.%26aulast%3DMasin%26aufirst%3DM.%26aulast%3DRettinger%26aufirst%3DJ.%26aulast%3DMarquez-Klaka%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DO.%26aulast%3DG%25C3%25B3recki%26aufirst%3DD.%2BC.%26aulast%3DMurrell-Lagnado%26aufirst%3DR.%2BD.%26aulast%3DSoto%26aufirst%3DF.%26atitle%3DA%2520Functional%2520P2X7%2520Splice%2520Variant%2520with%2520an%2520Alternative%2520Transmembrane%2520Domain%25201%2520Escapes%2520Gene%2520Inactivation%2520in%2520P2X7%2520Knock-out%2520Mice%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D25813%26epage%3D25822%26doi%3D10.1074%2Fjbc.m109.033134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beissner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutertre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schemm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sporning, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicke, A.</span></span> <span> </span><span class="NLM_article-title">Efficient Binding of 4/7 Alpha-Conotoxins to Nicotinic Alpha4beta2 Receptors is Prevented by Arg185 and Pro195 in the Alpha4 Subunit</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1124/mol.112.078683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1124%2Fmol.112.078683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22802270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSmt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=711-718&author=M.+Beissnerauthor=S.+Dutertreauthor=R.+Schemmauthor=T.+Dankerauthor=A.+Sporningauthor=H.+Grubm%C3%BCllerauthor=A.+Nicke&title=Efficient+Binding+of+4%2F7+Alpha-Conotoxins+to+Nicotinic+Alpha4beta2+Receptors+is+Prevented+by+Arg185+and+Pro195+in+the+Alpha4+Subunit&doi=10.1124%2Fmol.112.078683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient binding of 4/7 α-conotoxins to nicotinic α4β2 receptors is prevented by Arg185 and Pro195 in the α4 subunit</span></div><div class="casAuthors">Beissner, Mirko; Dutertre, Sebastien; Schemm, Rudolf; Danker, Timm; Sporning, Annett; Grubmueller, Helmut; Nicke, Annette</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">711-718</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">α-Conotoxins are subtype-selective nicotinic acetylcholine receptor (nAChR) antagonists.  Although potent α3β2 nAChR-selective α-conotoxins have been identified, currently characterized α-conotoxins show no or only weak affinity for α4β2 nAChRs, which are, besides α7 receptors, the most abundant nAChRs in the mammalian brain.  To identify the determinants responsible for this difference, we substituted selected amino acid residues in the ligand-binding domain of the α4 subunit by the corresponding residues in the α3 subunit.  Two-electrode voltage clamp anal. of these mutants revealed increased affinity of α-conotoxins MII, TxIA, and [A10L]TxIA at the α4(R185I)β2 receptor.  Conversely, α-conotoxin potency was reduced at the reverse α3(I186R)β2 mutant.  Replacement of α4Arg185 by alanine, glutamate, and lysine demonstrated that a pos. charge in this position prevents α-conotoxin binding.  Combination of the R185I mutation with a P195Q mutation outside the binding site but in loop C completely transferred high α-conotoxin potency to the α4β2 receptor.  Mol. dynamics simulations of homol. models with docked α-conotoxin indicate that these residues control access to the α-conotoxin binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppLlOdT6gutbVg90H21EOLACvtfcHk0liJZ_NQVV623A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSmt7jN&md5=c95106b38d305084bd845b2d1a5da79f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.078683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.078683%26sid%3Dliteratum%253Aachs%26aulast%3DBeissner%26aufirst%3DM.%26aulast%3DDutertre%26aufirst%3DS.%26aulast%3DSchemm%26aufirst%3DR.%26aulast%3DDanker%26aufirst%3DT.%26aulast%3DSporning%26aufirst%3DA.%26aulast%3DGrubm%25C3%25BCller%26aufirst%3DH.%26aulast%3DNicke%26aufirst%3DA.%26atitle%3DEfficient%2520Binding%2520of%25204%252F7%2520Alpha-Conotoxins%2520to%2520Nicotinic%2520Alpha4beta2%2520Receptors%2520is%2520Prevented%2520by%2520Arg185%2520and%2520Pro195%2520in%2520the%2520Alpha4%2520Subunit%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D711%26epage%3D718%26doi%3D10.1124%2Fmol.112.078683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, G. R.</span></span> <span> </span><span class="NLM_article-title">Open Babel: An Open Chemical Toolbox</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/1758-2946-3-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1186%2F1758-2946-3-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=21982300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=33&author=N.+M.+O%E2%80%99Boyleauthor=M.+Banckauthor=C.+A.+Jamesauthor=C.+Morleyauthor=T.+Vandermeerschauthor=G.+R.+Hutchison&title=Open+Babel%3A+An+Open+Chemical+Toolbox&doi=10.1186%2F1758-2946-3-33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Open Babel: an open chemical toolbox</span></div><div class="casAuthors">O'Boyle, Noel M.; Banck, Michael; James, Craig A.; Morley, Chris; Vandermeersch, Tim; Hutchison, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Background: A frequent problem in computational modeling is the interconversion of chem. structures between different formats.  While std. interchange formats exist (for example, Chem. Markup Language) and de facto stds. have arisen (for example, SMILES format), the need to interconvert formats is a continuing problem due to the multitude of different application areas for chem. data, differences in the data stored by different formats (0D vs. 3D, for example), and competition between software along with a lack of vendor-neutral formats.  Results: We discuss, for the first time, Open Babel, an open-source chem. toolbox that speaks the many languages of chem. data.  Open Babel version 2.3 interconverts over 110 formats.  The need to represent such a wide variety of chem. and mol. data requires a library that implements a wide range of cheminformatics algorithms, from partial charge assignment and aromaticity detection, to bond order perception and canonicalization.  We detail the implementation of Open Babel, describe key advances in the 2.3 release, and outline a variety of uses both in terms of software products and scientific research, including applications far beyond simple format interconversion.  Conclusions: Open Babel presents a soln. to the proliferation of multiple chem. file formats.  In addn., it provides a variety of useful utilities from conformer searching and 2D depiction, to filtering, batch conversion, and substructure and similarity searching.  For developers, it can be used as a programming library to handle chem. data in areas such as org. chem., drug design, materials science, and computational chem.  It is freely available under an open-source license.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQ1lvaS5767Vg90H21EOLACvtfcHk0lhDJWJY0smGEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF&md5=74e4f19b7f87417f916d57f7abcfb761</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-3-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-3-33%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBanck%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DMorley%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DT.%26aulast%3DHutchison%26aufirst%3DG.%2BR.%26atitle%3DOpen%2520Babel%253A%2520An%2520Open%2520Chemical%2520Toolbox%26jtitle%3DJ.%2520Cheminf.%26date%3D2011%26volume%3D3%26spage%3D33%26doi%3D10.1186%2F1758-2946-3-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=Improving+the+Speed+and+Accuracy+of+Docking+with+a+New+Scoring+Function%2C+Efficient+Optimization%2C+and+Multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0lhDJWJY0smGEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DImproving%2520the%2520Speed%2520and%2520Accuracy%2520of%2520Docking%2520with%2520a%2520New%2520Scoring%2520Function%252C%2520Efficient%2520Optimization%252C%2520and%2520Multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couch, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrin, T. E.</span></span> <span> </span><span class="NLM_article-title">UCSF Chimera--a Visualization System for Exploratory Research and Analysis</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1605</span>– <span class="NLM_lpage">1612</span>, <span class="refDoi"> DOI: 10.1002/jcc.20084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fjcc.20084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=15264254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=1605-1612&author=E.+F.+Pettersenauthor=T.+D.+Goddardauthor=C.+C.+Huangauthor=G.+S.+Couchauthor=D.+M.+Greenblattauthor=E.+C.+Mengauthor=T.+E.+Ferrin&title=UCSF+Chimera%2D%2Da+Visualization+System+for+Exploratory+Research+and+Analysis&doi=10.1002%2Fjcc.20084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">UCSF Chimera-A visualization system for exploratory research and analysis</span></div><div class="casAuthors">Pettersen, Eric F.; Goddard, Thomas D.; Huang, Conrad C.; Couch, Gregory S.; Greenblatt, Daniel M.; Meng, Elaine C.; Ferrin, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1605-1612</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The design, implementation, and capabilities of an extensible visualization system, UCSF Chimera, are discussed.  Chimera is segmented into a core that provides basic services and visualization, and extensions that provide most higher level functionality.  This architecture ensures that the extension mechanism satisfies the demands of outside developers who wish to incorporate new features.  Two unusual extensions are presented: Multiscale, which adds the ability to visualize large-scale mol. assemblies such as viral coats, and Collab., which allows researchers to share a Chimera session interactively despite being at sep. locales.  Other extensions include Multalign Viewer, for showing multiple sequence alignments and assocd. structures; ViewDock, for screening docked ligand orientations; Movie, for replaying mol. dynamics trajectories; and Vol. Viewer, for display and anal. of volumetric data.  A discussion of the usage of Chimera in real-world situations is given, along with anticipated future directions.  Chimera includes full user documentation, is free to academic and nonprofit users, and is available for Microsoft Windows, Linux, Apple Mac OS X, SGI IRIX, and HP Tru64 Unix from http://www.cgl.ucsf.edu/chimera/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmD4M5S0cPbVg90H21EOLACvtfcHk0lhDJWJY0smGEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D&md5=944b175f440c1ff323705987cf937ee7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20084%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DE.%2BF.%26aulast%3DGoddard%26aufirst%3DT.%2BD.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DCouch%26aufirst%3DG.%2BS.%26aulast%3DGreenblatt%26aufirst%3DD.%2BM.%26aulast%3DMeng%26aufirst%3DE.%2BC.%26aulast%3DFerrin%26aufirst%3DT.%2BE.%26atitle%3DUCSF%2520Chimera--a%2520Visualization%2520System%2520for%2520Exploratory%2520Research%2520and%2520Analysis%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2004%26volume%3D25%26spage%3D1605%26epage%3D1612%26doi%3D10.1002%2Fjcc.20084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref6900':['cit6900'],'ref7000':['cit7000'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref79':['cit79'],'ref76':['cit76']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kendra L.  Nelson</span>, <span class="hlFld-ContribAuthor ">Venkata Saroja  Voruganti</span>. </span><span class="cited-content_cbyCitation_article-title">Purine metabolites and complex diseases: role of genes and nutrients. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Clinical Nutrition & Metabolic Care</span><span> <strong>2021,</strong> <em>24 </em>
                                    (4)
                                     , 296-302. <a href="https://doi.org/10.1097/MCO.0000000000000764" title="DOI URL">https://doi.org/10.1097/MCO.0000000000000764</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MCO.0000000000000764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMCO.0000000000000764%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Clinical%2520Nutrition%2520%2526%2520Metabolic%2520Care%26atitle%3DPurine%252Bmetabolites%252Band%252Bcomplex%252Bdiseases%25253A%252Brole%252Bof%252Bgenes%252Band%252Bnutrients%26aulast%3DNelson%26aufirst%3DKendra%2BL.%26date%3D2021%26date%3D2021%26volume%3D24%26issue%3D4%26spage%3D296%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunshuo  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaotong  Chen</span>, <span class="hlFld-ContribAuthor ">Sifan  Lyu</span>, <span class="hlFld-ContribAuthor ">Zhe  Ding</span>, <span class="hlFld-ContribAuthor ">Yahong  Wu</span>, <span class="hlFld-ContribAuthor ">Yanfeng  Gao</span>, <span class="hlFld-ContribAuthor ">Jiangfeng  Du</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel P2X7R antagonists by using structure‐based virtual screening and cell‐based assays. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>98 </em>
                                    (1)
                                     , 192-205. <a href="https://doi.org/10.1111/cbdd.13867" title="DOI URL">https://doi.org/10.1111/cbdd.13867</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13867%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DIdentification%252Bof%252Bnovel%252BP2X7R%252Bantagonists%252Bby%252Busing%252Bstructure%2525E2%252580%252590based%252Bvirtual%252Bscreening%252Band%252Bcell%2525E2%252580%252590based%252Bassays%26aulast%3DZhao%26aufirst%3DYunshuo%26date%3D2021%26date%3D2021%26volume%3D98%26issue%3D1%26spage%3D192%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramona  D’Amico</span>, <span class="hlFld-ContribAuthor ">Roberta  Fusco</span>, <span class="hlFld-ContribAuthor ">Rosalba  Siracusa</span>, <span class="hlFld-ContribAuthor ">Daniela  Impellizzeri</span>, <span class="hlFld-ContribAuthor ">Alessio Filippo  Peritore</span>, <span class="hlFld-ContribAuthor ">Enrico  Gugliandolo</span>, <span class="hlFld-ContribAuthor ">Livia  Interdonato</span>, <span class="hlFld-ContribAuthor ">Andrea Maria  Sforza</span>, <span class="hlFld-ContribAuthor ">Rosalia  Crupi</span>, <span class="hlFld-ContribAuthor ">Salvatore  Cuzzocrea</span>, <span class="hlFld-ContribAuthor ">Tiziana  Genovese</span>, <span class="hlFld-ContribAuthor ">Marika  Cordaro</span>, <span class="hlFld-ContribAuthor ">Rosanna  Di Paola</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of P2X7 Purinergic Receptor Ameliorates Fibromyalgia Syndrome by Suppressing NLRP3 Pathway. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (12)
                                     , 6471. <a href="https://doi.org/10.3390/ijms22126471" title="DOI URL">https://doi.org/10.3390/ijms22126471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22126471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22126471%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DInhibition%252Bof%252BP2X7%252BPurinergic%252BReceptor%252BAmeliorates%252BFibromyalgia%252BSyndrome%252Bby%252BSuppressing%252BNLRP3%252BPathway%26aulast%3DD%25E2%2580%2599Amico%26aufirst%3DRamona%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D12%26spage%3D6471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Chemical Structure of Some P2X7 Antagonists, Including the Adamantane-<i>o</i>-chlorobenzamide Scaffold Reported by Astra-Zeneca (<b>1</b>)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scheme of the designed molecules. A purine scaffold (blue) was linked to an <i>o</i>-halophenyl (green) through three different spacers (red): carbonyl (A), ethanoyl (B), or sulfonyl (C) groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>o</i>-Chlorobenzoylpurines <b>2</b> and <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TEA, DMAP, THF, 4.5–6 h, 0 °C to rt; (b) Na, MeOH, 2 h, 60 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Purinyl-2′,4′-disubstituted Phenylethanones (<b>6</b> and <b>12–20</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. For the synthesis of <b>6</b> and <b>12–18</b>: (a) NaH, DMF, 15–40 h, 0 °C to rt. For the synthesis of <b>19</b>: (a) KOH, Bu<sub>4</sub>NHSO<sub>4</sub>, DMF, 26 h, 0 °C to rt. For the synthesis of <b>20</b>: (a) K<sub>2</sub>CO<sub>3</sub>, Bu<sub>4</sub>NHSO<sub>4</sub>, DMF, 30 h, 0 to 80 °C.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray diffraction of compounds <b>19</b> and <b>31</b>. Purine and theophylline scaffolds used in this study have the same influence on N7 and N9 nucleophilicity for all the respective derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 3-(6-Chloro-9<i>H</i>-purin-9-yl)-1-(2′,4′-dichlorophenyl)-propan-1-one <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AlCl<sub>3</sub>, 4 h, rt to 60 °C; (b) 6-chloropurine, NaH, DMF, 18 h, 0 °C to rt.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 2-Chlorophenylsulfonyl Purines (<b>23–27</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TEA, DMAP, CH<sub>2</sub>Cl<sub>2</sub>/THF, 0 °C to rt, 2–4 h.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 2′,4′-Dichlorophenylethanones and 2′-Chlorobenzamides, Using Xanthine Derivatives as the Starting Material<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-chlorobenzoyl chloride, TEA, DMAP, THF, 48 h, 0 to 70 °C; (b) 2-chloro-1-(2,4-dichlorophenyl)ethan-1-one (<b>5</b>), K<sub>2</sub>CO<sub>3</sub>, Bu<sub>4</sub>NHSO<sub>4</sub>, DMF, 1–6 h, 150 °C.</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Arylsulfonyl Theophyllines (<b>31–38</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, THF, 4–48 h, 0 °C to rt.</p></p></figure><figure data-id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of 2-Chloro-1-(2′-chlorobenzyl)-9-methyl-1,9-dihydro-6<i>H</i>-purin-6-one (<b>40</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) basic alumina, MeOH, 24 h, 70 °C; (b) 1-chloro-2-(chloromethyl)benzene, NaHCO<sub>3</sub>, DMF, overnight, 75 °C.</p></p></figure><figure data-id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Raw data representation of a FURA-2 intracellular Ca<sup>2+</sup> dynamics experiment in the presence of increasing concentrations of compound <b>6</b> (ITH15004). The BzATP (100 μM) control response is shown in black. (B) Dose–response curve of <b>6</b> (ITH15004) in [Ca<sup>2+</sup>]<sub>c</sub> dynamics. Dots represent the mean ± S.E.M. of three triplicates of three different cell cultures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. IL-1β release (%) from LPS-primed, ATP-stimulated MPMs in comparison to control (only ATP; black bar). (A) Cells were primed with LPS for 4 h and the compounds were added for 15 min at 1 μM. Cells were then stimulated with ATP for 30 min and the levels of IL-1β in medium were determined by ELISA. (B) Dose–response effect of compound <b>6</b>. (C) Dose–response effect of compound <b>31</b>. JNJ-47965567 (JNJ, tested at 0.1 μM) was used as the reference compound. Data are mean ± S.E.M. of triplicates of three different mice. *<i>P</i> < 0.05, <sup>**</sup><i>p</i> < 0.01, <sup>***</sup><i>p</i> < 0.001 with respect to control (black bar).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Evaluation of <b>6</b> by TEVC analysis. (A) Typical TEVC recording of ATP (300 μM, 2 s)-activated hP2X7 currents in the presence (red) and absence (black) of <b>6</b> at 100 μM. (B) Selective inhibition of hP2X7 but not of rP2X1, rP2X2, and rP2X4 by <b>6</b> at 100 μM. Data represent the mean ± S.E.M. of three oocytes from two different frogs, normalized to control current amplitude (marked as a horizontal dashed red line). *<i>P</i> < 0.001 compared to control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Permeability values of selected new compounds (reddish bars are purine analogues and bluish bars are xanthine analogues), measured by PAMPA experiments. Theophylline (T), piroxicam (P), and verapamil (V) were used as low-, middle-, and high-permeability standards, respectively. Their permeability constants in 10<sup>–6</sup>·cm·s<sup>–1</sup> are 0.12 (T), 2.5 (P), and 16 (V), similar to those described by Di et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The red line at 4·10<sup>–6</sup>·cm·s<sup>–1</sup> marks the theoretical threshold for guaranteeing CNS permeability. Data are presented as the mean ± S.E.M. of triplicates of three individual experiments performed in three different days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compounds <b>6</b> and <b>31</b> on Pgp ATPase activity compared with those of the Pgp substrate verapamil and the P2X7 blocker JNJ-47965567 (JNJ). Data are presented as the mean ± S.E.M. of triplicates of three individual experiments. *<i>P</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/medium/jm0c02145_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0010.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lateral (A) and top (B) views of the ribbon-like representation of P2X7. The predicted binding site of compound <b>6</b> is indicated by the black frame. The residues defining the binding pocket are shown in C. The protein model was provided by Dayel et al.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> with permission (crystal templates PDB IDs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1U">5U1U</a>,<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1V">5U1V</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1W">5U1W</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1X">5U1X</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1Y">5U1Y</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c02145/20210218/images/large/jm0c02145_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02145&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32670" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32670" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 79 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiLuca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, J.</span></span> <span> </span><span class="NLM_article-title">The Cost of Brain Diseases: a Burden or a Challenge?</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1208</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2014.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.neuron.2014.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=24945765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCju7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=1205-1208&author=M.+DiLucaauthor=J.+Olesen&title=The+Cost+of+Brain+Diseases%3A+a+Burden+or+a+Challenge%3F&doi=10.1016%2Fj.neuron.2014.05.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Cost of Brain Diseases: A Burden or a Challenge?</span></div><div class="casAuthors">DiLuca, Monica; Olesen, Jes</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1205-1208</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Brain diseases represent a considerable social and economic burden in Europe.  With yearly costs of about 800 billion euros and an estd. 179 million people afflicted in 2010, brain diseases are an unquestionable emergency and a grand challenge for neuroscientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlTAjvSGNAV7Vg90H21EOLACvtfcHk0lhzHBMY9q4bsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCju7rL&md5=853d1eec0a4175cb42d9b639ec2cebc4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2014.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2014.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DDiLuca%26aufirst%3DM.%26aulast%3DOlesen%26aufirst%3DJ.%26atitle%3DThe%2520Cost%2520of%2520Brain%2520Diseases%253A%2520a%2520Burden%2520or%2520a%2520Challenge%253F%26jtitle%3DNeuron%26date%3D2014%26volume%3D82%26spage%3D1205%26epage%3D1208%26doi%3D10.1016%2Fj.neuron.2014.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gustavsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allgulander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faravelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fratiglioni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gannon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennum, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karampampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobelt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljungcrantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maercker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscarelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musayev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norwood, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preisig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliatti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvador-Carulla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlehofer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhausen, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stovner, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallat, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Bergh, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Os, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittchen, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Group, C. D.</span></span> <span> </span><span class="NLM_article-title">Cost of Disorders of the Brain in Europe 2010</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2011.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.euroneuro.2011.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=21924589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12itr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=718-779&author=A.+Gustavssonauthor=M.+Svenssonauthor=F.+Jacobiauthor=C.+Allgulanderauthor=J.+Alonsoauthor=E.+Beghiauthor=R.+Dodelauthor=M.+Ekmanauthor=C.+Faravelliauthor=L.+Fratiglioniauthor=B.+Gannonauthor=D.+H.+Jonesauthor=P.+Jennumauthor=A.+Jordanovaauthor=L.+J%C3%B6nssonauthor=K.+Karampampaauthor=M.+Knappauthor=G.+Kobeltauthor=T.+Kurthauthor=R.+Liebauthor=M.+Lindeauthor=C.+Ljungcrantzauthor=A.+Maerckerauthor=B.+Melinauthor=M.+Moscarelliauthor=A.+Musayevauthor=F.+Norwoodauthor=M.+Preisigauthor=M.+Pugliattiauthor=J.+Rehmauthor=L.+Salvador-Carullaauthor=B.+Schlehoferauthor=R.+Simonauthor=H.-C.+Steinhausenauthor=L.+J.+Stovnerauthor=J.-M.+Vallatauthor=P.+V.+den+Berghauthor=J.+van+Osauthor=P.+Vosauthor=W.+Xuauthor=H.-U.+Wittchenauthor=B.+J%C3%B6nssonauthor=J.+Olesenauthor=C.+D.+Group&title=Cost+of+Disorders+of+the+Brain+in+Europe+2010&doi=10.1016%2Fj.euroneuro.2011.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cost of disorders of the brain in Europe 2010</span></div><div class="casAuthors">Gustavsson, Anders; Svensson, Mikael; Jacobi, Frank; Allgulander, Christer; Alonso, Jordi; Beghi, Ettore; Dodel, Richard; Ekman, Mattias; Faravelli, Carlo; Fratiglioni, Laura; Gannon, Brenda; Jones, David Hilton; Jennum, Poul; Jordanova, Albena; Joensson, Linus; Karampampa, Korinna; Knapp, Martin; Kobelt, Gisela; Kurth, Tobias; Lieb, Roselind; Linde, Mattias; Ljungcrantz, Christina; Maercker, Andreas; Melin, Beatrice; Moscarelli, Massimo; Musayev, Amir; Norwood, Fiona; Preisig, Martin; Pugliatti, Maura; Rehm, Juergen; Salvador-Carulla, Luis; Schlehofer, Brigitte; Simon, Roland; Steinhausen, Hans-Christoph; Stovner, Lars Jacob; Vallat, Jean-Michel; Van den Bergh, Peter; van Os, Jim; Vos, Pieter; Xu, Weili; Wittchen, Hans-Ulrich; Joensson, Bengt; Olesen, Jes</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">718-779</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background: The spectrum of disorders of the brain is large, covering hundreds of disorders that are listed in either the mental or neurol. disorder chapters of the established international diagnostic classification systems.  These disorders have a high prevalence as well as short- and long-term impairments and disabilities.  Therefore they are an emotional, financial and social burden to the patients, their families and their social network.  In a 2005 landmark study, we estd. for the first time the annual cost of 12 major groups of disorders of the brain in Europe and gave a conservative est. of (euro sign)386 billion for the year 2004.  This est. was limited in scope and conservative due to the lack of sufficiently comprehensive epidemiol. and/or economic data on several important diagnostic groups.  We are now in a position to substantially improve and revise the 2004 ests.  In the present report we cover 19 major groups of disorders, 7 more than previously, of an increased range of age groups and more cost items.  We therefore present much improved cost ests.  Our revised ests. also now include the new EU member states, and hence a population of 514 million people.  Aims: To est. the no. of persons with defined disorders of the brain in Europe in 2010, the total cost per person related to each disease in terms of direct and indirect costs, and an est. of the total cost per disorder and country.  Methods: The best available ests. of the prevalence and cost per person for 19 groups of disorders of the brain (covering well over 100 specific disorders) were identified via a systematic review of the published literature.  Together with the twelve disorders included in 2004, the following range of mental and neurol. groups of disorders is covered: addictive disorders, affective disorders, anxiety disorders, brain tumor, childhood and adolescent disorders (developmental disorders), dementia, eating disorders, epilepsy, mental retardation, migraine, multiple sclerosis, neuromuscular disorders, Parkinson's disease, personality disorders, psychotic disorders, sleep disorders, somatoform disorders, stroke, and traumatic brain injury.  Epidemiol. panels were charged to complete the literature review for each disorder in order to est. the 12-mo prevalence, and health economic panels were charged to est. best cost-ests.  A cost model was developed to combine the epidemiol. and economic data and est. the total cost of each disorder in each of 30 European countries (EU27 + Iceland, Norway and Switzerland).  The cost model was populated with national statistics from Eurostat to adjust all costs to 2010 values, converting all local currencies to Euro, imputing costs for countries where no data were available, and aggregating country ests. to purchasing power parity adjusted ests. for the total cost of disorders of the brain in Europe 2010.  Results: The total cost of disorders of the brain was estd. at (euro sign)798 billion in 2010.  Direct costs constitute the majority of costs (37% direct healthcare costs and 23% direct non-medical costs) whereas the remaining 40% were indirect costs assocd. with patients' prodn. losses.  On av., the estd. cost per person with a disorder of the brain in Europe ranged between (euro sign)285 for headache and (euro sign)30,000 for neuromuscular disorders.  The European per capita cost of disorders of the brain was (euro sign)1550 on av. but varied by country.  The cost (in billion (euro sign)PPP 2010) of the disorders of the brain included in this study was as follows: addiction: (euro sign)65.7; anxiety disorders: (euro sign)74.4; brain tumor: (euro sign)5.2; child/adolescent disorders: (euro sign)21.3; dementia: (euro sign)105.2; eating disorders: (euro sign)0.8; epilepsy: (euro sign)13.8; headache: (euro sign)43.5; mental retardation: (euro sign)43.3; mood disorders: (euro sign)113.4; multiple sclerosis: (euro sign)14.6; neuromuscular disorders: (euro sign)7.7; Parkinson's disease: (euro sign)13.9; personality disorders: (euro sign)27.3; psychotic disorders: (euro sign)93.9; sleep disorders: (euro sign)35.4; somatoform disorder: (euro sign)21.2; stroke: (euro sign)64.1; traumatic brain injury: (euro sign)33.0.  It should be noted that the revised est. of those disorders included in the previous 2004 report constituted (euro sign)477 billion, by and large confirming our previous study results after considering the inflation and population increase since 2004.  Further, our results were consistent with administrative data on the health care expenditure in Europe, and comparable to previous studies on the cost of specific disorders in Europe.  Our ests. were lower than comparable ests. from the US.  Discussion: This study was based on the best currently available data in Europe and our model enabled extrapolation to countries where no data could be found.  Still, the scarcity of data is an important source of uncertainty in our ests. and may imply over- or underestimations in some disorders and countries.  Even though this review included many disorders, diagnoses, age groups and cost items that were omitted in 2004, there are still remaining disorders that could not be included due to limitations in the available data.  We therefore consider our est. of the total cost of the disorders of the brain in Europe to be conservative.  In terms of the health economic burden outlined in this report, disorders of the brain likely constitute the no. one economic challenge for European health care, now and in the future.  Data presented in this report should be considered by all stakeholder groups, including policy makers, industry and patient advocacy groups, to reconsider the current science, research and public health agenda and define a coordinated plan of action of various levels to address the assocd. challenges.  Recommendations: Political action is required in light of the present high cost of disorders of the brain.  Funding of brain research must be increased; care for patients with brain disorders as well as teaching at medical schools and other health related educations must be quant. and qual. improved, including psychol. treatments.  The current move of the pharmaceutical industry away from brain related indications must be halted and reversed.  Continued research into the cost of the many disorders not included in the present study is warranted.  It is essential that not only the EU but also the national governments forcefully support these initiatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_5YCk7AoEdrVg90H21EOLACvtfcHk0lgazpXQfBQ2GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12itr7E&md5=8f1a90ef1c8e218bcb974ab5839fce6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2011.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2011.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DGustavsson%26aufirst%3DA.%26aulast%3DSvensson%26aufirst%3DM.%26aulast%3DJacobi%26aufirst%3DF.%26aulast%3DAllgulander%26aufirst%3DC.%26aulast%3DAlonso%26aufirst%3DJ.%26aulast%3DBeghi%26aufirst%3DE.%26aulast%3DDodel%26aufirst%3DR.%26aulast%3DEkman%26aufirst%3DM.%26aulast%3DFaravelli%26aufirst%3DC.%26aulast%3DFratiglioni%26aufirst%3DL.%26aulast%3DGannon%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DD.%2BH.%26aulast%3DJennum%26aufirst%3DP.%26aulast%3DJordanova%26aufirst%3DA.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DL.%26aulast%3DKarampampa%26aufirst%3DK.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DKobelt%26aufirst%3DG.%26aulast%3DKurth%26aufirst%3DT.%26aulast%3DLieb%26aufirst%3DR.%26aulast%3DLinde%26aufirst%3DM.%26aulast%3DLjungcrantz%26aufirst%3DC.%26aulast%3DMaercker%26aufirst%3DA.%26aulast%3DMelin%26aufirst%3DB.%26aulast%3DMoscarelli%26aufirst%3DM.%26aulast%3DMusayev%26aufirst%3DA.%26aulast%3DNorwood%26aufirst%3DF.%26aulast%3DPreisig%26aufirst%3DM.%26aulast%3DPugliatti%26aufirst%3DM.%26aulast%3DRehm%26aufirst%3DJ.%26aulast%3DSalvador-Carulla%26aufirst%3DL.%26aulast%3DSchlehofer%26aufirst%3DB.%26aulast%3DSimon%26aufirst%3DR.%26aulast%3DSteinhausen%26aufirst%3DH.-C.%26aulast%3DStovner%26aufirst%3DL.%2BJ.%26aulast%3DVallat%26aufirst%3DJ.-M.%26aulast%3Dden%2BBergh%26aufirst%3DP.%2BV.%26aulast%3Dvan%2BOs%26aufirst%3DJ.%26aulast%3DVos%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWittchen%26aufirst%3DH.-U.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DB.%26aulast%3DOlesen%26aufirst%3DJ.%26aulast%3DGroup%26aufirst%3DC.%2BD.%26atitle%3DCost%2520of%2520Disorders%2520of%2520the%2520Brain%2520in%2520Europe%25202010%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2011%26volume%3D21%26spage%3D718%26epage%3D779%26doi%3D10.1016%2Fj.euroneuro.2011.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Virgilio, F.</span></span> <span> </span><span class="NLM_article-title">P2X Receptors and Inflammation</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">866</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.2174/0929867322666141210155311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.2174%2F0929867322666141210155311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=25524252" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=866-877&author=F.+Virgilio&title=P2X+Receptors+and+Inflammation&doi=10.2174%2F0929867322666141210155311"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F0929867322666141210155311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666141210155311%26sid%3Dliteratum%253Aachs%26aulast%3DVirgilio%26aufirst%3DF.%26atitle%3DP2X%2520Receptors%2520and%2520Inflammation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D866%26epage%3D877%26doi%3D10.2174%2F0929867322666141210155311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calzaferri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diego, A. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Méndez-López, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano-Abad, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ríos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandía, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, A. G.</span></span> <span> </span><span class="NLM_article-title">The Purinergic P2X7 Receptor as a Potential Drug Target to Combat Neuroinflammation in Neurodegenerative Diseases</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2465</span>, <span class="refDoi"> DOI: 10.1002/med.21710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fmed.21710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=32677086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVKlurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=2427-2465&author=F.+Calzaferriauthor=C.+Ruiz-Ruizauthor=A.+M.+G.+Diegoauthor=R.+Pascualauthor=I.+M%C3%A9ndez-L%C3%B3pezauthor=M.+F.+Cano-Abadauthor=V.+Maneuauthor=C.+R%C3%ADosauthor=L.+Gand%C3%ADaauthor=A.+G.+Garc%C3%ADa&title=The+Purinergic+P2X7+Receptor+as+a+Potential+Drug+Target+to+Combat+Neuroinflammation+in+Neurodegenerative+Diseases&doi=10.1002%2Fmed.21710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases</span></div><div class="casAuthors">Calzaferri, Francesco; Ruiz-Ruiz, Cristina; de Diego, Antonio M. G.; de Pascual, Ricardo; Mendez-Lopez, Iago; Cano-Abad, Maria F.; Maneu, Victoria; de los Rios, Cristobal; Gandia, Luis; Garcia, Antonio G.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2427-2465</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review of the purinergic P2X7 receptors (P2X7Rs)are gatekeepers of inflammation, they could be developed as drug targets for NDDs.  Herein, we review this challenging hypothesis and comment on the numerous studies that have investigated P2X7Rs, emphasizing their mol. structure and functions, as well as their role in inflammation.  Then, we elaborate on research undertaken in the field of medicinal chem. to det. potential P2X7R antagonists.  Subsequently, we review the state of neuroinflammation and P2X7R expression in the brain, in animal models and patients suffering from AD, Parkinson's disease, amyotrophic lateral sclerosis, Huntington disease, multiple sclerosis, and retinal degeneration.  Next, we summarize the in vivo studies testing the hypothesis that by mitigating neuroinflammation, P2X7R blockers afford neuroprotection, increasing neuroplasticity and neuronal repair in animal models of NDDs.  Finally, we reviewed previous and ongoing CTs investigating compds. directed toward targets assocd. with NDDs; we propose that CTs with P2X7R antagonists should be initiated.  Despite the high expectations for putative P2X7Rs antagonists in various central nervous system diseases, the field is moving forward at a relatively slow pace, presumably due to the complexity of P2X7Rs.  A better pharmacol. approach to combat NDDs would be a dual strategy, combining P2X7R antagonism with drugs targeting a selective pathway in a given NDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6K9cEDPmFNLVg90H21EOLACvtfcHk0lhy3tPDPyJT4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVKlurbM&md5=61c929af816b30378efcdb9a89e8b56a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fmed.21710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21710%26sid%3Dliteratum%253Aachs%26aulast%3DCalzaferri%26aufirst%3DF.%26aulast%3DRuiz-Ruiz%26aufirst%3DC.%26aulast%3DDiego%26aufirst%3DA.%2BM.%2BG.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DM%25C3%25A9ndez-L%25C3%25B3pez%26aufirst%3DI.%26aulast%3DCano-Abad%26aufirst%3DM.%2BF.%26aulast%3DManeu%26aufirst%3DV.%26aulast%3DR%25C3%25ADos%26aufirst%3DC.%26aulast%3DGand%25C3%25ADa%26aufirst%3DL.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DA.%2BG.%26atitle%3DThe%2520Purinergic%2520P2X7%2520Receptor%2520as%2520a%2520Potential%2520Drug%2520Target%2520to%2520Combat%2520Neuroinflammation%2520in%2520Neurodegenerative%2520Diseases%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D2427%26epage%3D2465%26doi%3D10.1002%2Fmed.21710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Surprenant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassendren, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buell, G.</span></span> <span> </span><span class="NLM_article-title">The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7)</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">738</span>, <span class="refDoi"> DOI: 10.1126/science.272.5262.735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1126%2Fscience.272.5262.735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=8614837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK28Xislamt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1996&pages=735-738&author=A.+Surprenantauthor=F.+Rassendrenauthor=E.+Kawashimaauthor=R.+A.+Northauthor=G.+Buell&title=The+Cytolytic+P2Z+Receptor+for+Extracellular+ATP+Identified+as+a+P2X+Receptor+%28P2X7%29&doi=10.1126%2Fscience.272.5262.735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The cytolytic P2Z receptor for extracellular ATP identified as a P2x receptor (P2X7)</span></div><div class="casAuthors">Surprenant, A.; Rassendren, F.; Kawashima, E.; North, R. A.; Buell, G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">5262</span>),
    <span class="NLM_cas:pages">735-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The P2Z receptor is responsible for ATP (ATP)-dependent lysis of macrophages through the formation of membrane pores permeable to large mols.  Other ATP-gated channels, the P2x receptors, are permeable only to small cations.  Here, an ATP receptor, the P2X7 receptor, was cloned from rat brain and exhibited both these properties.  This protein is homologous to other P2x receptors but has a unique carboxyl-terminal domain that was required for the lytic actions of ATP.  Thus, the P2X7 (or P2Z) receptor is a bifunctional mol. that could function in both fast synaptic transmission and the ATP-mediated lysis of antigen-presenting cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3JbVuyrvX37Vg90H21EOLACvtfcHk0lhTowK0ZiltYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislamt74%253D&md5=6417dd3fc96249f798858c369330f83a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.272.5262.735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.272.5262.735%26sid%3Dliteratum%253Aachs%26aulast%3DSurprenant%26aufirst%3DA.%26aulast%3DRassendren%26aufirst%3DF.%26aulast%3DKawashima%26aufirst%3DE.%26aulast%3DNorth%26aufirst%3DR.%2BA.%26aulast%3DBuell%26aufirst%3DG.%26atitle%3DThe%2520Cytolytic%2520P2Z%2520Receptor%2520for%2520Extracellular%2520ATP%2520Identified%2520as%2520a%2520P2X%2520Receptor%2520%2528P2X7%2529%26jtitle%3DScience%26date%3D1996%26volume%3D272%26spage%3D735%26epage%3D738%26doi%3D10.1126%2Fscience.272.5262.735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denlinger, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisette, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watters, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubyak, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertics, P. J.</span></span> <span> </span><span class="NLM_article-title">Cutting Edge: the Nucleotide Receptor P2X7 Contains Multiple Protein- and Lipid-Interaction Motifs Including a Potential Binding Site for Bacterial Lipopolysaccharide</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.167.4.1871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.4049%2Fjimmunol.167.4.1871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=11489964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFeqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2001&pages=1871-1876&author=L.+C.+Denlingerauthor=P.+L.+Fisetteauthor=J.+A.+Sommerauthor=J.+J.+Wattersauthor=U.+Prabhuauthor=G.+R.+Dubyakauthor=R.+A.+Proctorauthor=P.+J.+Bertics&title=Cutting+Edge%3A+the+Nucleotide+Receptor+P2X7+Contains+Multiple+Protein-+and+Lipid-Interaction+Motifs+Including+a+Potential+Binding+Site+for+Bacterial+Lipopolysaccharide&doi=10.4049%2Fjimmunol.167.4.1871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide</span></div><div class="casAuthors">Denlinger, Loren C.; Fisette, Philip L.; Sommer, Julie A.; Watters, Jyoti J.; Prabhu, Usha; Dubyak, George R.; Proctor, Richard A.; Bertics, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1871-1876</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The nucleotide receptor P2X7 has been shown to modulate LPS-induced macrophage prodn. of numerous inflammatory mediators.  Although the C-terminal portion of P2X7 is thought to be essential for multiple receptor functions, little is known regarding the structural motifs that lie within this region.  We show here that the P2X7 C-terminal domain contains several apparent protein-protein and protein-lipid interaction motifs with potential importance to macrophage signaling and LPS action.  Surprisingly, P2X7 also contains a conserved LPS-binding domain.  In this report, we demonstrate that peptides derived from this P2X7 sequence bind LPS in vitro.  Moreover, these peptides neutralize the ability of LPS to activate the extracellular signal-regulated kinases (ERK1, ERK2) and to promote the degrdn. of the inhibitor of κB-α isoform (IκB-α) in RAW 264.7 macrophages.  Collectively, these data suggest that the C-terminal domain of P2X7 may directly coordinate several signal transduction events related to macrophage function and LPS action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPpdlIBLcb2rVg90H21EOLACvtfcHk0lhTowK0ZiltYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFeqt7g%253D&md5=d189a60c471a8939babd7714591f3434</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.167.4.1871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.167.4.1871%26sid%3Dliteratum%253Aachs%26aulast%3DDenlinger%26aufirst%3DL.%2BC.%26aulast%3DFisette%26aufirst%3DP.%2BL.%26aulast%3DSommer%26aufirst%3DJ.%2BA.%26aulast%3DWatters%26aufirst%3DJ.%2BJ.%26aulast%3DPrabhu%26aufirst%3DU.%26aulast%3DDubyak%26aufirst%3DG.%2BR.%26aulast%3DProctor%26aufirst%3DR.%2BA.%26aulast%3DBertics%26aufirst%3DP.%2BJ.%26atitle%3DCutting%2520Edge%253A%2520the%2520Nucleotide%2520Receptor%2520P2X7%2520Contains%2520Multiple%2520Protein-%2520and%2520Lipid-Interaction%2520Motifs%2520Including%2520a%2520Potential%2520Binding%2520Site%2520for%2520Bacterial%2520Lipopolysaccharide%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D167%26spage%3D1871%26epage%3D1876%26doi%3D10.4049%2Fjimmunol.167.4.1871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adinolfi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemoli, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idzko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panther, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Virgilio, F.</span></span> <span> </span><span class="NLM_article-title">The P2X7 Receptor: a Key Player in IL-1 Processing and Release</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">3877</span>– <span class="NLM_lpage">3883</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.176.7.3877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.4049%2Fjimmunol.176.7.3877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=16547218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1ertL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=3877-3883&author=D.+Ferrariauthor=C.+Pizziraniauthor=E.+Adinolfiauthor=R.+M.+Lemoliauthor=A.+Curtiauthor=M.+Idzkoauthor=E.+Pantherauthor=F.+Di+Virgilio&title=The+P2X7+Receptor%3A+a+Key+Player+in+IL-1+Processing+and+Release&doi=10.4049%2Fjimmunol.176.7.3877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The P2X7 Receptor: A Key Player in IL-1 Processing and Release</span></div><div class="casAuthors">Ferrari, Davide; Pizzirani, Cinzia; Adinolfi, Elena; Lemoli, Roberto M.; Curti, Antonio; Idzko, Marco; Panther, Elisabeth; Di Virgilio, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3877-3883</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Human interleukin 1 (IL-1) family proteins are key mediators of the host response to infections, injury, and immunol. challenges.  The mechanism by which IL-1 activates proinflammatory responses in target cells, and the plasma membrane receptors involved, are fairly well known.  This has led to the development of innovative drugs that block IL-1 downstream to its synthesis and secretion.  On the contrary, the mechanism of IL-1 and other IL-1 family members (e.g., IL-18) maturation and release is incompletely understood.  Accruing evidence points to a plasma membrane receptor for extracellular ATP, the P2X7 receptor, as a key player in both processes.  A deeper understanding of the mechanism by which the P2X7 receptor triggers IL-1 maturation and exteriorization may suggest novel avenues for the treatment of inflammatory diseases and provide a deeper insight in the fundamental mechanism of protease activation and cellular export of proteins lacking a leader sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_AAKnLXk6DbVg90H21EOLACvtfcHk0lgKS3KoWqtq6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1ertL4%253D&md5=c64da9cb2a04420486b508cc6afd3a03</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.7.3877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.7.3877%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DD.%26aulast%3DPizzirani%26aufirst%3DC.%26aulast%3DAdinolfi%26aufirst%3DE.%26aulast%3DLemoli%26aufirst%3DR.%2BM.%26aulast%3DCurti%26aufirst%3DA.%26aulast%3DIdzko%26aufirst%3DM.%26aulast%3DPanther%26aufirst%3DE.%26aulast%3DDi%2BVirgilio%26aufirst%3DF.%26atitle%3DThe%2520P2X7%2520Receptor%253A%2520a%2520Key%2520Player%2520in%2520IL-1%2520Processing%2520and%2520Release%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D3877%26epage%3D3883%26doi%3D10.4049%2Fjimmunol.176.7.3877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piccini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasiglie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubartelli, A.</span></span> <span> </span><span class="NLM_article-title">ATP is Released by Monocytes Stimulated with Pathogen-Sensing Receptor Ligands and Induces IL-1beta and IL-18 Secretion in an Autocrine Way</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">8067</span>– <span class="NLM_lpage">8072</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709684105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1073%2Fpnas.0709684105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=18523012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1elsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=8067-8072&author=A.+Picciniauthor=S.+Cartaauthor=S.+Tassiauthor=D.+Lasiglieauthor=G.+Fossatiauthor=A.+Rubartelli&title=ATP+is+Released+by+Monocytes+Stimulated+with+Pathogen-Sensing+Receptor+Ligands+and+Induces+IL-1beta+and+IL-18+Secretion+in+an+Autocrine+Way&doi=10.1073%2Fpnas.0709684105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1β and IL-18 secretion in an autocrine way</span></div><div class="casAuthors">Piccini, Alessandra; Carta, Sonia; Tassi, Sara; Lasiglie, Denise; Fossati, Gianluca; Rubartelli, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8067-8072</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">IL-1β and IL-18 are crucial mediators of inflammation, and a defective control of their release may cause serious diseases.  Yet, the mechanisms regulating IL-1β and IL-18 secretion are partially undefined.  Both cytokines are produced as inactive cytoplasmic precursors.  Processing to the active form is mediated by caspase-1, which is in turn activated by the multiprotein complex inflammasome.  Here, the authors show that in primary human monocytes microbial components acting on different pathogen-sensing receptors and the danger-assocd. mol. uric acid are all competent to induce maturation and secretion of IL-1β and IL-18 through a process that involves as a first event the extracellular release of endogenous ATP.  ATP release is followed by autocrine stimulation of the purinergic receptors P2X7.  Indeed, antagonists of the P2X7 receptor (P2X7R), or treatment with apyrase, prevent IL-1β and IL-18 maturation and secretion triggered by the different stimuli.  At variance, blocking P2X7R activity has no effects on IL-1β secretion by monocytes carrying a mutated inflammasome that does not require exogenous ATP for activation.  P2X7R engagement is followed by K+ efflux and activation of phospholipase A2.  Both events are required for processing and secretion induced by all of the stimuli.  Thus, stimuli acting on different pathogen-sensing receptors converge on a common pathway where ATP externalization is the first step in the cascade of events leading to inflammasome activation and IL-1β and IL-18 secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwcfFNCJ8BPLVg90H21EOLACvtfcHk0lgKS3KoWqtq6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1elsLs%253D&md5=56a17ac4ddb6d5565c10db31957fc19f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709684105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709684105%26sid%3Dliteratum%253Aachs%26aulast%3DPiccini%26aufirst%3DA.%26aulast%3DCarta%26aufirst%3DS.%26aulast%3DTassi%26aufirst%3DS.%26aulast%3DLasiglie%26aufirst%3DD.%26aulast%3DFossati%26aufirst%3DG.%26aulast%3DRubartelli%26aufirst%3DA.%26atitle%3DATP%2520is%2520Released%2520by%2520Monocytes%2520Stimulated%2520with%2520Pathogen-Sensing%2520Receptor%2520Ligands%2520and%2520Induces%2520IL-1beta%2520and%2520IL-18%2520Secretion%2520in%2520an%2520Autocrine%2520Way%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D8067%26epage%3D8072%26doi%3D10.1073%2Fpnas.0709684105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karasawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawate, T.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Subtype-Specific Inhibition of the P2X7 Receptor</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e22153</span> <span class="refDoi"> DOI: 10.7554/elife.22153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.7554%2FeLife.22153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=27935479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslentLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=A.+Karasawaauthor=T.+Kawate&title=Structural+Basis+for+Subtype-Specific+Inhibition+of+the+P2X7+Receptor&doi=10.7554%2Felife.22153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for subtype-specific inhibition of the P2X7 receptor</span></div><div class="casAuthors">Karasawa, Akira; Kawate, Toshimitsu</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e22153/1-e22153/17</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">The P2X7 receptor is a non-selective cation channel activated by extracellular ATP (ATP).  Chronic activation of P2X7 underlies many health problems such as pathol. pain, yet we lack effective antagonists due to poorly understood mechanisms of inhibition.  Here we present crystal structures of a mammalian P2X7 receptor complexed with five structurally-unrelated antagonists.  Unexpectedly, these drugs all bind to an allosteric site distinct from the ATP-binding pocket in a groove formed between two neighboring subunits.  This novel drug-binding pocket accommodates a diversity of small mols. mainly through hydrophobic interactions.  Functional assays propose that these compds. allosterically prevent narrowing of the drug-binding pocket and the turret-like architecture during channel opening, which is consistent with a site of action distal to the ATP-binding pocket.  These novel mechanistic insights will facilitate the development of P2X7-specific drugs for treating human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeIo_gt316wbVg90H21EOLACvtfcHk0lgKS3KoWqtq6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslentLrE&md5=76fcd0704f055ebb98c500c731da71b1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7554%2FeLife.22153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.22153%26sid%3Dliteratum%253Aachs%26aulast%3DKarasawa%26aufirst%3DA.%26aulast%3DKawate%26aufirst%3DT.%26atitle%3DStructural%2520Basis%2520for%2520Subtype-Specific%2520Inhibition%2520of%2520the%2520P2X7%2520Receptor%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26doi%3D10.7554%2Felife.22153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bidula, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, L.</span></span> <span> </span><span class="NLM_article-title">Mapping a Novel Positive Allosteric Modulator Binding Site in the Central Vestibule Region of Human P2X7</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3231</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-39771-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1038%2Fs41598-019-39771-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=30824738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BB3cfpsFWitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=3231&author=S.+M.+Bidulaauthor=B.+A.+Cromerauthor=S.+Walpoleauthor=J.+Anguloauthor=L.+Stokes&title=Mapping+a+Novel+Positive+Allosteric+Modulator+Binding+Site+in+the+Central+Vestibule+Region+of+Human+P2X7&doi=10.1038%2Fs41598-019-39771-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping a novel positive allosteric modulator binding site in the central vestibule region of human P2X7</span></div><div class="casAuthors">Bidula Stefan M; Walpole Samuel; Angulo Jesus; Stokes Leanne; Cromer Brett A; Cromer Brett A</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">P2X7 receptors are important in the regulation of inflammatory responses and immune responses to intracellular pathogens such as Mycobacterium tuberculosis and Toxoplasma gondii.  Enhancement of P2X7 receptor responses may be useful in pathogen clearance particularly in individuals with defective microbial killing mechanisms.  Ginsenosides from Panax ginseng have been discovered to act as positive allosteric modulators of P2X7.  Here we describe a novel modulator binding site identified by computational docking located in the central vestibule of P2X7 involving S60, D318, and L320 in the lower body β-sheets lining the lateral portals.  Potentiation of ATP-mediated responses by ginsenosides CK and Rd caused enhanced ionic currents, Ca(2+) influx and YOPRO-1 uptake in stably transfected HEK-293 cells (HEK-hP2X7) plus enhanced cell death responses.  Potentiation of ATP responses by CK and Rd was markedly reduced by mutations S59A, S60A, D318L and L320A supporting the proposed allosteric modulator binding site.  Furthermore, mutation of the conserved residues S60 and D318 led to alterations in P2X7 response and a higher sensitivity to ATP in the absence of modulators suggesting residues in the connecting rods play an important role in regulating P2X7 gating.  Identification of this novel binding site location in the central vestibule may also be relevant for structurally similar channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtbLKZwETEnuqrn-c4Of3KfW6udTcc2ebzeeLXU25QHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfpsFWitA%253D%253D&md5=ae11ec0dad23ef1b10374e48cace7fbe</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-39771-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-39771-5%26sid%3Dliteratum%253Aachs%26aulast%3DBidula%26aufirst%3DS.%2BM.%26aulast%3DCromer%26aufirst%3DB.%2BA.%26aulast%3DWalpole%26aufirst%3DS.%26aulast%3DAngulo%26aufirst%3DJ.%26aulast%3DStokes%26aufirst%3DL.%26atitle%3DMapping%2520a%2520Novel%2520Positive%2520Allosteric%2520Modulator%2520Binding%2520Site%2520in%2520the%2520Central%2520Vestibule%2520Region%2520of%2520Human%2520P2X7%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D3231%26doi%3D10.1038%2Fs41598-019-39771-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dayel, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R.</span></span> <span> </span><span class="NLM_article-title">Mapping the Site of Action of Human P2X7 Receptor Antagonists AZ11645373, Brilliant Blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit Allosteric Pocket</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1124/mol.119.116715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1124%2Fmol.119.116715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31263019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCqsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2019&pages=355-363&author=A.+B.+Dayelauthor=R.+J.+Evansauthor=R.+Schmid&title=Mapping+the+Site+of+Action+of+Human+P2X7+Receptor+Antagonists+AZ11645373%2C+Brilliant+Blue+G%2C+KN-62%2C+Calmidazolium%2C+and+ZINC58368839+to+the+Intersubunit+Allosteric+Pocket&doi=10.1124%2Fmol.119.116715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the site of action of human P2X7 receptor antagonists AZ11645373, brilliant blue G, KN-62, calmidazolium, and ZINC58368839 to the Intersubunit allosteric pocket</span></div><div class="casAuthors">Dayel, Anfal Bin; Evans, Richard J.; Schmid, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-363</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The P2X7 receptor is a trimeric ligand-gated ion channel activated by ATP.  It is implicated in the cellular response to trauma/disease and considered to have significant therapeutic potential.  Using chimeras and point mutants we have mapped the binding site of the P2X7R-selective antagonist AZ11645373 to the known allosteric binding pocket at the interface between two subunits, in proximity to, but sepd. from the ATP binding site.  Our structural model of AZ11645373 binding is consistent with effects of mutations on antagonist sensitivity, and the proposed binding mode explains variation in antagonist sensitivity between the human and rat P2X7 receptors.  We have also detd. the site of action for the P2X7R-selective antagonists ZINC58368839, brilliant blue G, KN-62, and calmidazolium.  The effect of intersubunit allosteric pocket "signature mutants" F88A, T90V, D92A, F103A, and V312A on antagonist sensitivity suggests that ZINC58368839 comprises a binding mode similar to AZ11645373 and other previously characterized antagonists.  For the larger antagonists, brilliant blue G, KN-62, and calmidazolium, our data imply an overlapping but distinct binding mode involving the central upper vestibule of the receptor in addn. to the intersubunit allosteric pocket.  Our work explains the site of action for a series of P2X7R antagonists and establishes "signature mutants" for P2X7R binding-mode characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV___L68o7D7Vg90H21EOLACvtfcHk0lg9j_21KDbxhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCqsb%252FM&md5=979f15602e1ab0d78f1d25c123d79f2b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fmol.119.116715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.119.116715%26sid%3Dliteratum%253Aachs%26aulast%3DDayel%26aufirst%3DA.%2BB.%26aulast%3DEvans%26aufirst%3DR.%2BJ.%26aulast%3DSchmid%26aufirst%3DR.%26atitle%3DMapping%2520the%2520Site%2520of%2520Action%2520of%2520Human%2520P2X7%2520Receptor%2520Antagonists%2520AZ11645373%252C%2520Brilliant%2520Blue%2520G%252C%2520KN-62%252C%2520Calmidazolium%252C%2520and%2520ZINC58368839%2520to%2520the%2520Intersubunit%2520Allosteric%2520Pocket%26jtitle%3DMol.%2520Pharmacol.%26date%3D2019%26volume%3D96%26spage%3D355%26epage%3D363%26doi%3D10.1124%2Fmol.119.116715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caseley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muench, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishwick, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.-H.</span></span> <span> </span><span class="NLM_article-title">Docking of Competitive Inhibitors to the P2X7 Receptor Family Reveals Key Differences Responsible for Changes in Response Between Rat and Human</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3164</span>– <span class="NLM_lpage">3167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2015.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=26099538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVejtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3164-3167&author=E.+A.+Caseleyauthor=S.+P.+Muenchauthor=S.+A.+Baldwinauthor=K.+Simmonsauthor=C.+W.+Fishwickauthor=L.-H.+Jiang&title=Docking+of+Competitive+Inhibitors+to+the+P2X7+Receptor+Family+Reveals+Key+Differences+Responsible+for+Changes+in+Response+Between+Rat+and+Human&doi=10.1016%2Fj.bmcl.2015.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Docking of competitive inhibitors to the P2X7 receptor family reveals key differences responsible for changes in response between rat and human</span></div><div class="casAuthors">Caseley, Emily A.; Muench, Stephen P.; Baldwin, Stephen A.; Simmons, Katie; Fishwick, Colin W.; Jiang, Lin-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3164-3167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The P2X7 receptor is a calcium permeable cationic channel activated by extracellular ATP, playing a role in chronic pain, osteoporosis and arthritis.  A no. of potential lead compds. are inactive against the rat isoform, despite good activity against the human homolog, making animal model studies problematic.  Here we have produced P2X7 models and docked three structurally distinct inhibitors using in silico approaches and show they have a similar mode of binding in which Phe95 plays a key role by forming pi-stacking interactions.  Importantly this residue is replaced by Leu in the rat P2X7 receptor resulting in a significantly reduced binding affinity.  This work provides new insights into binding of P2X7 inhibitors and shows the structural difference in human and rat P2X7 receptors which results in a difference in affinity.  Such information is useful both for the rational design of inhibitors based on these scaffolds and also the way in which these compds. are tested in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouJ81BAAXBurVg90H21EOLACvtfcHk0lhNPpko4PMYIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVejtL%252FM&md5=4af63cdf4b5861d4b8c2ca1ecd6605a1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DCaseley%26aufirst%3DE.%2BA.%26aulast%3DMuench%26aufirst%3DS.%2BP.%26aulast%3DBaldwin%26aufirst%3DS.%2BA.%26aulast%3DSimmons%26aufirst%3DK.%26aulast%3DFishwick%26aufirst%3DC.%2BW.%26aulast%3DJiang%26aufirst%3DL.-H.%26atitle%3DDocking%2520of%2520Competitive%2520Inhibitors%2520to%2520the%2520P2X7%2520Receptor%2520Family%2520Reveals%2520Key%2520Differences%2520Responsible%2520for%2520Changes%2520in%2520Response%2520Between%2520Rat%2520and%2520Human%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3164%26epage%3D3167%26doi%3D10.1016%2Fj.bmcl.2015.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parvathenani, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tertyshnikova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posmantur, R.</span></span> <span> </span><span class="NLM_article-title">P2X7 Mediates Superoxide Production in Primary Microglia and is Up-Regulated in a Transgenic Mouse Model of Alzheimer’s Disease</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">13309</span>– <span class="NLM_lpage">13317</span>, <span class="refDoi"> DOI: 10.1074/jbc.m209478200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1074%2Fjbc.M209478200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=12551918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislGru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=13309-13317&author=L.+K.+Parvathenaniauthor=S.+Tertyshnikovaauthor=C.+R.+Grecoauthor=S.+B.+Robertsauthor=B.+Robertsonauthor=R.+Posmantur&title=P2X7+Mediates+Superoxide+Production+in+Primary+Microglia+and+is+Up-Regulated+in+a+Transgenic+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1074%2Fjbc.m209478200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 Mediates Superoxide Production in Primary Microglia and Is Up-regulated in a Transgenic Mouse Model of Alzheimer's Disease</span></div><div class="casAuthors">Parvathenani, Lav K.; Tertyshnikova, Svetlana; Greco, Corinne R.; Roberts, Susan B.; Robertson, Barbara; Posmantur, Rand</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">13309-13317</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Primary rat microglia stimulated with either ATP or 2'- and 3'-O-(4-benzoylbenzoyl)-ATP (BzATP) release copious amts. of superoxide (O2•-).  ATP and BzATP stimulate O2•- prodn. through purinergic receptors, primarily the P2X7 receptor.  O2•- is produced through the activation of the NADPH oxidase.  Although both p42/44 MAPK and p38 MAPK were activated rapidly in cells stimulated with BzATP, only pharmacol. inhibition of p38 MAPK attenuated O2•- prodn.  Furthermore, an inhibitor of phosphatidylinositol 3-kinase attenuated O2•- prodn. to a greater extent than an inhibitor of p38 MAPK.  Both ATP and BzATP stimulated microglia-induced cortical cell death indicating this pathway may contribute to neurodegeneration.  Consistent with this hypothesis, P2X7 receptor was specifically up-regulated around β-amyloid plaques in a mouse model of Alzheimer's disease (Tg2576).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU2RQIXjn6I7Vg90H21EOLACvtfcHk0lhNPpko4PMYIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislGru7o%253D&md5=b2222cd7a8f22f3b491c2c97f1f54109</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M209478200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M209478200%26sid%3Dliteratum%253Aachs%26aulast%3DParvathenani%26aufirst%3DL.%2BK.%26aulast%3DTertyshnikova%26aufirst%3DS.%26aulast%3DGreco%26aufirst%3DC.%2BR.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DRobertson%26aufirst%3DB.%26aulast%3DPosmantur%26aufirst%3DR.%26atitle%3DP2X7%2520Mediates%2520Superoxide%2520Production%2520in%2520Primary%2520Microglia%2520and%2520is%2520Up-Regulated%2520in%2520a%2520Transgenic%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D13309%26epage%3D13317%26doi%3D10.1074%2Fjbc.m209478200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Frailes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Lauro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Diego-Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebastian-Serrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Hernandez, M.</span></span> <span> </span><span class="NLM_article-title">Amyloid Peptide Induced Neuroinflammation Increases the P2X7 Receptor Expression in Microglial Cells, Impacting on Its Functionality</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">143</span>, <span class="refDoi"> DOI: 10.3389/fncel.2019.00143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3389%2Ffncel.2019.00143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31031598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=143&author=C.+Martinez-Frailesauthor=C.+Di+Lauroauthor=C.+Bianchiauthor=L.+de+Diego-Garciaauthor=A.+Sebastian-Serranoauthor=L.+Boscaauthor=M.+Diaz-Hernandez&title=Amyloid+Peptide+Induced+Neuroinflammation+Increases+the+P2X7+Receptor+Expression+in+Microglial+Cells%2C+Impacting+on+Its+Functionality&doi=10.3389%2Ffncel.2019.00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid peptide induced neuroinflammation increases the P2X7 receptor expression in microglial cells, impacting on its functionality</span></div><div class="casAuthors">Martinez-Frailes, Carlos; Di Lauro, Caterina; Bianchi, Carolina; de Diego-Garcia, Laura; Sebastian-Serrano, Alvaro; Bosca, Lisardo; Diaz-Hernandez, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">143</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Alzheimer disease is a neurodegenerative disease characterized by the presence of senile plaques composed of amyloid-β (Aβ) peptide, neurofibrillary tangles, neuronal loss and neuroinflammation.  Previous works have revealed that extracellular ATP, through its selective receptor P2X7 (P2X7R), is essential to neuroinflammation and neurotoxicity induced by Aβ.  P2X7R is upregulated on microglial cells around the senile plaques.  This upregulation progressively rises with age and is parallel with an accumulation of senile plaques and also correlates with the synaptic toxicity detected both in animal models reproducing AD and human patients of AD.  Furthermore, the late onset of the first AD-assocd. symptoms suggests that aging assocd.-changes may be relevant to the disease progression.  Thus, microglia motility and its capacity to respond to exogenous ATP stimulus decrease with aging.  To evaluate whether the P2X7R age related-changes on microglia cells may be relevant to the AD progression, we generated a new transgenic mouse model crossing an Aβ peptide mouse model, J20 mice and the P2X7R reporter mice P2X7REGFP.  Our results indicate that neuroinflammation induced by Ab peptide causes changes in the P2X7R distribution pattern, increasing it s expression in microglial cells at advanced and late stages, when microgliosis occurs, but not in the early stages, in the absence of microgliosis.  In addn., we found that P2X7R activation promotes microglial cells migration to senile plaques but decreases their phagocytic capacity.  Moreover, we found a significant redn. of P2X7R transcription on neuronal cells at the early and advanced stages, but not at the late stages.  Since previous studies have reported that either pharmacol. inhibition or selective downregulation of P2X7R significantly improve behavioral alterations and reduce the incidence and size of senile plaques in the early and advanced stages of AD, the results presented here provide new evidence, indicating that this therapeutic approach could be also efficient in the late stages of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9sWfRgDcePbVg90H21EOLACvtfcHk0lhBhWs8QL8jhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKms7o%253D&md5=0935599fb6c9a7d85ba46babe28bc5bb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2019.00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2019.00143%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Frailes%26aufirst%3DC.%26aulast%3DDi%2BLauro%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3Dde%2BDiego-Garcia%26aufirst%3DL.%26aulast%3DSebastian-Serrano%26aufirst%3DA.%26aulast%3DBosca%26aufirst%3DL.%26aulast%3DDiaz-Hernandez%26aufirst%3DM.%26atitle%3DAmyloid%2520Peptide%2520Induced%2520Neuroinflammation%2520Increases%2520the%2520P2X7%2520Receptor%2520Expression%2520in%2520Microglial%2520Cells%252C%2520Impacting%2520on%2520Its%2520Functionality%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D143%26doi%3D10.3389%2Ffncel.2019.00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Hernandez, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Villafuertes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León-Otegui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hontecillas-Prieto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Puerto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trejo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gualix, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miras-Portugal, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Hernandez, M.</span></span> <span> </span><span class="NLM_article-title">In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease through GSK3β and secretases</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1816</span>– <span class="NLM_lpage">1828</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2011.09.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.neurobiolaging.2011.09.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22048123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFaksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=1816-1828&author=J.+I.+Diaz-Hernandezauthor=R.+Gomez-Villafuertesauthor=M.+Le%C3%B3n-Oteguiauthor=L.+Hontecillas-Prietoauthor=A.+Del+Puertoauthor=J.+L.+Trejoauthor=J.+J.+Lucasauthor=J.+J.+Garridoauthor=J.+Gualixauthor=M.+T.+Miras-Portugalauthor=M.+Diaz-Hernandez&title=In+vivo+P2X7+inhibition+reduces+amyloid+plaques+in+Alzheimer%E2%80%99s+disease+through+GSK3%CE%B2+and+secretases&doi=10.1016%2Fj.neurobiolaging.2011.09.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases</span></div><div class="casAuthors">Diaz-Hernandez, Juan Ignacio; Gomez-Villafuertes, Rosa; Leon-Otegui, Miriam; Hontecillas-Prieto, Lourdes; del Puerto, Ana; Trejo, Jose Luis; Lucas, Jose Javier; Garrido, Juan Jose; Gualix, Javier; Miras-Portugal, Maria Teresa; Diaz-Hernandez, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1816-1828</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">β-Amyloid (Aβ) peptide prodn. from amyloid precursor protein (APP) is essential in the formation of the β-amyloid plaques characteristic of Alzheimer's disease.  However, the extracellular signals that maintain the balance between nonpathogenic and pathol. forms of APP processing, mediated by α-secretase and β-secretase resp., remain poorly understood.  In the present work, we describe regulation of the processing of APP via the ATP receptor P2X7R.  In 2 different cellular lines, the inhibition of either native or overexpressed P2X7R increased α-secretase activity through inhibition of glycogen synthase kinase 3 (GSK-3).  In vivo inhibition of the P2X7R in J20 mice, transgenic for mutant human APP, induced a significant decrease in the no. of hippocampal amyloid plaques.  This redn. correlated with a decrease in glycogen synthase kinase 3 activity in J20 mice, increasing the proteolytic processing of APP through an increase in α-secretase activity.  The in vivo findings presented here demonstrate for the first time the therapeutic potential of P2X7R antagonism in the treatment of familiar Alzheimer's disease (FAD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquJ7Scs2MZhbVg90H21EOLACvtfcHk0lhBhWs8QL8jhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFaksrY%253D&md5=a455fc370ac113fffea9029fbc44c055</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2011.09.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2011.09.040%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz-Hernandez%26aufirst%3DJ.%2BI.%26aulast%3DGomez-Villafuertes%26aufirst%3DR.%26aulast%3DLe%25C3%25B3n-Otegui%26aufirst%3DM.%26aulast%3DHontecillas-Prieto%26aufirst%3DL.%26aulast%3DDel%2BPuerto%26aufirst%3DA.%26aulast%3DTrejo%26aufirst%3DJ.%2BL.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26aulast%3DGarrido%26aufirst%3DJ.%2BJ.%26aulast%3DGualix%26aufirst%3DJ.%26aulast%3DMiras-Portugal%26aufirst%3DM.%2BT.%26aulast%3DDiaz-Hernandez%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520P2X7%2520inhibition%2520reduces%2520amyloid%2520plaques%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520through%2520GSK3%25CE%25B2%2520and%2520secretases%26jtitle%3DNeurobiol.%2520Aging%26date%3D2012%26volume%3D33%26spage%3D1816%26epage%3D1828%26doi%3D10.1016%2Fj.neurobiolaging.2011.09.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durrenberger, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünblatt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monoranu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dexter, D. T.</span></span> <span> </span><span class="NLM_article-title">Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study</span>. <i>Parkinsons Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">214714</span>, <span class="refDoi"> DOI: 10.1155/2012/214714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1155%2F2012%2F214714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22548201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BC38rpsVGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=214714&author=P.+F.+Durrenbergerauthor=E.+Gr%C3%BCnblattauthor=F.+S.+Fernandoauthor=C.+M.+Monoranuauthor=J.+Evansauthor=P.+Riedererauthor=R.+Reynoldsauthor=D.+T.+Dexter&title=Inflammatory+Pathways+in+Parkinson%E2%80%99s+Disease%3B+A+BNE+Microarray+Study&doi=10.1155%2F2012%2F214714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study</span></div><div class="casAuthors">Durrenberger Pascal F; Grunblatt Edna; Fernando Francesca S; Monoranu Camelia Maria; Evans Jordan; Riederer Peter; Reynolds Richard; Dexter David T</div><div class="citationInfo"><span class="NLM_cas:title">Parkinson's disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214714</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The aetiology of Parkinson's disease (PD) is yet to be fully understood but it is becoming more and more evident that neuronal cell death may be multifactorial in essence.  The main focus of PD research is to better understand substantia nigra homeostasis disruption, particularly in relation to the wide-spread deposition of the aberrant protein α-synuclein.  Microarray technology contributed towards PD research with several studies to date and one gene, ALDH1A1 (Aldehyde dehydrogenase 1 family, member A1), consistently reappeared across studies including the present study, highlighting dopamine (DA) metabolism dysfunction resulting in oxidative stress and most probably leading to neuronal cell death.  Neuronal cell death leads to increased inflammation through the activation of astrocytes and microglia.  Using our dataset, we aimed to isolate some of these pathways so to offer potential novel neuroprotective therapeutic avenues.  To that effect our study has focused on the upregulation of P2X7 (purinergic receptor P2X, ligand-gated ion channel, 7) receptor pathway (microglial activation) and on the NOS3 (nitric oxide synthase 3) pathway (angiogenesis).  In summary, although the exact initiator of striatal DA neuronal cell death remains to be determined, based on our analysis, this event does not remain without consequence.  Extracellular ATP and reactive astrocytes appear to be responsible for the activation of microglia which in turn release proinflammatory cytokines contributing further to the parkinsonian condition.  In addition to tackling oxidative stress pathways we also suggest to reduce microglial and endothelial activation to support neuronal outgrowth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJPAiA5hY20hFwe7cAcrfPfW6udTcc2eYjqUN7b0-l2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rpsVGrsw%253D%253D&md5=3086796fc740f8a890a6831979ac4b2c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1155%2F2012%2F214714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F214714%26sid%3Dliteratum%253Aachs%26aulast%3DDurrenberger%26aufirst%3DP.%2BF.%26aulast%3DGr%25C3%25BCnblatt%26aufirst%3DE.%26aulast%3DFernando%26aufirst%3DF.%2BS.%26aulast%3DMonoranu%26aufirst%3DC.%2BM.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DRiederer%26aufirst%3DP.%26aulast%3DReynolds%26aufirst%3DR.%26aulast%3DDexter%26aufirst%3DD.%2BT.%26atitle%3DInflammatory%2520Pathways%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%253B%2520A%2520BNE%2520Microarray%2520Study%26jtitle%3DParkinsons%2520Dis.%26date%3D2012%26volume%3D2012%26spage%3D214714%26doi%3D10.1155%2F2012%2F214714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-T.</span></span> <span> </span><span class="NLM_article-title">Extracellular ATP Mediates Necrotic Cell Swelling in SN4741 Dopaminergic Neurons Through P2X7 Receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">37350</span>– <span class="NLM_lpage">37358</span>, <span class="refDoi"> DOI: 10.1074/jbc.m707915200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1074%2Fjbc.M707915200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=17962183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGjtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=37350-37358&author=D.-J.+Junauthor=J.+Kimauthor=S.-Y.+Jungauthor=R.+Songauthor=J.-H.+Nohauthor=Y.-S.+Parkauthor=S.-H.+Ryuauthor=J.-H.+Kimauthor=Y.-Y.+Kongauthor=J.-M.+Chungauthor=K.-T.+Kim&title=Extracellular+ATP+Mediates+Necrotic+Cell+Swelling+in+SN4741+Dopaminergic+Neurons+Through+P2X7+Receptors&doi=10.1074%2Fjbc.m707915200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular ATP Mediates Necrotic Cell Swelling in SN4741 Dopaminergic Neurons through P2X7 Receptors</span></div><div class="casAuthors">Jun, Dong-Jae; Kim, Jaeyoon; Jung, Sang-Yong; Song, Ran; Noh, Ji-Hyun; Park, Yong-Soo; Ryu, Sung-Ho; Kim, Joung-Hun; Kong, Young-Yun; Chung, Jun-Mo; Kim, Kyong-Tai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">37350-37358</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Extracellular ATP has recently been identified as an important regulator of cell death in response to pathol. insults.  When SN4741 cells, which are dopaminergic neurons derived from the substantia nigra of transgenic mouse embryos, are exposed to ATP, cell death occurs.  This cell death is assocd. with prominent cell swelling, loss of ER integrity, the formation of many large cytoplasmic vacuoles, and subsequent cytolysis and DNA release.  In addn., the cleavage of caspase-3, a hallmark of apoptosis, is induced by ATP treatment.  However, caspase inhibitors do not overcome ATP-induced cell death, indicating that both necrosis and apoptosis are assocd. with ATP-induced cell death and suggesting that a necrotic event might override the apoptotic process.  In this study we also found that P2X7 receptors (P2X7Rs) are abundantly expressed in SN4741 cells, and both ATP-induced swelling and cell death are reversed by pretreatment with the P2X7Rs antagonist, KN62, or by knock-down of P2X7Rs with small interfering RNAs.  Therefore, extracellular ATP release from injured tissues may act as an accelerating factor in necrotic SN4741 dopaminergic cell death via P2X7Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFFDWZ-00b77Vg90H21EOLACvtfcHk0liRWDfCL_1Uqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGjtrzO&md5=499d267c28421155c676226cd3e1eccf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M707915200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M707915200%26sid%3Dliteratum%253Aachs%26aulast%3DJun%26aufirst%3DD.-J.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DS.-Y.%26aulast%3DSong%26aufirst%3DR.%26aulast%3DNoh%26aufirst%3DJ.-H.%26aulast%3DPark%26aufirst%3DY.-S.%26aulast%3DRyu%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DKong%26aufirst%3DY.-Y.%26aulast%3DChung%26aufirst%3DJ.-M.%26aulast%3DKim%26aufirst%3DK.-T.%26atitle%3DExtracellular%2520ATP%2520Mediates%2520Necrotic%2520Cell%2520Swelling%2520in%2520SN4741%2520Dopaminergic%2520Neurons%2520Through%2520P2X7%2520Receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D37350%26epage%3D37358%26doi%3D10.1074%2Fjbc.m707915200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carmo, M. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, A. P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, A. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pliássova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeira, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canas, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, G. M.</span></span> <span> </span><span class="NLM_article-title">The P2X7 Receptor Antagonist Brilliant Blue G Attenuates Contralateral Rotations in a Rat Model of Parkinsonism Through a Combined Control of Synaptotoxicity, Neurotoxicity and Gliosis</span>. <i>Neuropharmacol</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.01.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.neuropharm.2014.01.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=24508709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Wku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2014&pages=142-152&author=M.+R.+S.+Carmoauthor=A.+P.+F.+Menezesauthor=A.+C.+L.+Nunesauthor=A.+Pli%C3%A1ssovaauthor=A.+P.+Roloauthor=C.+M.+Palmeiraauthor=R.+A.+Cunhaauthor=P.+M.+Canasauthor=G.+M.+Andrade&title=The+P2X7+Receptor+Antagonist+Brilliant+Blue+G+Attenuates+Contralateral+Rotations+in+a+Rat+Model+of+Parkinsonism+Through+a+Combined+Control+of+Synaptotoxicity%2C+Neurotoxicity+and+Gliosis&doi=10.1016%2Fj.neuropharm.2014.01.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis</span></div><div class="casAuthors">Carmo, Marta R. S.; Menezes, Ana Paula F.; Nunes, Ana Carla L.; Pliassova, Anna; Rolo, Anabela P.; Palmeira, Carlos M.; Cunha, Rodrigo A.; Canas, Paula M.; Andrade, Geanne M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">142-152</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) involves an initial loss of striatal dopaminergic terminals evolving into a degeneration of dopaminergic neurons in the substantia nigra (SN), which can be modeled by 6-hydroxydopamine (6-OHDA) administration.  Since ATP is a danger signal acting through its P2X7 receptors (P2X7R), we now tested if a blood-brain barrier-permeable P2X7R antagonist, Brilliant Blue G (BBG), controlled the 6-OHDA-induced PD-like features in rats.  BBG (45 mg/kg) attenuated the 6-OHDA-induced: 1) increase of contralateral rotations in the apomorphine test, an effect mimicked by another P2X7R antagonist A438079 applied intra-cerebroventricularly; 2) short-term memory impairment in the passive avoidance and cued version of the Morris Water maze; 3) redn. of dopamine content in the striatum and SN; 4) microgliosis and astrogliosis in the striatum.  To grasp the mechanism of action of BBG, we used in vitro models exploring synaptotoxicity (striatal synaptosomes) and neurotoxicity (dopamine-differentiated neuroblastoma SH-SY5Y cells).  P2X7R were present in striatal dopaminergic terminals, and BBG (100 nM) prevented the 6-OHDA-induced synaptosomal dysfunction.  P2X7R were also co-localized with tyrosine hydroxylase in SH-SY5Y cells, where BBG (100 nM) attenuated the 6-OHDA-induced neurotoxicity.  This suggests that P2X7R contribute to PD pathogenesis through a triple impact on synaptotoxicity, gliosis and neurotoxicity, highlighting the therapeutic potential of P2X7R antagonists in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpri1wRg8e8HLVg90H21EOLACvtfcHk0lgevm3dswGKWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Wku7k%253D&md5=be760e2f1bb8da76d1782f3fe0665007</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.01.045%26sid%3Dliteratum%253Aachs%26aulast%3DCarmo%26aufirst%3DM.%2BR.%2BS.%26aulast%3DMenezes%26aufirst%3DA.%2BP.%2BF.%26aulast%3DNunes%26aufirst%3DA.%2BC.%2BL.%26aulast%3DPli%25C3%25A1ssova%26aufirst%3DA.%26aulast%3DRolo%26aufirst%3DA.%2BP.%26aulast%3DPalmeira%26aufirst%3DC.%2BM.%26aulast%3DCunha%26aufirst%3DR.%2BA.%26aulast%3DCanas%26aufirst%3DP.%2BM.%26aulast%3DAndrade%26aufirst%3DG.%2BM.%26atitle%3DThe%2520P2X7%2520Receptor%2520Antagonist%2520Brilliant%2520Blue%2520G%2520Attenuates%2520Contralateral%2520Rotations%2520in%2520a%2520Rat%2520Model%2520of%2520Parkinsonism%2520Through%2520a%2520Combined%2520Control%2520of%2520Synaptotoxicity%252C%2520Neurotoxicity%2520and%2520Gliosis%26jtitle%3DNeuropharmacol%26date%3D2014%26volume%3D81%26spage%3D142%26epage%3D152%26doi%3D10.1016%2Fj.neuropharm.2014.01.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrazoli, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, H. D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nascimento, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira-Giacomelli, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwindt, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britto, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, H.</span></span> <span> </span><span class="NLM_article-title">Brilliant Blue G, But Not Fenofibrate, Treatment Reverts Hemiparkinsonian Behavior and Restores Dopamine Levels in an Animal Model of Parkinson’s Disease</span>. <i>Cell Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.3727/096368917x695227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3727%2F096368917X695227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=28403913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnt1Klsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=669-677&author=E.+G.+Ferrazoliauthor=H.+D.+N.+de+Souzaauthor=I.+C.+Nascimentoauthor=%C3%81.+Oliveira-Giacomelliauthor=T.+T.+Schwindtauthor=L.+R.+Brittoauthor=H.+Ulrich&title=Brilliant+Blue+G%2C+But+Not+Fenofibrate%2C+Treatment+Reverts+Hemiparkinsonian+Behavior+and+Restores+Dopamine+Levels+in+an+Animal+Model+of+Parkinson%E2%80%99s+Disease&doi=10.3727%2F096368917x695227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Brilliant Blue G, But Not Fenofibrate, Treatment Reverts Hemiparkinsonian Behavior and Restores Dopamine Levels in an Animal Model of Parkinson's Disease</span></div><div class="casAuthors">Ferrazoli Eneas G; de Souza Hellio D N; Nascimento Isis C; Oliveira-Giacomelli Agatha; Schwindt Telma T; Britto Luiz R; Ulrich Henning</div><div class="citationInfo"><span class="NLM_cas:title">Cell transplantation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">669-677</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson's disease (PD) is a neurodegenerative disorder, characterized by the loss of dopaminergic neurons in the substantia nigra and their projections to the striatum.  Several processes have been described as potential inducers of the dopaminergic neuron death, such as inflammation, oxidative stress, and mitochondrial dysfunction.  However, the death of dopaminergic neurons seems to be multifactorial, and its cause remains unclear.  ATP-activating purinergic receptors influence various physiological functions in the CNS, including neurotransmission.  Purinergic signaling is also involved in pathological scenarios, where ATP is extensively released and promotes sustained purinergic P2X7 receptor (P2X7R) activation and consequent induction of cell death.  This effect occurs, among other factors, by oxidative stress and during the inflammatory response.  On the other hand, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) is involved in energy metabolism and mitochondrial biogenesis.  Expression and activity upregulation of this protein has been related with reduction of oxidative stress and neuroprotection.  Therefore, P2X7R and PGC-1α are potential targets in the treatment of PD.  Here hemiparkinsonism was induced by unilateral stereotactic injection of 6-OHDA in a rat model.  After 7 days, the establishment of PD was confirmed and followed by treatment with the P2X7R antagonist Brilliant Blue G (BBG) or PGC-1α agonist fenofibrate.  BBG, but not fenofibrate, reverted hemiparkinsonian behavior accompanied by an increase in tyrosine hydroxylase immunoreactivity in the substantia nigra.  Our results suggest that the P2X7R may be a therapeutic target in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxS5Q_1W1J1TAyhZbj3lKdfW6udTcc2eaFxvM5M9TUg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnt1Klsg%253D%253D&md5=c457be4238ee10d3b97e14ae2f8de38d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3727%2F096368917X695227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3727%252F096368917X695227%26sid%3Dliteratum%253Aachs%26aulast%3DFerrazoli%26aufirst%3DE.%2BG.%26aulast%3Dde%2BSouza%26aufirst%3DH.%2BD.%2BN.%26aulast%3DNascimento%26aufirst%3DI.%2BC.%26aulast%3DOliveira-Giacomelli%26aufirst%3D%25C3%2581.%26aulast%3DSchwindt%26aufirst%3DT.%2BT.%26aulast%3DBritto%26aufirst%3DL.%2BR.%26aulast%3DUlrich%26aufirst%3DH.%26atitle%3DBrilliant%2520Blue%2520G%252C%2520But%2520Not%2520Fenofibrate%252C%2520Treatment%2520Reverts%2520Hemiparkinsonian%2520Behavior%2520and%2520Restores%2520Dopamine%2520Levels%2520in%2520an%2520Animal%2520Model%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DCell%2520Transplant.%26date%3D2017%26volume%3D26%26spage%3D669%26epage%3D677%26doi%3D10.3727%2F096368917x695227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzaferri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. G.</span></span> <span> </span><span class="NLM_article-title">P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">93</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2020.00093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3389%2Ffnmol.2020.00093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=32595451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlOltbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=93&author=C.+Ruiz-Ruizauthor=F.+Calzaferriauthor=A.+G.+Garcia&title=P2X7+Receptor+Antagonism+as+a+Potential+Therapy+in+Amyotrophic+Lateral+Sclerosis&doi=10.3389%2Ffnmol.2020.00093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 receptor antagonism as a potential therapy in amyotrophic lateral sclerosis</span></div><div class="casAuthors">Ruiz-Ruiz, Cristina; Calzaferri, Francesco; Garcia, Antonio G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">This review focuses on the purinergic ionotropic receptor P2X7 (P2X7R) as a potential target for developing drugs that delay the onset and/or disease progression in patients with amyotrophic lateral sclerosis (ALS).  Description of clin. and genetic ALS features is followed by an anal. of advantages and drawbacks of transgenic mouse models of disease based on mutations in a bunch of proteins, particularly Cu/Zn superoxide dismutase (SOD1), TAR-DNA binding protein-43 (TDP-43), Fused in Sarcoma/Translocated in Sarcoma (FUS), and Chromosome 9 open reading frame 72 (C9orf72).  Though of limited value, these models are however crit. to study the proof of concept of new compds., before reaching clin. trials.  The authors also provide a description of ALS pathogenesis including protein aggregation, calcium-dependent excitotoxicity, dysfunction of calcium-binding proteins, ultrastructural mitochondrial alterations, disruption of mitochondrial calcium handling, and overprodn. of reactive oxygen species (ROS).  Understanding disease pathogenic pathways may ease the identification of new drug targets.  Subsequently, neuroinflammation linked with P2X7Rs in ALS pathogenesis is described in order to understand the rationale of placing the use of P2X7R antagonists as a new therapeutic pharmacol. approach to ALS.  This is the basis for the hypothesis that a P2X7R blocker could mitigate the neuroinflammatory state, indirectly leading to neuroprotection and higher motoneuron survival in ALS patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA9x1VgsfP-7Vg90H21EOLACvtfcHk0ljXGjlymXZC7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlOltbjK&md5=27333c993e8771e3036baf3adc2b4d06</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2020.00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2020.00093%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz-Ruiz%26aufirst%3DC.%26aulast%3DCalzaferri%26aufirst%3DF.%26aulast%3DGarcia%26aufirst%3DA.%2BG.%26atitle%3DP2X7%2520Receptor%2520Antagonism%2520as%2520a%2520Potential%2520Therapy%2520in%2520Amyotrophic%2520Lateral%2520Sclerosis%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2020%26volume%3D13%26spage%3D93%26doi%3D10.3389%2Ffnmol.2020.00093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yiangou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrenberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessell, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banati, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span> <span> </span><span class="NLM_article-title">COX-2, CB2 and P2X7-Immunoreactivities are Increased in Activated Microglial Cells/Macrophages of Multiple Sclerosis and Amyotrophic Lateral Sclerosis Spinal Cord</span>. <i>BMC Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1186/1471-2377-6-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1186%2F1471-2377-6-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=16512913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BD287mvFCitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=12&author=Y.+Yiangouauthor=P.+Facerauthor=P.+Durrenbergerauthor=I.+P.+Chessellauthor=A.+Naylorauthor=C.+Bountraauthor=R.+R.+Banatiauthor=P.+Anand&title=COX-2%2C+CB2+and+P2X7-Immunoreactivities+are+Increased+in+Activated+Microglial+Cells%2FMacrophages+of+Multiple+Sclerosis+and+Amyotrophic+Lateral+Sclerosis+Spinal+Cord&doi=10.1186%2F1471-2377-6-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord</span></div><div class="casAuthors">Yiangou Yiangos; Facer Paul; Durrenberger Pascal; Chessell Iain P; Naylor Alan; Bountra Chas; Banati Richard R; Anand Praveen</div><div class="citationInfo"><span class="NLM_cas:title">BMC neurology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  While multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are primarily inflammatory and degenerative disorders respectively, there is increasing evidence for shared cellular mechanisms that may affect disease progression, particularly glial responses.  Cyclooxygenase 2 (COX-2) inhibition prolongs survival and cannabinoids ameliorate progression of clinical disease in animal models of ALS and MS respectively, but the mechanism is uncertain.  Therefore, three key molecules known to be expressed in activated microglial cells/macrophages, COX-2, CB2 and P2X7, which plays a role in inflammatory cascades, were studied in MS and ALS post-mortem human spinal cord.  METHODS:  Frozen human post mortem spinal cord specimens, controls (n = 12), ALS (n = 9) and MS (n = 19), were available for study by immunocytochemistry and Western blotting, using specific antibodies to COX-2, CB2 and P2X7, and markers of microglial cells/macrophages (CD 68, ferritin).  In addition, autoradiography for peripheral benzodiazepine binding sites was performed on some spinal cord sections using [3H] (R)-PK11195, a marker of activated microglial cells/macrophages.  Results of immunostaining and Western blotting were quantified by computerized image and optical density analysis respectively.  RESULTS:  In control spinal cord, few small microglial cells/macrophages-like COX-2-immunoreactive cells, mostly bipolar with short processes, were scattered throughout the tissue, whilst MS and ALS specimens had significantly greater density of such cells with longer processes in affected regions, by image analysis.  Inflammatory cell marker CD68-immunoreactivity, [3H] (R)-PK11195 autoradiography, and double-staining against ferritin confirmed increased production of COX-2 by activated microglial cells/macrophages.  An expected 70-kDa band was seen by Western blotting which was significantly increased in MS spinal cord.  There was good correlation between the COX-2 immunostaining and optical density of the COX-2 70-kDa band in the MS group (r = 0.89, P = 0.0011, n = 10).  MS and ALS specimens also had significantly greater density of P2X7 and CB2-immunoreactive microglial cells/macrophages in affected regions.  CONCLUSION:  It is hypothesized that the known increase of lesion-associated extracellular ATP contributes via P2X7 activation to release IL-1 beta which in turn induces COX-2 and downstream pathogenic mediators.  Selective CNS-penetrant COX-2 and P2X7 inhibitors and CB2 specific agonists deserve evaluation in the progression of MS and ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTre1M4-XAP9f6xYuD7tu2XfW6udTcc2eZEpwQD7nsHGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287mvFCitA%253D%253D&md5=33b344093a3cdbab389d158bf731e597</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2F1471-2377-6-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2377-6-12%26sid%3Dliteratum%253Aachs%26aulast%3DYiangou%26aufirst%3DY.%26aulast%3DFacer%26aufirst%3DP.%26aulast%3DDurrenberger%26aufirst%3DP.%26aulast%3DChessell%26aufirst%3DI.%2BP.%26aulast%3DNaylor%26aufirst%3DA.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBanati%26aufirst%3DR.%2BR.%26aulast%3DAnand%26aufirst%3DP.%26atitle%3DCOX-2%252C%2520CB2%2520and%2520P2X7-Immunoreactivities%2520are%2520Increased%2520in%2520Activated%2520Microglial%2520Cells%252FMacrophages%2520of%2520Multiple%2520Sclerosis%2520and%2520Amyotrophic%2520Lateral%2520Sclerosis%2520Spinal%2520Cord%26jtitle%3DBMC%2520Neurol.%26date%3D2006%26volume%3D6%26spage%3D12%26doi%3D10.1186%2F1471-2377-6-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cervetto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattaroli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoli, M.</span></span> <span> </span><span class="NLM_article-title">Motor Neuron Dysfunction in a Mouse Model of ALS: Gender-Dependent Effect of P2X7 Antagonism</span>. <i>Toxicol</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2013.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.tox.2013.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=23583883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVWhtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2013&pages=69-77&author=C.+Cervettoauthor=D.+Frattaroliauthor=G.+Mauraauthor=M.+Marcoli&title=Motor+Neuron+Dysfunction+in+a+Mouse+Model+of+ALS%3A+Gender-Dependent+Effect+of+P2X7+Antagonism&doi=10.1016%2Fj.tox.2013.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Motor neuron dysfunction in a mouse model of ALS: Gender-dependent effect of P2X7 antagonism</span></div><div class="casAuthors">Cervetto, Chiara; Frattaroli, Daniela; Maura, Guido; Marcoli, Manuela</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">69-77</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative progressive currently untreatable disease, characterized by selective motor neuron degeneration; the incidence and prevalence of ALS are greater in men than in women.  Although some important mechanisms that might contribute to the death of motor neurons have been identified, the mechanisms underlying disease pathophysiol. are still uncertain.  In particular, the mechanisms underlying the role of gender in ALS and whether treatments should take into account sexual dimorphism remain only partially understood.  Recently, the P2X7 receptor for ATP was reported to display neurotoxic potential in motor neuron disorders, and antagonism of the receptor has been suggested to be helpful in these disorders.  Studying transgenic mice with superoxide dismutase 1 gene mutations, widely used as model for ALS, may provide a better understanding of pathogenic mechanisms and of toxicity towards motor neurons, also possibly helping to understand whether treatments for ALS should take into account sexual dimorphism.The aim of the work was (1) investigating on gender-dependence of disease progression in the std. model for ALS - the transgenic mouse bearing superoxide dismutase 1 gene mutations - and (2) assessing if a P2X7 receptor antagonist treatment should take into account sexual dimorphism.  We evaluated if gender affect the disease course, the motor performance, the wt. loss and the lifespan in mice overexpressing mutant superoxide dismutase 1.  We measured motor impairment, motor strength and coordination by rotarod and grip strength testing.  Further, we assessed if a treatment with the P2X7 receptor antagonist Brilliant Blue G - a dye that can cross the blood-brain barrier, has low toxicity, and has exhibited therapeutic effects in animal models of neurodegenerative diseases - impact on the disease progression, in male and female ALS mice.  We found that (1) the onset and the disease progression, and the survival were dependent on gender: male performed worst than female, lost body wt. and died before; (2) treatment with the P2X7 receptor antagonist Brilliant Blue G ameliorated the disease progression.  The treatment effect was gender-dependent: amelioration was greater in male than in female.  In conclusion, we suggest that not only pathogenetic mechanism of motor neuron toxicity but also the drug treatment effectiveness may depend on gender; sexual dimorphism should be considered when investigating on ALS treatment efficacy in the ALS animal model.  Our findings also point on the potential relevance of P2X7 receptor antagonism for ALS treatment, and highlight the importance of adopting a sex-specific approach to searching for treatment of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppk8x0xfmJsLVg90H21EOLACvtfcHk0ljXGjlymXZC7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVWhtro%253D&md5=530b1f3a994923f49d7311847c94319d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2013.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2013.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DCervetto%26aufirst%3DC.%26aulast%3DFrattaroli%26aufirst%3DD.%26aulast%3DMaura%26aufirst%3DG.%26aulast%3DMarcoli%26aufirst%3DM.%26atitle%3DMotor%2520Neuron%2520Dysfunction%2520in%2520a%2520Mouse%2520Model%2520of%2520ALS%253A%2520Gender-Dependent%2520Effect%2520of%2520P2X7%2520Antagonism%26jtitle%3DToxicol%26date%3D2013%26volume%3D311%26spage%3D69%26epage%3D77%26doi%3D10.1016%2Fj.tox.2013.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dongol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthbertson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraghty, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sophocleous, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerbury, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluyter, R.</span></span> <span> </span><span class="NLM_article-title">The P2X7 Receptor Antagonist JNJ-47965567 Administered Thrice Weekly from Disease Onset Does not Alter Progression of Amyotrophic Lateral Sclerosis in SOD1(G93A) Mice</span>. <i>Purinergic Signal.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1007/s11302-020-09692-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1007%2Fs11302-020-09692-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=32170537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltFSjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=109-122&author=D.+Lyauthor=A.+Dongolauthor=P.+Cuthbertsonauthor=T.+V.+Guyauthor=N.+J.+Geraghtyauthor=R.+A.+Sophocleousauthor=L.+Sinauthor=B.+J.+Turnerauthor=D.+Watsonauthor=J.+J.+Yerburyauthor=R.+Sluyter&title=The+P2X7+Receptor+Antagonist+JNJ-47965567+Administered+Thrice+Weekly+from+Disease+Onset+Does+not+Alter+Progression+of+Amyotrophic+Lateral+Sclerosis+in+SOD1%28G93A%29+Mice&doi=10.1007%2Fs11302-020-09692-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice.</span></div><div class="casAuthors">Ly, Diane; Dongol, Anjila; Cuthbertson, Peter; Guy, Thomas V.; Geraghty, Nicholas J.; Sophocleous, Reece A.; Sin, Lucia; Turner, Bradley J.; Watson, Debbie; Yerbury, Justin J.; Sluyter, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-122</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The ATP-gated P2X7 ion channel has emerging roles in amyotrophic lateral sclerosis (ALS) progression.  Therefore, the current study aimed to det. whether the CNS-penetrant P2X7 antagonist, JNJ-47965567, could ameliorate ALS progression in SOD1G93A mice.  A flow cytometric assay revealed that JNJ-47965567 impaired ATP-induced cation dye uptake in a concn.-dependent manner in murine J774 macrophages.  Female and male SOD1G93A mice were injected i.p. with JNJ-47965567 (30 mg/kg) or 2-(hydroxypropyl)-beta-cyclodextrin (vehicle control) three times a week from disease onset until end stage, when tissues were collected and studied.  JNJ-47965567 did not impact wt. loss, clin. score, motor (rotarod) coordination or survival compared to control mice.  NanoString anal. revealed altered spinal cord gene expression in JNJ-47965567 mice compared to control mice, but such differences were not confirmed by quant. PCR.  Flow cytometric analyses revealed no differences between treatments in the frequencies or activation status of T cell or dendritic cell subsets in lymphoid tissues or in the concns. of serum cytokines.  Notably, serum IL-27, IFNbetaand IL-10 were present in relatively high concns. compared to other cytokines in both groups.  In conclusion, JNJ-47965567 administered thrice weekly from disease onset did not alter disease progression or mol. and cellular parameters in SOD1G93A mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ2BFtzdZIAbVg90H21EOLACvtfcHk0ljXGjlymXZC7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltFSjurg%253D&md5=8c6e7a8b9740851014d14f34cd4b22e8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11302-020-09692-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-020-09692-4%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DD.%26aulast%3DDongol%26aufirst%3DA.%26aulast%3DCuthbertson%26aufirst%3DP.%26aulast%3DGuy%26aufirst%3DT.%2BV.%26aulast%3DGeraghty%26aufirst%3DN.%2BJ.%26aulast%3DSophocleous%26aufirst%3DR.%2BA.%26aulast%3DSin%26aufirst%3DL.%26aulast%3DTurner%26aufirst%3DB.%2BJ.%26aulast%3DWatson%26aufirst%3DD.%26aulast%3DYerbury%26aufirst%3DJ.%2BJ.%26aulast%3DSluyter%26aufirst%3DR.%26atitle%3DThe%2520P2X7%2520Receptor%2520Antagonist%2520JNJ-47965567%2520Administered%2520Thrice%2520Weekly%2520from%2520Disease%2520Onset%2520Does%2520not%2520Alter%2520Progression%2520of%2520Amyotrophic%2520Lateral%2520Sclerosis%2520in%2520SOD1%2528G93A%2529%2520Mice%26jtitle%3DPurinergic%2520Signal.%26date%3D2020%26volume%3D16%26spage%3D109%26epage%3D122%26doi%3D10.1007%2Fs11302-020-09692-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narcisse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scemes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosnan, C. F.</span></span> <span> </span><span class="NLM_article-title">The Cytokine IL-1beta Transiently Enhances P2X7 Receptor Expression and Function in Human Astrocytes</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1002/glia.20110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fglia.20110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=15472991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BD2crpsF2kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=245-258&author=L.+Narcisseauthor=E.+Scemesauthor=Y.+Zhaoauthor=S.+C.+Leeauthor=C.+F.+Brosnan&title=The+Cytokine+IL-1beta+Transiently+Enhances+P2X7+Receptor+Expression+and+Function+in+Human+Astrocytes&doi=10.1002%2Fglia.20110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes</span></div><div class="casAuthors">Narcisse Leontine; Scemes Eliana; Zhao Yongmei; Lee Sunhee C; Brosnan Celia F</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-58</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">Extracellular nucleotide di- and triphosphates such as ATP and ADP mediate their effects through purinergic P2 receptors belonging to either the metabotropic P2Y or the ionotropic P2X receptor family.  The P2X7R is a unique member of the P2X family, which forms a pore in response to ligand stimulation, regulating cell permeability, cytokine release, and/or apoptosis.  This receptor is also unique in that its affinity for the ligand benzoyl-benzoyl ATP (BzATP) is at least 10-fold greater than that of ATP.  Primary human fetal astrocytes in culture express low-levels of P2X7R mRNA and protein, and BzATP induces only a slight influx in intracellular calcium [Ca2+]i, with little demonstrable effect on gene expression or pore formation in these cells.  We now show that, following treatment with the proinflammatory cytokine IL-1beta, BzATP induces a robust rise in [Ca2+]i with agonist and antagonist profiles indicative of the P2X7R.  IL-1beta also induced the formation of membrane pores as evidenced by the uptake of YO-PRO-1 (375 Da).  Quantitative real-time PCR demonstrated transient upregulation of P2X7R mRNA in IL-1beta-treated cells, while FACS analysis indicated a similar upregulation of P2X7R protein at the cell membrane.  In multiple sclerosis lesions, immunoreactivity for the P2X7R was demonstrated on reactive astrocytes in autopsy brain tissues.  In turn, P2X7R stimulation increased the production of IL-1-induced nitric oxide synthase activity by astrocytes in culture.  These studies suggest that signaling via the P2X7R may modulate the astrocytic response to inflammation in the human central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTisPFlwsWFEa-9TkgmBqTqfW6udTcc2eYXqo_ImOiOibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpsF2kug%253D%253D&md5=67358b4c1409471f1bf905c560c11f27</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fglia.20110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.20110%26sid%3Dliteratum%253Aachs%26aulast%3DNarcisse%26aufirst%3DL.%26aulast%3DScemes%26aufirst%3DE.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DBrosnan%26aufirst%3DC.%2BF.%26atitle%3DThe%2520Cytokine%2520IL-1beta%2520Transiently%2520Enhances%2520P2X7%2520Receptor%2520Expression%2520and%2520Function%2520in%2520Human%2520Astrocytes%26jtitle%3DGlia%26date%3D2005%26volume%3D49%26spage%3D245%26epage%3D258%26doi%3D10.1002%2Fglia.20110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guile, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkinshaw, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Antagonists of the P2X(7) Receptor. From Lead Identification to Drug Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3123</span>– <span class="NLM_lpage">3141</span>, <span class="refDoi"> DOI: 10.1021/jm801528x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801528x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFWnsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3123-3141&author=S.+D.+Guileauthor=L.+Alcarazauthor=T.+N.+Birkinshawauthor=K.+C.+Bowersauthor=M.+R.+Ebdenauthor=M.+Furberauthor=M.+J.+Stocks&title=Antagonists+of+the+P2X%287%29+Receptor.+From+Lead+Identification+to+Drug+Development&doi=10.1021%2Fjm801528x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of the P2X7 Receptor. From Lead Identification to Drug Development</span></div><div class="casAuthors">Guile, Simon D.; Alcaraz, Lilian; Birkinshaw, Timothy N.; Bowers, Keith C.; Ebden, Mark R.; Furber, Mark; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3123-3141</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3KAnZB1iwlLVg90H21EOLACvtfcHk0lh3Ydk5_hoNbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFWnsbw%253D&md5=00684268474169015a967ad8daabec15</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm801528x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801528x%26sid%3Dliteratum%253Aachs%26aulast%3DGuile%26aufirst%3DS.%2BD.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBirkinshaw%26aufirst%3DT.%2BN.%26aulast%3DBowers%26aufirst%3DK.%2BC.%26aulast%3DEbden%26aufirst%3DM.%2BR.%26aulast%3DFurber%26aufirst%3DM.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DAntagonists%2520of%2520the%2520P2X%25287%2529%2520Receptor.%2520From%2520Lead%2520Identification%2520to%2520Drug%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3123%26epage%3D3141%26doi%3D10.1021%2Fjm801528x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murgia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rippa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Virgilio, F.</span></span> <span> </span><span class="NLM_article-title">Oxidized ATP. An Irreversible Inhibitor of the Macrophage Purinergic P2Z Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">8199</span>– <span class="NLM_lpage">8203</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(18)53082-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2FS0021-9258%2818%2953082-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=8463330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK3sXit1Kgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=8199-8203&author=M.+Murgiaauthor=S.+Hanauauthor=P.+Pizzoauthor=M.+Rippaauthor=F.+Di+Virgilio&title=Oxidized+ATP.+An+Irreversible+Inhibitor+of+the+Macrophage+Purinergic+P2Z+Receptor&doi=10.1016%2Fs0021-9258%2818%2953082-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2z receptor</span></div><div class="casAuthors">Murgia, Marta; Hanau, Stefania; Pizzo, Paola; Rippa, Mario; Di Virgilio, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8199-203</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The effects of oxidized ATP (oATP) on responses triggered by extracellular ATP (ATPe) were investigated in the mouse macrophage-like cell line J774.  ATPe induced in this cell line two kinds of responses mediated by two different P2 purinergic receptors: 1) an early permeabilization of the plasma membrane to extracellular hydrophilic markers of Mr ≤900 mediated by P2Z receptors; and 2) a fast mobilization of Ca2+ from intracellular stores mediated by P2Y receptors.  Low oATP concns. (100 μM) completely blocked the first response without affecting the second.  ATPe-dependent cell swelling, vacuolization, and lysis were also inhibited.  Antagonism developed slowly, as an incubation at 37° for at least 2 h in the presence of oATP was needed and was irreversible, thus suggesting that the inhibitory action was due to covalent modification of the receptor.  The rate of hydrolysis of exogenous ATP was slightly decreased by oATP, indicating a minor blocking effect of this compd. on plasma membrane ecto-ATPases in the concn. range tested.  These observations suggest that oATP may be a potentially very useful tool for isolation and characterization of the P2Z purinergic receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxT6uQQf5BrbVg90H21EOLACvtfcHk0lh3Ydk5_hoNbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit1Kgurs%253D&md5=c85fbd67af69bdc020809d3e0f71dcd4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2953082-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252953082-9%26sid%3Dliteratum%253Aachs%26aulast%3DMurgia%26aufirst%3DM.%26aulast%3DHanau%26aufirst%3DS.%26aulast%3DPizzo%26aufirst%3DP.%26aulast%3DRippa%26aufirst%3DM.%26aulast%3DDi%2BVirgilio%26aufirst%3DF.%26atitle%3DOxidized%2520ATP.%2520An%2520Irreversible%2520Inhibitor%2520of%2520the%2520Macrophage%2520Purinergic%2520P2Z%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D8199%26epage%3D8203%26doi%3D10.1016%2Fs0021-9258%2818%2953082-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotrina, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedergaard, M.</span></span> <span> </span><span class="NLM_article-title">Systemic Administration of an Antagonist of the ATP-Sensitive Receptor P2X7 Improves Recovery after Spinal Cord Injury</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">12489</span>– <span class="NLM_lpage">12493</span>, <span class="refDoi"> DOI: 10.1073/pnas.0902531106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1073%2Fpnas.0902531106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19666625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpslCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=12489-12493&author=W.+Pengauthor=M.+L.+Cotrinaauthor=X.+Hanauthor=H.+Yuauthor=L.+Bekarauthor=L.+Blumauthor=T.+Takanoauthor=G.-F.+Tianauthor=S.+A.+Goldmanauthor=M.+Nedergaard&title=Systemic+Administration+of+an+Antagonist+of+the+ATP-Sensitive+Receptor+P2X7+Improves+Recovery+after+Spinal+Cord+Injury&doi=10.1073%2Fpnas.0902531106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic administration of an antagonist of the ATP-sensitive receptor P2x7 improves recovery after spinal cord injury</span></div><div class="casAuthors">Peng, Weiguo; Cotrina, Maria L.; Han, Xiaoning; Yu, Hongmei; Bekar, Lane; Blum, Livnat; Takano, Takahiro; Tian, Guo-Feng; Goldman, Steven A.; Nedergaard, Maiken</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">12489-12493, S12489/1-S12489/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Traumatic spinal cord injury is characterized by an immediate, irreversible loss of tissue at the lesion site, as well as a secondary expansion of tissue damage over time.  Although secondary injury should, in principle, be preventable, no effective treatment options currently exist for patients with acute spinal cord injury (SCI).  Excessive release of ATP by the traumatized tissue, followed by activation of high-affinity P2X7 receptors, has previously been implicated in secondary injury, but no clin. relevant strategy by which to antagonize P2X7 receptors has yet, to the best of our knowledge, been reported.  Here we have tested the neuroprotective effects of a systemically administered P2X7R antagonist, Brilliant blue G (BBG), in a wt.-drop model of thoracic SCI in rats.  Administration of BBG 15 min after injury reduced spinal cord anat. damage and improved motor recovery without evident toxicity.  Moreover, BBG treatment directly reduced local activation of astrocytes and microglia, as well as neutrophil infiltration.  These observations suggest that BBG not only protected spinal cord neurons from purinergic excitotoxicity, but also reduced local inflammatory responses.  Importantly, BBG is a deriv. of a commonly used blue food color (FD&C blue No. 1), which crosses the blood-brain barrier.  Systemic administration of BBG may thus comprise a readily feasible approach by which to treat traumatic SCI in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Yf3jpAKlxbVg90H21EOLACvtfcHk0lhq0LlkoTCMnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpslCisbc%253D&md5=2a6f8aa6f802c71540c74c74fdcc1809</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0902531106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0902531106%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DCotrina%26aufirst%3DM.%2BL.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DBekar%26aufirst%3DL.%26aulast%3DBlum%26aufirst%3DL.%26aulast%3DTakano%26aufirst%3DT.%26aulast%3DTian%26aufirst%3DG.-F.%26aulast%3DGoldman%26aufirst%3DS.%2BA.%26aulast%3DNedergaard%26aufirst%3DM.%26atitle%3DSystemic%2520Administration%2520of%2520an%2520Antagonist%2520of%2520the%2520ATP-Sensitive%2520Receptor%2520P2X7%2520Improves%2520Recovery%2520after%2520Spinal%2520Cord%2520Injury%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D12489%26epage%3D12493%26doi%3D10.1073%2Fpnas.0902531106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lambrecht, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friebe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windscheif, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungardt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bäumert, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spatz-Kümbel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutschler, E.</span></span> <span> </span><span class="NLM_article-title">PPADS, a Novel Functionally Selective Antagonist of P2 Purinoceptor-Mediated Responses</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>217</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(92)90877-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2F0014-2999%2892%2990877-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1330591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK38XltVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=1992&pages=217-219&author=G.+Lambrechtauthor=T.+Friebeauthor=U.+Grimmauthor=U.+Windscheifauthor=E.+Bungardtauthor=C.+Hildebrandtauthor=H.+G.+B%C3%A4umertauthor=G.+Spatz-K%C3%BCmbelauthor=E.+Mutschler&title=PPADS%2C+a+Novel+Functionally+Selective+Antagonist+of+P2+Purinoceptor-Mediated+Responses&doi=10.1016%2F0014-2999%2892%2990877-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses</span></div><div class="casAuthors">Lambrecht, Guenter; Friebe, Thomas; Grimm, Ulrike; Windscheif, Ursula; Bungardt, Edwin; Hildebrandt, Caren; Baeumert, Hans G.; Spatz-Kuembel, Gerhard; Mutschler, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">217-19</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">PPADS (pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid) has been characterized as a novel antagonist which selectively blocks P2 purinoceptor-mediated responses in rabbit vas deferens at pre- and postjunctional sites.  PPADS did not interact with α1-adrenoceptors, muscarinic M2 and M3 receptors, histamine H1 and adenosine A1 receptors.  Thus, PPADS is a novel and useful pharmacol. tool to study cotransmission in tissues where ATP and coexisting neurotransmitters act in concert.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlvJYA0GOQO7Vg90H21EOLACvtfcHk0lhq0LlkoTCMnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltVCqurk%253D&md5=9cc352930fb06540bff8ea1007b9e819</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2892%2990877-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252892%252990877-7%26sid%3Dliteratum%253Aachs%26aulast%3DLambrecht%26aufirst%3DG.%26aulast%3DFriebe%26aufirst%3DT.%26aulast%3DGrimm%26aufirst%3DU.%26aulast%3DWindscheif%26aufirst%3DU.%26aulast%3DBungardt%26aufirst%3DE.%26aulast%3DHildebrandt%26aufirst%3DC.%26aulast%3DB%25C3%25A4umert%26aufirst%3DH.%2BG.%26aulast%3DSpatz-K%25C3%25BCmbel%26aufirst%3DG.%26aulast%3DMutschler%26aufirst%3DE.%26atitle%3DPPADS%252C%2520a%2520Novel%2520Functionally%2520Selective%2520Antagonist%2520of%2520P2%2520Purinoceptor-Mediated%2520Responses%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1992%26volume%3D217%26spage%3D217%26epage%3D219%26doi%3D10.1016%2F0014-2999%2892%2990877-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gargett, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. S.</span></span> <span> </span><span class="NLM_article-title">The Isoquinoline Derivative KN-62 a Potent Antagonist of the P2Z-Receptor of Human Lymphocytes</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0701081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1038%2Fsj.bjp.0701081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=9113369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK2sXjtVGrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1997&pages=1483-1490&author=C.+E.+Gargettauthor=J.+S.+Wiley&title=The+Isoquinoline+Derivative+KN-62+a+Potent+Antagonist+of+the+P2Z-Receptor+of+Human+Lymphocytes&doi=10.1038%2Fsj.bjp.0701081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes</span></div><div class="casAuthors">Gargett, Caroline E.; Wiley, James S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1483-1490</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Extracellular ATP is an agonist for a P2Z receptor on human lymphocytes which mediates opening of a cation-selective ion channel, activation of phospholipase D, and shedding of the adhesion mol., L-selectin, from the cell surface.  The isoquinolinesulfonamides, KN-62, (1-[N, O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine), a selective antagonist of Ca2+/calmodulin-dependent protein kinase II (CaMKII), and KN-04, (N-[1-[N-methyl-p-(5 isoquinoline sulfonyl)benzyl]-2-(4 phenylpiperazine)ethyl]-5-isoquinolinesulfonamide) an inactive analog, were used to investigate the possible role of CaMKII in these diverse effects of extracellular ATP.  KN-62 potently antagonized ATP-stimulated Ba2+ influx into fura-2 loaded human lymphocytes with an IC50 of 12.7 nM and complete inhibition of the flux at a concn. of 500 nM.  Similarly, KN-62 inhibited ATP-stimulated ethidium+ uptake, measured by time resolved flow cytometry, with an IC50 of 13.1 nM and complete inhibition of the flux at 500 nM.  KN-04 antagonized ATP-stimulated Ba2+ influx with an IC50 of 17.3 nM.  Similarly, KN-04 inhibited ATP-stimulated ethidium+ uptake with an IC50 of 37.2 nM.  Both fluxes were completely inhibited at 500 nM KN-04.  ATP-stimulated phospholipase D activity, measured in [3H]-oleic acid-labeled lymphocytes by the transphosphatidylation reaction, was antagonized by KN-62 and KN-04, with 50% inhibition at 5.9 and 9.7 nM, resp.  Both KN-62 and KN-04 inhibited ATP-stimulated shedding of L-selectin, measured by flow cytometric anal. of cell surface L-selectin, with IC50 values of 31.5 and 78.7 nM, resp.  Neither of the isoquinolinesulfonamides (500 nM) inhibited phorbol ester- or ionomycin-stimulated phospholipase D activity or phorbol ester-induced shedding of L-selectin.  The inhibitory effect of KN-62 or KN-04 on P2Z-mediated responses was slow in onset (5 min) and only partially reversed by washing the cells.  Both KN-62 and KN-04 (at 500 nM) had no effect on UTP-stimulated Ca2+ transients in fura-2 loaded human neutrophils, a response which is mediated by the P2Y2 receptor.  Thus, KN-62 and KN-04 are potent antagonists of the P2Z receptor and at nanomolar concns. inhibit all known responses mediated by the P2Z receptor of human lymphocytes.  In contrast, KN-62 and KN-04 had no effect on responses mediated by the P2Y2 receptor of neutrophils.  Moreover, since KN-62 and KN-04 are almost equipotent, the P2Z-mediated responses do not involve CaMKII, but indicate that the isoquinolinesulfonamides are potent and direct inhibitors of the P2Z-receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0JeOmP3i4hbVg90H21EOLACvtfcHk0lhq0LlkoTCMnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtVGrs78%253D&md5=e64ed73e3517f2a1d6caf22c5230979e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0701081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0701081%26sid%3Dliteratum%253Aachs%26aulast%3DGargett%26aufirst%3DC.%2BE.%26aulast%3DWiley%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520Isoquinoline%2520Derivative%2520KN-62%2520a%2520Potent%2520Antagonist%2520of%2520the%2520P2Z-Receptor%2520of%2520Human%2520Lymphocytes%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D120%26spage%3D1483%26epage%3D1490%26doi%3D10.1038%2Fsj.bjp.0701081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship Studies of Pyrimidine-2,4-dione Derivatives as Potent P2X7 Receptor Antagonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.10.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.ejmech.2015.10.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=26547056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyhtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2015&pages=180-193&author=J.-H.+Parkauthor=G.-E.+Leeauthor=S.-D.+Leeauthor=H.+Koauthor=Y.-C.+Kim&title=Structure-Activity+Relationship+Studies+of+Pyrimidine-2%2C4-dione+Derivatives+as+Potent+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.ejmech.2015.10.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists</span></div><div class="casAuthors">Park, Jin-Hee; Lee, Ga-Eun; Lee, So-Deok; Ko, Hyojin; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">180-193</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As an optimization strategy, the flexible structure of KN-62, a known P2X7 receptor antagonist, was converted into conformationally constrained derivs. using pyrimidine-2,4-dione as the core skeleton.  Various modifications at the 4-position of the piperazine moiety of the new lead compd. were performed to improve P2X7 receptor antagonistic activities, which were evaluated in HEK293 cells stably expressing the human P2X7 receptor (EtBr uptake assay) and in THP-1 cells (IL-1β ELISA assay).  According to the results, polycycloalkyl acyl or di-halogenated benzoyl substituents were much more favorable than the original Ph group of KN-62.  Among these compds., I and adamantyl carbonyl derivs. showed potent antagonistic effects, with IC50 values ranging from 10 to 30 nM.  In addn., the in vitro adsorption, distribution, metab., excretion, and toxicity (ADMET) profile of I was detd. to be in acceptable ranges in terms of metabolic stability and cytotoxicity.  These results suggest that pyrimidine-2,4-dione derivs. may be promising novel P2X7 receptor antagonists for the development of anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz1HGQYz3nQrVg90H21EOLACvtfcHk0lj-0yx6S7d_kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyhtb7J&md5=04245371468145d95704d2bd721bb142</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.10.036%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DG.-E.%26aulast%3DLee%26aufirst%3DS.-D.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DStructure-Activity%2520Relationship%2520Studies%2520of%2520Pyrimidine-2%252C4-dione%2520Derivatives%2520as%2520Potent%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D106%26spage%3D180%26epage%3D193%26doi%3D10.1016%2Fj.ejmech.2015.10.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationships of Novel, Substituted 5,6-dihydrodibenzo[a,g]quinolizinium P2X7 Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.11.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2008.11.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19110420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2itb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=954-958&author=G.+E.+Leeauthor=H.-S.+Leeauthor=S.+D.+Leeauthor=J.-H.+Kimauthor=W.-K.+Kimauthor=Y.-C.+Kim&title=Synthesis+and+Structure-Activity+Relationships+of+Novel%2C+Substituted+5%2C6-dihydrodibenzo%5Ba%2Cg%5Dquinolizinium+P2X7+Antagonists&doi=10.1016%2Fj.bmcl.2008.11.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of novel, substituted 5,6-dihydrodibenzo[a,g]quinolizinium P2X7 antagonists</span></div><div class="casAuthors">Lee, Ga Eun; Lee, Ho-Sung; Lee, So Deok; Kim, Jung-Ho; Kim, Won-Ki; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">954-958</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Iminium quaternary protoberberine alkaloids (QPA) have been found to be novel P2X7 antagonists.  To assess their structure-activity relationships, these compds. were modified at their R1 and R2 groups and assayed for their ability to inhibit the 2'(3')-O-(4-benzoylbenzoyl)-ATP (BzATP)-induced uptake of fluorescent ethidium by HEK-293 cells stably expressing the human P2X7 receptor, and their ability to inhibit BzATP-induced IL-1β release by differentiated THP-1 cells.  Compds. I (R1 = Et) and I (R1 = allyl), and esp. compd. II (R1 = Et, R2 = 2-nitro-4,5-dimethoxybenzyl) had potent inhibitory efficacy as P2X7 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEth-82I2_jLVg90H21EOLACvtfcHk0lj-0yx6S7d_kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2itb0%253D&md5=4b2b38a38cf59d4ca688811ee7224b0f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.11.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.11.088%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DG.%2BE.%26aulast%3DLee%26aufirst%3DH.-S.%26aulast%3DLee%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DW.-K.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationships%2520of%2520Novel%252C%2520Substituted%25205%252C6-dihydrodibenzo%255Ba%252Cg%255Dquinolizinium%2520P2X7%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D954%26epage%3D958%26doi%3D10.1016%2Fj.bmcl.2008.11.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reekie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barron, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werry, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and Pharmacological Evaluation of a Novel Series of Adamantyl Cyanoguanidines as P2X7 Receptor Antagonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.02.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.ejmech.2017.02.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=28279849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFymu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=433-439&author=J.+O%E2%80%99Brien-Brownauthor=A.+Jacksonauthor=T.+A.+Reekieauthor=M.+L.+Barronauthor=E.+L.+Werryauthor=P.+Schiaviniauthor=M.+McDonnellauthor=L.+Munozauthor=S.+Wilkinsonauthor=B.+Nollauthor=S.+Wangauthor=M.+Kassiou&title=Discovery+and+Pharmacological+Evaluation+of+a+Novel+Series+of+Adamantyl+Cyanoguanidines+as+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.ejmech.2017.02.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists</span></div><div class="casAuthors">O'Brien-Brown, James; Jackson, Alexander; Reekie, Tristan A.; Barron, Melissa L.; Werry, Eryn L.; Schiavini, Paolo; McDonnell, Michelle; Munoz, Lenka; Wilkinson, Shane; Noll, Benjamin; Wang, Shudong; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">433-439</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Here we report adamantyl cyanoguanidine compds. based on hybrids of the adamantyl amide scaffold reported by AstraZeneca and cyanoguanidine scaffold reported by Abbott Labs.  Compd. 27 displayed five-fold greater inhibitory potency than the lead compd. 2 in both pore-formation and interleukin-1β release assays, while 35-treated mice displayed an antidepressant phenotype in behavioral studies.  This SAR study provides a proof of concept for hybrid compds., which will help in the further development of P2X7R antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDxomOTDTbzbVg90H21EOLACvtfcHk0lj-0yx6S7d_kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFymu7g%253D&md5=b7376e07daebfe826167802febe47f8d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.02.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.02.060%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien-Brown%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DA.%26aulast%3DReekie%26aufirst%3DT.%2BA.%26aulast%3DBarron%26aufirst%3DM.%2BL.%26aulast%3DWerry%26aufirst%3DE.%2BL.%26aulast%3DSchiavini%26aufirst%3DP.%26aulast%3DMcDonnell%26aufirst%3DM.%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DWilkinson%26aufirst%3DS.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520Pharmacological%2520Evaluation%2520of%2520a%2520Novel%2520Series%2520of%2520Adamantyl%2520Cyanoguanidines%2520as%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D130%26spage%3D433%26epage%3D439%26doi%3D10.1016%2Fj.ejmech.2017.02.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merriman, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shum, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabol, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirtz-Brugger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of Novel 4,5-Diarylimidazolines as Potent P2X7 Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.10.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2004.10.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=15603968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFanu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=435-438&author=G.+H.+Merrimanauthor=L.+Maauthor=P.+Shumauthor=D.+McGarryauthor=F.+Volzauthor=J.+S.+Sabolauthor=A.+Grossauthor=Z.+Zhaoauthor=D.+Rampeauthor=L.+Wangauthor=F.+Wirtz-Bruggerauthor=B.+A.+Harrisauthor=D.+Macdonald&title=Synthesis+and+SAR+of+Novel+4%2C5-Diarylimidazolines+as+Potent+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2004.10.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists</span></div><div class="casAuthors">Merriman, Gregory H.; Ma, Liang; Shum, Patrick; McGarry, Daniel; Volz, Frank; Sabol, Jeffrey S.; Gross, Alexandre; Zhao, Zhicheng; Rampe, David; Wang, Lin; Wirtz-Brugger, Friederike; Harris, Bruce A.; Macdonald, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435-438</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 4,5-diarylimidazoline libraries were prepd. using high-throughput solid-phase and microwave techniques.  The compds., e.g., I, were evaluated as P2X7 antagonists and their SAR is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo80lFJGWZNXrVg90H21EOLACvtfcHk0lgnZS2yhJisZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFanu7bP&md5=fd6134b90dc1a22ae66543e375fdc37f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.10.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.10.052%26sid%3Dliteratum%253Aachs%26aulast%3DMerriman%26aufirst%3DG.%2BH.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DShum%26aufirst%3DP.%26aulast%3DMcGarry%26aufirst%3DD.%26aulast%3DVolz%26aufirst%3DF.%26aulast%3DSabol%26aufirst%3DJ.%2BS.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DRampe%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWirtz-Brugger%26aufirst%3DF.%26aulast%3DHarris%26aufirst%3DB.%2BA.%26aulast%3DMacdonald%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520Novel%25204%252C5-Diarylimidazolines%2520as%2520Potent%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D435%26epage%3D438%26doi%3D10.1016%2Fj.bmcl.2004.10.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationships of Pyrazolodiazepine Derivatives as Human P2X7 Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6053</span>– <span class="NLM_lpage">6058</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2009.09.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19800793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GmurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6053-6058&author=J.-Y.+Leeauthor=J.+Yuauthor=W.+J.+Choauthor=H.+Koauthor=Y.-C.+Kim&title=Synthesis+and+Structure-Activity+Relationships+of+Pyrazolodiazepine+Derivatives+as+Human+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2009.09.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists</span></div><div class="casAuthors">Lee, Ju-Yeon; Yu, Juan; Cho, Won Je; Ko, Hyojin; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6053-6058</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Screening of library compds. has yielded pyrazolodiazepine derivs. with P2X7 receptor antagonist activity.  To explore the structure-activity relationships (SAR) of these pyrazolodiazepines as human P2X7 receptor antagonists, derivs. were synthesized by substitutions at positions 4 and 6 of the pyrazolodiazepine skeleton.  Using a 2'(3')-O-(4-benzoylbenzoyl)ATP (BzATP)-induced fluorescent ethidium uptake assay, the activities of these derivs. were tested in HEK-293 cells stably expressing human P2X7 receptors.  Moreover, the effect of these derivs. was assessed by measuring their effect on IL-1β release induced by BzATP-induced activation of differentiated THP-1 cells.  A 2-phenethyl pyrazolodiazepine deriv. with a 1-methyl-1H-3-indolyl ester group at position 6 had fivefold greater activity than the deriv. with a 5-isoquinolinyl ester group.  Moreover, a benzyl moiety at the 4-position had fivefold greater activity than a bicyclic moiety.  The stereochem. effect at C-6 showed a preference for the (R)-isomer.  Among the series of active derivs., I exhibited activity similar to that of the pos. control, KN-62, as shown by the inhibitory effects of IL-1β release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodk4lmKyYRoLVg90H21EOLACvtfcHk0lgnZS2yhJisZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GmurzE&md5=db9d429514bae8e8a6155196960973c5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.053%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.-Y.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DW.%2BJ.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationships%2520of%2520Pyrazolodiazepine%2520Derivatives%2520as%2520Human%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6053%26epage%3D6058%26doi%3D10.1016%2Fj.bmcl.2009.09.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7410</span>– <span class="NLM_lpage">7430</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01690</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01690" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyitLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7410-7430&author=J.-H.+Parkauthor=D.+R.+Williamsauthor=J.-H.+Leeauthor=S.-D.+Leeauthor=J.-H.+Leeauthor=H.+Koauthor=G.-E.+Leeauthor=S.+Kimauthor=J.-M.+Leeauthor=A.+Abdelrahmanauthor=C.+E.+M%C3%BCllerauthor=D.-W.+Jungauthor=Y.-C.+Kim&title=Potent+Suppressive+Effects+of+1-Piperidinylimidazole+Based+Novel+P2X7+Receptor+Antagonists+on+Cancer+Cell+Migration+and+Invasion&doi=10.1021%2Facs.jmedchem.5b01690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion</span></div><div class="casAuthors">Park, Jin-Hee; Williams, Darren R.; Lee, Ji-Hyung; Lee, So-Deok; Lee, Je-Heon; Ko, Hyojin; Lee, Ga-Eun; Kim, Sujin; Lee, Jeong-Min; Abdelrahman, Aliaa; Muller, Christa E.; Jung, Da-Woon; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7410-7430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The P2X7 receptor (P2X7R) has been reported as a key mediator in inflammatory processes and cancer invasion/metastasis.  In this study, we report the discovery of novel P2X7R antagonists and their functional activities as potential antimetastatic agents.  Modifications of the hydantoin core-skeleton and the side chain substituents of the P2X7R antagonist 7 were performed.  The structure-activity relationships (SAR) and optimization demonstrated the importance of the sulfonyl group at the R1 position and the substituted position and overall size of R2 for P2X7R antagonism.  The optimized novel analogs displayed potent P2X7 receptor antagonism (IC50 = 0.11-112 nM) along with significant suppressive effects on IL-1β release (IC50 = 0.32-210 nM).  Moreover, representative antagonists (12g, 13k, and 17d) with imidazole and uracil core skeletons significantly inhibited the invasion of MDA-MB-231 triple neg. breast cancer cells and cancer cell migration in a zebrafish xenograft model, suggesting the potential therapeutic application of these novel P2X7 antagonists to block metastatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCjP9mbj45cbVg90H21EOLACvtfcHk0lgnZS2yhJisZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyitLjP&md5=14aaace65aac1eb7f159f6e18d4fd725</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01690%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DWilliams%26aufirst%3DD.%2BR.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DS.-D.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DG.-E.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.-M.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJung%26aufirst%3DD.-W.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DPotent%2520Suppressive%2520Effects%2520of%25201-Piperidinylimidazole%2520Based%2520Novel%2520P2X7%2520Receptor%2520Antagonists%2520on%2520Cancer%2520Cell%2520Migration%2520and%2520Invasion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7410%26epage%3D7430%26doi%3D10.1021%2Facs.jmedchem.5b01690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, W. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationships of Quinolinone and Quinoline-Based P2X7 Receptor Antagonists and Their anti-Sphere Formation Activities in Glioblastoma Cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.ejmech.2018.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=29649742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1Kgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=462-481&author=S.-H.+Kwakauthor=S.+Shinauthor=J.-H.+Leeauthor=J.-K.+Shimauthor=M.+Kimauthor=S.-D.+Leeauthor=A.+Leeauthor=J.+Baeauthor=J.-H.+Parkauthor=A.+Abdelrahmanauthor=C.+E.+M%C3%BCllerauthor=S.+K.+Choauthor=S.-G.+Kangauthor=M.+A.+Baeauthor=J.+Y.+Yangauthor=H.+Koauthor=W.+A.+Goddardauthor=Y.-C.+Kim&title=Synthesis+and+Structure-Activity+Relationships+of+Quinolinone+and+Quinoline-Based+P2X7+Receptor+Antagonists+and+Their+anti-Sphere+Formation+Activities+in+Glioblastoma+Cells&doi=10.1016%2Fj.ejmech.2018.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells</span></div><div class="casAuthors">Kwak, Seung-Hwa; Shin, Seungheon; Lee, Ji-Hyun; Shim, Jin-Kyoung; Kim, Minjeong; Lee, So-Deok; Lee, Aram; Bae, Jinsu; Park, Jin-Hee; Abdelrahman, Aliaa; Muller, Christa E.; Cho, Steve K.; Kang, Seok-Gu; Bae, Myung Ae; Yang, Jung Yoon; Ko, Hyojin; Goddard, William A., III; Kim, Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">462-481</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A compd. library of quinolinone derivs. identified compd. I [R2 = C6H5(CH2)2CO] as a new P2X7 receptor antagonist was screened.  To optimize its activity, structure-activity relationships (SAR) at three different positions, R1, R2 and R3, of the quinolinone scaffold I [R1 = C(O)2H, C(O)2CH3, CONHCH3, etc.; R2 = (adamantan-1-yl)carbonyl, C6H5CO, C6H5(CH2)2CO, etc.; R3 = 4-F, 4-OCH3, 4-C2H5, etc.] were assessed .  SAR anal. suggested that a carboxylic acid Et ester group at the R1 position, an adamantyl carboxamide group at R2 and a 4-methoxy substitution at the R3 position are the best substituents for the antagonism of P2X7R activity.  However, because most of the quinolinone derivs. showed low inhibitory effects in an IL-1β ELISA assay, the core structure was further modified to a quinoline skeleton with chloride or substituted Ph groups.  The optimized antagonists with the quinoline scaffold included 2-chloro-5-adamantyl-quinoline deriv. II and 2-(4-hydroxymethylphenyl)-5-adamantyl-quinoline deriv. III (R4 = C6H4CH2OH), with IC50 values of 4 and 3nM, resp.  In contrast to the quinolinone derivs., the antagonistic effects of the quinoline compds. II and III (R4 = C6H4CH2OH) were paralleled by their ability to inhibit the release of the pro-inflammatory cytokine, IL-1β, from LPS/IFN-γ/BzATP-stimulated THP-1cells (IC50 of 7 and 12nM, resp.).  In addn., potent P2X7R antagonists significantly inhibited the sphere size of TS15-88 glioblastoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6WGfJxxJ4t7Vg90H21EOLACvtfcHk0lgDYyq-ybYMZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1Kgsb0%253D&md5=f0bd8ff36450d00af3aa950fe1d37b5f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DS.-H.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DShim%26aufirst%3DJ.-K.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DS.-D.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DBae%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DCho%26aufirst%3DS.%2BK.%26aulast%3DKang%26aufirst%3DS.-G.%26aulast%3DBae%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BY.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DGoddard%26aufirst%3DW.%2BA.%26aulast%3DKim%26aufirst%3DY.-C.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationships%2520of%2520Quinolinone%2520and%2520Quinoline-Based%2520P2X7%2520Receptor%2520Antagonists%2520and%2520Their%2520anti-Sphere%2520Formation%2520Activities%2520in%2520Glioblastoma%2520Cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D462%26epage%3D481%26doi%3D10.1016%2Fj.ejmech.2018.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goutopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanabal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seenisamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayadevan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chekler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriraman, V.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR Development of Quinoline Analogs as Novel P2X7 Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1660</span>– <span class="NLM_lpage">1664</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2019.04.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31031055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVOktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1660-1664&author=Y.+Xiaoauthor=S.+Karraauthor=A.+Goutopoulosauthor=N.+T.+Morseauthor=S.+Zhangauthor=M.+Dhanabalauthor=H.+Tianauthor=J.+Seenisamyauthor=J.+Jayadevanauthor=R.+Caldwellauthor=J.+Potnickauthor=M.+Bleichauthor=E.+Cheklerauthor=B.+Shererauthor=V.+Sriraman&title=Synthesis+and+SAR+Development+of+Quinoline+Analogs+as+Novel+P2X7+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2019.04.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR development of quinoline analogs as novel P2X7 receptor antagonists</span></div><div class="casAuthors">Xiao, Yufang; Karra, Srinivasa; Goutopoulos, Andreas; Morse, Noune Tahmassian; Zhang, Susan; Dhanabal, Mohanraj; Tian, Hui; Seenisamy, Jeyaprakashnarayanan; Jayaadevan, Jayashankaran; Caldwell, Richard; Potnick, Justin; Bleich, Matthew; Chekler, Eugene; Sherer, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1660-1664</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The P2X7 receptor (P2X7R) plays an important role in diverse conditions assocd. with tissue damage and inflammation, suggesting that the human P2X7R (hP2X7R) is an attractive therapeutic target.  In the present study, the synthesis and structure-activity relationship (SAR) of a novel series of quinoline derivs. as P2X7R antagonists are described herein.  These compds. exhibited mechanistic activity (YO PRO) in an engineered HEK293 expressing hP2X7R as well as a functional response (IL-1β) in human THP-1 (hTHP-1) cellular assays.  Compd. I was identified as the most promising compd. in this series with excellent cellular potency, low liver microsomal clearance, good permeability and low efflux ratio.  In addn., this compd. also displayed good pharmacokinetic properties and acceptable brain permeability (Kp,uu of 0.37).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbtcX1ZlznvrVg90H21EOLACvtfcHk0lgDYyq-ybYMZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVOktLc%253D&md5=348c4bedb949191227b38730e4c5b1ae</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.033%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKarra%26aufirst%3DS.%26aulast%3DGoutopoulos%26aufirst%3DA.%26aulast%3DMorse%26aufirst%3DN.%2BT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DDhanabal%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DSeenisamy%26aufirst%3DJ.%26aulast%3DJayadevan%26aufirst%3DJ.%26aulast%3DCaldwell%26aufirst%3DR.%26aulast%3DPotnick%26aufirst%3DJ.%26aulast%3DBleich%26aufirst%3DM.%26aulast%3DChekler%26aufirst%3DE.%26aulast%3DSherer%26aufirst%3DB.%26aulast%3DSriraman%26aufirst%3DV.%26atitle%3DSynthesis%2520and%2520SAR%2520Development%2520of%2520Quinoline%2520Analogs%2520as%2520Novel%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1660%26epage%3D1664%26doi%3D10.1016%2Fj.bmcl.2019.04.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faria, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Hiller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resende, J. A. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diogo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Ranke, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Luna Martins, D.</span></span> <span> </span><span class="NLM_article-title">Arylboronic Acids Inhibit P2X7 Receptor Function and the Acute Inflammatory Response</span>. <i>J. Bioenerg. Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1007/s10863-019-09802-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1007%2Fs10863-019-09802-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31256283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yktr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=277-290&author=R.+X.+Fariaauthor=N.+de+Jesus+Hillerauthor=J.+P.+Sallesauthor=J.+A.+L.+C.+Resendeauthor=R.+T.+Diogoauthor=N.+L.+von+Rankeauthor=M.+L.+Belloauthor=C.+R.+Rodriguesauthor=H.+C.+Castroauthor=D.+de+Luna+Martins&title=Arylboronic+Acids+Inhibit+P2X7+Receptor+Function+and+the+Acute+Inflammatory+Response&doi=10.1007%2Fs10863-019-09802-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response</span></div><div class="casAuthors">Faria, Robson Xavier; de Jesus Hiller, Noemi; Salles, Juliana Pimenta; Resende, Jackson Antonio Lamounier Camargos; Diogo, Roberta Tosta; von Ranke, Natalia Lidmar; Bello, Murilo Lamim; Rodrigues, Carlos Rangel; Castro, Helena Carla; de Luna Martins, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bioenergetics and Biomembranes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-290</span>CODEN:
                <span class="NLM_cas:coden">JBBID4</span>;
        ISSN:<span class="NLM_cas:issn">0145-479X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The P2X7 receptor (P2X7R) is an ion channel which is activated by interactions with the extracellular ATP mols.  The mol. complex P2X7R/ATP induces conformational changes in the protein subunits, opening a pore in the ion channel macromol. structure.  Currently, the P2X7R has been studied as a potential therapeutic target of anti-inflammatory drugs.  Based on this, a series of eight boronic acids (NO) analogs were evaluated on the biol. effect of this pharmacophoric group on the human and murine P2X7R.  The boronic acids derivs. NO-01 and NO-12 inhibited in vitro human and murine P2X7R function.  These analogs compds. showed effect better than compd. BBG and similar to inhibitor A740003 for inhibiting dye uptake, in vitro IL-1β release and ATP-induced paw edema in vivo.  In both, in vitro and in vivo assays the compd. NO-01 showed to be the hit compd. in the present series of the arylboronic acids analogs.  The mol. docking suggests that the NO derivs. bind into the upper body domain of the P2X7 pore and that the main intermol. interaction with the two most active NO derivs. occur with the residues Phe 95, 103 and 293 by hydrophobic interactions and with Leu97, Gln98 and Ser101 by hydrogen bonds..  These results indicate that the boronic acid deriv. NO-01 shows the lead compd. characteristics to be used as a scaffold structure to the development of new P2X7R inhibitors with anti-inflammatory action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRTu0LGKMrfLVg90H21EOLACvtfcHk0lgDYyq-ybYMZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yktr%252FI&md5=890cbcd9a93fff4b98c68d8c73778772</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10863-019-09802-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10863-019-09802-x%26sid%3Dliteratum%253Aachs%26aulast%3DFaria%26aufirst%3DR.%2BX.%26aulast%3Dde%2BJesus%2BHiller%26aufirst%3DN.%26aulast%3DSalles%26aufirst%3DJ.%2BP.%26aulast%3DResende%26aufirst%3DJ.%2BA.%2BL.%2BC.%26aulast%3DDiogo%26aufirst%3DR.%2BT.%26aulast%3Dvon%2BRanke%26aufirst%3DN.%2BL.%26aulast%3DBello%26aufirst%3DM.%2BL.%26aulast%3DRodrigues%26aufirst%3DC.%2BR.%26aulast%3DCastro%26aufirst%3DH.%2BC.%26aulast%3Dde%2BLuna%2BMartins%26aufirst%3DD.%26atitle%3DArylboronic%2520Acids%2520Inhibit%2520P2X7%2520Receptor%2520Function%2520and%2520the%2520Acute%2520Inflammatory%2520Response%26jtitle%3DJ.%2520Bioenerg.%2520Biomembr.%26date%3D2019%26volume%3D51%26spage%3D277%26epage%3D290%26doi%3D10.1007%2Fs10863-019-09802-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzaga, D. T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Ranke, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinho, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, C. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leme, R. P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mafra, J. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, L. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelz, L. V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boechat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faria, R. X.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Biological Evaluation, and Molecular Modeling Studies of New Thiadiazole Derivatives as Potent P2X7 Receptor Inhibitors</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">261</span>, <span class="refDoi"> DOI: 10.3389/fchem.2019.00261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3389%2Ffchem.2019.00261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=31134177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKisbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=261&author=D.+T.+G.+Gonzagaauthor=F.+H.+Oliveiraauthor=N.+L.+von+Rankeauthor=G.+Q.+Pinhoauthor=J.+P.+Sallesauthor=M.+L.+Belloauthor=C.+R.+Rodriguesauthor=H.+C.+Castroauthor=H.+de+Souzaauthor=C.+R.+C.+Reisauthor=R.+P.+P.+Lemeauthor=J.+C.+M.+Mafraauthor=L.+C.+S.+Pinheiroauthor=L.+V.+B.+Hoelzauthor=N.+Boechatauthor=R.+X.+Faria&title=Synthesis%2C+Biological+Evaluation%2C+and+Molecular+Modeling+Studies+of+New+Thiadiazole+Derivatives+as+Potent+P2X7+Receptor+Inhibitors&doi=10.3389%2Ffchem.2019.00261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation, and molecular modeling studies of new thiadiazole derivatives as potent P2X7 receptor inhibitors</span></div><div class="casAuthors">Gonzaga, Daniel T. G.; Oliveira, Felipe H.; von Ranke, N. L.; Pinho, G. Q.; Salles, Juliana P.; Bello, Murilo L.; Rodrigues, Carlos R.; Castro, Helena C.; de Souza, Hellen V. C. M.; Reis, Caroline R. C.; Leme, Rennan P. P.; Mafra, Joao C. M.; Pinheiro, Luiz C. S.; Hoelz, Lucas V. B.; Boechat, Nubia; Faria, Robson X.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">261</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Twenty new 2-(1H-pyrazol-1-yl)-1,3,4-thiadiazole analogs were synthesized to develop P2X7 receptor (P2X7R) inhibitors.  P2X7R inhibition in vitro was evaluated in mouse peritoneal macrophages, HEK-293 cells transfected with hP2X7R (dye uptake assay), and THP-1 cells (IL-1β release assay).  The 1-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-pyrazol-5-amine derivs. 9b, 9c, and 9f, and 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-(4-fluorophenyl)-1,3,4-thiadiazole (11c) showed inhibitory effects with IC50 values ranging from 16 to 122 nM for reduced P2X7R-mediated dye uptake and 20 to 300 nM for IL-1β release.  In addn., the in vitro ADMET profile of the four most potent derivs. was detd. to be in acceptable ranges concerning metabolic stability and cytotoxicity.  Mol. docking and mol. dynamics simulation studies of the mol. complexes human P2X7R/9f and murine P2X7R/9f indicated the putative intermol. interactions.  Compd. 9f showed affinity mainly for the Arg268, Lys377, and Asn266 residues.  These results suggest that 2-(1H-pyrazol-1-yl)-1,3,4-thiadiazole analogs may be promising novel P2X7R inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryovcXZRpZIrVg90H21EOLACvtfcHk0liXNgj4Kk9CCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKisbnL&md5=645c4a32b5a1e66887a6aa773f81ba10</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2019.00261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2019.00261%26sid%3Dliteratum%253Aachs%26aulast%3DGonzaga%26aufirst%3DD.%2BT.%2BG.%26aulast%3DOliveira%26aufirst%3DF.%2BH.%26aulast%3Dvon%2BRanke%26aufirst%3DN.%2BL.%26aulast%3DPinho%26aufirst%3DG.%2BQ.%26aulast%3DSalles%26aufirst%3DJ.%2BP.%26aulast%3DBello%26aufirst%3DM.%2BL.%26aulast%3DRodrigues%26aufirst%3DC.%2BR.%26aulast%3DCastro%26aufirst%3DH.%2BC.%26aulast%3Dde%2BSouza%26aufirst%3DH.%26aulast%3DReis%26aufirst%3DC.%2BR.%2BC.%26aulast%3DLeme%26aufirst%3DR.%2BP.%2BP.%26aulast%3DMafra%26aufirst%3DJ.%2BC.%2BM.%26aulast%3DPinheiro%26aufirst%3DL.%2BC.%2BS.%26aulast%3DHoelz%26aufirst%3DL.%2BV.%2BB.%26aulast%3DBoechat%26aufirst%3DN.%26aulast%3DFaria%26aufirst%3DR.%2BX.%26atitle%3DSynthesis%252C%2520Biological%2520Evaluation%252C%2520and%2520Molecular%2520Modeling%2520Studies%2520of%2520New%2520Thiadiazole%2520Derivatives%2520as%2520Potent%2520P2X7%2520Receptor%2520Inhibitors%26jtitle%3DFront.%2520Chem.%26date%3D2019%26volume%3D7%26spage%3D261%26doi%3D10.3389%2Ffchem.2019.00261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Medrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly-Roberts, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florjancic, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namovic, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltynek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, W. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in Vitro Activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine P2X(7) Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3297</span>– <span class="NLM_lpage">3300</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2011.04.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=21536435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsVOgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3297-3300&author=A.+Perez-Medranoauthor=D.+L.+Donnelly-Robertsauthor=A.+S.+Florjancicauthor=D.+W.+Nelsonauthor=T.+Liauthor=M.+T.+Namovicauthor=S.+Peddiauthor=C.+R.+Faltynekauthor=M.+F.+Jarvisauthor=W.+A.+Carroll&title=Synthesis+and+in+Vitro+Activity+of+N-benzyl-1-%282%2C3-dichlorophenyl%29-1H-tetrazol-5-amine+P2X%287%29+Antagonists&doi=10.1016%2Fj.bmcl.2011.04.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine as P2X7 antagonists</span></div><div class="casAuthors">Perez-Medrano, Arturo; Donnelly-Roberts, Diana L.; Florjancic, Alan S.; Nelson, Derek W.; Li, Tongmei; Namovic, Marian T.; Peddi, Sridhar; Faltynek, Connie R.; Jarvis, Michael F.; Carroll, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3297-3300</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis and biol. evaluation of a novel class of substituted N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine derivs. resulted in the identification of potent P2X7 antagonists.  These compds. were assayed for activity at both the human and rat P2X7 receptors.  On the benzyl moiety, a variety of functional groups were tolerated, including both electron-withdrawing and electron-donating substituents.  Ortho-substitution on the benzyl group provided the greatest potency.  The ortho-substituted analogs showed approx. 2.5-fold greater potency at human compared to rat P2X7 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp91q681OLzurVg90H21EOLACvtfcHk0liXNgj4Kk9CCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsVOgsL4%253D&md5=1bdcd33feb9fb3cd1b39e15d199b5d9a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Medrano%26aufirst%3DA.%26aulast%3DDonnelly-Roberts%26aufirst%3DD.%2BL.%26aulast%3DFlorjancic%26aufirst%3DA.%2BS.%26aulast%3DNelson%26aufirst%3DD.%2BW.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DNamovic%26aufirst%3DM.%2BT.%26aulast%3DPeddi%26aufirst%3DS.%26aulast%3DFaltynek%26aufirst%3DC.%2BR.%26aulast%3DJarvis%26aufirst%3DM.%2BF.%26aulast%3DCarroll%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%2520and%2520in%2520Vitro%2520Activity%2520of%2520N-benzyl-1-%25282%252C3-dichlorophenyl%2529-1H-tetrazol-5-amine%2520P2X%25287%2529%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3297%26epage%3D3300%26doi%3D10.1016%2Fj.bmcl.2011.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00089</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00089" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=671-676&author=B.+M.+Savallauthor=D.+Wuauthor=M.+De+Angelisauthor=N.+I.+Carruthersauthor=H.+Aoauthor=Q.+Wangauthor=B.+Lordauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Synthesis%2C+SAR%2C+and+Pharmacological+Characterization+of+Brain+Penetrant+P2X7+Receptor+Antagonists&doi=10.1021%2Facsmedchemlett.5b00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists</span></div><div class="casAuthors">Savall, Brad M.; Wu, Duncan; De Angelis, Meri; Carruthers, Nicholas I.; Ao, Hong; Wang, Qi; Lord, Brian; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-676</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and SAR of 1,2,3-triazolopiperidines, e.g., I, as a novel series of potent, brain penetrant P2X7 antagonists was described.  Initial efforts yielded a series of potent human P2X7R antagonists with moderate to weak rodent potency, some CYP inhibition, poor metabolic stability, and low soly.  Further work in this series, which focused on the SAR of the N-linked heterocycle, not only increased the potency at the human P2X7R but also provided compds. with good potency at the rat P2X7R.  These efforts eventually delivered a potent rat and human P2X7R antagonist with good physicochem. properties, an excellent pharmacokinetic profile, good partitioning into the CNS, and demonstrated in vivo target engagement after oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfae7yM_oV1bVg90H21EOLACvtfcHk0liXNgj4Kk9CCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGisbo%253D&md5=11d93747bb8b71d0ca108a3946e3a758</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00089%26sid%3Dliteratum%253Aachs%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%252C%2520SAR%252C%2520and%2520Pharmacological%2520Characterization%2520of%2520Brain%2520Penetrant%2520P2X7%2520Receptor%2520Antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D671%26epage%3D676%26doi%3D10.1021%2Facsmedchemlett.5b00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beswick, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billinton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collis, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonfria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejeune, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livermore, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medhurst, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingsby, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, J. G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, D. S.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structure-Activity Relationships of a Series of Pyroglutamic Acid Amide Antagonists of the P2X7 Receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5080</span>– <span class="NLM_lpage">5084</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.bmcl.2010.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=20673717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5080-5084&author=M.+H.+Abdiauthor=P.+J.+Beswickauthor=A.+Billintonauthor=L.+J.+Chambersauthor=A.+Charltonauthor=S.+D.+Collinsauthor=K.+L.+Collisauthor=D.+K.+Deanauthor=E.+Fonfriaauthor=R.+J.+Gleaveauthor=C.+L.+Lejeuneauthor=D.+G.+Livermoreauthor=S.+J.+Medhurstauthor=A.+D.+Michelauthor=A.+P.+Mosesauthor=L.+Pageauthor=S.+Patelauthor=S.+A.+Romanauthor=S.+Sengerauthor=B.+Slingsbyauthor=J.+G.+A.+Steadmanauthor=A.+J.+Stevensauthor=D.+S.+Walter&title=Discovery+and+Structure-Activity+Relationships+of+a+Series+of+Pyroglutamic+Acid+Amide+Antagonists+of+the+P2X7+Receptor&doi=10.1016%2Fj.bmcl.2010.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor</span></div><div class="casAuthors">Abdi, Muna H.; Beswick, Paul J.; Billinton, Andy; Chambers, Laura J.; Charlton, Andrew; Collins, Sue D.; Collis, Katharine L.; Dean, David K.; Fonfria, Elena; Gleave, Robert J.; Lejeune, Clarisse L.; Livermore, David G.; Medhurst, Stephen J.; Michel, Anton D.; Moses, Andrew P.; Page, Lee; Patel, Sadhana; Roman, Shilina A.; Senger, Stefan; Slingsby, Brian; Steadman, Jon G. A.; Stevens, Alexander J.; Walter, Daryl S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5080-5084</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A computational lead-hopping exercise identified compd. 4 (I) as a structurally distinct P2X7 receptor antagonist.  Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogs of 4 were investigated and compd. 31 was identified as a potent P2X7 antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDVRhpk7pAFrVg90H21EOLACvtfcHk0lhj_5vhr5-LZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehsbbE&md5=7ffef75090b4baf3bba946701ec9dd8f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DAbdi%26aufirst%3DM.%2BH.%26aulast%3DBeswick%26aufirst%3DP.%2BJ.%26aulast%3DBillinton%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DL.%2BJ.%26aulast%3DCharlton%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DS.%2BD.%26aulast%3DCollis%26aufirst%3DK.%2BL.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DFonfria%26aufirst%3DE.%26aulast%3DGleave%26aufirst%3DR.%2BJ.%26aulast%3DLejeune%26aufirst%3DC.%2BL.%26aulast%3DLivermore%26aufirst%3DD.%2BG.%26aulast%3DMedhurst%26aufirst%3DS.%2BJ.%26aulast%3DMichel%26aufirst%3DA.%2BD.%26aulast%3DMoses%26aufirst%3DA.%2BP.%26aulast%3DPage%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DRoman%26aufirst%3DS.%2BA.%26aulast%3DSenger%26aufirst%3DS.%26aulast%3DSlingsby%26aufirst%3DB.%26aulast%3DSteadman%26aufirst%3DJ.%2BG.%2BA.%26aulast%3DStevens%26aufirst%3DA.%2BJ.%26aulast%3DWalter%26aufirst%3DD.%2BS.%26atitle%3DDiscovery%2520and%2520Structure-Activity%2520Relationships%2520of%2520a%2520Series%2520of%2520Pyroglutamic%2520Acid%2520Amide%2520Antagonists%2520of%2520the%2520P2X7%2520Receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5080%26epage%3D5084%26doi%3D10.1016%2Fj.bmcl.2010.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honore, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly-Roberts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namovic, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusa, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvin, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medrano, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltynek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, M. F.</span></span> <span> </span><span class="NLM_article-title">A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">1376</span>– <span class="NLM_lpage">1385</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.111559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1124%2Fjpet.106.111559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=16982702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2006&pages=1376-1385&author=P.+Honoreauthor=D.+Donnelly-Robertsauthor=M.+T.+Namovicauthor=G.+Hsiehauthor=C.+Z.+Zhuauthor=J.+P.+Mikusaauthor=G.+Hernandezauthor=C.+Zhongauthor=D.+M.+Gauvinauthor=P.+Chandranauthor=R.+Harrisauthor=A.+P.+Medranoauthor=W.+Carrollauthor=K.+Marshauthor=J.+P.+Sullivanauthor=C.+R.+Faltynekauthor=M.+F.+Jarvis&title=A-740003+%5BN-%281-%7B%5B%28cyanoimino%29%285-quinolinylamino%29+methyl%5Damino%7D-2%2C2-dimethylpropyl%29-2-%283%2C4-dimethoxyphenyl%29acetamide%5D%2C+a+Novel+and+Selective+P2X7+Receptor+Antagonist%2C+Dose-Dependently+Reduces+Neuropathic+Pain+in+the+Rat&doi=10.1124%2Fjpet.106.111559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat</span></div><div class="casAuthors">Honore, Prisca; Donnelly-Roberts, Diana; Namovic, Marian T.; Hsieh, Gin; Zhu, Chang Z.; Mikusa, Joe P.; Hernandez, Gricelda; Zhong, Chengmin; Gauvin, Donna M.; Chandran, Prasant; Harris, Richard; Medrano, Arturo Perez; Carroll, William; Marsh, Kennan; Sullivan, James P.; Faltynek, Connie R.; Jarvis, Michael F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1376-1385</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">ATP-sensitive P2X7 receptors are localized on cells of immunol. origin including glial cells in the central nervous system.  Activation of P2X7 receptors leads to rapid changes in intracellular calcium concns., release of the proinflammatory cytokine interleukin-1β (IL-1β), and following prolonged agonist exposure, cytolytic plasma membrane pore formation.  P2X7 knockout mice show reduced inflammation as well as decreased nociceptive sensitivity following peripheral nerve injury.  A-740003 (N-(1-{[(cyanoimino)(5-quinolinylamino) methyl] amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) is a novel competitive antagonist of P2X7 receptors (IC50 values = 40 nM for human and 18 nM for rat) as measured by agonist-stimulated changes in intracellular calcium concns.  A-740003 showed weak or no activity (IC50 > 10 μM) at other P2 receptors and an array of other neurotransmitter and peptide receptors, ion channels, reuptake sites, and enzymes.  A-740003 potently blocked agonist-evoked IL-1β release (IC50 = 156 nM) and pore formation (IC50 = 92 nM) in differentiated human THP-1 cells.  Systemic administration of A-740003 produced dose-dependent antinociception in a spinal nerve ligation model (ED50 = 19 mg/kg i.p.) in the rat.  A-740003 also attenuated tactile allodynia in two other models of neuropathic pain, chronic constriction injury of the sciatic nerve and vincristine-induced neuropathy.  In addn., A-740003 effectively reduced thermal hyperalgesia obsd. following intraplantar administration of carrageenan or complete Freund's adjuvant (ED50 = 38-54 mg/kg i.p.).  A-740003 was ineffective in attenuating acute thermal nociception in normal rats and did not alter motor performance at analgesic doses.  These data demonstrate that selective blockade of P2X7 receptors in vivo produces significant antinociception in animal models of neuropathic and inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKvrIcS3OJT7Vg90H21EOLACvtfcHk0lj9nDIyxW2Wzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltLrP&md5=a7d3bfa9cfc728ab7730ec7b351ecb1d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.111559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.111559%26sid%3Dliteratum%253Aachs%26aulast%3DHonore%26aufirst%3DP.%26aulast%3DDonnelly-Roberts%26aufirst%3DD.%26aulast%3DNamovic%26aufirst%3DM.%2BT.%26aulast%3DHsieh%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DC.%2BZ.%26aulast%3DMikusa%26aufirst%3DJ.%2BP.%26aulast%3DHernandez%26aufirst%3DG.%26aulast%3DZhong%26aufirst%3DC.%26aulast%3DGauvin%26aufirst%3DD.%2BM.%26aulast%3DChandran%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DMedrano%26aufirst%3DA.%2BP.%26aulast%3DCarroll%26aufirst%3DW.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DFaltynek%26aufirst%3DC.%2BR.%26aulast%3DJarvis%26aufirst%3DM.%2BF.%26atitle%3DA-740003%2520%255BN-%25281-%257B%255B%2528cyanoimino%2529%25285-quinolinylamino%2529%2520methyl%255Damino%257D-2%252C2-dimethylpropyl%2529-2-%25283%252C4-dimethoxyphenyl%2529acetamide%255D%252C%2520a%2520Novel%2520and%2520Selective%2520P2X7%2520Receptor%2520Antagonist%252C%2520Dose-Dependently%2520Reduces%2520Neuropathic%2520Pain%2520in%2520the%2520Rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D319%26spage%3D1376%26epage%3D1385%26doi%3D10.1124%2Fjpet.106.111559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly-Roberts, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namovic, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidyanathan, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Medrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, M. F.</span></span> <span> </span><span class="NLM_article-title">[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a Novel, potent, and selective antagonist radioligand for P2X7 receptors</span>. <i>Neuropharmacol</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.neuropharm.2008.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=18602931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252Fksl2luw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2009&pages=223-229&author=D.+L.+Donnelly-Robertsauthor=M.+T.+Namovicauthor=B.+Surberauthor=S.+X.+Vaidyanathanauthor=A.+Perez-Medranoauthor=Y.+Wangauthor=W.+A.+Carrollauthor=M.+F.+Jarvis&title=%5B3H%5DA-804598+%28%5B3H%5D2-cyano-1-%5B%281S%29-1-phenylethyl%5D-3-quinolin-5-ylguanidine%29+is+a+Novel%2C+potent%2C+and+selective+antagonist+radioligand+for+P2X7+receptors&doi=10.1016%2Fj.neuropharm.2008.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors</span></div><div class="casAuthors">Donnelly-Roberts Diana L; Namovic Marian T; Surber Bruce; Vaidyanathan Srirajan X; Perez-Medrano Arturo; Wang Ying; Carroll William A; Jarvis Michael F</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-9</span>
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    </div><div class="casAbstract">ATP-sensitive P2X7 receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.  Activation of P2X7 receptors leads to rapid changes in intracellular calcium concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.  Data from gene knockout studies and recently described selective antagonists indicate a role for P2X7 receptor activation in inflammation and pain.  While several species selective P2X7 antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.  A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.  A-804598 was tritiated ([3H]A-804598; 8.1Ci/mmol) and utilized to study recombinant rat P2X7 receptors expressed in 1321N1 cells. [3H]A-804598 labeled a single class of high affinity binding sites (Kd=2.4 nM and apparent Bmax=0.56 pmol/mg).  No specific binding was observed in untransfected 1321N1 cells.  The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05).  These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQY3sRlI5qwG8ERNNga7KD-fW6udTcc2eb-yO6oI8RFFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252Fksl2luw%253D%253D&md5=3d983a02c52691e211b092e7036b9982</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly-Roberts%26aufirst%3DD.%2BL.%26aulast%3DNamovic%26aufirst%3DM.%2BT.%26aulast%3DSurber%26aufirst%3DB.%26aulast%3DVaidyanathan%26aufirst%3DS.%2BX.%26aulast%3DPerez-Medrano%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCarroll%26aufirst%3DW.%2BA.%26aulast%3DJarvis%26aufirst%3DM.%2BF.%26atitle%3D%255B3H%255DA-804598%2520%2528%255B3H%255D2-cyano-1-%255B%25281S%2529-1-phenylethyl%255D-3-quinolin-5-ylguanidine%2529%2520is%2520a%2520Novel%252C%2520potent%252C%2520and%2520selective%2520antagonist%2520radioligand%2520for%2520P2X7%2520receptors%26jtitle%3DNeuropharmacol%26date%3D2009%26volume%3D56%26spage%3D223%26epage%3D229%26doi%3D10.1016%2Fj.neuropharm.2008.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrovian, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soyode-Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepassi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=207-223&author=C.+C.+Chrovianauthor=A.+Soyode-Johnsonauthor=A.+A.+Petersonauthor=C.+F.+Gelinauthor=X.+Dengauthor=C.+A.+Dvorakauthor=N.+I.+Carruthersauthor=B.+Lordauthor=I.+Fraserauthor=L.+Aluisioauthor=K.+J.+Coeauthor=B.+Scottauthor=T.+Koudriakovaauthor=F.+Schoetensauthor=K.+Sepassiauthor=D.+J.+Gallacherauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=A+Dipolar+Cycloaddition+Reaction+To+Access+6-Methyl-4%2C5%2C6%2C7-tetrahydro-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-c%5Dpyridines+Enables+the+Discovery+Synthesis+and+Preclinical+Profiling+of+a+P2X7+Antagonist+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b01279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate</span></div><div class="casAuthors">Chrovian, Christa C.; Soyode-Johnson, Akinola; Peterson, Alexander A.; Gelin, Christine F.; Deng, Xiaohu; Dvorak, Curt A.; Carruthers, Nicholas I.; Lord, Brian; Fraser, Ian; Aluisio, Leah; Coe, Kevin J.; Scott, Brian; Koudriakova, Tatiana; Schoetens, Freddy; Sepassi, Kia; Gallacher, David J.; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">207-223</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A single pot dipolar cycloaddn. reaction/Cope elimination sequence was developed to access novel 1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridine P2X7 antagonists that contain a synthetically challenging chiral center.  The structure-activity relationships of the new compds. are described.  Two of these compds., (S)-(2-fluoro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone (I) and (S)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone (II), were found to have robust P2X7 receptor occupancy at low doses in rat with ED50 values of 0.06 and 0.07 mg/kg, resp.  Compd. II had notable soly. compared to I and showed good tolerability in preclin. species.  Compd. II was chosen as a clin. candidate for advancement into phase I clin. trials to assess safety and tolerability in healthy human subjects prior to the initiation of proof of concept studies for the treatment of mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0Y2r79JhbbVg90H21EOLACvtfcHk0lh3PQaVKiTO2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrnN&md5=a97dfbda53f249894c7e4ef409601c95</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01279%26sid%3Dliteratum%253Aachs%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DSoyode-Johnson%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%2BA.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DSepassi%26aufirst%3DK.%26aulast%3DGallacher%26aufirst%3DD.%2BJ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DA%2520Dipolar%2520Cycloaddition%2520Reaction%2520To%2520Access%25206-Methyl-4%252C5%252C6%252C7-tetrahydro-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-c%255Dpyridines%2520Enables%2520the%2520Discovery%2520Synthesis%2520and%2520Preclinical%2520Profiling%2520of%2520a%2520P2X7%2520Antagonist%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D207%26epage%3D223%26doi%3D10.1021%2Facs.jmedchem.7b01279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceusters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoetens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenden, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span> <span> </span><span class="NLM_article-title">4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4572</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Wms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4559-4572&author=M.+A.+Letavicauthor=B.+M.+Savallauthor=B.+D.+Allisonauthor=L.+Aluisioauthor=J.+I.+Andresauthor=M.+De+Angelisauthor=H.+Aoauthor=D.+A.+Beauchampauthor=P.+Bonaventureauthor=S.+Bryantauthor=N.+I.+Carruthersauthor=M.+Ceustersauthor=K.+J.+Coeauthor=C.+A.+Dvorakauthor=I.+C.+Fraserauthor=C.+F.+Gelinauthor=T.+Koudriakovaauthor=J.+Liangauthor=B.+Lordauthor=T.+W.+Lovenbergauthor=M.+A.+Otienoauthor=F.+Schoetensauthor=D.+M.+Swansonauthor=Q.+Wangauthor=A.+D.+Wickendenauthor=A.+Bhattacharya&title=4-Methyl-6%2C7-dihydro-4H-triazolo%5B4%2C5-c%5Dpyridine-Based+P2X7+Receptor+Antagonists%3A+Optimization+of+Pharmacokinetic+Properties+Leading+to+the+Identification+of+a+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b00408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate</span></div><div class="casAuthors">Letavic, Michael A.; Savall, Brad M.; Allison, Brett D.; Aluisio, Leah; Andres, Jose Ignacio; De Angelis, Meri; Ao, Hong; Beauchamp, Derek A.; Bonaventure, Pascal; Bryant, Stewart; Carruthers, Nicholas I.; Ceusters, Marc; Coe, Kevin J.; Dvorak, Curt A.; Fraser, Ian C.; Gelin, Christine F.; Koudriakova, Tatiana; Liang, Jimmy; Lord, Brian; Lovenberg, Timothy W.; Otieno, Monicah A.; Schoetens, Freddy; Swanson, Devin M.; Wang, Qi; Wickenden, Alan D.; Bhattacharya, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4559-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and preclin. characterization of novel 4-(R)-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridines that are potent and selective brain penetrant P2X7 antagonists are described.  Optimization efforts based on previously disclosed unsubstituted 6,7-dihydro-4H-triazolo[4,5-c]pyridines, Me substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazines, and several other series lead to the identification of a series of 4-(R)-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridines that are selective P2X7 antagonists with potency at the rodent and human P2X7 ion channels.  These novel P2X7 antagonists have suitable physicochem. properties, and several analogs have an excellent pharmacokinetic profile, good partitioning into the CNS and show robust in vivo target engagement after oral dosing.  Improvements in metabolic stability led to the identification of JNJ-54175446 (I) as a candidate for clin. development.  The drug discovery efforts and strategies that resulted in the identification of the clin. candidate are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkx8e5Sq5aYbVg90H21EOLACvtfcHk0lh3PQaVKiTO2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Wms7Y%253D&md5=5b5465d8f64d527da6647997efe34aee</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00408%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DAllison%26aufirst%3DB.%2BD.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBeauchamp%26aufirst%3DD.%2BA.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DBryant%26aufirst%3DS.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DCeusters%26aufirst%3DM.%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DSchoetens%26aufirst%3DF.%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWickenden%26aufirst%3DA.%2BD.%26aulast%3DBhattacharya%26aufirst%3DA.%26atitle%3D4-Methyl-6%252C7-dihydro-4H-triazolo%255B4%252C5-c%255Dpyridine-Based%2520P2X7%2520Receptor%2520Antagonists%253A%2520Optimization%2520of%2520Pharmacokinetic%2520Properties%2520Leading%2520to%2520the%2520Identification%2520of%2520a%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4559%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.7b00408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">US National Library of Medicine</span>. <a href="https://clinicaltrials.gov/" class="extLink">https://clinicaltrials.gov/</a>, (accessed Jan 15, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+National+Library+of+Medicine.+https%3A%2F%2Fclinicaltrials.gov%2F%2C+%28accessed+Jan+15%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Recourt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevets, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nueten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanhai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebenga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuiker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravenstijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gerven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, P.</span></span> <span> </span><span class="NLM_article-title">Characterisation of the Pharmacodynamic Effects of the P2X7 Receptor Antagonist JNJ-54175446 Using an Oral Dexamphetamine Challenge Model in Healthy Males in a Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1030</span>– <span class="NLM_lpage">1042</span>, <span class="refDoi"> DOI: 10.1177/0269881120914206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1177%2F0269881120914206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=32248747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1aitbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=1030-1042&author=K.+Recourtauthor=J.+van+der+Aartauthor=G.+Jacobsauthor=M.+de+Kamauthor=W.+Drevetsauthor=L.+van+Nuetenauthor=K.+Kanhaiauthor=P.+Siebengaauthor=R.+Zuikerauthor=P.+Ravenstijnauthor=M.+Timmersauthor=J.+van+Gervenauthor=P.+de+Boer&title=Characterisation+of+the+Pharmacodynamic+Effects+of+the+P2X7+Receptor+Antagonist+JNJ-54175446+Using+an+Oral+Dexamphetamine+Challenge+Model+in+Healthy+Males+in+a+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C+Multiple+Ascending+Dose+Trial&doi=10.1177%2F0269881120914206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial</span></div><div class="casAuthors">Recourt, Kasper; van der Aart, Jasper; Jacobs, Gabriel; de Kam, Marieke; Drevets, Wayne; van Nueten, Luc; Kanhai, Kawita; Siebenga, Pieter; Zuiker, Rob; Ravenstijn, Paulien; Timmers, Maarten; van Gerven, Joop; de Boer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1030-1042</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">First report of pharmacodynamic (PD) effects of selective, potent and brain-penetrant P2X7 receptor (P2X7R) antagonist JNJ-54175446.  Activation of P2X7R, an ATP-gated ion channel, leads to prodn. of pro-inflammatory cytokines which is linked to neuroinflammation and pathogenesis of mood disorders.  Previous studies with JNJ-54175446 showed its peripheral target engagement by assessing ex vivo lipopolysaccharide (LPS)-stimulated cytokine prodn and blood-brain barrier penetration.  Objectives of this double-blind, placebo-controlled, translational study were to assess safety and tolerability of administering multiple doses of JNJ-54175446 and to explore its PD effects using dexamphetamine challenge.  Subjects were randomised to either JNJ-54175446(50-450 mg) or placebo and underwent baseline oral 20 mg dexamphetamine challenge followed by 11 consecutive days q.d. dosing with JNJ-54175446/placebo and randomised crossover dexamphetamine/placebo challenge.  At all doses tested, JNJ-54175446 was well tolerated and suppressed ex vivo LPS-induced release of cytokines.  At doses ≥100 mg, JNJ-54175446 attenuated dexamphetamine-induced increases in locomotion and enhanced mood-elevating effects of dexamphetamine, suggesting that dose twice as high is needed to obtain central PD response compared to dose needed for max. peripheral occupancy.  Obsd. pharmacol. profile of JNJ-54175446 in dexamphetamine challenge paradigm is compatible with potential mood-modulating effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5ioGr5SHM87Vg90H21EOLACvtfcHk0lhNXMTGn0A_zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1aitbnF&md5=4cf8fc3621e3c1476113a2ae197cf3e0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F0269881120914206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881120914206%26sid%3Dliteratum%253Aachs%26aulast%3DRecourt%26aufirst%3DK.%26aulast%3Dvan%2Bder%2BAart%26aufirst%3DJ.%26aulast%3DJacobs%26aufirst%3DG.%26aulast%3Dde%2BKam%26aufirst%3DM.%26aulast%3DDrevets%26aufirst%3DW.%26aulast%3Dvan%2BNueten%26aufirst%3DL.%26aulast%3DKanhai%26aufirst%3DK.%26aulast%3DSiebenga%26aufirst%3DP.%26aulast%3DZuiker%26aufirst%3DR.%26aulast%3DRavenstijn%26aufirst%3DP.%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%26aulast%3Dde%2BBoer%26aufirst%3DP.%26atitle%3DCharacterisation%2520of%2520the%2520Pharmacodynamic%2520Effects%2520of%2520the%2520P2X7%2520Receptor%2520Antagonist%2520JNJ-54175446%2520Using%2520an%2520Oral%2520Dexamphetamine%2520Challenge%2520Model%2520in%2520Healthy%2520Males%2520in%2520a%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Multiple%2520Ascending%2520Dose%2520Trial%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2020%26volume%3D34%26spage%3D1030%26epage%3D1042%26doi%3D10.1177%2F0269881120914206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keystone, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Team, D. C. S.</span></span> <span> </span><span class="NLM_article-title">Clinical Evaluation of the Efficacy of the P2X7 Purinergic Receptor Antagonist AZD9056 on the Signs and Symptoms of Rheumatoid Arthritis in Patients with Active Disease Despite Treatment with Methotrexate or Sulphasalazine</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1630</span>– <span class="NLM_lpage">1635</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2011-143578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1136%2Fannrheumdis-2011-143578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22966146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1SqurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2012&pages=1630-1635&author=E.+C.+Keystoneauthor=M.+M.+Wangauthor=M.+Laytonauthor=S.+Hollisauthor=I.+B.+McInnesauthor=D.+C.+S.+Team&title=Clinical+Evaluation+of+the+Efficacy+of+the+P2X7+Purinergic+Receptor+Antagonist+AZD9056+on+the+Signs+and+Symptoms+of+Rheumatoid+Arthritis+in+Patients+with+Active+Disease+Despite+Treatment+with+Methotrexate+or+Sulphasalazine&doi=10.1136%2Fannrheumdis-2011-143578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine</span></div><div class="casAuthors">Keystone, Edward C.; Wang, Millie M.; Layton, Mark; Hollis, Sally; McInnes, Iain B.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1630-1635</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: The P2X7 purinergic receptor antagonist AZD9056 was evaluated in a phase IIa study and subsequently in a phase IIb study to assess the effects of orally administered AZD9056 on the signs/symptoms of rheumatoid arthritis (RA), with American College of Rheumatol. 20% response criteria (ACR20) as the primary outcome.  Methods: Both studies were randomized, double-blind, placebo-controlled, parallel-group studies in patients with RA receiving methotrexate or sulphasalazine.  Phase IIa was an ascending-dose trial in two cohorts (n=75) using AZD9056 administered daily over 4 wk.  Phase IIb included an open-label etanercept treatment group.  Patients were randomized to receive treatment for 6 mo with 50, 100, 200 or 400 mg AZD9056 (oral, once a day) or matching placebo (oral, once a day), or s.c. etanercept (50 mg once a week).  Results: In phase IIa, 65% of AZD9056 recipients at 400 mg/day responded at the ACR20 level compared with 27% of placebo-treated patients.  A significant redn. in swollen and tender joint count was obsd. in the actively treated group compared with placebo, whereas no effect on acute-phase response was obsd.  Of 385 randomized patients in the phase IIb study, 383 received treatment.  AZD9056 (all doses) had no clin. or statistically significant effect on RA relative to placebo as measured by the proportion of patients meeting the ACR20 criteria at 6 mo and further supported by secondary end points.  In both studies AZD9056 was well tolerated up to 400 mg/day.  Conclusions: AZD9056 does not have significant efficacy in the treatment of RA, and the P2X7 receptor does not appear to be a therapeutically useful target in RA.  Trial registration no. ClinicalTrials.gov NCT00520572.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzCebkc5d0gLVg90H21EOLACvtfcHk0lhNXMTGn0A_zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1SqurzL&md5=97ca48663327aa8578f11001fa96d8c0</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2011-143578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2011-143578%26sid%3Dliteratum%253Aachs%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DWang%26aufirst%3DM.%2BM.%26aulast%3DLayton%26aufirst%3DM.%26aulast%3DHollis%26aufirst%3DS.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DTeam%26aufirst%3DD.%2BC.%2BS.%26atitle%3DClinical%2520Evaluation%2520of%2520the%2520Efficacy%2520of%2520the%2520P2X7%2520Purinergic%2520Receptor%2520Antagonist%2520AZD9056%2520on%2520the%2520Signs%2520and%2520Symptoms%2520of%2520Rheumatoid%2520Arthritis%2520in%2520Patients%2520with%2520Active%2520Disease%2520Despite%2520Treatment%2520with%2520Methotrexate%2520or%2520Sulphasalazine%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2012%26volume%3D71%26spage%3D1630%26epage%3D1635%26doi%3D10.1136%2Fannrheumdis-2011-143578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombel, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutgeerts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelsang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braddock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinisch, W.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn’s Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study</span>. <i>Inflamm. Bowel Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2247</span>– <span class="NLM_lpage">2253</span>, <span class="refDoi"> DOI: 10.1097/MIB.0000000000000514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1097%2FMIB.0000000000000514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=26197451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FltVSqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2247-2253&author=A.+Eserauthor=J.+F.+Colombelauthor=P.+Rutgeertsauthor=S.+Vermeireauthor=H.+Vogelsangauthor=M.+Braddockauthor=T.+Perssonauthor=W.+Reinisch&title=Safety+and+Efficacy+of+an+Oral+Inhibitor+of+the+Purinergic+Receptor+P2X7+in+Adult+Patients+with+Moderately+to+Severely+Active+Crohn%E2%80%99s+Disease%3A+A+Randomized+Placebo-controlled%2C+Double-blind%2C+Phase+IIa+Study&doi=10.1097%2FMIB.0000000000000514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study</span></div><div class="casAuthors">Eser Alexander; Colombel Jean-Frederic; Rutgeerts Paul; Vermeire Severine; Vogelsang Harald; Braddock Martin; Persson Tore; Reinisch Walter</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2247-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9056 is a selective orally active inhibitor of the purinergic receptor P2X7, which is a key player in the generation and secretion of several proinflammatory cytokines involved in the pathogenesis of Crohn's disease (CD).  The aim of this phase IIa study was to assess the efficacy and safety of AZD9056 for the treatment of moderately to severely active CD.  METHODS:  We conducted a placebo-controlled, multicenter, double-blind phase IIa study in patients with moderately to severely active CD as defined by a CD Activity Index (CDAI) of at least 220.  Patients were randomized in a 2:1 mode either to 200 mg of AZD9056 administered orally as a tablet once daily for 28 days or matching placebo.  Primary endpoint was the change in CDAI from baseline at day 28, and secondary endpoints included clinical remission (CDAI < 150) and CDAI 70 response and improvement in the quality of life measures Short Form 36 and Inflammatory Bowel Disease Questionnaire.  Changes in serum C-reactive protein and fecal calprotectin were assessed.  RESULTS:  In total, 34 patients were enrolled, 24 to AZD9056 and 10 to placebo.  The CDAI dropped in AZD9056-treated subjects from a baseline mean of 311 to 242 and from 262 to 239 in placebo-treated subjects (P = 0.049).  Remission and response rates were numerically higher with AZD9056 versus placebo, (n = 5, 24% versus n = 1, 11%, P = 0.43 and n = 11, 52% versus n = 2, 22%, P = 0.13, respectively).  Marked decrease in disease activity was observed for the CDAI subcomponents, pain and general well-being.  Apart from a statistically significant improvement in the Mental Component Score of Short Form 36 for AZD9056 versus placebo (P = 0.017), no other differences in measurements of quality of life could be observed.  There was no decrease in concentrations of serum C-reactive protein and fecal calprotectin during treatment.  AZD9056 was well-tolerated, and no serious adverse events were reported.  CONCLUSIONS:  Our data suggest that the purinergic receptor P2X7 antagonist AZD9056 has the potential to improve symptoms in patients with moderate-to-severe CD combined with a beneficial risk profile.  Although the lack in change of inflammatory biomarkers questions its anti-inflammatory potential, the results obtained in this study rather suggest P2X7 antagonism for the treatment of chronic abdominal pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHjK0qgS5fO0g6wdEZmT2rfW6udTcc2eYOrhk49HHPcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FltVSqtA%253D%253D&md5=8ade69d316c57adae49fb595e35ab2f7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1097%2FMIB.0000000000000514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMIB.0000000000000514%26sid%3Dliteratum%253Aachs%26aulast%3DEser%26aufirst%3DA.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DRutgeerts%26aufirst%3DP.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DVogelsang%26aufirst%3DH.%26aulast%3DBraddock%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DT.%26aulast%3DReinisch%26aufirst%3DW.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520an%2520Oral%2520Inhibitor%2520of%2520the%2520Purinergic%2520Receptor%2520P2X7%2520in%2520Adult%2520Patients%2520with%2520Moderately%2520to%2520Severely%2520Active%2520Crohn%25E2%2580%2599s%2520Disease%253A%2520A%2520Randomized%2520Placebo-controlled%252C%2520Double-blind%252C%2520Phase%2520IIa%2520Study%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2015%26volume%3D21%26spage%3D2247%26epage%3D2253%26doi%3D10.1097%2FMIB.0000000000000514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchilibon, S.</span></span> <span> </span><span class="NLM_article-title">Molecular Recognition at Purine and Pyrimidine Nucleotide (P2) Receptors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.2174/1568026043450961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.2174%2F1568026043450961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=15078212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVeju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=805-819&author=K.+Jacobsonauthor=S.+Costanziauthor=M.+Ohnoauthor=B.+Joshiauthor=P.+Besadaauthor=B.+Xuauthor=S.+Tchilibon&title=Molecular+Recognition+at+Purine+and+Pyrimidine+Nucleotide+%28P2%29+Receptors&doi=10.2174%2F1568026043450961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition at purine and pyrimidine nucleotide (P2) receptors</span></div><div class="casAuthors">Jacobson, Kenneth A.; Costanzi, Stefano; Ohno, Michihiro; Joshi, Bhalchandra V.; Besada, Pedro; Xu, Bin; Tchilibon, Susanna</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">805-819</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In comparison to other classes of cell surface receptors, the medicinal chem. at P2X (ligand-gated ion channels) and P2Y (G protein-coupled) nucleotide receptors has been relatively slow to develop.  Recent effort to design selective agonists and antagonists based on a combination of library screening, empirical modification of known ligands, and rational design have led to the introduction of potent antagonists of the P2X1 (derivs. of pyridoxal phosphates and suramin), P2X3 (A-317491), P2X7 (derivs. of the isoquinoline KN-62), P2Y1 (nucleotide analogs MRS 2179 and MRS 2279), P2Y2 (thiouracil derivs. such as AR-C126313), and P2Y12 (nucleotide/nucleoside analogs AR-C69931X and AZD6140) receptors.  A variety of native agonist ligands (ATP, ADP, UTP, UDP, and UDP-glucose) are currently the subject of structural modification efforts to improve selectivity.  MRS2365 is a selective agonist for P2Y1 receptors.  The dinucleotide INS 37217 potently activates the P2Y2 receptor.  UTP-γ-S and UDP-β-S are selective agonists for P2Y2/P2Y4 and P2Y6 receptors, resp.  The current knowledge of the structures of P2X and P2Y receptors, is derived mainly from mutagenesis studies.  Site-directed mutagenesis has shown that ligand recognition in the human P2Y1 receptor involves individual residues of both the TMs (3, 5, 6, and 7), as well as EL 2 and 3.  The binding of the neg.-charged phosphate moiety is dependent on pos. charged lysine and arginine residues near the exofacial side of TMs 3 and 7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmJE-OmgZig7Vg90H21EOLACvtfcHk0lhWlLhbonU1rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVeju70%253D&md5=7fe4929a95451294ba6852c46326d2e7</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F1568026043450961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026043450961%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DK.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DOhno%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DB.%26aulast%3DBesada%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DTchilibon%26aufirst%3DS.%26atitle%3DMolecular%2520Recognition%2520at%2520Purine%2520and%2520Pyrimidine%2520Nucleotide%2520%2528P2%2529%2520Receptors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D805%26epage%3D819%26doi%3D10.2174%2F1568026043450961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soltani
Rad, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrouz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asrari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalafi-Nezhad, A.</span></span> <span> </span><span class="NLM_article-title">A Simple and Regioselective One-Pot Procedure for the Direct N-Acylation of Some Purine and Pyrimidine Nucleobases via Carboxylic Acids Using Cyanuric Chloride</span>. <i>Monatsh. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">1933</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1007/s00706-014-1270-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1007%2Fs00706-014-1270-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1yksrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2014&pages=1933-1940&author=M.+N.+Soltani%0ARadauthor=S.+Behrouzauthor=Z.+Asrariauthor=A.+Khalafi-Nezhad&title=A+Simple+and+Regioselective+One-Pot+Procedure+for+the+Direct+N-Acylation+of+Some+Purine+and+Pyrimidine+Nucleobases+via+Carboxylic+Acids+Using+Cyanuric+Chloride&doi=10.1007%2Fs00706-014-1270-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A simple and regioselective one-pot procedure for the direct N-acylation of some purine and pyrimidine nucleobases via carboxylic acids using cyanuric chloride</span></div><div class="casAuthors">Soltani Rad, Mohammad Navid; Behrouz, Somayeh; Asrari, Zeinab; Khalafi-Nezhad, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Monatshefte fuer Chemie</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1933-1940</span>CODEN:
                <span class="NLM_cas:coden">MOCMB7</span>;
        ISSN:<span class="NLM_cas:issn">0026-9247</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A facile and selective one-pot N-acylation of nucleobases via carboxylic acids using cyanuric chloride (2,4,6-trichloro-1,3,5-triazine) is described.  In this protocol, the reaction of diverse carboxylic acids with pyrimidine and/or purine nucleobases is efficiently achieved in the presence of cyanuric chloride and NaH/Et3N in DMF/MeCN (1:1, vol./vol.) to afford the corresponding N-acyl nucleobases in good yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqORc1JzfkbXLVg90H21EOLACvtfcHk0lhWlLhbonU1rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1yksrfL&md5=550d913665a837b7437fb971bf8b011a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs00706-014-1270-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00706-014-1270-1%26sid%3Dliteratum%253Aachs%26aulast%3DSoltani%2BRad%26aufirst%3DM.%2BN.%26aulast%3DBehrouz%26aufirst%3DS.%26aulast%3DAsrari%26aufirst%3DZ.%26aulast%3DKhalafi-Nezhad%26aufirst%3DA.%26atitle%3DA%2520Simple%2520and%2520Regioselective%2520One-Pot%2520Procedure%2520for%2520the%2520Direct%2520N-Acylation%2520of%2520Some%2520Purine%2520and%2520Pyrimidine%2520Nucleobases%2520via%2520Carboxylic%2520Acids%2520Using%2520Cyanuric%2520Chloride%26jtitle%3DMonatsh.%2520Chem.%26date%3D2014%26volume%3D145%26spage%3D1933%26epage%3D1940%26doi%3D10.1007%2Fs00706-014-1270-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tumma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. V.</span></span> <span> </span><span class="NLM_article-title">N-Alkylation of 2,6-Dichloropurine Hydrochloride with a Variety of Alcohols over Alumina Catalyst</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1856</span>– <span class="NLM_lpage">1866</span>, <span class="refDoi"> DOI: 10.1080/00397910903162791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1080%2F00397910903162791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFCntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=1856-1866&author=H.+Tummaauthor=N.+Nagarajuauthor=K.+V.+Reddy&title=N-Alkylation+of+2%2C6-Dichloropurine+Hydrochloride+with+a+Variety+of+Alcohols+over+Alumina+Catalyst&doi=10.1080%2F00397910903162791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">N-Alkylation of 2,6-Dichloropurine Hydrochloride with a Variety of Alcohols over Alumina Catalyst</span></div><div class="casAuthors">Tumma, Harikrishna; Nagaraju, N.; Reddy, K. Vijayakumar</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1856-1866</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">2,6-Dichloropurine hydrochloride reacts with various types of alcs. using different alumina catalysts and converts into its N-9-alkyl-2-chloro-6-hydroxy-9H-purine products to an extent of 49-74%.  The product selectivity depends on the stability of carbocation generated from the alc.  More stable carbocation formulates both N-7 and N-9-alkyl-2,6-dichloropurine products, whereas the less stable carbocation results in exclusively N-9-alkyl-2-chloro-6-hydroxy-9H-purine.  The catalytic activity of alumina prepd. using the sol-gel method has larger Brunauer, Emmett, and Teller (BET) surface area and hence shows significantly greater catalytic activity than the com. available alumina samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNw2OE3l1pfrVg90H21EOLACvtfcHk0liQPgH5SUHYKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFCntbc%253D&md5=68fdb430d196ba1ce8b2dcce4567c56d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F00397910903162791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910903162791%26sid%3Dliteratum%253Aachs%26aulast%3DTumma%26aufirst%3DH.%26aulast%3DNagaraju%26aufirst%3DN.%26aulast%3DReddy%26aufirst%3DK.%2BV.%26atitle%3DN-Alkylation%2520of%25202%252C6-Dichloropurine%2520Hydrochloride%2520with%2520a%2520Variety%2520of%2520Alcohols%2520over%2520Alumina%2520Catalyst%26jtitle%3DSynth.%2520Commun.%26date%3D2010%26volume%3D40%26spage%3D1856%26epage%3D1866%26doi%3D10.1080%2F00397910903162791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakx, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutot, M.</span></span> <span> </span><span class="NLM_article-title">A Fast and Reproducible Cell- and 96-Well Plate-Based Method for the Evaluation of P2X7 Receptor Activation Using YO-PRO-1 Fluorescent Dye</span>. <i>J. Microbiol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e64</span> <span class="refDoi"> DOI: 10.14440/jbm.2017.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.14440%2Fjbm.2017.136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&author=P.+Ratauthor=E.+Olivierauthor=C.+Tanterauthor=A.+Wakxauthor=M.+Dutot&title=A+Fast+and+Reproducible+Cell-+and+96-Well+Plate-Based+Method+for+the+Evaluation+of+P2X7+Receptor+Activation+Using+YO-PRO-1+Fluorescent+Dye&doi=10.14440%2Fjbm.2017.136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.14440%2Fjbm.2017.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14440%252Fjbm.2017.136%26sid%3Dliteratum%253Aachs%26aulast%3DRat%26aufirst%3DP.%26aulast%3DOlivier%26aufirst%3DE.%26aulast%3DTanter%26aufirst%3DC.%26aulast%3DWakx%26aufirst%3DA.%26aulast%3DDutot%26aufirst%3DM.%26atitle%3DA%2520Fast%2520and%2520Reproducible%2520Cell-%2520and%252096-Well%2520Plate-Based%2520Method%2520for%2520the%2520Evaluation%2520of%2520P2X7%2520Receptor%2520Activation%2520Using%2520YO-PRO-1%2520Fluorescent%2520Dye%26jtitle%3DJ.%2520Microbiol.%2520Methods%26date%3D2017%26volume%3D4%26doi%3D10.14440%2Fjbm.2017.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helliwell, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ShioukHuey, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molero, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, L.</span></span> <span> </span><span class="NLM_article-title">Selected Ginsenosides of the Protopanaxdiol Series are Novel Positive Allosteric Modulators of P2X7 Receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">3326</span>– <span class="NLM_lpage">3340</span>, <span class="refDoi"> DOI: 10.1111/bph.13123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1111%2Fbph.13123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=25752193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaqt7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=3326-3340&author=R.+M.+Helliwellauthor=C.+O.+ShioukHueyauthor=K.+Dhunaauthor=J.+C.+Moleroauthor=J.-M.+Yeauthor=C.+C.+Xueauthor=L.+Stokes&title=Selected+Ginsenosides+of+the+Protopanaxdiol+Series+are+Novel+Positive+Allosteric+Modulators+of+P2X7+Receptors&doi=10.1111%2Fbph.13123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Selected ginsenosides of the protopanaxdiol series are novel positive allosteric modulators of P2X7 receptors</span></div><div class="casAuthors">Helliwell, R. M.; ShioukHuey, C. O.; Dhuna, K.; Molero, J. C.; Ye, J.-M.; Xue, C. C.; Stokes, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3326-3340</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The P2X7 receptor is an ATP-gated ion channel predominantly expressed in immune cells and plays a key role in inflammatory processes.  Ginseng is a well-known Chinese herb with both pro- and anti-inflammatory properties and many of its actions have been ascribed to constituent ginsenosides.  We screened a no. of ginsenoside compds. for pharmacol. activity at P2X7 receptors, that might contribute to the reported immunomodulatory actions of ginseng.  Exptl. Approach : We used several assays to measure responses of P2X7 receptors, ATP-mediated dye uptake, intracellular calcium measurement and whole-cell patch-clamp recordings.  HEK-293 cells stably expressing human P2X7 receptors were used in addn. to mouse macrophages endogenously expressing P2X7 receptors.  Key Results : Four ginsenosides of the protopanaxdiol series, Rb1, Rh2, Rd and the metabolite compd. K (CK) potentiated the dye uptake responses of P2X7 receptors, whereas other ginsenosides tested were ineffective (1-10 μM).  The potentiation was rapid in onset, required a threshold concn. of ATP (>50 μM) and had an EC50 of 1.08 μM.  CK markedly enhanced ATP-activated P2X7 currents, probably via an extracellular site of action.  One of the consequences of this potentiation effect is a sustained rise in intracellular Ca2+ that could account for the decrease in cell viability in mouse macrophages after a combination of 500 μM ATP and 10 μM CK that are non-toxic when applied alone.  Conclusions and Implications : This study identifies selected ginsenosides as novel potent allosteric modulators of P2X7 channels that may account for some of the reported immune modulatory actions of protopanaxdiol ginsenosides in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreyTdb5rbxbrVg90H21EOLACvtfcHk0liQPgH5SUHYKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaqt7rL&md5=cd14c1318acff8b717a1db3ea17fbfaa</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1111%2Fbph.13123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13123%26sid%3Dliteratum%253Aachs%26aulast%3DHelliwell%26aufirst%3DR.%2BM.%26aulast%3DShioukHuey%26aufirst%3DC.%2BO.%26aulast%3DDhuna%26aufirst%3DK.%26aulast%3DMolero%26aufirst%3DJ.%2BC.%26aulast%3DYe%26aufirst%3DJ.-M.%26aulast%3DXue%26aufirst%3DC.%2BC.%26aulast%3DStokes%26aufirst%3DL.%26atitle%3DSelected%2520Ginsenosides%2520of%2520the%2520Protopanaxdiol%2520Series%2520are%2520Novel%2520Positive%2520Allosteric%2520Modulators%2520of%2520P2X7%2520Receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D3326%26epage%3D3340%26doi%3D10.1111%2Fbph.13123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jo, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasakawa, C.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms Regulating NLRP3 Inflammasome Activation</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1038/cmi.2015.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1038%2Fcmi.2015.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=26549800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Gms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=148-159&author=E.-K.+Joauthor=J.+K.+Kimauthor=D.-M.+Shinauthor=C.+Sasakawa&title=Molecular+Mechanisms+Regulating+NLRP3+Inflammasome+Activation&doi=10.1038%2Fcmi.2015.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms regulating NLRP3 inflammasome activation</span></div><div class="casAuthors">Jo, Eun-Kyeong; Kim, Jin Kyung; Shin, Dong-Min; Sasakawa, Chihiro</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-159</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">Inflammasomes are multi-protein signaling complexes that trigger the activation of inflammatory caspases and the maturation of interleukin-1β.  Among various inflammasome complexes, the NLRP3 inflammasome is best characterized and has been linked with various human autoinflammatory and autoimmune diseases.  Thus, the NLRP3 inflammasome may be a promising target for anti-inflammatory therapies.  In this review, we summarize the current understanding of the mechanisms by which the NLRP3 inflammasome is activated in the cytosol.  We also describe the binding partners of NLRP3 inflammasome complexes activating or inhibiting the inflammasome assembly.  Our knowledge of the mechanisms regulating NLRP3 inflammasome signaling and how these influence inflammatory responses offers further insight into potential therapeutic strategies to treat inflammatory diseases assocd. with dysregulation of the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBv_NNzcwFLVg90H21EOLACvtfcHk0liQPgH5SUHYKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Gms7s%253D&md5=90c508a823912cf69f86cefac7aaaaec</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2015.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2015.95%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DE.-K.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DShin%26aufirst%3DD.-M.%26aulast%3DSasakawa%26aufirst%3DC.%26atitle%3DMolecular%2520Mechanisms%2520Regulating%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2016%26volume%3D13%26spage%3D148%26epage%3D159%26doi%3D10.1038%2Fcmi.2015.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barberà-Cremades, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baroja-Mazo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Virgilio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrín, P.</span></span> <span> </span><span class="NLM_article-title">P2X7 Receptor-Stimulation Causes Fever via PGE2 and IL-1beta Release</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2951</span>– <span class="NLM_lpage">2962</span>, <span class="refDoi"> DOI: 10.1096/fj.12-205765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1096%2Ffj.12-205765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22490780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFartL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2951-2962&author=M.+Barber%C3%A0-Cremadesauthor=A.+Baroja-Mazoauthor=A.+I.+Gomezauthor=F.+Machadoauthor=F.+Di+Virgilioauthor=P.+Pelegr%C3%ADn&title=P2X7+Receptor-Stimulation+Causes+Fever+via+PGE2+and+IL-1beta+Release&doi=10.1096%2Ffj.12-205765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release</span></div><div class="casAuthors">Barbera-Cremades, Maria; Baroja-Mazo, Alberto; Gomez, Ana I.; Machado, Francisco; Di Virgilio, Francesco; Pelegrin, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2951-2962, 10.1096/fj.12-205765</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Prostaglandins (PGs) are important lipid mediators involved in the development of inflammatory assocd. pain and fever.  PGE2 is a well-established endogenous pyrogen activated by proinflammatory cytokine interleukin (IL)-1β.  P2X7 receptors (P2X7Rs) expressed by inflammatory cells are stimulated by the danger signal extracellular ATP to activate the inflammasome and release IL-1β.  Here we show that P2X7R activation is required for the release of PGE2 and other autacoids independent of inflammasome activation, with an ATP EC50 for PGE2 and IL-1β release of 1.58 and 1.23 mM, resp.  Furthermore, lack of P2X7R or specific antagonism of P2X7R decreased the febrile response in mice triggered after i.p. LPS or IL-1β inoculation.  Accordingly, LPS inoculation caused i.p. ATP accumulation.  Therefore, P2X7R antagonists emerge as novel therapeutics for the treatment for acute inflammation, pain and fever, with wider anti-inflammatory activity than currently used cyclooxygenase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkUeT1_7VD3rVg90H21EOLACvtfcHk0lh0koxnBN5Brg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFartL%252FO&md5=6f6acbbafe803ea4d74b9ed343efd5a8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1096%2Ffj.12-205765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.12-205765%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%25C3%25A0-Cremades%26aufirst%3DM.%26aulast%3DBaroja-Mazo%26aufirst%3DA.%26aulast%3DGomez%26aufirst%3DA.%2BI.%26aulast%3DMachado%26aufirst%3DF.%26aulast%3DDi%2BVirgilio%26aufirst%3DF.%26aulast%3DPelegr%25C3%25ADn%26aufirst%3DP.%26atitle%3DP2X7%2520Receptor-Stimulation%2520Causes%2520Fever%2520via%2520PGE2%2520and%2520IL-1beta%2520Release%26jtitle%3DFASEB%2520J.%26date%3D2012%26volume%3D26%26spage%3D2951%26epage%3D2962%26doi%3D10.1096%2Ffj.12-205765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">High Throughput Artificial Membrane Permeability Assay for Blood-Brain Barrier</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/s0223-5234(03)00012-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2FS0223-5234%2803%2900012-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=12667689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=223-232&author=L.+Diauthor=E.+H.+Kernsauthor=K.+Fanauthor=O.+J.+McConnellauthor=G.+T.+Carter&title=High+Throughput+Artificial+Membrane+Permeability+Assay+for+Blood-Brain+Barrier&doi=10.1016%2Fs0223-5234%2803%2900012-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput artificial membrane permeability assay for blood-brain barrier</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Fan, Kristi; McConnell, Oliver J.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The recent advances in high throughput screening for biol. activities and combinatorial chem. have greatly expanded the no. of drug candidates.  Rapid screening for BBB penetration potential early in drug discovery programs provides important information for compd. selection and guidance of synthesis for desirable CNS properties.  In this paper, we discuss a modification of the parallel artificial membrane permeation assay (PAMPA) for the prediction of blood-brain barrier penetration (PAMPA-BBB).  The assay was developed with 30 structurally diverse com. drugs and validated with 14 Wyeth Research compds.  The PAMPA-BBB assay has the advantages of: predicting passive blood-brain barrier penetration with high success, high throughput, low cost, and reproducibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCg9Ka4mziLVg90H21EOLACvtfcHk0lh0koxnBN5Brg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D&md5=d228d5808ba8df23deed92c5e2bf3863</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900012-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900012-6%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DFan%26aufirst%3DK.%26aulast%3DMcConnell%26aufirst%3DO.%2BJ.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DHigh%2520Throughput%2520Artificial%2520Membrane%2520Permeability%2520Assay%2520for%2520Blood-Brain%2520Barrier%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D223%26epage%3D232%26doi%3D10.1016%2Fs0223-5234%2803%2900012-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.-d.</span></span> <span> </span><span class="NLM_article-title">Photoaffinity Substrates for P-Glycoprotein</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(92)90665-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2F0006-2952%2892%2990665-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1346496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK38Xht1Shtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=89-93&author=W.+T.+Beckauthor=X.-d.+Qian&title=Photoaffinity+Substrates+for+P-Glycoprotein&doi=10.1016%2F0006-2952%2892%2990665-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity substrates for P-glycoprotein</span></div><div class="casAuthors">Beck, William T.; Qian, Xiao Dong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-93</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review with 42 refs.  A variety of compds. can inhibit the function of P-glycoprotein (Pgp) by binding to it and preventing the efflux of anticancer drug substrates.  While the mol. architecture of the drug binding site(s) in Pgp is not known, it is clear that modulators in general appear to conform to some general phys.-chem. rules.  In this paper, the authors discuss the basic concepts of drug recognition by Pgp as currently understood.  The authors also examine the compds. used to photoaffinity label this protein and discuss their utility in identifying drug binding sites.  Finally, the authors show that a photoaffinity analog of daunorubicin, [3H]azidobenzoyl-daunorubicin ([3H]AB-DNR), is a good affinity labeling reagent for Pgp.  A finding of interest is that vinblastine and verapamil compete more effectively than daunorubicin for [3H]AB-DNR binding to Pgp, suggesting that vinblastine and verapamil have similar structural features not shared by daunorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUsQxdfkM8xbVg90H21EOLACvtfcHk0lh0koxnBN5Brg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xht1Shtrk%253D&md5=7fcd989f8728521a5d6920a27da8ef15</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2892%2990665-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252892%252990665-6%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DW.%2BT.%26aulast%3DQian%26aufirst%3DX.-d.%26atitle%3DPhotoaffinity%2520Substrates%2520for%2520P-Glycoprotein%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1992%26volume%3D43%26spage%3D89%26epage%3D93%26doi%3D10.1016%2F0006-2952%2892%2990665-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoblock, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aluisio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neff, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovenberg, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenden, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Characterization of a Novel Centrally Permeable P2X7 Receptor Antagonist: JNJ-47965567</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1111/bph.12314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1111%2Fbph.12314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=23889535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2ntrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=624-640&author=A.+Bhattacharyaauthor=Q.+Wangauthor=H.+Aoauthor=J.+R.+Shoblockauthor=B.+Lordauthor=L.+Aluisioauthor=I.+Fraserauthor=D.+Nepomucenoauthor=R.+A.+Neffauthor=N.+Weltyauthor=T.+W.+Lovenbergauthor=P.+Bonaventureauthor=A.+D.+Wickendenauthor=M.+A.+Letavic&title=Pharmacological+Characterization+of+a+Novel+Centrally+Permeable+P2X7+Receptor+Antagonist%3A+JNJ-47965567&doi=10.1111%2Fbph.12314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567</span></div><div class="casAuthors">Bhattacharya, Anindya; Wang, Qi; Ao, Hong; Shoblock, James R.; Lord, Brian; Aluisio, Leah; Fraser, Ian; Nepomuceno, Diane; Neff, Robert A.; Welty, Natalie; Lovenberg, Timothy W.; Bonaventure, Pascal; Wickenden, Alan D.; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">624-640</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : An increasing body of evidence suggests that the purinergic receptor P2X, ligand-gated ion channel, 7 (P2X7) in the CNS may play a key role in neuropsychiatry, neurodegeneration and chronic pain.  In this study, we characterized JNJ-47965567, a centrally permeable, high-affinity, selective P2X7 antagonist.  Exptl. Approach : We have used a combination of in vitro assays (calcium flux, radioligand binding, electrophysiol., IL-1β release) in both recombinant and native systems.  Target engagement of JNJ-47965567 was demonstrated by ex vivo receptor binding autoradiog. and in vivo blockade of Bz-ATP induced IL-1β release in the rat brain.  Finally, the efficacy of JNJ-47965567 was tested in std. models of depression, mania and neuropathic pain.  Key Results : JNJ-47965567 is potent high affinity (pKi 7.9 ± 0.07), selective human P2X7 antagonist, with no significant obsd. speciation.  In native systems, the potency of the compd. to attenuate IL-1β release was 6.7 ± 0.07 (human blood), 7.5 ± 0.07 (human monocytes) and 7.1 ± 0.1 (rat microglia).  JNJ-47965567 exhibited target engagement in rat brain, with a brain EC50 of 78 ± 19 ng·mL-1 (P2X7 receptor autoradiog.) and functional block of Bz-ATP induced IL-1β release.  JNJ-47965567 (30 mg·kg-1) attenuated amphetamine-induced hyperactivity and exhibited modest, yet significant efficacy in the rat model of neuropathic pain.  No efficacy was obsd. in forced swim test.  Conclusion and Implications : JNJ-47965567 is centrally permeable, high affinity P2X7 antagonist that can be used to probe the role of central P2X7 in rodent models of CNS pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS_bU7fI8KzLVg90H21EOLACvtfcHk0lh0koxnBN5Brg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2ntrnI&md5=29d3bc1d3ecedda01f3d33b53d96c289</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1111%2Fbph.12314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12314%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DShoblock%26aufirst%3DJ.%2BR.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DNepomuceno%26aufirst%3DD.%26aulast%3DNeff%26aufirst%3DR.%2BA.%26aulast%3DWelty%26aufirst%3DN.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DWickenden%26aufirst%3DA.%2BD.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DPharmacological%2520Characterization%2520of%2520a%2520Novel%2520Centrally%2520Permeable%2520P2X7%2520Receptor%2520Antagonist%253A%2520JNJ-47965567%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D624%26epage%3D640%26doi%3D10.1111%2Fbph.12314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letavic, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rech, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sales, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velter, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenden, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carruthers, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1021/ml400040v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400040v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVahtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=419-422&author=M.+A.+Letavicauthor=B.+Lordauthor=F.+Bischoffauthor=N.+A.+Hawrylukauthor=S.+Pietersauthor=J.+C.+Rechauthor=Z.+Salesauthor=A.+I.+Velterauthor=H.+Aoauthor=P.+Bonaventureauthor=V.+Contrerasauthor=X.+Jiangauthor=K.+L.+Mortonauthor=B.+Scottauthor=Q.+Wangauthor=A.+D.+Wickendenauthor=N.+I.+Carruthersauthor=A.+Bhattacharya&title=Synthesis+and+Pharmacological+Characterization+of+Two+Novel%2C+Brain+Penetrating+P2X7+Antagonists&doi=10.1021%2Fml400040v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists</span></div><div class="casAuthors">Letavic, Michael A.; Lord, Brian; Bischoff, Francois; Hawryluk, Natalie A.; Pieters, Serge; Rech, Jason C.; Sales, Zachary; Velter, Adriana I.; Ao, Hong; Bonaventure, Pascal; Contreras, Victor; Jiang, Xiaohui; Morton, Kirsten L.; Scott, Brian; Wang, Qi; Wickenden, Alan D.; Carruthers, Nicholas I.; Bhattacharya, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-422</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and preclin. characterization of two novel, brain penetrating P2X7 compds. will be described.  Both compds. are shown to be high potency P2X7 antagonists in human, rat, and mouse cell lines and both were shown to have high brain concns. and robust receptor occupancy in rat.  Compd. I is of particular interest as a probe compd. for the preclin. assessment of P2X7 blockade in animal models of neuro-inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFnpKdjd4_XLVg90H21EOLACvtfcHk0ljFsDPsjiipcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVahtbw%253D&md5=7c1d0561aad7338b75840181756c9295</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fml400040v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400040v%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBischoff%26aufirst%3DF.%26aulast%3DHawryluk%26aufirst%3DN.%2BA.%26aulast%3DPieters%26aufirst%3DS.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DSales%26aufirst%3DZ.%26aulast%3DVelter%26aufirst%3DA.%2BI.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DContreras%26aufirst%3DV.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DMorton%26aufirst%3DK.%2BL.%26aulast%3DScott%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWickenden%26aufirst%3DA.%2BD.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DBhattacharya%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Characterization%2520of%2520Two%2520Novel%252C%2520Brain%2520Penetrating%2520P2X7%2520Antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D419%26epage%3D422%26doi%3D10.1021%2Fml400040v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span> <span> </span><span class="NLM_article-title">Interspecies Comparison of Putative Ligand Binding Sites of Human, Rat and Mouse P-Glycoprotein</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2018.06.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2Fj.ejps.2018.06.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=29936088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Kms7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2018&pages=134-143&author=S.+Jainauthor=M.+Granditsauthor=G.+F.+Ecker&title=Interspecies+Comparison+of+Putative+Ligand+Binding+Sites+of+Human%2C+Rat+and+Mouse+P-Glycoprotein&doi=10.1016%2Fj.ejps.2018.06.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Interspecies comparison of putative ligand binding sites of human, rat and mouse P-glycoprotein</span></div><div class="casAuthors">Jain, Sankalp; Grandits, Melanie; Ecker, Gerhard F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prior to the clin. phases of testing, safety, efficacy and pharmacokinetic profiles of lead compds. are evaluated in animal studies.  These tests are primarily performed in rodents, such as mouse and rats.  In order to reduce the no. of animal expts., computational models that predict the outcome of these studies and thus aid in prioritization of preclin. candidates are heavily needed.  However, although computational models for human off-target interactions with decent quality are available, they cannot easily be transferred to rodents due to lack of resp. data.  In this study, we assess the transferability of human P-glycoprotein activity data for development of in silico models to predict in vivo effects in rats and mouse using a structure-based approach.  P-glycoprotein (P-gp) is an ATP-dependent efflux transporter that transports xenobiotic compds. such as toxins and drugs out of cells and has a broad substrate and inhibitor specificity.  Being mostly expressed at barriers, it influences the bioavailability of drugs and thus contributes also to toxicity.  Comparison of the binding site interaction profiles of human, rat and mouse P-gp derived from docking studies with a set of common inhibitors suggests that the inhibitors share potentially similar binding modes.  These findings encourage the use of in vitro human P-gp data for predicting in vivo effects in rodents and thus contributes to the 3Rs (Replace, Reduce and Refine) of animal expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql3AvJfNmhRbVg90H21EOLACvtfcHk0ljFsDPsjiipcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Kms7bM&md5=c52c06b5a6ce21fafabc41008c6eae56</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2018.06.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2018.06.022%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%26aulast%3DGrandits%26aufirst%3DM.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26atitle%3DInterspecies%2520Comparison%2520of%2520Putative%2520Ligand%2520Binding%2520Sites%2520of%2520Human%252C%2520Rat%2520and%2520Mouse%2520P-Glycoprotein%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D122%26spage%3D134%26epage%3D143%26doi%3D10.1016%2Fj.ejps.2018.06.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinan, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryan, J. F.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein Inhibition Increases the Brain Distribution and Antidepressant-Like Activity of Escitalopram in Rodents</span>. <i>Neuropsychopharmacol</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2209</span>– <span class="NLM_lpage">2219</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1038%2Fnpp.2013.120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCqur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=2209-2219&author=F.+E.+O%E2%80%99Brienauthor=R.+M.+O%E2%80%99Connorauthor=G.+Clarkeauthor=T.+G.+Dinanauthor=B.+T.+Griffinauthor=J.+F.+Cryan&title=P-Glycoprotein+Inhibition+Increases+the+Brain+Distribution+and+Antidepressant-Like+Activity+of+Escitalopram+in+Rodents&doi=10.1038%2Fnpp.2013.120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein Inhibition Increases the Brain Distribution and Antidepressant-Like Activity of Escitalopram in Rodents</span></div><div class="casAuthors">O'Brien, Fionn E.; O'Connor, Richard M.; Clarke, Gerard; Dinan, Timothy G.; Griffin, Brendan T.; Cryan, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite the clin. prevalence of the antidepressant escitalopram, over 30% of escitalopram-treated patients fail to respond to treatment.  Recent gene assocn. studies have highlighted a potential link between the drug efflux transporter P-glycoprotein (P-gp) and response to escitalopram.  The present studies investigated pharmacokinetic and pharmacodynamic interactions between P-gp and escitalopram.  In vitro bidirectional transport studies revealed that escitalopram is a transported substrate of human P-gp.  Microdialysis-based pharmacokinetic studies demonstrated that administration of the P-gp inhibitor cyclosporin A resulted in increased brain levels of escitalopram without altering plasma escitalopram levels in the rat, thereby showing that P-gp restricts escitalopram transport across the blood-brain barrier (BBB) in vivo.  The tail suspension test (TST) was carried out to elucidate the pharmacodynamic impact of P-gp inhibition on escitalopram effect in a mouse model of antidepressant activity.  Pre-treatment with the P-gp inhibitor verapamil enhanced the response to escitalopram in the TST.  Taken together, these data indicate that P-gp may restrict the BBB transport of escitalopram in humans, potentially resulting in subtherapeutic brain concns. in certain patients.  Moreover, by verifying that increasing escitalopram delivery to the brain by P-gp inhibition results in enhanced antidepressant-like activity, we suggest that adjunctive treatment with a P-gp inhibitor may represent a beneficial approach to augment escitalopram therapy in depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLDTWggs2-TLVg90H21EOLACvtfcHk0ljx_7fDfvy5bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCqur%252FF&md5=f34540814671ef20080a7deb1ecb681d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.120%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DF.%2BE.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BM.%26aulast%3DClarke%26aufirst%3DG.%26aulast%3DDinan%26aufirst%3DT.%2BG.%26aulast%3DGriffin%26aufirst%3DB.%2BT.%26aulast%3DCryan%26aufirst%3DJ.%2BF.%26atitle%3DP-Glycoprotein%2520Inhibition%2520Increases%2520the%2520Brain%2520Distribution%2520and%2520Antidepressant-Like%2520Activity%2520of%2520Escitalopram%2520in%2520Rodents%26jtitle%3DNeuropsychopharmacol%26date%3D2013%26volume%3D38%26spage%3D2209%26epage%3D2219%26doi%3D10.1038%2Fnpp.2013.120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshitomi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">Species Differences of Inhibitory Effects on P-Glycoprotein-Mediated Drug Transport</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1609</span>– <span class="NLM_lpage">1618</span>, <span class="refDoi"> DOI: 10.1002/jps.20787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fjps.20787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=17094122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1CisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=1609-1618&author=N.+Suzuyamaauthor=M.+Katohauthor=T.+Takeuchiauthor=S.+Yoshitomiauthor=T.+Higuchiauthor=S.+Asashiauthor=T.+Yokoi&title=Species+Differences+of+Inhibitory+Effects+on+P-Glycoprotein-Mediated+Drug+Transport&doi=10.1002%2Fjps.20787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Species differences of inhibitory effects on P-glycoprotein-mediated drug transport</span></div><div class="casAuthors">Suzuyama, Naoto; Katoh, Miki; Takeuchi, Toshiyuki; Yoshitomi, Sumie; Higuchi, Tomoaki; Asashi, Satoru; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1609-1618</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Previously, we clarified the species differences in P-glycoprotein (P-gp)-mediated drug transport activity using human MDR1, monkey MDR1, canine MDR1, rat MDR1a, rat MDR1b, mouse mdr1a, and mouse mdr1b transfected LLC-PK1 cell lines.  However, the species differences in the inhibitory effects on P-gp-mediated drug transport have not been clarified yet.  The purpose of the present study was to evaluate the species differences in the inhibitory effects of typical P-gp inhibitors, quinidine and verapamil, on P-gp-mediated drug transport using MDR1 transfected cell lines.  The transcellular transport of [3H] daunorubicin, [3H] digoxin, and [mebmt-β-3H] cyclosporin A across monolayers of the MDR1 transfected cells were measured in the presence or absence of P-gp inhibitors.  On daunorubicin transport, the relative IC50 value (quinidine IC50/verapamil IC50) of human P-gp was 5.25 and those from other species ranged from 0.89 to 10.70.  The transport of digoxin and cyclosporin A also showed different relative IC50 values among human, monkey, canine, rat, and mouse P-gps.  The present study revealed that species differences in the inhibitory effects on P-gp-mediated drug transport should not be disregarded among human, monkey, canine, rat, and mouse.  This study will provide useful information for predicting drug interactions mediated by P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3shbk_L6sQbVg90H21EOLACvtfcHk0ljIDJZqsdLSTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1CisL8%253D&md5=789ae2c96c2400cd5830e07c7fe0194f</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fjps.20787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20787%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuyama%26aufirst%3DN.%26aulast%3DKatoh%26aufirst%3DM.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DYoshitomi%26aufirst%3DS.%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DAsashi%26aufirst%3DS.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DSpecies%2520Differences%2520of%2520Inhibitory%2520Effects%2520on%2520P-Glycoprotein-Mediated%2520Drug%2520Transport%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2007%26volume%3D96%26spage%3D1609%26epage%3D1618%26doi%3D10.1002%2Fjps.20787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirimulla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegesna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, M.</span></span> <span> </span><span class="NLM_article-title">Halogen Interactions in Protein-Ligand Complexes: Implications of Halogen Bonding for Rational Drug Design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2781</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1021/ci400257k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci400257k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cisr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=2781-2791&author=S.+Sirimullaauthor=J.+B.+Baileyauthor=R.+Vegesnaauthor=M.+Narayan&title=Halogen+Interactions+in+Protein-Ligand+Complexes%3A+Implications+of+Halogen+Bonding+for+Rational+Drug+Design&doi=10.1021%2Fci400257k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen Interactions in Protein-Ligand Complexes: Implications of Halogen Bonding for Rational Drug Design</span></div><div class="casAuthors">Sirimulla, Suman; Bailey, Jake B.; Vegesna, Rahulsimham; Narayan, Mahesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2781-2791</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Halogen bonding interactions between halogenated ligands and proteins were examd. using the crystal structures deposited to date in the PDB.  The data was analyzed as a function of halogen bonding to main chain Lewis bases, viz. oxygen of backbone carbonyl and backbone amide nitrogen.  This anal. also examd. halogen bonding to side-chain Lewis bases (O, N, and S) and to the electron-rich arom. amino acids.  All interactions were restricted to van der Waals radii with resp. atoms.  The data reveals that while fluorine and chlorine have strong tendencies favoring interactions with the backbone Lewis bases at glycine, the trend is not restricted to the achiral amino acid backbone for larger halogens.  Halogen side-chain interactions are not restricted to amino acids contg. O, N, and S as Lewis bases.  Electron-rich arom. amino acids host a high frequency of halogen bonds as does Leu.  A closer examn. of the latter hydrophobic side chain reveals that the "propensity of interactions" of halogen ligands at this oily residue is an outcome of strong classical halogen bonds with Lewis bases in the vicinity.  Finally, an examn. of Θ1 (C-X···O and C-X···N) and Θ2 (X···O-Z and X···N-Z) angles reveals that very few ligands adopt classical halogen bonding angles, suggesting that steric and other factors may influence these angles.  The data is discussed in the context of ligand design for pharmaceutical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wcnZDXmkYrVg90H21EOLACvtfcHk0ljIDJZqsdLSTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cisr3O&md5=a73378681587e3ac13143452ecb78882</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fci400257k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400257k%26sid%3Dliteratum%253Aachs%26aulast%3DSirimulla%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DJ.%2BB.%26aulast%3DVegesna%26aufirst%3DR.%26aulast%3DNarayan%26aufirst%3DM.%26atitle%3DHalogen%2520Interactions%2520in%2520Protein-Ligand%2520Complexes%253A%2520Implications%2520of%2520Halogen%2520Bonding%2520for%2520Rational%2520Drug%2520Design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D2781%26epage%3D2791%26doi%3D10.1021%2Fci400257k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishaq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mebus, C. A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">720</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.3899/jrheum.110874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.3899%2Fjrheum.110874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22382341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVOnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=720-727&author=T.+C.+Stockauthor=B.+J.+Bloomauthor=N.+Weiauthor=S.+Ishaqauthor=W.+Parkauthor=X.+Wangauthor=P.+Guptaauthor=C.+A.+Mebus&title=Efficacy+and+Safety+of+CE-224%2C535%2C+an+Antagonist+of+P2X7+Receptor%2C+in+Treatment+of+Patients+with+Rheumatoid+Arthritis+Inadequately+Controlled+by+Methotrexate&doi=10.3899%2Fjrheum.110874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate</span></div><div class="casAuthors">Stock, Thomas C.; Bloom, Bradley J.; Wei, Nathan; Ishaq, Saliha; Park, Won; Wang, Xin; Gupta, Pankaj; Mebus, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">720-727</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">To evaluate efficacy and safety of CE-224,535, a selective P2X7 receptor antagonist, vs. placebo, in patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX).  In our phase IIA study (ClinicalTrials.gov no. NCT00628095; A6341009), patients aged ≥ 18 years with active RA were randomized to receive either CE-224,535 (500 mg bid) or placebo for 12 wk; all patients continued a stable background dose of ≥ 7.5 mg MTX.  The American College of Rheumatol. 20% (ACR20) response rate (primary efficacy endpoint) was not significantly different from placebo for CE-224,535 (34.0% vs 36.2%; p = 0.591) at Week 12, or at any timepoint over the 12-wk treatment period.  There was no significant difference at Week 12 for the ACR20 response rate following subgroup analyses by age, sex, baseline disease activity, baseline duration of disease, geog. region, or concomitant use of steroids.  ACR50/ACR70 response rates and change from baseline in Disease Activity Score 28-joint C-reactive protein (DAS28-3-CRP) and Health Assessment Questionnaire-Disability Index for CE-224,535 were not significant at Week 12 vs. placebo.  Treatment-emergent adverse events (AE) were reported by 62.3% (CE-224,535) and 55.3% (placebo) of patients; the most common AE were nausea (11.3%, CE-224,535; 4.3%, placebo) and diarrhea (7.5%, CE-224,535; 4.3%, placebo).  The proportion of patients discontinuing due to an AE was 9.4% (CE-224,535) and 6.4% (placebo); no deaths were reported.  Serious AE occurred in 3.8% (CE-224,535) and 2.1% (placebo) of patients; none was considered treatment-related.  CE-224,535 was not efficacious, compared with placebo, for the treatment of RA in patients with an inadequate response to MTX.  CE-224,535 demonstrated an acceptable safety and tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorblWg-aNBNLVg90H21EOLACvtfcHk0ljIDJZqsdLSTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVOnsro%253D&md5=dc919436c3c6e7f3f624c57b77c5dbb2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.110874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.110874%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DWei%26aufirst%3DN.%26aulast%3DIshaq%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMebus%26aufirst%3DC.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520CE-224%252C535%252C%2520an%2520Antagonist%2520of%2520P2X7%2520Receptor%252C%2520in%2520Treatment%2520of%2520Patients%2520with%2520Rheumatoid%2520Arthritis%2520Inadequately%2520Controlled%2520by%2520Methotrexate%26jtitle%3DJ.%2520Rheumatol.%26date%3D2012%26volume%3D39%26spage%3D720%26epage%3D727%26doi%3D10.3899%2Fjrheum.110874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosnan, C. F.</span></span> <span> </span><span class="NLM_article-title">Exacerbation of Experimental Autoimmune Encephalomyelitis in P2X7R-/- Mice: Evidence for Loss of Apoptotic Activity in Lymphocytes</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">3115</span>– <span class="NLM_lpage">3126</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.176.5.3115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.4049%2Fjimmunol.176.5.3115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=16493071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1eru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=3115-3126&author=L.+Chenauthor=C.+F.+Brosnan&title=Exacerbation+of+Experimental+Autoimmune+Encephalomyelitis+in+P2X7R-%2F-+Mice%3A+Evidence+for+Loss+of+Apoptotic+Activity+in+Lymphocytes&doi=10.4049%2Fjimmunol.176.5.3115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Exacerbation of Experimental Autoimmune Encephalomyelitis in P2X7R-/- Mice: Evidence for Loss of Apoptotic Activity in Lymphocytes</span></div><div class="casAuthors">Chen, Lanfen; Brosnan, Celia F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3115-3126</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The purinergic receptor P2X7R is a nucleotide-gated ion channel that has been proposed to function as a major regulator of inflammation.  Here, the authors examd. the role of this receptor in regulating inflammation in the CNS by detg. the effects of the loss of this receptor (P2X7R-/-) on exptl. autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis.  They show here that P2X7R-/- mice developed more severe clin. and pathol. expression of EAE than wild type (WT) controls and that spleen and lymph node cells from P2X7R-/- mice proliferated more vigorously to antigen in vitro.  Bone marrow (BM) radiation chimeras revealed that enhanced susceptibility to EAE was detected in chimeric mice of WT host engrafted with P2X7R-/- BM cells, indicating that the genotype of the BM cells regulated disease susceptibility.  Coculture of P2X7R-/- macrophages with WT lymphocytes and vice versa showed that enhanced proliferative activity resided within the P2X7R-/- lymphocyte population and correlated with reduced levels of IFN-γ and NO and apoptosis of lymphocytes.  MRNA and protein for IFN-γ were also reduced in the CNS of P2X7R-/- mice with EAE.  FACS anal. of cells isolated from the CNS showed fewer annexin V/propidium iodide-pos. lymphocytes in the CNS of P2X7R-/- mice early in the disease, and TUNEL staining of inflamed CNS tissues supported this result.  Thus, enhanced susceptibility of P2X7R-/- mice to EAE reflects a loss of apoptotic activity in lymphocytes, supporting an important role for this receptor in lymphocyte homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBCtaLZPgUpLVg90H21EOLACvtfcHk0liIozKANSTaEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1eru7w%253D&md5=ab8255f6409f17328596b64350300444</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.5.3115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.5.3115%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBrosnan%26aufirst%3DC.%2BF.%26atitle%3DExacerbation%2520of%2520Experimental%2520Autoimmune%2520Encephalomyelitis%2520in%2520P2X7R-%252F-%2520Mice%253A%2520Evidence%2520for%2520Loss%2520of%2520Apoptotic%2520Activity%2520in%2520Lymphocytes%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D3115%26epage%3D3126%26doi%3D10.4049%2Fjimmunol.176.5.3115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiessling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">The Ecstasy and Agony of Assay Interference Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2165</span>– <span class="NLM_lpage">2168</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00229</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00229" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtl2lsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2165-2168&author=C.+Aldrichauthor=C.+Bertozziauthor=G.+I.+Georgauthor=L.+Kiesslingauthor=C.+Lindsleyauthor=D.+Liottaauthor=K.+M.+Merzauthor=A.+Schepartzauthor=S.+Wang&title=The+Ecstasy+and+Agony+of+Assay+Interference+Compounds&doi=10.1021%2Facs.jmedchem.7b00229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The Ecstasy and Agony of Assay Interference Compounds</span></div><div class="casAuthors">Aldrich, Courtney; Bertozzi, Carolyn; Georg, Gunda I.; Kiessling, Laura; Lindsley, Craig; Liotta, Dennis; Merz, Kenneth M.; Schepartz, Alanna; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2165-2168</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ecstasy of discovering a new hit from screening can lead to a highly productive research effort to discover new bioactive compds.  However, in too many cases this ecstasy is followed by the agony of realizing that the compds. are not active against the desired target.  Many of these false hits are Pan Assay INterference compds. (PAINS) 1 or colloidal aggregators.  Whether the screen is conducted in silico or in the lab. and whether screening libraries, natural products, or drugs are used, all discovery efforts that rely on some form of screening to identify bioactivity are susceptible to this phenomenon.  Studies that omit crit. controls against exptl. artifacts caused by PAINS may waste years of research effort as useless compds. are progressed.  The American Chem. Society (ACS) is eager to alert the scientific community to this problem and to recommend protocols that will eliminate the publication of research articles based on compds. with artificial activity.  This editorial aims to summarize relevant concepts and to set the framework by which relevant ACS journals will address this issue going forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJUf5u51VEpbVg90H21EOLACvtfcHk0liIozKANSTaEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtl2lsLY%253D&md5=64bf087659a47fe7769208217ef8c989</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00229%26sid%3Dliteratum%253Aachs%26aulast%3DAldrich%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DC.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DKiessling%26aufirst%3DL.%26aulast%3DLindsley%26aufirst%3DC.%26aulast%3DLiotta%26aufirst%3DD.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DSchepartz%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DThe%2520Ecstasy%2520and%2520Agony%2520of%2520Assay%2520Interference%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2165%26epage%3D2168%26doi%3D10.1021%2Facs.jmedchem.7b00229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6900"><div class="reference"><strong class="refLabel"><a href="#ref6900" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit6900"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddileti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">2-Substitution of Adenine Nucleotide Analogues Containing a Bicyclo[3.1.0]hexane Ring System Locked in a Northern Conformation: Enhanced Potency as P2Y1 Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4987</span>, <span class="refDoi"> DOI: 10.1021/jm030127+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030127%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6900/cit6900&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVWqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4974-4987&author=H.+S.+Kimauthor=M.+Ohnoauthor=B.+Xuauthor=H.+O.+Kimauthor=Y.+Choiauthor=X.+D.+Jiauthor=S.+Maddiletiauthor=V.+E.+Marquezauthor=T.+K.+Hardenauthor=K.+A.+Jacobson&title=2-Substitution+of+Adenine+Nucleotide+Analogues+Containing+a+Bicyclo%5B3.1.0%5Dhexane+Ring+System+Locked+in+a+Northern+Conformation%3A+Enhanced+Potency+as+P2Y1+Receptor+Antagonists&doi=10.1021%2Fjm030127%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6900R"><div class="casContent"><span class="casTitleNuber">6900</span><div class="casTitle"><span class="NLM_cas:atitle">2-Substitution of Adenine Nucleotide Analogues Containing a Bicyclo[3.1.0]hexane Ring System Locked in a Northern Conformation: Enhanced Potency as P2Y1 Receptor Antagonists</span></div><div class="casAuthors">Kim, Hak Sung; Ohno, Michihiro; Xu, Bin; Kim, Hea Ok; Choi, Yongseok; Ji, Xiao D.; Maddileti, Savitri; Marquez, Victor E.; Harden, T. Kendall; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4974-4987</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Preference for the northern (N) ring conformation of the ribose moiety of adenine nucleotide 3',5'-bisphosphate antagonists of P2Y1 receptors was established by using a ring-constrained Methanocarba (a bicyclo[3.1.0]hexane) ring as a ribose substitute (Nandanan et al. J. Med. Chem. 2000, 43, 829-842).  We have now combined the ring-constrained (N)-Methanocarba modification with other functionalities at the 2-position of the adenine moiety.  A new synthetic route to this series of bisphosphate derivs. was introduced, consisting of phosphorylation of the pseudo-ribose moiety prior to coupling with the adenine base.  The activity of the newly synthesized analogs was detd. by measuring antagonism of 2-methylthio-ADP-stimulated phospholipase C (PLC) activity in 1321N1 human astrocytoma cells expressing the recombinant human P2Y1 receptor and by using the radiolabeled antagonist [3H]2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine 3',5'-bisphosphate (I) in a newly developed binding assay in Sf9 cell membranes.  Within the series of 2-halo analogs, the most potent mol. at the hP2Y1 receptor was an (N)-methanocarba N6-methyl-2-iodo analog II, which displayed a Ki value in competition for binding of [3H]I of 0.79 nM and a KB value of 1.74 nM for inhibition of PLC.  Thus, II is the most potent antagonist selective for the P2Y1 receptor yet reported.  The 2-iodo group was substituted with trimethyltin, thus providing a parallel synthetic route for the introduction of an iodo group in this high-affinity antagonist.  The (N)-methanocarba-2-methylthio, 2-methylseleno, 2-hexyl, 2-(1-hexenyl), and 2-(1-hexynyl) analogs bound less well, exhibiting micro-molar affinity at P2Y1 receptors.  An enzymic method of synthesis of the 3',5'-bisphosphate from the corresponding 3'-monophosphate, suitable for the prepn. of a radio-phosphorylated analog, was explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8otZqmpOhbVg90H21EOLACvtfcHk0liIozKANSTaEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVWqtbw%253D&md5=ddcf40be66d691b6d64b6f696d83bb12</span></div><a href="/servlet/linkout?suffix=cit6900&amp;dbid=16384&amp;doi=10.1021%2Fjm030127%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030127%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DOhno%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DH.%2BO.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DX.%2BD.%26aulast%3DMaddileti%26aufirst%3DS.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DHarden%26aufirst%3DT.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3D2-Substitution%2520of%2520Adenine%2520Nucleotide%2520Analogues%2520Containing%2520a%2520Bicyclo%255B3.1.0%255Dhexane%2520Ring%2520System%2520Locked%2520in%2520a%2520Northern%2520Conformation%253A%2520Enhanced%2520Potency%2520as%2520P2Y1%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4974%26epage%3D4987%26doi%3D10.1021%2Fjm030127%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7000"><div class="reference"><strong class="refLabel"><a href="#ref7000" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit7000"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tobrman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, D.</span></span> <span> </span><span class="NLM_article-title">Magnesiation of Chloro-iodopurines: an Efficient Approach to New Purine Derivatives</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1294</span>, <span class="refDoi"> DOI: 10.1021/ol053013w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol053013w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7000/cit7000&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFamtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=1291-1294&author=T.+Tobrmanauthor=D.+Dvorak&title=Magnesiation+of+Chloro-iodopurines%3A+an+Efficient+Approach+to+New+Purine+Derivatives&doi=10.1021%2Fol053013w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7000R"><div class="casContent"><span class="casTitleNuber">7000</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Magnesiation of Chloro-iodopurines: An Efficient Approach to New Purine Derivatives</span></div><div class="casAuthors">Tobrman, Tomas; Dvorak, Dalimil</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1291-1294</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">I (R = CMe2, CH2Ph) undergo a selective I/Mg exchange reaction with iPrMgCl at -80 °C.  The reaction course at 0 °C is different.  Magnesiation of I (R = CMe2) proceeds with the migration of magnesium to the 8 position of the purine nuclei.  In the case of I (R = CH2Ph), substitution of iodine with an alkyl group from the Grignard reagent accompanied with a Cl/Mg exchange reaction takes place, and 6-alkyl-2-magnesiated purines (II) are formed.  Thus prepd. Grignard reagents afford the corresponding alcs. by the reaction with aldehydes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWL41kOV9j0bVg90H21EOLACvtfcHk0lhABO85bdjZVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFamtrc%253D&md5=c0034eebb93cf92a465c5f8554db6d6a</span></div><a href="/servlet/linkout?suffix=cit7000&amp;dbid=16384&amp;doi=10.1021%2Fol053013w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol053013w%26sid%3Dliteratum%253Aachs%26aulast%3DTobrman%26aufirst%3DT.%26aulast%3DDvorak%26aufirst%3DD.%26atitle%3DMagnesiation%2520of%2520Chloro-iodopurines%253A%2520an%2520Efficient%2520Approach%2520to%2520New%2520Purine%2520Derivatives%26jtitle%3DOrg.%2520Lett.%26date%3D2006%26volume%3D8%26spage%3D1291%26epage%3D1294%26doi%3D10.1021%2Fol053013w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span>; <span class="NLM_string-name">Grether, U.</span>; <span class="NLM_string-name">Kimbara, A.</span>; <span class="NLM_string-name">Nettekoven, M.</span>; <span class="NLM_string-name">Roever, S.</span>; <span class="NLM_string-name">Rogers-Evans, M.</span>; <span class="NLM_string-name">Schulz-Gasch, T.</span></span> <span> </span><span class="NLM_article-title">Purine Derivatives as CB2 Receptor Agonists</span>. <span class="NLM_patent">WO 2014177490 A1</span>, Nov.6, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Bendels&author=U.+Grether&author=A.+Kimbara&author=M.+Nettekoven&author=S.+Roever&author=M.+Rogers-Evans&author=T.+Schulz-Gasch&title=Purine+Derivatives+as+CB2+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBendels%26aufirst%3DS.%26atitle%3DPurine%2520Derivatives%2520as%2520CB2%2520Receptor%2520Agonists%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szarek, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakawa, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activity of Nucleoside Analogs Involving Modifications in the Carbohydrate Ring</span>. <i>Can. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2149</span>– <span class="NLM_lpage">2161</span>, <span class="refDoi"> DOI: 10.1139/v85-354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1139%2Fv85-354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaL2MXmtFGksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1985&pages=2149-2161&author=W.+A.+Szarekauthor=B.+M.+Pintoauthor=M.+Iwakawa&title=Synthesis+and+Biological+Activity+of+Nucleoside+Analogs+Involving+Modifications+in+the+Carbohydrate+Ring&doi=10.1139%2Fv85-354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activity of nucleoside analogs involving modifications in the carbohydrate ring</span></div><div class="casAuthors">Szarek, Walter A.; Pinto, B. Mario; Iwakawa, Masaharu</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2149-61</span>CODEN:
                <span class="NLM_cas:coden">CJCHAG</span>;
        ISSN:<span class="NLM_cas:issn">0008-4042</span>.
    </div><div class="casAbstract">The synthesis of a variety of nucleoside analogs involving modifications in the carbohydrate ring is described.  In particular, 6-substituted purin-9-yl derivs. of 1-oxa-4-thiacyclohexane and 1,4-dioxacyclohexane have been synthesized.  A no. of 6-chloropurin-9-yl derivs. of substituted 1-oxa-4-thiacyclohexane have also been derived from the parent compds. by way of a Pummerer rearrangement.  A route to nucleoside analogs of 1-oxa-4-thiacyclohexane from naturally occurring nucleosides is illustrated for the case of inosine.  A route to nucleoside analogs in which the carbohydrate moiety is replaced by an acyclic moiety bearing α,β-unsatd. esters is also illustrated for the case of uridine.  The results of biol. screening of these analogs and others previously synthesized against leukemia L-1210 cells in vitro are presented; some of these compds. showed marginal antitumor activity.  The screening results of selected compds. against the human HeLa cell line in vitro are also presented; none of the compds. that were tested showed significant inhibitory activity of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZRqxcJClXlLVg90H21EOLACvtfcHk0lhABO85bdjZVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXmtFGksro%253D&md5=06bb3a22b740b4f7affea942da0b0f58</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1139%2Fv85-354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fv85-354%26sid%3Dliteratum%253Aachs%26aulast%3DSzarek%26aufirst%3DW.%2BA.%26aulast%3DPinto%26aufirst%3DB.%2BM.%26aulast%3DIwakawa%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520Nucleoside%2520Analogs%2520Involving%2520Modifications%2520in%2520the%2520Carbohydrate%2520Ring%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D1985%26volume%3D63%26spage%3D2149%26epage%3D2161%26doi%3D10.1139%2Fv85-354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grynkiewicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poenie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsien, R. Y.</span></span> <span> </span><span class="NLM_article-title">A New Generation of Ca2+ Indicators with Greatly Improved Fluorescence Properties</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">3440</span>– <span class="NLM_lpage">3450</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(19)83641-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2FS0021-9258%2819%2983641-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=3838314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaL2MXitVSmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=3440-3450&author=G.+Grynkiewiczauthor=M.+Poenieauthor=R.+Y.+Tsien&title=A+New+Generation+of+Ca2%2B+Indicators+with+Greatly+Improved+Fluorescence+Properties&doi=10.1016%2Fs0021-9258%2819%2983641-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A new generation of calcium indicators with greatly improved fluorescence properties</span></div><div class="casAuthors">Grynkiewicz, Grzegorz; Poenie, Martin; Tsien, Roger Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3440-50</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">A new family of highly fluorescent indicators has been synthesized for biochem. studies of the physiol. role of cytosolic free Ca2+.  The compds. combine an 8-coordinate tetracarboxylate chelating site with stilbene chromophores.  Incorporation of the ethylenic linkage of the stilbene into a heterocyclic ring enhances the quantum efficiency and photochem. stability of the fluorophore.  Compared to their widely used predecessor, quin2, the new dyes offer up to 30-fold brighter fluorescence, major changes in wavelength not just intensity upon Ca2+ binding, slightly lower affinities for Ca2+, slightly longer wavelengths of excitation, and considerably improved selectivity for Ca2+ over other divalent cations.  These properties, particularly the wavelength sensitivity to Ca2+, should make these dyes the preferred fluorescent indicators for many intracellular applications, esp. in single cells, adherent cell layers, or bulk tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWLBb9bdhjwrVg90H21EOLACvtfcHk0lhABO85bdjZVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXitVSmu7s%253D&md5=b78f3fc8d29fe8bae7cb8a6f2170d8d1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2983641-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252983641-4%26sid%3Dliteratum%253Aachs%26aulast%3DGrynkiewicz%26aufirst%3DG.%26aulast%3DPoenie%26aufirst%3DM.%26aulast%3DTsien%26aufirst%3DR.%2BY.%26atitle%3DA%2520New%2520Generation%2520of%2520Ca2%252B%2520Indicators%2520with%2520Greatly%2520Improved%2520Fluorescence%2520Properties%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D3440%26epage%3D3450%26doi%3D10.1016%2Fs0021-9258%2819%2983641-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongs, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalzing, G.</span></span> <span> </span><span class="NLM_article-title">A vector for the Synthesis of cRNAs Encoding Myc Epitope-Tagged Proteins in Xenopus Laevis Oocytes</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1016/0378-1119(95)00226-v</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1016%2F0378-1119%2895%2900226-V" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=7543868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADyaK2MXns1CqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1995&pages=213-217&author=S.+Gloorauthor=O.+Pongsauthor=G.+Schmalzing&title=A+vector+for+the+Synthesis+of+cRNAs+Encoding+Myc+Epitope-Tagged+Proteins+in+Xenopus+Laevis+Oocytes&doi=10.1016%2F0378-1119%2895%2900226-v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A vector for the synthesis of cRNAs encoding Myc epitope-tagged proteins in Xenopus laevis oocytes</span></div><div class="casAuthors">Gloor, Sergio; Pongs, Olaf; Schmalzing, Guenther</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-17</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We describe a plasmid, pNKS2-myc, designed for convenient in-frame fusion of an antibody-specific epitope sequence to the N terminus of a desired cDNA and subsequent synthesis of transcripts that direct the synthesis of the tagged polypeptide in Xenopus laevis (Xl) oocytes.  Plasmid pNKS2-myc contains an SP6 promoter, followed by the translation initiation sequence of the Na,K-pump β3 subunit of Xl and the sequence encoding an epitope derived from the human c-myc proto-oncogene product.  Appropriate restriction sites allow one to insert virtually any desired cDNA fragment directly behind the epitope-specific sequence and before a long poly(A) tail.  After linearization with EcoRI or NotI, polyadenylated cRNA can be synthesized that is efficiently translated in Xl oocytes.  The utility of pNKS2-myc is demonstrated by cloning cDNAs coding for Na,K-pump subunits into this vector and injecting the corresponding cRNAs into oocytes.  The tagged mouse β1 and β2 subunit isoforms could be purified from detergent exts. of these cells by immunopptn. with a generally available monoclonal antibody (mAb) to the tag, 9E10, as well as with specific mAb that recognize individual β subunit isoforms.  Under native conditions, endogenous and coexpressed exogenous α1 subunits (the catalytic subunit of the Na,K-pump) were co-pptd., indicating that the N-terminal addn. of the decapeptide epitope has no adverse effect on the folding of β subunits nor on their assembly with α subunits.  Furthermore, the Myc-specific mAb likewise pptd. a Myc-tagged Na,K-pump α1 subunit together with any of the co-synthesized β subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTAkcR9G9iabVg90H21EOLACvtfcHk0libjwg_PErr4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXns1CqtbY%253D&md5=1a5b393899fc11d5790465500fdcad94</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2F0378-1119%2895%2900226-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-1119%252895%252900226-V%26sid%3Dliteratum%253Aachs%26aulast%3DGloor%26aufirst%3DS.%26aulast%3DPongs%26aufirst%3DO.%26aulast%3DSchmalzing%26aufirst%3DG.%26atitle%3DA%2520vector%2520for%2520the%2520Synthesis%2520of%2520cRNAs%2520Encoding%2520Myc%2520Epitope-Tagged%2520Proteins%2520in%2520Xenopus%2520Laevis%2520Oocytes%26jtitle%3DGene%26date%3D1995%26volume%3D160%26spage%3D213%26epage%3D217%26doi%3D10.1016%2F0378-1119%2895%2900226-v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuan, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez-Klaka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Górecki, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrell-Lagnado, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, F.</span></span> <span> </span><span class="NLM_article-title">A Functional P2X7 Splice Variant with an Alternative Transmembrane Domain 1 Escapes Gene Inactivation in P2X7 Knock-out Mice</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">25813</span>– <span class="NLM_lpage">25822</span>, <span class="refDoi"> DOI: 10.1074/jbc.m109.033134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1074%2Fjbc.M109.033134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19546214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWhtr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=25813-25822&author=A.+Nickeauthor=Y.-H.+Kuanauthor=M.+Masinauthor=J.+Rettingerauthor=B.+Marquez-Klakaauthor=O.+Benderauthor=D.+C.+G%C3%B3reckiauthor=R.+D.+Murrell-Lagnadoauthor=F.+Soto&title=A+Functional+P2X7+Splice+Variant+with+an+Alternative+Transmembrane+Domain+1+Escapes+Gene+Inactivation+in+P2X7+Knock-out+Mice&doi=10.1074%2Fjbc.m109.033134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A Functional P2X7 Splice Variant with an Alternative Transmembrane Domain 1 Escapes Gene Inactivation in P2X7 Knock-out Mice</span></div><div class="casAuthors">Nicke, Annette; Kuan, Yung-Hui; Masin, Marianela; Rettinger, Juergen; Marquez-Klaka, Benjamin; Bender, Olaf; Gorecki, Dariusz C.; Murrell-Lagnado, Ruth D.; Soto, Florentina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">25813-25822</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The ATP-activated P2X7 receptor channel is involved in immune function and inflammatory pain and represents an important drug target.  Here the authors describe a new P2X7 splice variant (P2X7(k)), contg. an alternative intracellular N terminus and first transmembrane domain encoded by a novel exon 1 in the rodent P2rx7 gene.  Whole cell patch clamp recordings of the rat isoform expressed in HEK293 cells revealed an 8-fold higher sensitivity to the agonist Bz-ATP and much slower deactivation kinetics when compared with the P2X7(a) receptor.  Permeability measurements in Xenopus oocytes show a high permeability for N-methyl-D-glucamine immediately upon activation, suggesting that the P2X7(k) channel is constitutively dilated upon opening.  The rates of agonist-induced dye uptake and membrane blebbing in HEK cells were also increased.  PCR analyses and biochem. anal. by SDS-PAGE and BN-PAGE indicate that the P2X7(k) variant escapes gene deletion in one of the available P2X7-/- mice strains and is strongly expressed in the spleen.  Taken together, the authors describe a novel P2X7 isoform with distinct functional properties that contributes to the diversity of P2X7 receptor signaling.  Its presence in one of the P2X7-/- strains has important implications for the understanding of the role of this receptor in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWSNK2OAuzmLVg90H21EOLACvtfcHk0libjwg_PErr4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWhtr%252FO&md5=d8b22d751bce21e574abc90ce8136a58</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.033134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.033134%26sid%3Dliteratum%253Aachs%26aulast%3DNicke%26aufirst%3DA.%26aulast%3DKuan%26aufirst%3DY.-H.%26aulast%3DMasin%26aufirst%3DM.%26aulast%3DRettinger%26aufirst%3DJ.%26aulast%3DMarquez-Klaka%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DO.%26aulast%3DG%25C3%25B3recki%26aufirst%3DD.%2BC.%26aulast%3DMurrell-Lagnado%26aufirst%3DR.%2BD.%26aulast%3DSoto%26aufirst%3DF.%26atitle%3DA%2520Functional%2520P2X7%2520Splice%2520Variant%2520with%2520an%2520Alternative%2520Transmembrane%2520Domain%25201%2520Escapes%2520Gene%2520Inactivation%2520in%2520P2X7%2520Knock-out%2520Mice%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D25813%26epage%3D25822%26doi%3D10.1074%2Fjbc.m109.033134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beissner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutertre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schemm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sporning, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicke, A.</span></span> <span> </span><span class="NLM_article-title">Efficient Binding of 4/7 Alpha-Conotoxins to Nicotinic Alpha4beta2 Receptors is Prevented by Arg185 and Pro195 in the Alpha4 Subunit</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1124/mol.112.078683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1124%2Fmol.112.078683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=22802270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSmt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=711-718&author=M.+Beissnerauthor=S.+Dutertreauthor=R.+Schemmauthor=T.+Dankerauthor=A.+Sporningauthor=H.+Grubm%C3%BCllerauthor=A.+Nicke&title=Efficient+Binding+of+4%2F7+Alpha-Conotoxins+to+Nicotinic+Alpha4beta2+Receptors+is+Prevented+by+Arg185+and+Pro195+in+the+Alpha4+Subunit&doi=10.1124%2Fmol.112.078683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient binding of 4/7 α-conotoxins to nicotinic α4β2 receptors is prevented by Arg185 and Pro195 in the α4 subunit</span></div><div class="casAuthors">Beissner, Mirko; Dutertre, Sebastien; Schemm, Rudolf; Danker, Timm; Sporning, Annett; Grubmueller, Helmut; Nicke, Annette</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">711-718</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">α-Conotoxins are subtype-selective nicotinic acetylcholine receptor (nAChR) antagonists.  Although potent α3β2 nAChR-selective α-conotoxins have been identified, currently characterized α-conotoxins show no or only weak affinity for α4β2 nAChRs, which are, besides α7 receptors, the most abundant nAChRs in the mammalian brain.  To identify the determinants responsible for this difference, we substituted selected amino acid residues in the ligand-binding domain of the α4 subunit by the corresponding residues in the α3 subunit.  Two-electrode voltage clamp anal. of these mutants revealed increased affinity of α-conotoxins MII, TxIA, and [A10L]TxIA at the α4(R185I)β2 receptor.  Conversely, α-conotoxin potency was reduced at the reverse α3(I186R)β2 mutant.  Replacement of α4Arg185 by alanine, glutamate, and lysine demonstrated that a pos. charge in this position prevents α-conotoxin binding.  Combination of the R185I mutation with a P195Q mutation outside the binding site but in loop C completely transferred high α-conotoxin potency to the α4β2 receptor.  Mol. dynamics simulations of homol. models with docked α-conotoxin indicate that these residues control access to the α-conotoxin binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppLlOdT6gutbVg90H21EOLACvtfcHk0libjwg_PErr4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSmt7jN&md5=c95106b38d305084bd845b2d1a5da79f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.078683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.078683%26sid%3Dliteratum%253Aachs%26aulast%3DBeissner%26aufirst%3DM.%26aulast%3DDutertre%26aufirst%3DS.%26aulast%3DSchemm%26aufirst%3DR.%26aulast%3DDanker%26aufirst%3DT.%26aulast%3DSporning%26aufirst%3DA.%26aulast%3DGrubm%25C3%25BCller%26aufirst%3DH.%26aulast%3DNicke%26aufirst%3DA.%26atitle%3DEfficient%2520Binding%2520of%25204%252F7%2520Alpha-Conotoxins%2520to%2520Nicotinic%2520Alpha4beta2%2520Receptors%2520is%2520Prevented%2520by%2520Arg185%2520and%2520Pro195%2520in%2520the%2520Alpha4%2520Subunit%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D711%26epage%3D718%26doi%3D10.1124%2Fmol.112.078683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, G. R.</span></span> <span> </span><span class="NLM_article-title">Open Babel: An Open Chemical Toolbox</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/1758-2946-3-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1186%2F1758-2946-3-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=21982300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=33&author=N.+M.+O%E2%80%99Boyleauthor=M.+Banckauthor=C.+A.+Jamesauthor=C.+Morleyauthor=T.+Vandermeerschauthor=G.+R.+Hutchison&title=Open+Babel%3A+An+Open+Chemical+Toolbox&doi=10.1186%2F1758-2946-3-33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Open Babel: an open chemical toolbox</span></div><div class="casAuthors">O'Boyle, Noel M.; Banck, Michael; James, Craig A.; Morley, Chris; Vandermeersch, Tim; Hutchison, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Background: A frequent problem in computational modeling is the interconversion of chem. structures between different formats.  While std. interchange formats exist (for example, Chem. Markup Language) and de facto stds. have arisen (for example, SMILES format), the need to interconvert formats is a continuing problem due to the multitude of different application areas for chem. data, differences in the data stored by different formats (0D vs. 3D, for example), and competition between software along with a lack of vendor-neutral formats.  Results: We discuss, for the first time, Open Babel, an open-source chem. toolbox that speaks the many languages of chem. data.  Open Babel version 2.3 interconverts over 110 formats.  The need to represent such a wide variety of chem. and mol. data requires a library that implements a wide range of cheminformatics algorithms, from partial charge assignment and aromaticity detection, to bond order perception and canonicalization.  We detail the implementation of Open Babel, describe key advances in the 2.3 release, and outline a variety of uses both in terms of software products and scientific research, including applications far beyond simple format interconversion.  Conclusions: Open Babel presents a soln. to the proliferation of multiple chem. file formats.  In addn., it provides a variety of useful utilities from conformer searching and 2D depiction, to filtering, batch conversion, and substructure and similarity searching.  For developers, it can be used as a programming library to handle chem. data in areas such as org. chem., drug design, materials science, and computational chem.  It is freely available under an open-source license.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQ1lvaS5767Vg90H21EOLACvtfcHk0lhJvunb5Su6wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF&md5=74e4f19b7f87417f916d57f7abcfb761</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-3-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-3-33%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBanck%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DMorley%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DT.%26aulast%3DHutchison%26aufirst%3DG.%2BR.%26atitle%3DOpen%2520Babel%253A%2520An%2520Open%2520Chemical%2520Toolbox%26jtitle%3DJ.%2520Cheminf.%26date%3D2011%26volume%3D3%26spage%3D33%26doi%3D10.1186%2F1758-2946-3-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=Improving+the+Speed+and+Accuracy+of+Docking+with+a+New+Scoring+Function%2C+Efficient+Optimization%2C+and+Multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0lhJvunb5Su6wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DImproving%2520the%2520Speed%2520and%2520Accuracy%2520of%2520Docking%2520with%2520a%2520New%2520Scoring%2520Function%252C%2520Efficient%2520Optimization%252C%2520and%2520Multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couch, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrin, T. E.</span></span> <span> </span><span class="NLM_article-title">UCSF Chimera--a Visualization System for Exploratory Research and Analysis</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1605</span>– <span class="NLM_lpage">1612</span>, <span class="refDoi"> DOI: 10.1002/jcc.20084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=10.1002%2Fjcc.20084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=15264254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=1605-1612&author=E.+F.+Pettersenauthor=T.+D.+Goddardauthor=C.+C.+Huangauthor=G.+S.+Couchauthor=D.+M.+Greenblattauthor=E.+C.+Mengauthor=T.+E.+Ferrin&title=UCSF+Chimera%2D%2Da+Visualization+System+for+Exploratory+Research+and+Analysis&doi=10.1002%2Fjcc.20084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">UCSF Chimera-A visualization system for exploratory research and analysis</span></div><div class="casAuthors">Pettersen, Eric F.; Goddard, Thomas D.; Huang, Conrad C.; Couch, Gregory S.; Greenblatt, Daniel M.; Meng, Elaine C.; Ferrin, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1605-1612</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The design, implementation, and capabilities of an extensible visualization system, UCSF Chimera, are discussed.  Chimera is segmented into a core that provides basic services and visualization, and extensions that provide most higher level functionality.  This architecture ensures that the extension mechanism satisfies the demands of outside developers who wish to incorporate new features.  Two unusual extensions are presented: Multiscale, which adds the ability to visualize large-scale mol. assemblies such as viral coats, and Collab., which allows researchers to share a Chimera session interactively despite being at sep. locales.  Other extensions include Multalign Viewer, for showing multiple sequence alignments and assocd. structures; ViewDock, for screening docked ligand orientations; Movie, for replaying mol. dynamics trajectories; and Vol. Viewer, for display and anal. of volumetric data.  A discussion of the usage of Chimera in real-world situations is given, along with anticipated future directions.  Chimera includes full user documentation, is free to academic and nonprofit users, and is available for Microsoft Windows, Linux, Apple Mac OS X, SGI IRIX, and HP Tru64 Unix from http://www.cgl.ucsf.edu/chimera/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmD4M5S0cPbVg90H21EOLACvtfcHk0lhJvunb5Su6wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D&md5=944b175f440c1ff323705987cf937ee7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20084%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DE.%2BF.%26aulast%3DGoddard%26aufirst%3DT.%2BD.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DCouch%26aufirst%3DG.%2BS.%26aulast%3DGreenblatt%26aufirst%3DD.%2BM.%26aulast%3DMeng%26aufirst%3DE.%2BC.%26aulast%3DFerrin%26aufirst%3DT.%2BE.%26atitle%3DUCSF%2520Chimera--a%2520Visualization%2520System%2520for%2520Exploratory%2520Research%2520and%2520Analysis%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2004%26volume%3D25%26spage%3D1605%26epage%3D1612%26doi%3D10.1002%2Fjcc.20084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1U','PDB','5U1U'); return false;">PDB: 5U1U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1V','PDB','5U1V'); return false;">PDB: 5U1V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1W','PDB','5U1W'); return false;">PDB: 5U1W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1X','PDB','5U1X'); return false;">PDB: 5U1X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1Y','PDB','5U1Y'); return false;">PDB: 5U1Y</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i78"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02145">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_74201"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02145?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02145</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Scheme for the synthesis of <b>14</b>, summary of pharmacological data of the tested compounds, NMR spectra, current inhibition in rat P2X7 by <b>6</b>, HPLC, and X-ray (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_002.csv">CSV</a>)</p></li><li><p class="inline">PDB coordinates for the computational model used, modified from the protein model by Dayel et al.<a class="ref ref11" href="javascript:void(0);">(11)</a> with permission (crystal templates PDB IDs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1U">5U1U</a>,<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1V">5U1V</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1W">5U1W</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1X">5U1X</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U1Y">5U1Y</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_003.txt">TXT</a>)</p></li><li><p class="inline">Compound <b>6</b> pose at the P2X7 binding site (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_004.mp4">MP4</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_001.pdf">jm0c02145_si_001.pdf (7.56 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_002.csv">jm0c02145_si_002.csv (3.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_003.txt">jm0c02145_si_003.txt (737.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02145/suppl_file/jm0c02145_si_004.mp4">jm0c02145_si_004.mp4 (3.66 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02145&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02145%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02145" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c94bcec63d06","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
